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Abstract 
Background: Microbial Keratitis (MK) is the leading cause of unilateral blindness after 
cataract in Tropical regions and is responsible for 2 million cases of blindness per year. In 
Sub-Saharan Africa, MK is a neglected problem, most ophthalmic centres do not have 
diagnostic services, patients present late, appropriate drugs are often not available, corneal 
transplant services are rarely available. Subsequently, outcomes are poor in this area. 
Currently there are very limited data to guide policy and practice. 
Methods: In a main cohort design, individuals with MK presenting to the two referral eye 
hospitals in South Western Uganda were enrolled over a one-year period. Clinical history and 
presentation journey were recorded. Their eyes were carefully examined, and samples were 
collected for microbiology. Patients were tested for HIV and Diabetes. At three months, 
patients were followed up in their homes and at this point healthy community controls were 
enrolled to compare risk factors in a nested case-control study and assess the impact of the 
disease on the Quality of Life (QoL). A separate situation analysis survey of lower health 
centres was additionally conducted to understand the role of the health system in management 
of MK. 
Traditional Eye Medicine (TEM) use was reported in 188/313. TEM users had a delayed 
presentation; median presenting time 18 days versus 14 days, p= 0.005; had larger ulcers 5.6 
mm versus 4.3 mm p=0.0005; a worse presenting visual acuity median logarithm of the 
minimum angle of resolution (Log MAR) 1.5 versus 0.6, p=0.005; and, a worse visual acuity 
at 3 months median Log MAR 0.6 versus 0.2, p=0.010. In the qualitative analysis, reasons for 
TEM use included lack of confidence in conventional medicine, health system breakdown, 
poverty, fear of the eye hospital, cultural belief in TEM, influence from traditional healers, 
personal circumstances and ignorance. 
Results: Three hundred and thirteen individuals were enrolled. Median age was 47 years (ra
nge 18-96) and 174 (56%) were male. Median presentation time to the eye hospital  was 17 
days from onset (IQR 8-32). Trauma was reported by 29%. Majority presented with severe in
fections (median infiltrate size 5.2 mm); 47% were blind in the affected eye (vision <3/60), fu
ngal cases were 62%. At 3-months, 30% of participants were blind in the affected eye, while 
9% had lost their eye from the infection. Predictors of poor vision at 3-months were: baseline 
vision (aOR 2.98 [95%CI  2.12-4.19],  p<0.0001),  infiltrate  size  (aOR  1.19  [95%CI  1.03-1.3
6],  p<0.020)  and perforation at presentation (aOR 9.93 [95% CI 3.70-26.6], p<0.0001). 
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In the case-control analysis, HIV OR 83.5 (95%CI 2.01-3456), p=0.020, Diabetes OR 9.38 
(95% CI 1.48-59.3), p=0.017 and a farming occupation OR 2.60 (95%CI 1.21-5.57), p=0.014 
were main risk factors of MK. In the Quality of Life (QoL) analysis, mean QoL scores of the 
cases were lower than controls across all domains. Determinants of QoL among the cases at 
3-months included visual acuity at 3-months and history of eye loss. 
Although most patients presented early to the primary health centres (median 2days IQR 0-5 
days), there were severe weaknesses along the health system in identification and early 
referral of MK. Only 12% of the health workers could make a diagnosis of MK. None of the 
health facilities had a stock of the recommended first line treatment options for MK 
(ciprofloxacin and Natamycin eye drops).  
Conclusion: This is the first large epidemiological cohort in SSA studying MK and provides a 
baseline understanding of the epidemiology, aetiology and outcomes, and what needs to be 
done to improve the situation and reduce the devastating visual outcomes currently 
experienced by many people 
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Format of the Thesis 
The thesis for this PhD utilises the “research papers” format, recently introduced by the 
London School of Hygiene and Tropical Medicine. It therefore includes several papers which 
are either published, accepted or in submitable format for publication in peer-reviewed 
journals. The chapters listed in italics in the Contents are in this research/review paper format, 
and each chapter includes publication details in a cover sheet, including acknowledgement of 
the contributions of other people. The other chapters of the thesis are composed of “linking 
material” which includes information/data not covered in the research papers and helps to 
make the thesis a coherent body. 
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Chapter 1. Background 
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Overview
Microbial keratitis (MK), or infection of the cornea, can be caused by a range of pathogens. The 
causative organisms include bacteria, viruses, protozoa (e.g. acanthamoeba), and fungi (yeasts, 
moulds and microsporidia). It is characterised by an acute or sub-acute onset of pain, conjunctival 
hyperaemia and corneal ulceration with a stromal inflammatory cell infiltrate. MK frequently leads to 
sight-loss from dense corneal scarring, or even loss of the eye, especially when the infection is 
severe and/or appropriate treatment is delayed.1 Blindness is defined as a presenting distance vision 
worse than 3/60; bilateral blindness is distance vision worse than 3/60 in the better eye.2
MK typically affects people in the most economically productive stage of life, median age ~40 
years.6,8 It reduces vision-related quality of life.9,10 Treatment is costly and prolonged. Outcomes in 
Low and Middle-Income Countries (LMIC) are typically poor, with ~60% of eyes rendered blind.8,11,12
A good outcome depends on early appropriate treatment, correct identification of the causative 
organism, and careful follow-up.8,9 In LMIC, MK presents major challenges. The outcomes in SSA 
are frequently poor.10-12 Presentation is usually delayed and advanced infections have poor 
outcomes.12 Patients may use TEM, which often contains plant matter or inappropriate 
“conventional” medication (such as a corticosteroid), exacerbating the problem.12-14 Primary health-
care staff have little training in recognising, treating and referring MK. It is frequently not possible to 
clinically distinguish bacterial and fungal MK. Microbiology services are usually unavailable. Fungal 
keratitis is particularly difficult to treat. Current topical anti-fungals are not consistently effective and 
infection can progress despite prompt treatment.12,15-19 Anti-fungal drops are rarely available in SSA 
and often scarce elsewhere.12 The eye may be lost through progressive deep corneal ulceration and 
perforation.12,16
MK  has  been  described  as  a  “silent  epidemic”,  which  leads  to  substantial  morbidity,  related  to 
blindness and other consequences such as pain and stigma.3 It is the leading cause of unilateral bli
ndness after cataract in tropical regions and is responsible for about 2 million cases of monocular b
lindness  per  year in Africa and Asia.4  The  World  Health  Organization  (WHO)  estimated  (2017)  
that  1.3  million individuals are bilaterally blind from corneal opacity globally (excluding trachoma a
nd vitamin A deficiency), accounting for 3.2% of binocular blindness globally5. In Sub-Saharan Afric
a (SSA), MK is  an  important  cause  of  binocular  blindness  and  is  responsible  for  about  15%  
of  monocular blindness in the Nigeria National Survey (personal communication).6,7 
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Epidemiology of Microbial Keratitis in Africa and Elsewhere 
Incidence 
The Incidence of MK varies between high-income countries and Low- and Middle-Income Countries 
(LMIC). A recent review has described global incidence rates.20 A summary of the global incidence 
rates is presented in Table 1. Overall, the incidence of MK is highest in Asian countries (except Hong 
Kong) and lowest in Europe and North America.21-24
There is only one older report of the incidence of MK in SSA from Malawi.14 In this study, all patients 
with corneal lesions ( in which fluorescein stain was visible with a torch) that presented to ophthalmic 
medical assistants at two district hospitals (Mulanje and Chikwawa) in Malawi were enrolled. For one 
district (Chikwawa) with a known population, the incidence of corneal disease per 10,000 population 
was calculated. From this district, most of the patients came from two main subdistricts (Kasisi and 
Katunga). Fifty-six patients came from Kasisi (total population 24,300, incidence 231/100,000 
persons) while twenty-four patients came from Katunga (total population 13,850, incidence 
173/100,000 persons). Pooling these cases gave an incidence of 210/100,000/year.14 However, a 
more recent update on the burden of serious fungal infections in Malawi has given a much lower 
figure of (10.3/100,000) fungal cases per year based on the number of cases presenting to the main 
eye hospital department in Malawi.25
Table 1. Incidence of microbial keratitis in population-base studies 
Country Year Estimate Source 
Africa 
Malawi (Kasisi, Katunga) 1994 210/100,000/year Courtright14
Malawi 2018 10.3/100,000/year Kalua25
Asia 
India (Madurai) 1997 113/100,000/year Gonzales26
Nepal (Bhaktapur) 2001 799/100,000/year Upadhyay22
Hongkong 2002 6.3/100,000/year Lam21
Myanmar 2004 710/100,000/year WHO / Country Report27
Bhutan 2004 339/100,000/year WHO / Country Report27
North America and Europe
USA 2010 27.6/100,000/year Jeng23
UK 2012 40.3/100,000/year Ibrahim24
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Variation in Causative Organisms by Geographical Region 
A wide range of microorganisms can infect the cornea: bacteria, fungi, viruses and protozoa. The 
pattern of causes seems to be more geographical although urbanisation and seasonal variation has 
also been reported to influence specific causes.28 There are only a few, limited studies of the 
microbiology of MK in SSA. Table 2 shows the distribution of the causes of MK in SSA. 
In global epidemiology of MK, three large reviews have looked at the distribution of organisms 
according to geographical region.20,29,30 The first review in 2002 looked at the global proportions of 
fungal keratitis.31 The authors mapped the proportion of fungal keratitis against latitude and 
demonstrated that the proportion of filamentous fungi as a cause of MK generally increases the lower 
the latitude, with the highest proportion being found around the equator (figure 2).31-34 In tropical 
regions filamentous fungi cause about half of MK.12,31,35 The second epidemiological review in 2011 
described associations between a country’s gross national income and types of causative 
organism.29 The highest proportion of bacterial corneal ulcers was reported in studies from North 
America, Australia, Europe and Singapore. The highest proportions of fungal infections were found 
in studies from India and Nepal.29 There was a significant correlation between a country’s gross 
national income and type of infection (fungal or bacterial). The higher the income of a country, the 
higher the proportion of bacterial MK and vice versa.29 A more recent review (2019) looked at the 
global incidence and proportions of MK based on large population studies and large case series.20
The summary of the reports considered in these reviews have been updated and presented in Table 
3.  
Generally, in temperate climates most corneal infections are bacterial and are frequently related to 
contact lens use although reports of recent increases in fungal keratitis in the UK have been 
reported.13 In the literature of large case series from North America, Europe and South America, the 
proportion of fungal keratitis was low ranging from 0-26%.24,36-40 Conversely, fungal rates from 
African and Asian studies were high ranging at an average of 50%.31,41-43
Specifically, regardless of geographical location, Gram positive organisms (Streptococcus 
pneumoniae, Staphylococcus aureus) and Gram-negative pathogens (Pseudomonas aeruginosa) 
are the most frequent bacterial causes while Fusarium spp and Aspergillus spp are the most 
common fungal causes.31,44-48 However, in temperate climates, Candida spp have been commonly 
reported. 24,36-40
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Figure 1  Distribution of filamentous fungi by Latitude31
Risk factors
There are many potential risk factors that may predispose a person towards developing MK with 
some risk factors being more specific to settings (region, income status and organism) and some 
being ubiquitous. Table 4 shows some of the summary results on studies from SSA that have 
reported data on risk factors of MK, and some select global studies. 
Age 
Although age may not be an independent risk factor for MK, infectious keratitis is a more severe 
disease in elderly than in younger patients with more complications and a worse prognosis. Elderly 
patients have multiple and more diverse risk factors, making prevention difficult to manage.49 Age 
influences other risk factors: for example, trauma is more common in the lower age groups versus 
ocular surface diseases which are more common in older folk.49 However, the peak affected age 
group in many African studies is between 20-40.50,51 Table 2 summarises the epidemiology of MK in 
SSA and shows that in almost all the studies the peak/median age of presentation was between 20-
40 years. Only one report from Nigeria indicated a dual peak in the age group of 21-30 years and 
51-60 years.52 In our pilot work before this project, we noted a similar picture in our setting as shown 
in Figure 3, the peak age group for MK was between 21-30 years. 
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Figure 2 Age distribution among patients presenting to Ruharo Eye Centre with MK, a pilot 
study (n=75) 
Sex 
Although sex is not an independent risk factor for MK, almost all papers from SSA have reported a 
male predominance among MK patients ranging from 54-87%.12,48,50,51,53,54 A similar pattern has been 
shown in Asian studies with an average of 60-70% of all the MK patients being male.41,43,45,55 In our 
settings, this difference might be due to occupational differences where males may be at a higher 
risk of trauma compared to females.).56-58 However, there does not seem to be a difference in the 
male and female proportions among studies from Europe and the USA with some reporting a lower 
proportion of males compared to females.23,59-61 This pattern has also been reported in other non-
European but equally developed regions such as Hong Kong.62 In this 10 year review study in a 
tertiary centre in Hong Kong where 347 scrapes were performed in the 10-year period, the proportion 
of males in this study was 43.4%.62
Trauma / Occupation 
Trauma has been reported in almost all studies regardless of geographical region as a key 
predisposing factor for MK (Table 4). Risk factors such as trauma especially with vegetative matter 
have been associated with fungal keratitis compared to a pre-existing ocular disease for bacterial 
keratitis.56,57 Injury with mud strongly linked to Acanthamoeba keratitis.57 In addition, agricultural work 
and foreign body in the eye have been implicated, these are fairly trauma related.56,58,63. In the reports 
from SSA, the rates of trauma range from 23-54%.12,48,50,51,53,54
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Traditional Eye Medicine (TEM) 
In Low and Middle-Income Countries (LMIC), use of Traditional Eye Medicine (TEM) for treatment 
of many eye conditions is a common practise.64-66 A recent large population-based study in 25 
randomly selected clusters of Rural Gurgaon, Haryana, India found that of the 2160 participants 
interviewed, 396 (18.2%) reported using ophthalmic medications without consulting an 
ophthalmologist, mainly for symptoms like watering (37.1%), redness (27.7%), itching (19.2%) and 
infection (13.6%).66 Additionally, 25.7% (529) participants resorted to home remedies like 
'kajal'(61.4%), honey (31.4%), ghee (11.7%) and rose water (9.1%).66
In SSA, one study from Malawi interviewed 800 adults in the study areas. Self-treatment was 
reported for the last episode of eye disease by 39.8% of the study population of which 72% had used 
TEM.65 Another prospective case-controlled study where 150 pterygium patients and 150 controls 
participated found that 52.6% of the 150 cases and 40% of the 150 controls had used TEM (odds 
ratio (OR) 2.03; p=0.009.64 Another study from Tanzania enrolled 257 consecutive patients with eye 
injury.67 TEM was used by 49% of all patients; the main types of traditional medicines used were 
plant juices, milk mixed with black powder and pounded roots; the main route of application was 
instillation into the conjunctival sac.67 In Uganda, small local study at Ruharo Eye Centre in Mbarara 
found that 60% of the people attending the outpatient clinic for various problems first used TEM, 
before coming to hospital (unpublished). The proportion of TEM among people presenting with MK 
in SSA has been reported varying from 4-35%.12,44,52,68 There may be some underreporting due to 
“fear” among patients. 
Since most of the TEM involves plant products such as fresh leaves, it could have a major role in 
the pathogenesis of fungal keratitis, which has been associated with injuries involving vegetative 
matter.45,69 One earlier report from Tanzania reported TEM as an independent risk factor for TEM.13
In this study, 103 patients presented with MK of which 26% admitted to having used TEM. Out of 
these, 58% had no other attributable risk factor for MK and were then considered as TEM induced 
MK.13
In addition, TEM has been found to lead to complications such as corneal scarring and delayed 
presentation of patients to hospital resulting in poor outcomes.67,70 In one study from Malawi, 197/583 
(33.8%) patients who presented with corneal disease reported using TEM during the current eye 
disease episode.14 The patients who reported TEM use took longer (mean 50 7 (SD 35 3) days) to 
reach the district hospital than patients who did not report TEM use (mean 12-9 (SD 17-8) days) 
(p<0001).14 In addition, patients who reported TEM use were more likely to have bilateral disease 
and poor vision on presentation.14
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The pilot study in Uganda found that patients had used different vegetative concoctions, including 
cow dung derivatives. Most patients reported a firm belief in TEM and did not appreciate the potential 
danger. This is compounded by the traditional understanding that MK, which is known as 
“akavurugye” in the local Bantu language (literally translated as ‘that which distorts the eye’), is only 
treatable by TEM. Patients presenting with severe MK reported, on being asked why they came late, 
that they first tried TEM for “akavurugye”. This belief has been reported in other parts of SSA. In the 
earlier study from Malawi, One hundred and ninety-four (33.3%) patients had consulted a traditional 
healer at least once before presentation at the district hospital (113 as first source and 81 as second 
source).14 Treatment received from the healers was perceived to be equally helpful (41.6%) as that 
received from health centres (42.8%). Of the 173 patients who attended a health centre first, 59 (34. 
1%) went to a traditional healer for subsequent care.14
HIV 
HIV is a common problem in many parts of SSA. In Uganda, the prevalence of HIV is at 6.3%.71 Two 
studies have reported HIV as a potential risk factor for MK.12,51 In the first study in 1999 enrolled 212 
patients with MK that presented to Muhimbili Medical Centre, Dar es salaam, Tanzania.51 As part of 
the work up, patients were tested for HIV as well as microbiological workup. There was a total of 
86/212 (40%) HIV positive patients in this study population. Twenty-six of 32 (80%) patients with 
fungal keratitis were HIV positive; and 33% patients with non-fungal keratitis were HIV positive (P-
value was < 0.001).51 This was before the onset of Anti Retro Viral Therapy (ART) for HIV care. Later 
in 2003, a study in Kilimanjaro (about 462km from Dar es salaam) enrolled 170 patients with MK 
over a 27-month period. As part of the work up, HIV infection was diagnosed in 16% of individuals 
tested, which was approximately twice the prevalence found in the wider population in Tanzania at 
that time.12 This study however did not specifically compare the HIV proportions in bacterial versus 
fungal MK. 
HIV is uncommon in other regions outside of SSA. However, one large population study in the USA 
recorded incidence rates of ulcerative keratitis over a 12-month period.23 Multivariate relative risk 
regression was conducted to evaluate potential risk factors for ulcerative keratitis. Within the target 
population of 1,093,210 patients, 302 developed ulcerative keratitis. The incidence of ulcerative 
keratitis was 27.6 per 100 000 person-years (95% confidence interval, 24.6-30.9).61 Seven of 2,944 
people known to be infected with HIV developed ulcerative keratitis giving an incidence of 238.1 per 
100 000 person-years (95% confidence interval, 95.7-490.5). Compared to HIV negative individuals, 
the with an odds of developing ulcerative keratitis among the HIV positive patients was 9.31 (7.42-
11.7; P < .001).23
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DM 
Diabetes Mellitus (DM) has been the most commonly reported systemic risk factor, especially 
following keratoplasty or corneal trauma.45,72,73 Diabetes Mellitus is a growing public health concern 
in many parts of the world. The latest International Diabetes Foundation (IDF) Diabetes atlas 
reported 451 million adults with Diabetes globally in 201774. The expected number will be 552 million 
by 2030 and 693 million in 2045 with the greatest increase in Low and Middle Income countries 
(LMICs) 74. The prevalence of DM in Uganda is about 2% in the rural population and 4% in the urban 
population.75 There is no report from SSA on DM as a risk factor for MK. However, a number of 
studies from India and Asia have reported DM as one of the risk factors for MK accounting for 3.2-
7.6% of MK cases (table 4).41,43,45,62
Steroids 
Topical steroids are used in ophthalmology to treat a number of conditions such as inflammatory 
conditions, uveitis, post-surgical care, allergic conditions and some forms of Peripheral Ulcerative 
Keratitis (PUK).76 However, they can impair the immune host response of the cornea making it 
susceptible to infection.77 In many parts of SSA, patients access these steroid eye drops as off over 
the counter medication. In one 10 year review from Nigeria, self-medication with topical steroids as 
a risk factor accounted for 5.7% of all the 82 MK cases.44 In another report from Tanzania, use of 
steroids as a risk factor accounted for 17.1% of all the 170 MK cases.12 In many other settings in 
SSA, the type of the drug used by the patients prior to presentation are difficult to ascertain especially 
if the patients do not present to hospital with the bottles/pack information of the medicines they have 
been using. 
Ocular Surface Disease (OSD) 
Pre-existing OSD includes several conditions such as scarring, dryness, eyelid problems such as 
blepharitis which compromise the integrity of the intact corneal epithelium.62 This has been reported 
more in studies from Europe, USA and Hong Kong ranging from 17-29% (table 4).61 Apart from a 
report from Ethiopia, a trachoma endemic region which reported a high proportion of blepharitis 
(29.2%) among the patients developing MK and an older report from Tanzania (another trachoma 
endemic area) which reported a 32% (previous corneal scar) proportion of OSD among the MK 
cases, other literature from SSA has not reported much lower rates of OSD compared to European 
studies.68,78
Contact Lens wear associated with MK affects more people in high-income countries as opposed to 
the use of traditional eye medicines, which is more of a problem in LMIC.12,14,59,79,80 For example, in 
the recent large multicentre study from Asia-pacific, the overall proportion of people who developed 
MK due to contact lens wear was 10.7% across all the countries.41 In the subgroup analysis by 
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country, contact lens wear was the greatest risk factor in Singapore (68.2%), Taiwan (43.3%), and 
Japan (25.6%) and lowest in India (0.8%) and China (0.4%).41
However, all previous African studies are limited by the absence of control subjects for comparison. 
One of the aims of this PhD, therefore, was to investigate the role of multiple risk factors (HIV 
infection, DM, farming) which are preventable or modifiable by comparing MK cases to disease free 
community controls, matched for age, sex and village in Uganda. 
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Table 2 Epidemiology of MK from studies in SSA 
Author Country N Males Mean age (%) culture positive Fungal* Bacterial* Bacteria (%) ǂ Fungi (%) ǂ 
Mafwiri50 Tanzania 202 66.8% - 76% 48% 52% Staphylococcus spp (37%), 
Streptococcus spp (23.5%) 
Escherichia Coli (7.4%) 
Pseudomonas aeruginosa 
(6.2%)
Candida spp 
(22%) 
Aliraki81 Uganda 78 66% 30 38% 12.5% 87.5% Staphylococcus aureus 
(7.5%), Streptococcus 
pneumoniae (7.5%) 
Pseudomonas aeruginosa 
(10%)
 Dermatophyte 
(2.5%) 
Poole68 Tanzania 44 66% 44 55% 50% 50% Staphylococcus epidermidis 
(6.8%)  
Staphylococcus aureus (4.6%) 
Pseudomonas aeruginosa 
(13.6%)
Fusarium spp 
(20.5%) 
Aspergillus 
(2.3%) 
Carmicheal54 South 
Africa 
283 87% 42 45% 5% 95% Streptococcus pneumoniae 
(37.7%), Pseudomonas 
aeruginosa (16.9%)
 - 
Hagan48 Ghana 207 69% 36 50% 56% 44% Streptococcus spp (8.6%) 
Staphylococcus spp (5.4%), 
Pseudomonas aeruginosa 
(12.5%)
Fusarium spp 
(26.5%) 
Aspergillus 
(7.8%)
Capriotti82 Sierra-
Leone 
73 - - 95% 32% 68% Staphylococcus aureus 
(27.4%, Pseudomonas 
aeruginosa (39.7%)
Aspergilus spp 
(5.5%) 
Burton12 Tanzania 170 54% 46 50% 51% 49% Staphylococcus epidermidis 
(14.1%), Pseudomonas 
aeruginosa (5.3%) 
Fillamentary
fungi (24.6%), 
Candida spp 
(3.5%)
Wani47 Zimbabwe 43 58% 33 26% 0% 100% Staphylococcus spp (54.5%), 
Escherichia Coli (18.5%), 
Pseudomonas aeruginosa 
(9.1%), Klebsiella spp (9.1%), 
Norcadia spp (9.1%)
 - 
Ezegwui52 Nigeria 82 46% - - - -  -  - 
Mselle83 Tanzania 212 59% - - 32% 68%  - Fusarium spp 
(75%), 
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Aspergillus spp 
(18.75%)
Oladigblou44 Nigeria 228 57% - 58% - - Staphylococcus aureus, 
Streptococcus pneumoniae 
Pseudomonas spp
-  
Limaiem84 Tunisia 100 55% - 42 21% 79%  - 
Leck31 Ghana 290 - - - 73% 27% Staphylococcus spp (10%) 
Streptococcus spp (20%), 
Pseudomonnas spp (52.5%)  
Fusarium spp 
(42.2%), 
Aspergillus 
(17.4%)
*proportion out of the culture positive cases, ǂ most common bacterial, fungal organisms identified 
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Table 3 Global epidemiology of MK, updated literature. 
Author Country/year N (%) culture positive Fungal* Bacterial* Bacteria (%) ǂ Fungi (%) ǂ
Khor41 Asia-pacific/2018 6626 43.1% 32.7% 38% Pseudomonas 
aeruginosa (10.7%), 
Streptococcus 
pneumoniae (6.3%),
Fusarium spp (18.3%), 
Aspergillus spp (8.3%)
Chidambaram43 India/2018 252 83% 77% 7% Streptococcus 
pneumoniae (47%), 
Pseudomonas 
aeruginosa (21%), 
Norcadia spp (16%)
Fusarium spp (39%), 
Aspergillus spp (18%)
Khanal85 Nepal/2005 447 64% 47.8% 34% Staphylococcus aureus 
(56.7%), Streptococcus 
pneumoniae (20%), 
Pseudomonas 
aeruginosa (20%)
Aspergillus spp (38.4%)  
Fusarium spp (22%). 
Aureobasidium spp. 
(12.3%) 
Dunlop86 Bangladesh/1994 142 63% 35.9% 53.5% Pseudomonas spp (24%) 
Streptococcus 
pneumoniae (17%)
Aspergillus spp (13%)  
Fusarium spp (7%) 
Culvularium spp (6%) 
Panda87 India/2007 1000 56.8% 49.1% 37.5% Staphylococcus spp 
(27.4), Pseudomonas spp 
(12.1%)
Aspergillus spp (20.4%)  
Sharma88 India/2007 170 69.4% 13% 55.2% Staphylococcus 
epidermidis (38.3%), 
Streptococcus 
pneumoniae (22.3%), 
Pseudomonas spp (6.3%)
Fusarium spp (72.7%), 
Bharathi India/2007 3183 71% 34.4% 32.77% Streptococcus 
pneumoniae (36%), 
Pseudomonas 
aeruginosa (20%)
Fusarium spp (41.92%), 
Aspergillus spp (25%) 
Basak55 India/2005 1198 68% 62.7% 22.7% Staphylococcus aureus 
(42.6%), Pseudomonas 
spp (21.1%)
Aspergillus spp (59.9%)  
Fusarium spp (21.2%) 
Sharma India/2002 1092 35% 37.5% 62.5% Staphylococcus spp 
(23.7), Streptococcus spp 
(15.4%), Pseudomonas 
spp (6.9%)
Aspergillus spp (11.1%)  
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Leck31 India/2002 800 69% 44% 29.3% Streptococcus spp 
(46.8%), Staphylococcus 
spp (24.7), Pseudomonas 
aeruginosa (14%)
Aspergillus spp (39.9%)  
Fusarium spp (21.5%) 
Culvularium spp (9.6%) 
Vajpayee89 India/2000 100 65% 20% 52% Staphylococcus spp 
(33.9%), Pseudomonas 
aeruginosa (15.4%)
Aspergillus spp (9%)  
Srinivasan90 India/1997 434 68% 46.8% 47.1% Streptococcus 
pneumoniae (44.3%), 
Pseudomonas spp 
(14.4%)
Fusarium spp (47.1%) 
Aspergillus spp (16.1%)  
Far East
Lin91 China/2017 2973 46.1 44.6% 41.9% Staphylococcus 
epidermidis (31.9%) 
Pseudomonas 
aeruginosa (12.4%)
Fusarium spp. 
(29.3%) 
Aspergillus spp. 
(24.1%)
Hsiao92 Taiwan/2016 2,012 49.3% 16% 81.1% Pseudomonas 
aeruginosa (24.4%) 
Staphylococcus spp 
(16.6%) 
- 
Xie42 China/2006 1,056 75.6% 77.9% 16.2% - Fusarium spp. 
(73.3%) 
Aspergillus spp. 
(12.1%)
Europe
Ting37 UK/2018 914 44.5% 4.2% 91.0% CoNS (28.5%) 
Staphylococcus aureus 
(14.9%) 
Streptococcus spp. 
(13.3%)
Yeasts (50.0%) 
Filamentous 
fungi (50.0%) 
Tan38,93 UK/2017 4,229 32.6% 7.1% 90.6% CoNS (26.9%) 
Staphylococcus aureus 
(16.7%) 
Streptococcus spp. 
(14.7%)
Yeasts (53.2) 
Fusarium spp. (25.7%)
Ibrahim24 UK/2009 1,254 63.8% 0% 85.4% Staphylococcus 
epidermidis (31.7%) 
Pseudomonas 
aeruginosa (12.0%) 
Staphylococcus aureus 
(11.5%)
- 
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North America
Hernandez39 Mexico/2015 1,638 37.6% 11.7% 88.3% Staphylococcus 
epidermidis (27.4%) 
Pseudomonas 
aeruginosa (12.1%) 
Staphylococcus aureus
(9.0%) 
Fusarium spp (50.0%)
Aspergillus spp (19.4%) 
Candida spp (8.3%) 
Lichtinger40 Canada/2012 1,701 57.4% 6.0% 91.8% CoNS (36.5%) 
Streptococcus spp
(17.4%) 
Staphylococcus aureus
(17.2) 
- 
Alexandrakis36 USA/2000 2,920 50.3% - 91.1%` Pseudomonas 
aeruginosa (25.7%) 
Staphylococcus aureus
(19.4%) 
- 
South America
Cariello94 Brazil/2011 6,804 48.6% 11.0% 78.9% CoNS (26.3%) 
Staphylococcus aureus
(21.1%) 
Pseudomonas 
aeruginosa (11.8%) 
Fusarium spp (51.9%) 
Candida spp (14.3%) 
Aspergillus spp (9.1%) 
Laspina95 Paraguay/2004 660 79.4% 26.0% 51.0% CoNS (25.1%) 
Staphylococcus aureus
(23.7%) 
Pseudomonas 
aeruginosa (10.7%) 
Acremonium spp (37.8%) 
Fusarium spp (19.6%) 
Aspergillus spp (17.7%) 
*proportion out of the culture positive cases, ǂ most common bacterial, fungal organisms identified. CoNS=Coagulase Negative Staphylococcus spp
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Table 4 Summary results of select papers on risk factors of MK 
Author Country year N
% 
fungal
% 
Bacterial
% 
Male
% 
Trauma
% 
Steroid
% 
TEM
%  
CL
% 
OSD
%  
POS
% 
HIV
% 
DM
Africa
Gebremariam78 Ethiopia 2015 24 - 100 87.5 37.5 - - - 29.2 - - - 
Mafwiri50 Tanzania 2013 202 37 40 66.8 
Burton12 Tanzania 2011 170 25 - 54 24 17.1 4 - 5.9 - 16 - 
Oladigbolu44 Nigeria 2013 228 57 51.3 5.7 17.1 0.4 4 - - - 
Ezegwui52 Nigeria 2010 82 - - 46 52.4 - 19.5 - - - - - 
Poole68 Tanzania 2002 44 27.3 27.3 66 38.7 - 9.1 - 32 - - - 
Mselle Tanzania 1999 212 15.1 32.5 59 23.1 - - - - - 40 - 
Hagan48 Ghana 1995 207 30.9 16.4 69 39.2 - - - - - - - 
Asia
Khor41 Asia-pacific 2018 6563 32. 38.0 60.8 34.7 - - 10.7 4.2 6.8 - - 
Chidambaram43 India 2018 252 77 7 64 72 11 19 - - - - 7 
Lap-Ki62 Hong Kong 2015 347 10 90 43.4 7.8 - - 31.9 23.6 - - 7 
Nath45 India 2011 310 60.6 31.6 69.3 71.3 - - - 2.5 0.6 -- 3.2 
Xie55 China 2006 654 61.9 - 60.6 25.7 - - - - - - - 
Basak55 India 2005 1198 62.7 22.7 70.6 82.9 19.3 - 0.3 10.1 0.6 - 7.6 
Gopinathan India 2002 1352 100 - 71.1 54.4 
Europe and USA
Ong96 UK 2016 112 100 - 41.4 11.6 32.1 - 57.1 22.3 22.3 - - 
Keay USA 2011 733 100 - 25 37 29 - - - 
Jeng23 USA 2010 302 - - 42.7 11 - - 55 17.9 2.3 - 
Saeed60 N.Ireland 2009 90 3 84.8 52.2 14.4 - - 37.4 21.1 1.1 - - 
TEM=Traditional Eye Medicine CL=Contact Lens OSD=Ocular Surface Disease POS=Prior Ocular surgery HIV=Human Immune Virus DM=Diabetes Mellitus 
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Causative organisms 
In SSA, the most common bacterial agents responsible for keratitis include Staphylococcus aureus, 
Streptococcus pneumoniae and Pseudomonas aeruginosa while the most frequent fungal causes 
are Fusarium spp and Aspergillus spp (Table 2-3). 31,44-48 Figure 4 shows the morphology of these 
organisms. In this section, we describe in brief the structure and virulence of these most common 
organisms.
Staphylococcus aureus
This gram-positive round shaped facultative anaerobe is part of the normal flora of the body and 
resides most frequently in the upper respiratory tract and on the skin.97 It is a major pathogen of the 
eye able to infect the tear duct, eyelid, conjunctiva, cornea, anterior and posterior chambers, and the 
vitreous chamber and has potential to cause a loss in visual acuity or even blindness.97 Although the 
ocular structures are inherently protected by a constitutive expression of antimicrobial factors and a 
protective host response to the organism, certain predisposing factors weaken this protection such 
as use of extended-wear contact lenses, the trauma caused by cataract surgery or intravitreal 
injection.97
Staphylococcus aureus produces numerous virulence factors which protect the organism from host 
defense and these include proteins among which are alpha-toxins, beta-toxins, gamma-toxins, 
leukocidins and protein A that mediate tissue damage and induce inflammatory response.98 Strains 
associated with keratitis are different with each strain containing genetic loci that encode virulence 
factors. One such locus encodes Panton-Valentine leukocidin (PVL), a pore-forming toxin 
comprising of protein subunits which bind to neutrophils, monocytes, and macrophages, but not to 
lymphocytes resulting in in leukocyte cell death and the release of inflammatory cytokines.99 Since 
there are several Staphylococcus aureus strains, Aminoglycosides, cephalosporins and synthetic 
Penicillins are used for treatment due to a broad spectrum of activity and they account for methicillin 
resistant and sensitive strains.100
Streptococcus pneumoniae
This gram-positive alpha haemolytic facultative anaerobe causes several illnesses such as 
Pneumonia, Meningitis, Bacteremia, Otitis media, Sinusitis and Keratitis.101 Surgery and trauma are 
predisposing factors of Streptococcus pneumoniae infection in Microbial Keratitis.101
Streptococcus pneumoniae has several virulence factors including a polysaccharide capsule which 
reduces IgG and C reactive protein binding in turn aiding in the evasion of host complement system; 
pneumolysin which is a family of cytolysins and includes perfringolysin, streptolysin and listeriolysin 
that have a damaging effect; neuraminidases which enable this pathogen to cause disease; and, 
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three zinc metalloproteinases, IgA1 protease, ZmpB, and ZmpC for bacterial adherence to epithelial 
cells102
Figure 3: Morphology of the different causative organisms of MK 
Corneal scrape stain showing Gram positive cocci. 
Photo courtesy of Dr Astrid Leck 
Corneal scrape stain showing Pneumococci. Photo 
courtesy of Dr Astrid Leck 
Corneal scrape stain showing Gram negative bacilli. 
Photo courtesy of Dr Astrid Leck 
Fungal Hyphae visible after gram stain of a corneal 
scrape. Photo courtesy of Dr Astrid Leck 
Aspergillus spp stained on Lacto Phenol Cotton Blue 
stain. Photo courtesy of Dr Astrid Leck 
Conidiophores and Conidia of Fusarium spp. Photo 
courtesy of Dr Astrid Leck 
Streptococcus pneumoniae elicits a wide array of antimicrobial peptide expression in corneal 
epithelial cells. The corneal epithelium mediates innate immune responses by secreting cytokines, 
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chemokines, and antimicrobial peptides.103 Treatment Streptococcus pneumoniae infection is with 
Aminoglycosides, cephalosporins and synthetic Penicillins.100
Pseudomonas aeruginosa 
This is an encapsulated, gram-negative, rod-shaped bacterium that is commonly found in 
environment.104 Pseudomonas aeruginosa keratitis is most commonly associated with contact lens 
use and can also occur following ocular trauma.104
Keratitis caused by Pseudomonas aeruginosa is associated with worse visual outcomes than that 
caused by other bacterial pathogens.105 This is attributed to its virulence factors which are involved 
in acute infection: ﬂagella, adhesins, toxin secretion, proteases, pili, lipopolysaccharides, proteases, 
Exotoxin A.105 Type III secretion system (T3SS) is another virulence factor that transports toxins to 
host cell and involves four effector proteins namely ExoU, ExoS, ExoT, and ExoY.106 These effector 
proteins determine type of T3SS exotoxin secreted, which categorizes Pseudomonas aeruginosa
strains as either invasive or cytotoxic genotypes.105,106 Invasive strains possess exoS gene and these 
are capable of invasion of corneal epithelium, cytotoxic strains with the exoU gene cause rapid 
necrotic death of host cells within 1 to 2 hours.106 Cytotoxic strains are associated with contact lens 
wear while invasive strains are related to poor prognosis and increased resistance to 
fluoroquinolones.107 These virulence factors interfere the innate response by influencing the cytokine 
profile and reducing neutrophil recruitment or activity hence promoting bacterial survival in the 
cornea.108
Treatment of Pseudomonas keratitis is either monotherapy with fluoroquinolones or fortified 
Aminoglycosides, cephalosporins and synthetic Penicillins.100
Aspergillus spp 
The most commonly isolated species in Aspergillus Keratitis includes Aspergillus fumigatus and
Aspergillus flavus.109,110 It is common among healthy young males engaged in agricultural or other 
outdoor work.109 These filamentary fungi do not penetrate the intact epithelium; infection occurs 
following traumatic inoculation of Aspergillus conidia into the cornea either through injury or corneal 
surgical procedures.45,111
Aspergillus conidia live ubiquitously in the air but do not cause inflammation and disease on 
inhalation except in immune suppressed individuals.112 The pathogenesis of Aspergillus keratitis 
arises out of an interplay of various factors which enhance the virulence of the organism. In many 
models, the most studied species is Aspergillus flavus. 
Firstly, Conidia are coated by a hydrophobic rodlet layer composed of regularly arranged RodA 
hydrophobins (RodA), which are covalently bound to cell wall polysaccharides by GPI anchor 
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proteins which helps them to evade the immune surveillance system.113 In the absence of RodA, 
beta 1,3-glucan and alpha-mannan are exposed on the cell wall of Aspergillus which activates the 
C-type lectins Dectin-1 and Dectin-2 to mediate the host response.114 Ability to evade early 
recognition by Dectin-1 and Dectin-2, enables conidia to germinate and form hyphae prior to immune 
recognition, which thereby enhances fungal survival during infection.114
Secondly, Aspergillus fumigatus conidia attenuates host proinflammatory responses through 
modulation of Toll-like receptor (TLR)2 and TLR4 signalling.115 In a model to study modulation effects 
of Aspergillus cell wall polysaccharide constituents responsible for the modulation of host capability 
to mount a proinflammatory response, Beta-glucan specifically suppressed TLR4-induced response, 
while alpha-glucan inhibited IL-6 induced through TLR2- and TLR4-stimulation. Galactomannan 
diminished TLR4-mediated response, while its inhibitory effects on TLR2-signalling were limited. 
Chitin, on the other hand, did not have significant immunomodulatory capability.115
Thirdly, Aspergillus fumigatus can form a biofilm both in the natural and artificial environments.116
Biofilms are a highly structured consortia of microorganisms that adhere to a substrate and are 
encased within an extracellular matrix (ECM) that is produced by the organisms themselves.116
Biofilm formation around the fungal hyphal colony in the cornea can reduce the ability of the host 
inflammatory cells to physically reach the fungi.116
Fourthly, Aspergils flavus has been shown to produce aflatoxin B1 which occurs more in keratitis 
causing strains of Aspergillus than environmental strains.117 In addition, keratitis causing Aspergillus 
spp strains produce proteases (ALP1) which have a role in corneal tissue destruction and can impair 
immune response.118
Fusarium spp.
Fusarium species are common plant pathogens, particularly of cereal crops or saprophytes of plant 
debris and are found in soil.31 The most implicated keratitis causing species in this genus are 
Fusarium solani and Fusarium oxysporum.56 Risk factors for keratitis are usually trauma often 
involving plant material where the conidia are inoculated into the breeched cornea.119
The virulence of Fusarium spp is dependent on several factors. The PacC gene in Fusarium 
oxysporum was demonstrated in a model to facilitate quick invasion and penetration of through 
corneal anterior stroma.120 This gene has a role in allowing the fungus to adhere to and grow 
successfully within corneal tissue.120 In addition, Fusarium spp have been shown to express 
extracellular proteases that are capable of degrading collagens in the host corneal tissue, thus 
enabling invasion into deeper stroma.118 Like in Aspergillus spp, Fusarium spp form biofilms around 
the fungal mass in the cornea, especially in Fusarium solani keratitis which protects the fungi from 
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the host immune response and antifungal treatments.121 Finally, Fusarium sp. are also able to 
generate myotoxins that could theoretically damage host cells.122
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Making the diagnosis 
Figure 4: Some of the clinical features of MK 
(A) Active microbial keratitis with signs of acute inflammation and 
corneal ulceration. 
(B) Corneal Scar, the sequel of a resolved episode of microbial 
keratitis, no current signs of acute inflammation
(C) Early filamentary fungal keratitis; admitted and started 
immediately on intensive topical natamycin treatment. 
(D) The same case as (C) one week later, unresponsive to intense 
anti-fungal treatment, with progression of the infection
(E) Bacterial Keratitis, rapid severe damage (F) Unknown cause, perforation with iris plugging 
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History 
The history might contain certain clues that point to the most likely agent. In most of the forms of MK 
ocular symptoms include a degree of pain, redness, discharge, blurred vision and photophobia.44 In 
some forms like Acanthamoeba, the pain is usually more marked than the clinical picture.123
The duration of symptoms are usually shorter in bacteria compared to other forms of MK. A study 
from India reviewed 345 patients with laboratory proven diagnoses (115 bacterial, 115 fungal, 115 
Acanthomoeba).124 In this report, differentiating features were more common for acanthamoeba 
keratitis than for bacterial or fungal keratitis. Compared to patients with bacterial or fungal keratitis, 
patients with acanthamoeba keratitis were more likely to be younger and to have a longer duration 
of symptoms.124
A history certain risk factors may be associated with as infection such as trauma, use of traditional 
eye medicine, immune suppression, swimming, contact lens wearing as Herpes Simplex Virus (HSV) 
keratitis, Varicella Zoster Virus (VZV) keratitis, previous bacterial keratitis, trauma, dry eye, and 
previous ocular surgery. These are discussed in the subsequent sections of this book. 
A recent prospective study of 252 participants with MK from India reported data on factors on patient 
history associated with bacterial, fungal and Acanthomoeba keratitis at presentation.43 A history of 
trauma was present in all forms of MK, although trauma with vegetative matter was more common 
in the bacterial keratitis (77%) group and least common in Acanthomoeba keratitis group (23%), 
p=0.033. In the same study, prior steroid use was more common in the Acanthomoeba group. There 
were 17 patients with DM of which 15 had fungal keratitis.43
Clinical diagnosis
The clinical features are usually dependant on the infectious agent and the presentation period.125
However, there have not been many well designed studies to objectively analyse the correlation 
between clinical features to microbiological diagnosis. One large prospective study in India looked 
at whether the presence of characteristic clinical features can be used as a diagnostic aid for 
suppurative keratitis caused by filamentous fungi.125 In this study, 360 patients presenting with 
suppurative keratitis in India underwent detailed clinical examination followed by microbiological 
investigation of corneal scrapes. A partial diagnostic score based upon the strength of the 
association, as estimated by the odds ratio, between reported clinical features and laboratory 
confirmed diagnoses was devised and subsequently tested using a case series from Ghana.31
Tables 5 shows the main findings from this study that were associated with a confirmed laboratory 
diagnosis. On univariable logistic regression analysis, serrated margins, raised slough, dry texture, 
satellite lesions and coloration other than yellow occurred more frequently in cases of filamentous 
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fungal keratitis than bacterial keratitis (p<0.05). Hypopyon and fibrinous exudate were observed 
more frequently in bacterial keratitis (p<0.05).125 When incorporated into a backwards stepwise 
logistic regression model, only serrated margins, raised slough, and colour were independently 
associated with fungal keratitis; these features were used in the scoring system. The probability of 
fungal infection if one clinical feature was present was 63%, increasing to 83% if all three features 
were present.125 Another study by the Proctor and Aravind group randomised 80 corneal 
photographs of eyes with culture-proven bacterial keratitis (40 photographs) or smear-proven fungal 
keratitis (40 photographs) were randomly selected from 2 clinical trials (Steroids for Corneal Ulcer 
Treatment trial (SCUT) trial and Mycotic Ulcer Treatment Trial (MUTT)).126 Fifteen cornea specialists 
from the Proctor Foundation and the Aravind Eye Care System assessed the photographs for 
prespecified clinical signs of keratitis, and they identified the most likely causative organism. The 
study found that using pre specified clinical signs of keratitis, clinicians were able to correctly 
distinguish bacterial from fungal aetiology 66% of the time (p < 0.001). The presence of an 
irregular/feathery border was associated with fungal keratitis, whereas a wreath infiltrate or an 
epithelial plaque was associated with bacterial keratitis.126
In a more recent prospective observational study of 252 adults presenting with severe microbial 
keratitis (MK), ulcer clinical features were recorded at presentation and compared to aetiologic agent 
in a regression model.43 Fungal keratitis cases were 191 (75.7%), 18 had Acanthamoeba keratitis 
(7.1%), 19 had Bacterial keratitis (7.5%), 4 (1.6%) had mixed bacterial and fungal while 20 were 
microbiologically negative.43 Logistic regression analysis of fungal ulcers versus all others showed 
that feathery margins were strongly associated with fungal ulcers, ring infiltrate associated with 
Acanthamoeba while Bacterial ulcers were more likely to have a hypopyon.43
Using clinical data correlated with microbiological diagnosis, a diagnostic algorithm was suggested 
by colleagues to aid in making a clinical diagnosis (Figure 6).30 An example in this algorithm is that 
the probability of an ulcer being fungal keratitis is 89% if the ulcer margin is serrated, the surface 
profile raised and no fibrin. Conversely, if the ulcer margin is well defined, the surface profile flat and 
fibrin present, the probability of fungal keratitis in such an ulcer is only 16%. 
44
Simon Arunga PhD Thesis 2019 
Figure 5: Algorithm for clinical differentiating between fungal and bacterial keratitis in a 
tropical environment.30
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Microbiology 
A major challenge in the management of MK is the identification of the causative organism. In many 
resource-limited settings, little is known about the possible infectious causes of MK. This is because 
routine microbiology investigations are not readily available outside the larger centres. It is very 
important to understand the "local" aetiology of MK to develop a rational, empirical protocol if there 
is limited access to microscopy and culture in a given region.31
Current techniques used to isolate the pathogen are direct staining of corneal smears or inoculation 
of media for microbiological culture. Gram stain, 10% potassium hydroxide (KOH), Calcofluor white 
and Giemsa stains are all used to visualise corneal pathogens as part of standard practice in many 
centres throughout the world. The techniques on how to take a corneal scrapping have been 
previously reported (Figure 7).127 The recommendations from this guide mention that in a resource 
limited setting, the minimum resources needed to do a corneal scrape include 21-gauge needles or 
Kimura scalpel, 2 clean microscope slides, 1 blood agar plate, 1 Sabouraud/Potato Dextrose Agar 
plate, 1 brain heart infusion broth.127
KOH staining can identify fungus in corneal ulcers with a sensitivity of 90-94% of those which are 
culture positive and has been considered in some studies to be a confirmed fungal diagnosis even 
in the absence of a positive culture result.31,128,129 Overall, usually about half of the corneal scrapping 
samples will show a positive yield on microscopy (Tables 2 and 3).12,31
Although microbiological culture remains the gold standard in diagnosis of the causative organism 
in microbial keratitis, it is positive in only 50-65% of cases.31,130,131 There are many reasons for this 
low culture positivity rate, which include only partially viable organisms in the corneal scrape due to 
previous antimicrobial therapy, and the small sample size of corneal scrape specimens.132 Yield can 
be improved by withdrawing the use of antimicrobial agents for 24 hours prior to sampling (if 
possible), using liquid phase media which serves as a diluent that reduces the concentration of the 
drug below the minimum inhibitory concentration (MIC), using preservative free anaesthetic drops 
and deep tissue scrapping when fungal or amoebic infection is suspected.127 In addition, after 
collecting the sample, it should be gently smeared on the surface of agar in C-streaks (taking care 
not to puncture the surface of the agar), the lid of the plate should be sellotaped and incubation 
should be immediately after.127 The agar plates should have been taken out of the fridge and allowed 
to warm to room temperature not to shock the inoculated microorganisms.127
46
Simon Arunga PhD Thesis 2019 
Figure 6: Corneal scraping and media inoculation 
Corneal scrapping on a slit lamp while the 
assistant retracts the eyelid 
Zoomed in image of taking a corneal scrape 
(Image courtesy of Prof John Dart) 
C streaking on the surface of the slide 
(Image courtesy of Dr Astrid Leck) 
Bacterial growth in a C streak pattern 
(Image courtesy of Dr Astrid Leck) 
Polymerase chain reaction (PCR) is useful in such settings as it can detect the presence of nucleic 
acid from small samples and even non-viable organisms. It involves cyclical amplification of small 
amounts of nucleic acid and synthesis of new complementary strands until adequate amounts of 
nucleic acid material (billion copies) have reached detectable levels.133 This usually takes about 30 
cycles in most standard PCR machines.133 One challenge with this method is that it is difficult to rule 
out contamination especially where organisms such as fungi are ubiquitously living in the 
environment. In such a scenario, quantitative PCR (real time PCR) allows for estimation of the 
amount of DNA in the initial sample.134 In this technique, the amount of product formed is monitored 
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during the course of the reaction by monitoring the fluorescence of dyes or probes introduced into 
the reaction that is proportional to the amount of product formed, and the number of amplification 
cycles required to obtain a particular amount of DNA molecules is registered. Assuming a certain 
amplification efficiency, which typically is close to a doubling of the number of molecules per 
amplification cycle, it is possible to calculate the number of DNA molecules of the amplified sequence 
that were initially present in the sample.134
Previous studies employing this technique for microbial keratitis have found PCR to be effective in 
detecting organisms and often display higher overall pick up rates than culture or microscopy.135 In 
this study, patients with eye findings suspected of fungal keratitis were enrolled for cornea sampling. 
Scrapings from the affected areas of the infected corneas were divided into two parts one for 
microbiology and the other for PCR.135 Potassium hydroxide, Gram staining, culture and nested PCR 
results (either positive or negative) matched in 76.3, 42.1, 68.4 and 81.6%, respectively.135 In another 
large prospective study from India, 108 consecutive corneal ulcers were cultured and analyzed by 
PCR using pan-bacterial and pan-fungal primers and compared to culture results.130 Of the 108 
samples, 56 were culture-positive, 25 for bacteria and 31 for fungi; 52 were culture-negative. After 
eliminating false-positive PCR products, 94 of 108 were positive by PCR, 37 for bacteria and 57 for 
fungi. Nineteen of 25 bacterial culture-positive samples were positive by PCR, and 29 of 31 samples 
culture-positive for fungi were positive by PCR equivalent to a sensitivity of 76% and 93.5%, 
respectively.130
There is an even newer technique called Matrix-Assisted Laser Desorption/Ionization Time Of Flight 
(MALDI-TOF) mass spectrometry.136 According to the patent description, this method involves, 
providing a liquid biological sample containing any proteins and/or lipids and/or salts and/or 
polysaccharides and/or oligosaccharides and/or monosaccharides capable of forming complexes 
with said proteins and/or lipids and/or salts from an infected mammal. The sample is then treated 
with a biological liquid to extract said polysaccharides and/or oligosaccharides and/or 
monosaccharides. After extraction, the presence of these markers is then determined by MALDI-
TOF mass spectrometry which confirms presence of a fungal infection.136 This method is thought to 
be easier and cheaper to run than PCR.137
Although the use of this technique has not been widely reported in clinical studies, one report that 
compared MALDI-TOF with conventional morphology and PCR on 24 consecutive clinical isolates 
of Aspergillus collected during 2012-2014 in Turkey.138 In this study, there was good agreement 
between the conventional morphology and PCR and MALDI-TOF methods.138 Two other reports 
described use of MALDI-TOF to detect uncommon bacterial strains for microbial keratitis.137,139 One 
was a case report of a 94-year woman with suppurative keratitis due to Corynebacterium propinquum
and another was a case series of ocular infections caused by Moraxella spp in Japan.  
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In Vivo Confocal Microscopy (IVCM) 
Figure 7: Images of IVCM 
Corneal picture of a patient with filamentary keratitis, 
satellite lesions and a ring infiltrate. (photo Courtesy of Prof 
Matthew Burton) 
IVCM scan of the same cornea showing 
extensive, branching fungal hyphae. Scale 
bar 100µm. (photo Courtesy of Prof Matthew 
Burton) 
In vivo confocal microscopy (IVCM) is a non-invasive imaging technique that allows direct 
visualization of pathogens within the patient’s cornea.140 The 2 imaging modalities in current clinical 
use are the scanning slit IVCM (ConfoScan, Nidek Technologies, Fremont, CA) and the laser 
scanning IVCM (HRT3 with Rostock Corneal Module [RCM], Heidelberg Engineering, Heidelberg, 
Germany). The ConfoScan has a resolution of 1 micron laterally and up to 24 microns axially; the 
HRT3/RCM also has a lateral resolution of 1 micron but higher axial resolution of 7.6 microns.141
One recent large double masked prospective study from India tested the diagnostic accuracy of 
IVCM for moderate to severe microbial keratitis (MK).141 In this study, The study enrolled 239 patients 
presenting to Aravind Eye Hospital, Madurai, India were consecutively enrolled. Following 
examination, the corneal ulcer was scanned by IVCM (HRT3/RCM, Heidelberg Engineering, 
Heidelberg, Germany). Images were graded for the presence or absence of fungal hyphae or 
Acanthamoeba cysts by the confocal microscopist who performed the scan (masked to microbial 
diagnosis) and 4 other experienced confocal graders (masked to clinical features and 
microbiology).141 The regrading of the shuffled image set was performed by 3 graders, 3 weeks later. 
Corneal-scrape samples were collected for microscopy and culture. The main outcome measures 
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were sensitivity, specificity, and positive and negative predictive values of IVCM compared with 
those of a reference standard of positive culture or light microscopy. Fungal infection was detected 
in 176/239 (74%) and Acanthamoeba in 17/239 (7%) by microbiological methods. IVCM had an 
overall pooled (5 graders) sensitivity of 85.7% (95% confidence interval [CI]: 82.2%-88.6%) and 
pooled specificity of 81.4% (95% CI: 76.0%-85.9%) for fungal filament detection. For Acanthamoeba, 
the pooled sensitivity was 88.2% (95% CI: 76.2%-94.6%) and pooled specificity was 98.2% (95% 
CI: 94.9%-99.3%).141 The authors of this study concluded that Laser scanning IVCM performed with 
experienced confocal graders has high sensitivity, specificity, and test reproducibility for detecting 
fungal filaments and Acanthamoeba cysts in moderate to large corneal ulcers in India. This imaging 
modality was particularly useful for detecting organisms in deep ulcers in which culture and light 
microscopy results were negative.141
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Differential Diagnosis 
Figure 8: Differential diagnosis of microbial keratitis 
A case of Mooren’s Ulcer with rapidly encircling 
limbal thinning. (photo Courtesy of Prof Matthew 
Burton) 
The same case of Mooren’s after resolving of the 
inflammation with total corneal opacification. (photo 
Courtesy of Prof Matthew Burton) 
Rheumatoid Arthritis (photo Courtesy of Prof John 
Dart) 
Wegner’s Granulomatosis (photo Courtesy of Prof 
John Dart) 
A patient with PUK and a sealed perforation. (photo 
Courtesy of Prof Matthew Burton) 
The hands of the same patients showing peripheral 
joint distortions for Rheumatoid Arthritis. (photo 
Courtesy of Prof Matthew Burton) 
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The differential diagnosis for microbial keratitis includes Peripheral Ulcerative Keratitis (PUK), 
Mooren’s and non-infectious degenerative lesions (Figure 9). 
PUK is a corneal inflammatory disease syndrome that has multiple associations. It usually presents 
as juxta-limbal peripheral thinning/ulcer, there can be stromal infiltration and an epithelial defect ± 
perforations. In SSA, the most common differential diagnosis is Mooren’s ulcer. 
Mooren’s ulcer is described as a chronic and painful ulceration of the cornea that often starts in the 
periphery and may gradually progress centrally or circumferentially to eventually involve the entire 
cornea.142 In one audit from Nigeria, the demographic and clinical characteristics of patients with 
Mooren’s ulcer seen over a 10 year period were described.143 Thirty-one eyes of 23 patients were 
enrolled. The mean age of participants was 31±16.6 years, males were 18/23 (78%). Eight (34.8%) 
patients had bilateral lesions. Most common presenting symptoms were redness and pain, with an 
average of 6.8 clock hour-limbal involvement. In this group, the presenting visual acuity was >6/18 
in 29%, 6/18 to 3/60 in 58% and <3/60 in 13%.143 Treatment options included topical and systemic 
steroids, systemic methotrexate or cyclophosphamide (8 patients who did not respond to steroids) 
and surgical treatment with conjunctival resection and cryotherapy in 14 (60.9%) patients (21 
eyes).143 Patients presenting with perforation also had scleral patch graft or direct repair. The ulcer 
healed with varying degrees of corneal opacity in 18 (85.7%) of the 21 eyes, while the remaining 
three eyes developed descemetocele, anterior staphyloma or corneal perforation.143
Our group recently described a series of Mooren’s ulcer cases from Uganda.144 In this 3 year audit, 
52 patients (80% male) presented with Mooren’s ulcer to our hospital, majority (90.4%) had unilateral 
disease. The median age was 24.5 IQR 16.5 years. At the last follow-up, 40.4% of the patients had 
a worse visual acuity, 20 patients (38.5%) had no change in visual acuity while 21.2% had an 
improvement in vision.144
In comparison to India, there have been two large case series from North and South India.145 One 
large prospective study from North India, 76 eyes of 65 consecutive patients with PUK were 
evaluated over an 18 month period and followed for 3 years.145 The mean age of the study 
participants was 45.5±17.9 years and 66% were male. Unilateral disease was present in 83% of 
patients (54/65). The most common aetiology was Mooren's ulcer (31.5% cases (24/76 eyes)) 
followed by infection (20%) and systemic collagen vascular disease (20%). 
The other study from South India described the clinical characteristics at presentation of 166 patients 
(242 eyes) that presented to the cornea clinic at Aravind Eye Hospital Madurai, Tamil Nadu, India, 
over a 10-year period.146 The median and mean ages at presentation were 65 and 61 years, 
respectively, with a range of 13–95 years. The proportion of males was 82% while bilateral ulcers 
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were present in 46% of the cases.146 One eye was affected in 90 of 166 (54%) patients. Visual acuity 
in the affected eye at presentation was 6/12 or better in 34 of 242 (14%) eyes, between 6/12 and 
3/60 in 168 (69%) eyes, and worse than 3/60 in 40 (17%) eyes.146 Identified risk factors in the cohort 
included evidence of prior corneal surgery (22%), corneal trauma (17%) and corneal infection 
(2%).146
In comparison with the far east, one large study from China reported on clinical characteristics and 
treatment of 550 consecutive cases of Mooren's ulcer (715 eyes) over a period of 36 years. 147 The 
average age of onset was 48.4 years of age. The proportion of males was 56% and 165 (30%) cases 
had bilateral disease.147
PUK can be associated with several causes such as presenting sign of a systemic disease Collagen 
Vascular Disease. Studies from the UK reported on PUK with other differential diagnoses. One 3 
year prospective study reported on 21 cases enrolled from 1995-1997.148 The proportion of males in 
this study was 50%, mean age was 65-years and the most common systemic associations were 
Rheumatoid Arthritis (71%), Wegner’s Granulomatosis (24%) and Microscopic polyarteritis (2%).148
Another 10-year audit reviewed case notes of all the patients attending a specialist corneal 
immunosuppression clinic between June 2002 and July 2012. Of the 70 cases, 57% were female 
and the mean age was 65-years.149 The most common associations were Rheumatoid Arthritis 
(66%), Wegner’s Granulomatosis (3%) and Psoriasis (6%).149
In Rheumatoid Arthritis, PUK is a rare but very serious inflammatory condition: a warning sign of 
impending vasculitis which can led to mortality.150 Treatment is with Immune suppressive therapy.150
Wegner’s granulomatosis, the ocular manifestations range from mild conjunctivitis and episcleritis to 
more severe inflammation with keratitis, scleritis, uveitis, and retinal vasculitis.151 Ocular involvement 
will not respond to topical agents, but rather to systemic anti-inflammatory and immunosuppressive 
regimens.151 Other differentials include ocular rosacea.152 This is part of the general syndrome that 
includes facial and ocular manifestations. There is facial flushing, the appearance of telangiectatic 
vessels and persistent redness of the face, eruption of inflammatory papules and pustules on the 
central face, and hypertrophy of the sebaceous glands of the nose. Ocular changes are present in 
more than 50 percent of patients and range from mild dryness and irritation with blepharitis and 
conjunctivitis (common symptoms) to sight-threatening keratitis (rare).153 Treatment is with artificial 
tears, eyelid hygiene, fucidic acid, and metronidazole gel applied to lid margins if there is associated 
blepharitis.153 Keratitis can also be as a result of hypersensitivity to bacterial antigen most common 
being Staphylococcus aureus in cases of chronic blepharitis.154 Treatment is with steroids and lid 
hygiene.154
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Corneal degenerations with thinning can occur in other benign conditions such as Dellen, Terriens 
marginal degeneration and pellucid marginal degeneration.  
Dellen are small, saucer-like excavations at the margin of the cornea.155 They occur most often 
following processes which produce a paralimbal elevation such as a conjunctival growth and a post 
trabeculectomy bleb.156 This elevation induces a localized break in the precorneal oily film layer of 
the tears which, in turn, causes a localized dehydration and thinning of the cornea. Treatment is 
directed towards rehydration of the cornea and reduction of the limbal elevation.155
Terrien's disease occurs in middle-aged patients and is characterised by an insidious thinning of the 
cornea near the limbus.157 In most cases, this results in a peripheral ectasia associated with a severe 
degree of astigmatism.157 Although thought to be non-inflammatory in nature, there have been 
reports to show that patients can get recurrent, disabling, episodic inflammation with severe pain 
and an associated episcleritis or superficial.158 Management is symptomatic during episodes of 
inflammation and penetrating keratoplasty for the corneal ectasia.157
Pellucid Marginal Corneal Degeneration (PMCD) of the cornea is a bilateral, clear, inferior, peripheral 
corneal-thinning disorder.159 Protrusion of the cornea occurs above a band of thinning, which is 
located 1 to 2 mm from the limbus and measures 1 to 2 mm in width.159 In one large series from 
India, clinical presentation of 116 eyes of 58 patients with PMCD seen between 1990 and 2002 was 
described.160 The diagnosis of PMCD was based on the presence of corneal thinning with ectasia of 
the normal cornea above or below the area of thinning with no evidence of scarring, vascularization, 
or lipid deposition and typical topographic features whenever topography was performed.160 In this 
study, all cases were bilateral, 77.6% were male and the mean ager was 34.0±14.8 years.160 In these 
series, PMCD was not strongly associated with Vernal Kerato Conjunctivitis (VKC).160 However, the 
most common associations were Keratoconus (10% of the eyes) and Keratoglobus (13%). The most 
common site was inferior PMCD (85%). Severe astigmatism was present in 42.6% of the eyes and 
6% had hydrops. Most patients were treated with spectacles or contact lens.160 Surgery for PMCD 
lamellar keratoplasty and crescentic lamellar keratoplasty, if indicated usually results in significant 
residual astigmatism. 
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Table 5: Uni and multivariate analysis of clinical features occurring in fungal and bacterial Keratitis 
Clinical feature n (% fungal) n (% bacterial) OR (CI) p value aOR (CI) P value 
Serrated margins 180/228 79% 63/132 48% 4.09 (2.57-6.56) <0.0001 3.45 (2.12-5.68) <0.0001 
Raised slough 135/228 59% 52/132 39% 2.23 (1.44-3.55) <0.0001 2.32 (1.43-3.74) <0.0001 
Dry texture of slough 101/228 44% 37/132 28% 2.04 (1.29-3.26) <0.0001 
Satellite lesions 51/222 23% 17/132 13% 1.95 (1.08-3.61) 0.04 
Hypopyon 105/219 48% 83/128 65% 0.5 (0.32-0.78) <0.0001 
Fibrin 21/210 10% 28/125 22% 0.38 (0.20-0.70) <0.0001 0.39 (0.20-0.77) 0.01 
Colour (not yellow) 213/228 93% 106/132 80% 3.47 (1.77-6.98) <0.0001 2.85 (1.34-6.06) 0.01 
OR=univariable Odds Ratio, aOR=adjusted Odds Ration Sens=sensitivity, Spec=specificity, PPV=positive predictive value. Table reproduced with 
permission from a previous report by Leck et al.30
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Management of Microbial Keratitis 
Bacterial Keratitis 
A recent review of treatment options for bacterial keratitis concluded that topical antibiotics 
remain the best treatment for bacterial keratitis.161 In that review, all commonly prescribed 
topical antibiotics were found to be equally effective. A 2014 Cochrane review also found no 
comparative differences between fluoroquinolones, aminoglycosides and cephalosporines.162
In this review, a total of 16 high quality RCTs were included in the analysis; the main trial 
results are summarized in Table 6. In this report, a metanalysis of topical fluoroquinolone 
compared with topical fortified aminoglycoside–cephalosporin with a pooled total of 672 
individuals found no difference in chance of treatment success. However, the concentrations 
of some of the agents was variable. The evidence from these trials shows that 
fluoroquinolones can be given as monotherapy while aminoglycosides and cephalosporins 
should be as combination therapy. 
Although there seems to be no difference in efficacy of the antibiotics, the treatment of 
bacterial keratitis should take into consideration the local sensitivity patterns. Some of the 
background work conducted by our group on the local sensitivity patterns on bacterial keratitis 
isolates found that there was good sensitivity to ciprofloxacin and ofloxacin, modest sensitivity 
to gentamycin but resistance to chloramphenicol and tetracycline (Table 7). In a study of 
antimicrobial susceptibility patterns of external ocular surface bacterial isolates among 131 
per-operative routine cataract patients at Mulago National Hospital in Kampala, Uganda, 
eyelid margin and conjunctival swabs were collected and processed to identify bacterial 
isolates and their respective antimicrobial susceptibility patterns.163 The most common 
organisms identified were Coagulase-negative Staphylococci (CoNS) (65.9%) and 
Staphylococcus aureus (21.0%). CoNS showed the highest resistance to tetracycline (58.2%) 
and erythromycin (38.5%) whereas in S. aureus the resistance to tetracycline and 
erythromycin were 55.2% and 31.0% respectively. Methicillin resistant CoNS (MRS) and 
Methicillin resistance S. aureus (MRSA) were 31.9% and 27.6% (8/29) respectively. There 
were low resistance rates for CoNS, S. aureus and other bacterial isolates to ciprofloxacin 
(11.1%-24.2%), gentamicin (5.6-31.0%), tobramycin (17.2% -25.3%) and vancomycin 
0.0%).163
Recently, a review of antimicrobial resistance in East Africa was published.164 Following an 
extensive literature search across PubMed database and African Journals Online archives for 
published reports on antimicrobial resistance, a total of 12 studies were included in this 
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analysis. A summary of the sensitivity data published in this report is presented in Tables 8 
and 9. In this review, high levels of resistance to commonly used antibiotics were reported, 
including resistance to ampicillin and cotrimoxazole (50% – 100%), emerging resistance to 
gentamicin (20% – 47%) and relatively high levels of resistance to ceftriaxone (46% – 69%) 
among Gram-negative infections. Much of the resistance was reported to be in Klebsiella
species and Escherichia coli. Among Gram-positive infections, extensive resistance was 
reported to ampicillin (100%), gentamicin and ceftriaxone (50% – 100%), with methicillin-
resistant Staphylococcus aureus prevalence ranging from 2.6% – 4.0%. However, although it 
gives an indication of regional sensitivity patterns, its usefulness and applicability are limited 
for ocular infections. The method of sensitivity testing for the bacteria colonies reported was 
the Kirby-Bauer disc diffusion method.165This method tests a restricted concentration of the 
drug that can be used safely in the blood stream; however, the concentrations that can be 
achieved in the ocular structures with topical antibiotics are usually much higher. This means 
that an antibiotic reported as “resistant” might still be effective in treating ocular infections. 
Despite a good choice of antibiotic cover, outcomes remain poor secondary to corneal melting, 
scarring and perforation. Adjuvant therapies aimed at reducing the immune response 
responsible for much of the morbidity associated with keratitis seem to have a role. The large, 
randomized controlled Steroids for Corneal Ulcers trial randomised 500 patients with culture 
positive bacterial keratitis to topical Moxifloxacin 0.5% and prednisolone sodium phosphate 
solution 1% (250 patients) in one arm and to topical moxifloxacin 0.5% and placebo (250 
patients) in another arm. The primary outcome measure was best corrected visual acuity 
(BCVA) at 3 months. The study found that steroids provided no significant improvement overall 
in BCVA at 3-moths, scar size, time to re-epithelialization. However subgroup analyses by 
baseline BSCVA, ulcer location, and infiltrate depth showed a significant effect of 
corticosteroids.166 In this trial, there was no evidence of potential harmful effects of 
corticosteroids in treating bacterial keratitis. 
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Table 6 Major Randomised Controlled Trials on topical antibiotic therapy against bacterial keratitis 
Author Year Country N Arms Drugs Primary outcomes Finding
Sampaio167 1994 Spain 30 2  Ciprofloxacin 0.3% 
 Gentamycin 1.4% and Cefazolin 5%
Healing of the ulcer No difference across the 2 arms 
Obrien168 1995 248 2  Ofloxacin 0.3% 
 Tobramycin 1.5% and Cafazolin 10%
Time to healing of the 
ulcer 
No difference across the 2 arms 
Hyndiuk169 1996 India 176 2  Ciprofloxacin 0.3% (82) 
 Tobramycin 1.3% and Cefazolin 5% 
(94) 
Healing of the ulcer Overall healing 87% 
No difference across the 2 arms 
Pavesio170 1996 UK 122 2  Ofloxacin 0.3% ( 
 Gentamycin 1.5% and cefuroxime 5%
Healing of the ulcer No difference across the 2 arms 
Panda171 1999 India 30 2  Ofloxacin 0.3% (15) 
 Tobramycin 1.5% and Cafazolin 10% 
(15) 
Healing of the ulcer Overall healing 90% 
No difference across the 2 arms 
Kosrirukvongs172 2000 Thailand 41 2  Ciprofloxacin 0.3% (17) 
 Gentamycin 1.4% and Cafazolin 5% 
(24) 
Healing of the ulcer Overall healing 66% 
No difference across the 2 arms 
Zhang173 2000 China 132 2  Ofloxacin 0.3% 
 Levofloxacin 0.3%
Healing of the ulcer No difference across the 2 arms 
Prajna174 2001 India 217 2  Ofloxacin 0.3% (112) 
 Ciprofloxacin 0.3% (105)
Healing of the ulcer Overall healing 81% 
No difference across the 2 arms 
Erjongmanee175 2004 Thailand 40 2  Lomefloxacin 0.3% (20) 
 Gentamycin 1.5% and cefuroxime 5% 
(20) 
Time to healing of the 
ulcer 
No difference across the 2 arms 
Booranapong176 2004 Thailand 41 2  Lomefloxacin 0.3% (23) 
 Ciprofloxacin 0.3% (18) 
Healing of the ulcer No difference across the 2 arms 
Parmar177 2006 India 104 2  Gatifloxacin 0.3% (50) 
 Ciprofloxacin 0.3% (54) 
Healing of the ulcer Gatifloxacin 39/50 eyes (95.1%) 
vs Ciprofloxacin 38 (80.9%). 
p=0.042 
Constantinou178 2007 Australia 229 3  Moxifloxacin 1.0% (77) 
 Ofloxacin 0.3% (74) 
 Tobramycin 1.33% and Cafazolin 5% 
(78) 
Healing of the ulcer Overall healing 94% 
No difference across the 3 arms 
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Dehghani179 2009 Iran 89 2  Gentamycin and Cafazolin (41) 
 Vancomycin and Ceftazidime (48)
Time to healing Gentamycin group 17.7 ± 4.3 
days Vs Vancomycin group 13.8 
± 2.6 days, p=0.04 
Shah180 2010 India 61 3  Tobramycin 1.3% and Cafazolin 5% 
(20) 
 Gatifloxacin 0.3% (21) 
 Moxifloxacin 0.5% (20)
Healing of the ulcer Overall healing 93% 
No difference across the 3 arms 
Kasetsuwan181 2011 Thailand 71 2  Levofloxacin 0.5% (34) 
 Amikacin 5% and Cefazolin 5% (37)
Healing of the ulcer Overall healing 86% 
No difference across the 3 arms 
Sharma182 2012 India 224 2  Tobramycin 1.3% and Cafazolin 5% 
(114) 
 Moxifloxacin 0.5% (110)
Healing of the ulcer Overall healing 80% 
No difference across the 2 arms 
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Table 7 Showing culture and sensitivity of a pilot study in Mbarara, N=15 
Drug Sensitivity S. aureus  S. pneumonae Other strep P. aeruginosa Coliforms  Total   
N=4 (%) N=3 (%) N=1 (%) N=4 (%) N=3 (%) N=15 (%) 
Chloramphenicol S  1 (25) 1 (33.3) 1 (100) 0 (0) 2 (66.7) 5 (33.3) 
I 3 (75) 0 (0) 0 (0) 1 (25) 0 (0) 4 (26.7) 
R 0 (0) 2 (66.7) 0 (0) 3 (75) 1 (33.3) 6 (40) 
Ciprofloxacin S  2 (50) 1 (33.3) 1 (100) 4 (100) 2 (66.7) 10 (66.7) 
I 1 (25) 2 (66.7) 0 (0) 0 (0) 1 (33.3) 4 (26.7) 
R 1 (25) 0 (0) 0 (0) 0 (0) 0 (0) 1 (6.6) 
Gentamycin S  1 (33.3) 0 (0) 0 (0) 2 (50) 1 (33.3) 4 (26.7) 
I 3 (66.7) 2 (66.7) 1 (100) 1 (25) 1 (33.3) 8 (53.3) 
R 0 (0) 1 (33.3) 0 (0) 1 (25) 1 (33.3) 3 (20) 
Tetracycline S  2 (50) 1 (33.3) 1 (100) 1 (25) 1 (33.3) 6 (40) 
I 2 (50) 1 (33.3) 0 (0) 0 (0) 0 (0) 3 (20) 
R 0 (0) 1 (33.3) 0 (0) 3 (75) 2 (66.7) 6 (40) 
Ofloxacin S  4 (100) 3 (100) 1 (100) 4 (100) 2 (66.7) 14 (93) 
I 0 (0) 0 (0) 0 (0) 0 (0) 1 (33.3) 1 (6.7) 
R 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
S=sensitive, I=Intermediate, R=resistant 
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Table 8: Antibiotic resistance patterns among patients with bloodstream infections; percentage resistant by Kirby Bauer disk diffusion 
method 
Bacteria No of species AMP SXT CHLO PEN CRO GENT Author Country 
Gram-positive 
Staphylococcus aureus 20 35 77 37 - - 12 Kitara183,184 Uganda 
69 88 - 73 - - 4 Mugalu185 Uganda 
17 47 58 23 - - 29 Dagnew186 Ethiopia 
30 100 - - - - - Blomberg187 Tanzania 
Enterococcus faecalis 9† - - 62 83 - 44 Blomberg187 Tanzania 
6‡ - - 67 25 - 33 Blomberg187 Tanzania 
Enterococcus faecium 12† 75 63 - 90 - 23 Blomberg187 Tanzania 
9‡ 89 100 - 100 - 77 Blomberg187 Tanzania 
Streptococcus pneumoniae 11 27 100 27 - - - Bachou184 Uganda 
Streptococcus agalactiae 7 14 - 14 - - 57 Mugalu185 Uganda 
Gram-negative 
Escherichia coli 6 83 100 50 - - - Bachou184 Uganda 
17 - - - - - 29 Mugalu185 Uganda 
5 100 40 20 40 - - Dagnew186 Ethiopia 
24† 96 - - - 22 29 Blomberg187 Tanzania 
13‡ 85 - - - 4 46 Blomberg187 Tanzania 
Klebsiella spp 8 75 50 62 - 62 37 Dagnew186 Ethiopia 
19† 100 - - - 26 47 Blomberg187 Tanzania 
34‡ 100 - - - 15 47 Blomberg187 Tanzania 
Pseudomonas aeruginosa 4 100 75 25 - 25 - Dagnew186 Ethiopia 
7† 100 - - - 80 24 Blomberg187 Tanzania 
6‡ 100 - - - 100 27 Blomberg187 Tanzania 
Salmonella spp 5 80 80 - - - 20 Bachou184 Uganda 
3 - - - - - 33 Mugalu185 Uganda 
Haemophilus spp 2 100 100 50 - - - Bachou184 Uganda 
AMP, Ampicillin; CRO, Cefuroxime; CHLO, Chloramphenicol; GENT, Gentamicin; PEN, Penicillin; SXT, Trimethoprim-sulfamethoxazole. 
†, Hospital-acquired; ‡, Community acquired. Table reproduced with permission from a review paper by Ampaire et al.164
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Table 9 Antibiotic resistance patterns among patients with bloodstream infections; percentage resistant by Kirby Bauer disk diffusion 
method 
N
o.
 o
f 
sp
ec
ie
s
A
M
P
SX
T
TT
C
C
H
LO
ER
Y
G
EN
A
M
X
C
EF
T
C
IP
R
O
D
O
XY
F K
A
N
C
L
A
ut
ho
r
C
ou
nt
ry
Gram-positive 
Coagulase-negative 
Staphylococci
6 50 66 50 16 - 16 33 - 50 - 16 33 - Demilie188 Ethiopia 
9 100 11 55 55 55 44 - 44 44 33 - - - Kitara183 Uganda 
Staphylococcus aureus 3 66 33 66 33 - - - - 33 - 33 - - Demilie188 Ethiopia 
66 25 50 54.7 65.6 92.2 100 - - 98.4 - - - - Kitara183 Uganda 
64 100 89 42 15 46 18 - - - - - - - Seni189 Uganda 
300 - 62 - - 47 - - - - - - - 36 Mwambi190 Uganda 
Streptococcus 
agalactiae 
2 50 50 50 50 - 50 50 - 50 - - 50 - Seni189 Uganda 
Enterococcus spp 23 30 - 74 30 65 21 - - 60 - - - - Seni189 Uganda 
Gram-negative 
Escherichia coli 16 81 56 43 56 - 31 75 - 18 - - 63 - Demilie188 Ethiopia 
9 78 67 66 - - - 90 55 44 66 22 44 - Mulu191 Ethiopia 
6 67 67 100 17 - 67 50 50 50 - - - - Wondimeneh192 Ethiopia 
72 100 81 72 41 - 54 - 77 72 - - - - Seni189 Uganda 
Klebsiella pneumoniae 39 100 92 76 71 - 76 - 92 66 - - - - Seni189 Uganda 
Pseudomonas 
aeruginosa 
2 100 100 - 100 - 100 100 100 100 50 50 50 - Mulu191 Ethiopia 
2 100 50 50 100 - 50 50 - - - - 50 - Demilie188 Ethiopia 
5 100 60 20 80 - 40 100 100 40 80 100 60 - Mulu191 Ethiopia 
12 - 100 100 - - 16 - 16 - - - - - Seni189 Uganda 
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Proteus mirabilis 5 100 60 20 80 - 40 100 100 40 80 100 60 - Mulu191 Ethiopia 
2 50 50 - 50 - - 100 - - - 100 - - Mulatu193 Ethiopia 
Citrobacter freundi 13 69 54 62 77 - 62 69 46 54 - - - - Wondimeneh192 Ethiopia 
2 100 100 - 100 - - 100 - 100 - - - - Mulatu193 Ethiopia 
Salmonella 
Serogroup A 1 - - - - - - - 100 - - - - - Mulatu193 Ethiopia 
Serogroup B 3 - - - - - - - 100 - - - - - Mulatu193 Ethiopia 
Shigella spp 11 63 - 54 9 90 27 100 55 - - - - - Mulatu193 Ethiopia 
Campylobacter spp 20 30 20 15 - 55 70 80 - - - - - - Mulatu193 Ethiopia 
Acinetobacter spp 52 - 98 65 - - 88 - - 77 - - - - Seni189 Uganda 
Neisseria gonorrhoeae 123 - - - - - - - - 81 - - - - Vandepitte194 Uganda 
AMP, Ampicillin; AMX, Amoxicillin; CEFT, Ceftriaxone; CHLO, Chloramphenicol; CIPRO, Ciprofloxacin; CL, Clindamycin; DOXY, Doxycycline; 
ERY, Erythromycin; F, Nitrofurantoin; GENT, Gentamicin; KAN, Kanamycin; SXT, Trimethoprim-sulfamethoxazole; TTC, Tetracycline. Table 
reproduced with permission from a review paper by Ampaire et al.164
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Viral Keratitis 
Viral Keratitis is relatively uncommon in SSA. In many parts of SSA, topical acyclovir is the 
first line for Herpes Simplex Virus (HSV) Keratitis. According to the American Academy of 
Ophthalmology (AAO) treatment guidelines for HSV keratitis (2014), there are 2 topical agents 
(ganciclovir and trifluridine) and 3 systemic agents (acyclovir, famciclovir and valacyclovir) that 
are used in the treatment of HSV keratitis in the United States.77
Several trials have compared topical ganciclovir or trifluridine to acyclovir and found that all 
these agents are comparable in efficacy.77,195-197 In the trials that compared trifluridine to 
acyclovir, one multicentre double-blind trial of 59 herpes keratitis patients. Acyclovir 3% 
ophthalmic ointment was compared with trifluorothymidine 2 percent ointment. Ninety percent 
of acyclovir-treated patients and 75 percent of trifluorothymidine-treated patients had healed 
within 14 days. There was no significant difference in the rate of healing between the two 
treatment groups.195 In another double blind randomized study of 50 patients with epithelial 
HSV keratitis, 25 patients received 3% acyclovir ophthalmic ointment and other 25 patients 
2% trifluorothymidine ophthalmic ointment. The mean duration of treatment in the 2 study 
groups before healing of the epithelial ulceration was obtained was 6.7 days and 5.9 days, 
respectively (no statistically significant difference) and there were no clinically significant 
adverse effects recorded in the 2 arms.196 Another randomized double-blinded clinical trial 
compared four antiviral agents--1% idoxuridine ointment (group 1), 2% trifluorothymidine 
ointment (group 2), 3% acyclovir ointment (group 3) and 1% bromovinyldeoxyuridine (BVDU) 
ointment (group 4)-for uncomplicated and treatment naive cases of in HSV keratitis. Cure rates 
of 60%, 90%, 90% and 95% were obtained in groups 1, 2, 3 and 4 respectively. The average 
healing time was 13.4, 8.9, 8.5 and 7.5 days respectively. Side effects (follicular conjunctivitis, 
epithelial keratopathy and stinging) were more frequent in group 1 than in the other groups.197
In comparison of topical ganciclovir to acyclovir, one multicentre randomized clinical trial 
involving 67 patients compared 2 strengths of ganciclovir gel (0.05 and 0.15%) were compared 
with 3% acyclovir ointment in the treatment of superficial HSV keratitis.198 The results showed 
no statistically significant difference between the treatment groups, although local tolerance 
was found to be superior with the gel formulation of ganciclovir with fewer complaints of 
discomfort (stinging, burning) or blurred vision after application of the drug.198 Another 
randomised trial compared topical ganciclovir 0.15% gel and acyclovir 3% ointment in the 
treatment of HSV dendritic keratitis. Patients were assigned randomly to one of the two 
treatment groups for the purpose of the trial. They were then examined on days 2, 7, 10, and 
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14 to assess the rate of healing of the dendritic ulceration. There was no statistically significant 
difference detected in the rate of healing between the two treatment groups over the course 
of the trial.199 Evidence from these trials show that these agents (acyclovir, ganciclovir and 
trifluridine) may all be used as first line agents depending on local availability and tolerance. 
In addition to these topical agents, oral acyclovir and other oral anti-viral agents such as 
Valacyclovir and Valganciclovir are used in managing other non HSV keratitis.200,201
Depending on the site of active inflammation, adjunctive topical or oral steroids can be added 
in stromal type HSV keratitis. The Herpetic Eye Disease Study (HEDS) enrolled 106 
participants with stromal keratitis (57 treated with topical trifluridine and topical prednisolone 
phosphate and 49 with topical trifluridine and placebo). In this study, time to resolution of 
stromal keratitis and uveitis was significantly shorter in the steroid group compared with the 
placebo group.202
In addition, the HEDS also compared oral acyclovir in treating stromal keratitis caused by 
herpes simplex virus (HSV) in patients receiving concomitant topical corticosteroids and 
trifluridine. Patients were randomized to receive a 10-week course of either oral acyclovir (400 
mg 5 times daily, n = 51) or placebo (n = 53). All patients also received a standard regimen of 
topical prednisolone phosphate and trifluridine. There was no statistically or clinically 
significant beneficial effect of oral acyclovir in treating HSV stromal keratitis in patients 
receiving concomitant topical corticosteroids and trifluridine with regard to time to treatment 
failure, proportion of patients who failed treatment, proportion of patients whose keratitis 
resolved, time to resolution, or 6-month best-corrected visual acuity.203
One peculiar problem with HSV is the recurrent nature of the stromal keratitis which can result 
into significant visual impairment and blindness through corneal scarring and astigmatism. 
According to American Academy guidelines, evidence from 3 clinical trials suggests that long 
term low dose antiviral agents (oral acyclovir 400mg BD or oral valacyclovir 500mg OD) are 
the only proven agents to prevent incidence of recurrent HSV stromal keratitis. However, this 
effect is more useful among people with previous episodes of stromal keratitis and does not 
continue after cessation of the medication.204-206 In the first 2 studies by the HEDS, 703 
immunocompetent patients who had had ocular HSV disease within the preceding year were 
randomised to receive 400 mg of acyclovir or placebo orally twice daily. The study outcomes 
were the rates of development of ocular or nonocular HSV disease during a 12-month 
treatment period and a 6-month observation period.204,205 The cumulative probability of a 
recurrence of any type of ocular HSV disease during the 12-month treatment period was 19 
percent in the acyclovir group and 32 percent in the placebo group (P<0.001). Among the 337 
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patients with a history of stromal keratitis, the most common serious form of ocular HSV 
disease, the cumulative probability of recurrent stromal keratitis was 14 percent in the acyclovir 
group and 28 percent in the placebo group (P=0.005). The cumulative probability of a 
recurrence of nonocular (primarily orofacial) HSV disease was also lower in the acyclovir 
group than in the placebo group (19 percent vs. 36 percent, P<0.001). There was no rebound 
in the rate of HSV disease in the six months after treatment with acyclovir was stopped.205
Further analysis of these results showed that the magnitude of absolute benefit was greatest 
among patients with the highest number of prior episodes of ocular HSV disease. The benefit 
in preventing stromal keratitis was seen solely among patients with a history of stromal 
keratitis.204 In another smaller trial involving 52 immunocompetent patients with a history of 
recurrent ocular HSV disease, 26 were randomized to the valacyclovir group (one 500 mg 
tablet daily), and 26 patients were randomized to the acyclovir group (one 400 mg tablet twice 
daily). The recurrence rate of ocular HSV disease during 12 months of treatment and drug-
related side effects were monitored.206 Recurrence of any type of ocular HSV disease during 
the 12-month treatment period was 23.1% in the valacyclovir group, compared with 23.1% in 
the acyclovir group. No difference between the two groups was observed regarding the nature, 
frequency, or severity of adverse events. The most frequent adverse events were nausea and 
headache. The conclusion from this trial was that One-year suppression therapy with oral 
valacyclovir (500 mg tablet daily) was shown to be as effective and as well tolerated as 
acyclovir (400 mg tablet twice daily) in reducing the rate of recurrent ocular HSV disease.206
Acanthamoeba Keratitis 
Acanthamoeba is a difficult form of MK to treat because of the nature of the parasite which 
may occur in cystic (highly resistant to therapy) and trophozoite forms (more readily 
responsive).207 Acanthamoeba is not a known common cause of MK in SSA: only one case 
has been reported.53 Where it is prevalent, current treatment options for Acanthamoeba 
Keratitis include Diamidines and Biguanides.208 Diamidines such as propamidine-isethionate 
(Brolene), hexamidine-diisethionate (Hexacyl), and dibromopropamidine (Golden Eye) are 
used in 0.1% concentration while Biguanides, such as polyhexamethylene-biguanide 
(polyhexanid) (PHMB Lavasept), and chlorhexidine (Curasept) are applied in 0.02% 
concentration.208
These topical antimicrobials are administered every hour day and night immediately after 
corneal debridement or for the first several days of therapy. Depending on clinical response, 
they are then continued hourly (while the patient is awake) for 3 days depending on clinical 
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response. The frequency is then reduced to every 3-hourly. Two weeks may be required 
before a response is observed, and the total duration of therapy is a minimum of 3–4 weeks. 
Moreover, when therapy is discontinued, close observation of the patient is suggested in order 
to avoid recurrent infection.207
A more recent review of management of Acanthamoeba keratitis recommends PHMB or 
chlorhexidine as the most effective drugs for treatment of infection.207 They have been 
reported to be effective against both cysts and trophozoites.209 Some patients have been 
successfully treated using an antiseptic as monotherapy: one double-masked, randomize trial 
compared the therapeutic outcomes of PHMB and chlorhexidine for Acanthamoeba 
keratitis.210 Fifty-six eyes of 55 patients with Acanthamoeba keratitis were randomized to 
receiving PHMB 0.02% or chlorhexidine 0.02%.210 The primary outcome measure in this trial 
was treatment failure defined as failure to induce a favorable clinical response within two 
weeks.210 Outcomes were similar in the two arms, 18 (78%) PHMB patients were treatment 
successes compared with 24 (85.7%) chlorhexidine patients (P = .71). Five eyes worsened 
while receiving PHMB vs four eyes worsening while receiving chlorhexidine.210 In non-
responding cases,  
Polymicrobial Infections 
This is one of the causes of worsening infection if not detected and managed. Generally, the 
proportion of patients with polymicrobial infections has been reported to range between 1-6%. 
In an earlier study from Ghana in 1995, culture results of 199 patients with MK were reported.48
In that study, the proportion of mixed infections (bacterial/fungal) was 5.5%. This included a 
mix of Gram +ve and -ve bacteria only (1.5%), Gram +ve bacterial and fungus only (2%), Gram 
-ve bacteria and fungus only (1%), Gram +ve. Gram -ve and 1 fungus (0.5%) and Gram +ve, 
Gram -ve and 2 fungus (0.5%).48 Seven years later, in 2002, another study from Ghana 
reported a much less proportion of mixed infections (1.4%) among 290 patients with MK.31
This study also reported data on 800 patients with MK from India: the proportion of mixed 
infections was 5.5%. A more recent study of 252 patients with MK from India reported mixed 
infections 2%.43 In this study, all the mixed infections were Gram +ve bacteria and fungi.43
Treatment of polymicrobial infections requires good laboratory setup to be able to do initial 
and subsequent corneal scrapping analysis. In many reports, the preferred approach is to rule 
out mixed infections and proceed with mono microbial therapy.211-214 However, use of 
prophylactic antibiotic cover has been reported in treatment of fungal keratitis. In a trial by 
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Arora et al from India in 2011 that tested topical Natamycin 5% versus Voriconazole 1% for 
treatment of fungal keratitis, patients also received topical ofloxacin 0.3% as part of 
treatment.215 In another recent large series investigating the role of intracameral amphotericin 
B for treatment of recalcitrant fungal keratitis, patients received prophylactic topical 
moxifloxacin 0.5% three times a day as part of their management protocol.216
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Outcomes of MK in Sub Saharan Africa 
There is limited data on outcomes of MK in SSA. In the few papers that have reported on 
outcome, visual acuity, healing with corneal scarring and evisceration rates have been 
mentioned as outcome measures.52,217,218 In one study from Nigeria reviewed medical records 
of 82 patients with corneal ulcers and compared the pre and post treatment visual acuity. The 
follow-up duration was not indicated.52 The proportion of people with poor vision (VA <6/60) 
was 67.7% while 9.2% were eviscerated. The risk factors of a poor outcome in this study were 
not analyzed. Another study from Nigeria prospectively enrolled 54 patients with corneal ulcers 
and followed them up for at least 6 weeks after the start of their treatment. In this study, 93.5% 
of the patients healed with corneal scarring. The risk factors for poor outcome were centrally 
located lesion, a large lesion (greater than 4mm) and lesions affecting deeper layer of the 
corneal.218 One study from East Africa reported outcome data among patients with MK in 
Tanzania.12 In this study, a review of medical records of 170 individuals with microbial keratitis 
was conducted. At discharge (period not stipulated), 81% had poor vision (VA<6/60) while 8% 
had undergone evisceration. The risk factors to poor vision in this study were reported as a 
large infiltrate at presentation (>5mm), delayed presentation (>5 days) and corneal 
perforation. 
In comparing SSA to Asia, one recent large multicenter study by the Asia Cornea Society 
Infectious Keratitis Study group presented data of 6626 eyes of 6563 individuals recruited in 
a large multicenter study from thirteen study centers and 30 sub-centers across India, 
Singapore, China, Philippines, South Korea, Japan, Thailand and Hongkon.41 In this study, 
patients with MK were consecutively enrolled over a 12-18 months period where a performed 
standardized data collection protocol was used. Treatment of the infectious keratitis was 
decided by the managing ophthalmologist. Subjects were observed for up to 6 months. Main 
outcome measures were final visual acuity and the need for surgery during infection. Cornea 
transplantation was performed in 628 eyes to manage ongoing infection, but 289 grafts (46%) 
had failed by the end of the study. Moderate visual impairment (Snellen vision less than 20/60) 
was documented in 3478 eyes (53.6%). 
Until this project, we had no prospective medium or longer-term data on the outcome of 
treatment for MK in Uganda. Mostly this was due to poor follow up. However, our indication 
was that the outcomes were poor. For example, when we looked at the evisceration rate 
among 50 patients with MK who had been admitted from April to August 2014 at Ruharo Eye 
Centre (REC), one of the main eye hospitals in South Western Uganda, 28% had been 
eviscerated. This was a relatively high rate compared to 9.2% reported in a study in Nigeria 
and 8% in a Tanzania study 12,52. 
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Impact of Microbial Keratitis on Quality of Life 
Quality of Life (QoL) is a very important component of management of any disease and 
treatments should be targeted to improving QoL.219 There is a need to better understand how 
MK and its outcomes affect people, to develop improved ways of management, counselling 
and support. One way of doing this is to use validated vision and health related QoL tools, 
which collect data in a quantitative way to draw out differences between cases and controls. 
The most commonly used tools in eye care are the WHO generic Quality of Life tool 
(WHOQOL-BREF), the European Quality of Life Questionnaire (EQ-5D) and WHO Prevention 
of Blindness and Deafness 20-item Visual Functioning Questionnaire (WHO/PBD VF 20).220-
222
VRQoL: The WHO/PBD VF20 tool measures vision related quality of life, which was 
developed in India.220 It assesses the impact of visual impairment in several domains including 
mental wellbeing, dependency and social functioning. The WHO/PBD-VF20 consists of 20 
questions divided into four sub-scales: “General Vision” subscale (1 question); “Visual 
Symptoms” subscale (3 questions); “General Functioning” subscale (12 questions); and 
“Psychosocial” subscale (4 questions). It begins by asking the patient “Overall, how would you 
rate your eyesight using both eyes?”; and uses a five-point scale answer option such as “very 
good”, “good”, “moderate”, “bad”, “very bad”. Each subsequent question also has a 5-point 
response option: one indicates the highest and five the lowest score.220
HRQoL: The WHOQOL-BREF (WHOQOL Group, 1998) is a summarised version of the WHO 
generic QoL tool that was designed in 1991 (WHOQoL-100).223,224 It has good applicability in 
low and middle-income countries (LMIC) as it was developed simultaneously from concept 
across 18 countries in Africa, Asia and Latin America.221 It measures 4 domains of health: 
Physical Health, Psychological Health, Social Relationships, and Environment. It asks 
respondents 26 questions. These include the frequency they have experienced issues and/or 
were able to do things (e.g. feel safe, able to concentrate, enjoy life) in the past 4 weeks and 
how satisfied they are with certain aspects of their lives (e.g. sleep, capacity for work).221,224
EQ-5D: The European Quality of Life Questionnaire This scale was designed by the European 
quality of life (EuroQol) group to be brief, simple and practical for use in surveys alongside 
disease-specific measures.222 The EQ-5D includes two components. The first consists of five 
descriptive dimensions: mobility, self-care, usual activity, pain/discomfort and 
anxiety/depression, each with three response options: no problem, some problem or extreme 
problem. The second is a Visual Analogue Scale (VAS), with scores ranging from 0 (‘‘worst 
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imaginable health state’’) to 100 (‘‘best imaginable health state’’). Respondents are asked to 
indicate on the scale where they rate their ‘‘own health state today’’.222
These tools have been used in a number of other vision related studies such as cataract, 
trichiasis and even MK to show a difference in QoL.225,226 The first eye disease related QoL 
study in East Africa was conducted in Kenya in 2007 where the WHO/PBD VF20 and some 
questions from the European Quality of Life Questionnaire (EQ-5D) were used to describe the 
relationship between cataract visual impairment and vision and generic health-related quality 
of life, in people >50 years of age in Nakuru district, Kenya.225 In this study, 196 patients with 
visual impairment from cataract and 128 population-based controls without visual impairment 
from cataract were identified through a district-wide survey and additional cases were 
identified through case finding. The modified WHO/PBD VF20 demonstrated good 
psychometric properties and was found to be a valid and reliable scale to assess vision-related 
quality of life associated with cataract visual impairment in this Kenyan population.225 The 
second study was from Ethiopia in 2015 where the two tools WHOQOL-BREF WHO/PBDVF20 
were used to compare the mean QoL scores between 1000 adult trichiasis cases and 200 
trichiasis-free controls.227 In this study, trichiasis cases had substantially lower Vision and 
Health related QoL than controls.227
Although the visual function tools were designed for use on binocular vision, they have been 
demonstrated to be effective in detecting differences in monocular visual impairment in the 
MUTT1 trial in India and in another case series in China.10,228
In the MUTT1 trial, The Indian visual function questionnaire (IND-VFQ) was administered to 
MUTT I study participants at 3 months to determine the risk factors for a low vision related 
functioning.229 The IND-VFQ is a modified WHO/PBD VF 20 tool that is reduced to a 45 
questions of four subscales (mobility subscale, 6 questions; activity limitation subscale, 10 
questions; psychosocial impact subscale, 5 questions; visual function subscale, 7 questions 
.230 In this study involving 292 patients who completed the IND-VFQ at 3 months, baseline 
visual acuity, need for a therapeutic penetrating keratoplasty and being unemployed were 
strong predictors of a low vision related QoL at 3 months.229 The main conclusion of this study 
by the authors was that monocular vision loss from corneal opacity due to fungal keratitis 
reduced vision-related quality of life and that given the relatively high worldwide burden of 
corneal opacity, improving treatment outcomes of corneal infections should be a public health 
priority.229 In addition, this trial also compared the 3-months QoL scores among the study 
participants in the different treatment groups (Natamycin versus Voriconazole).231 In this study, 
the participants who had received Natamycin had a significantly better QoL score than those 
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who had received Voriconazole, and this difference was even more apparent among people 
where the causative agent was Fusarium spp.231
The Case series from China used the 25-item National Eye Institute Visual Function 
Questionnaire (NEI VFQ-25) to determine the vision related QoL in 65 patients with infectious 
keratitis.10 The 51-list-item NEI VFQ is a vision-targeted survey that assesses the influence of 
visual impairment on HRQOL and was specifically developed to target 5 common chronic 
conditions (age-related cataracts, age-related macular degeneration, diabetic retinopathy, 
primary open-angle glaucoma, cytomegalovirus retinitis) and low vision from any cause.232
The 51-list-item NEI VFQ includes a multi-list-item scales to rate overall health (2 list-items), 
overall vision (2 list-items), difficulty with near vision (7 list-items), difficulty with distance vision 
(7 list-items), limitations in social functioning due to vision (4 list-items), role limitations due to 
vision (5 list-items), dependency on others due to vision(5 list-items), mental health symptoms 
due to vision (8 list-items), future expectations for vision (3 list-items), driving difficulties (4 list-
items), and pain and discomfort around the eyes (2 list-items).232 In addition, it has single list-
items to assess peripheral and color vision. Each subscale is scored so that 0 represents the 
lowest and 100 the best possible score.232 In this study, there was a strong correlation between 
the QoL score and the Best Corrected Visual Acuity (BCVA) of the worse-seeing eye, duration 
of the disease, history of operation, and gender.10
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Specific problems of MK in SSA 
The problems of MK in SSA can be summarised in one sentence. MK is a neglected disease. 
There has been little investment in terms of research and improving care and outcomes. 
Neglected problem with limited literature 
Because of the limited research, there are many knowledge gaps in the epidemiology, risk 
factors and outcomes specific to the local context. A literature search on MK in SSA returned 
only a handful of papers most of which were of modest quality. Part of the aim of this research 
project was to make a scientific contribution by conducting well designed and powered studies. 
Poor outcomes 
Although there were only 2 studies that mentioned outcomes of MK in SSA, it is common 
knowledge among the ophthalmologists that outcomes for MK are grim.12,52 The predictors for 
these have been reported to be large ulcers, delayed presentation and perforation. We have 
no medium or longer-term data on the outcome of treatment after discharge in Uganda. Mostly 
this has been due to poor follow up. However, our small audit of 50 patients admitted at Ruharo 
Eye Centre with MK from January to August 2014 indicated that 28% had to be eviscerated.  
Limited resources 
SSA is generally a limited resource setting, this includes the human resources, diagnostics 
and medicines.233,234 There is limited access to appropriate treatment and care: people have 
to travel long distances to the capital to access an ophthalmologist. In addition, there is limited 
availability of effective medicines such as Natamycin which is currently not available in Uganda 
and many places in SSA yet the best current evidence indicates that topical natamycin is the 
treatment of choice for filamentous fungal keratitis.213 This drug was recently added to the 
WHO Essential Medicines List, which will hopefully result in greater availability. Even when 
available, challenges of cost will still be a barrier to access as many people may not be able 
to afford it. 
Weak health systems 
Because of weak health systems, there is poor triage and referral of patients which leads to 
late presentation and poor outcomes.12 For example, the Uganda health is a tier-based system 
with the lowest point of care being at the village level. However, physically, a Health Centre 
(HC) II is the lowest unit and is located at a parish level. These units have different staffing 
and capacity in terms of service provision. Patients are referred along the tier system 
depending on the complexity of their condition. Our experience is that there are many factors 
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along this system that further contribute to the delayed presentation of MK patients to the eye 
hospital. In an earlier retrospective study in Tanzania, a risk factor for corneal perforation 
among patients with MK was having visited a HC12,235 Although the authors argued that the 
association may be that the lower-level HC were more likely to refer the ‘bad’ cases, it is also 
plausible that some of these lower-level HC are inherently deficient in capacity to diagnose 
and offer appropriate treatment to patients with MK. Lower HC play a role in delayed referral 
and presentation of patients to eye hospitals, and could therefore be a key rate limiting step 
in the presentation journey of patients with MK. 
No corneal tissue 
Therapeutic keratoplasty is a good option to salvage the eye and control infection.236,237 Later, 
an optical keratoplasty can be done to improve visual outcomes.237 Although there is a rising 
number of corneal specialists in SSA, keratoplasty for corneal blindness (not even MK) is not 
routinely performed due to lack of tissue. There is only one known corneal bank in Ethiopia 
but there is no current legal framework available to export tissue to other countries in SSA.238
Role of TEM and self-medication 
Many people in SSA use TEM. Our experience is that by the time patients with MK come to 
hospital, about half have used some form of TEM. Many people probably choose to try TEM 
for several days before attending hospital as it can be easily obtained within or close to home. 
Its use appears to contribute to poor outcomes, substantially adding to the risk of poorer 
presenting vision. In Uganda, TEM is usually made from plant products. This is concerning, 
as such substances may be toxic or harbour infectious agents, such as fungal spores.13,14
Those who do not use TEM will use an off the counter eye drop without any expert advice. In 
Uganda, it is possible to obtain a range of medicines from pharmacies without a prescription. 
Our experience is that many eye-drop preparations sold over the counter in our region contain 
a corticosteroid component. This risks exacerbating fungal keratitis, compounding poor 
outcomes.239,240
Impact on QoL 
Although data is not available, our impression is that treatment of corneal infections is very 
challenging for patients. Firstly, most patients come when they have tried all sorts of 
medications, which leave them financially, physically and mentally fatigued. On admission, 
they may spend many days or even weeks in hospital. They are the ones “in the corner”. They 
are usually seen last on a ward round, because of appropriate concerns about transmission 
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of infection; which frequently means they are only reviewed by one of the more junior clinicians 
and our observation is that they are not actively or optimally managed. 
Most people with MK are adults who have financial responsibilities to earn the income to 
support their families. Loss of income and inability to provide for family members is a major 
concern. Some of the female patients we interact with are worried about being abandoned for 
a second wife by their husbands, or not being able to plant crop for the season because they 
are sick or not being able to get married because of their looks. These and many other 
examples we learn about daily show that MK has far reaching short and long term physical 
and psychosocial ramifications. This is contrary to what has been the general assumption that 
since MK tends to be a monocular condition, the person still has the “other eye” to live and 
work with and therefore, leads a “normal” quality of life. 
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ABSTRACT 
Purpose: To review published data on the treatment of fungal keratitis and make evidence-based 
recommendations. 
Methods: A literature search was performed using the search terms Fungal Corneal Ulcer, Fungal 
Keratitis, Fungal Corneal abscess, Fungal Infective Keratitis, Fungal Corneal abscess, Fungal 
corneal abscess, Mycotic keratitis and Mycotic corneal ulcer. Only Randomised Controlled Trials 
(RCTs) were considered for the topical and oral treatment groups. The search was updated on 
26/06/2019.  
Results: A total of 14,396 results were returned of which 55 papers were ultimately included. 
Treatments for fungal keratitis included medical, injections, surgery, corneal cross linking and argon 
laser. A meta-analysis of two trials comparing topical chlorohexidine to natamycin, found a non-
significant trend favouring chlorhexidine for cure / healing at 21 days (RR 0.72, 95% CI 0.46-1.12, 
RR> 1 favours natamycin). A meta-analysis of four trials comparing topical natamycin to 
voriconazole, found natamycin had favourable vision outcomes at 3 months (Standardised Mean 
Difference (SMD) in Log MAR units 0.34, 95% CI 0.17-0.50, SMD>0 favours natamycin). A meta-
analysis of two trials of intrastromal voriconazole found this was associated with increased risk of 
perforation and a worse vision at 3 months, compared to topical treatment alone (Standardised Mean 
Difference (SMD) in Log MAR units 0.56, 95% CI 0.16-0.96, SMD>0 favours topical treatment alone). 
Five studies on intra-cameral amphotericin B (ICAMB) reported favourable outcomes in patients with 
severe, deep infiltrates. The surgical interventions reported several different outcome measures: 
anatomical integrity (64-90%), graft clarity (26-94%), recurrence of infection (0-47%). One RCT 
reported increased perforation following CXL (p=0.02). Another RCT reported better outcomes in 
people with moderate fungal keratitis. Two RCTs for Argon laser reported better outcomes in 
recalcitrant fungal Keratitis. 
Conclusions: There was strong evidence favouring natamycin as the treatment of choice for 
filamentary fungi. Intrastromal voriconazole did not have favourable outcomes. Use of ICAMB 
showed benefit especially for deep lesions. Evidence for surgical techniques was inconclusive, 
however, there is a role of all these procedures in salvaging eyes and controlling infection. Evidence 
around the use of CXL and Argon laser is currently inconclusive, more studies are needed to define 
their potential indication.  
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INTRODUCTION 
 
Microbial Keratitis (MK), or corneal infection, is a major ophthalmic public health problem, particularly 
in low and middle-income countries (LMIC). Corneal scarring, which is frequently caused by MK, 
accounts for an estimated 3.2% (1.3 million people) of binocular blindness globally and ~10% in Sub-
Saharan Africa (SSA).1 In the Nigerian National Survey corneal scarring caused 15% of monocular 
blindness.2 Older estimates suggest ~2 million people in LMIC develop monocular blindness from MK 
annually, however, the true figure is probably somewhat higher.3 MK has been described as a “silent 
epidemic” leading to significant morbidity and sight loss.4 
 
Fungal Keratitis (FK) accounts for around 50% of MK occurring in tropical regions, becoming 
increasingly more common closer to the Equator.5 It is usually caused by filamentous organisms with 
Fusarium spp. and Aspergillus spp. the most frequent causes.6 In temperate regions, fungal corneal 
infections are much less frequent, accounting for less than 5% of all MK.7,8 Historically, yeast 
infections were more frequent in temperate areas, however, recent reports suggest a shift towards 
increasing numbers of filamentous infections.9-11 The predisposing factors for fungal keratitis are 
varied and include: trauma (particularly related to agricultural work), contact lens wear, chronic 
ocular surface disease, topical steroid use, corneal surgery, traditional eye medicine and 
immunosuppression.10,12,13 
 
Treating fungal keratitis is challenging as cases tend to be severe, particularly with late presentation 
in LMIC, and are often associated with poor outcomes.14,15 The armamentarium for treating fungal 
keratitis treatment is relatively limited, and drug availability very variable. Treatment options are 
broadly subdivided into medical, laser and surgical. Medical options include topical antifungal 
agents, systemic antifungal agents and injections which can be subconjunctival, intrastromal or 
intracameral. Surgical options for fungal keratitis include therapeutic penetrating keratoplasty (TPK), 
partial keratectomy, debridement, conjunctival flaps, amniotic membrane graft and corneal collagen 
crosslinking (CXL). 
 
Many studies have reported outcomes of specific treatments, although these are often simple case 
series of an individual treatment. There remains considerable uncertainty regarding the best 
management for fungal keratitis, and outcomes are often poor. Here we review the published 
evidence on the treatment of fungal keratitis, and propose a treatment approach to assist 
ophthalmologists in making decisions.  
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METHODS 
 
Treatments for fungal keratitis were grouped as follows: Medical treatment (topical and oral 
treatment), injections, surgical treatment (penetrating keratoplasty, lamellar keratoplasty, 
conjunctival flaps and amniotic membrane grafts), and, other treatment (corneal cross linking and 
argon laser). 
 
Search strategy 
We searched Embase and extended across Medline, Global health, Pubmed, Clinical Trials.Gov, 
Ethos, IndMed and google scholar. Authors approved the search strategy. Only Randomised 
Controlled Trials (RCTs) were considered for the topical and oral treatment groups. We allowed 
greater inclusion flexibility for other forms of treatment, because there were few if any RCTs for those 
treatment groups. We last searched electronic databases on 26/06/2019. The following key words 
were used for each individual treatment method: 
 
Topical and oral treatment; ((Fungal Corneal Ulcer OR Fungal Keratitis OR Fungal Corneal 
abscess OR Fungal Infective Keratitis OR Fungal Corneal abscess OR fungal corneal abscess OR 
Mycotic keratitis OR Mycotic corneal ulcer) AND (Management OR Treatment OR fluconazole OR 
natamycin OR econazole OR chlorohexidine OR clotrimazole OR voriconazole OR itraconazole OR 
amphotericin B OR fluconazole) AND (Randomised Controlled Trial OR RCT OR Trial OR Clinical 
Trial OR intervention study OR intervention trial )). TW. 
 
Fluconazole injection; ((Fungal Corneal Ulcer OR Fungal Keratitis OR Fungal Corneal abscess 
OR Fungal Infective Keratitis OR Fungal Corneal abscess OR fungal corneal abscess OR Mycotic 
keratitis OR Mycotic corneal ulcer) AND (Management OR Treatment OR fluconazole, 
Subconjunctival, Intrastromal, Intracameral)).TW. 
 
Amphotericin B injection; ((Fungal Corneal Ulcer OR Fungal Keratitis OR Fungal Corneal abscess 
OR Fungal Infective Keratitis OR Fungal Corneal abscess OR fungal corneal abscess OR Mycotic 
keratitis OR Mycotic corneal ulcer) AND (Management OR Treatment OR amphotericin B OR 
Subconjunctival Intrastromal OR Intracameral)).TW. 
 
Voriconazole injection; ((Fungal Corneal Ulcer OR Fungal Keratitis OR Fungal Corneal abscess 
OR Fungal Infective Keratitis OR Fungal Corneal abscess OR fungal corneal abscess OR Mycotic 
keratitis OR Mycotic corneal ulcer) AND (Management OR Treatment OR voriconazole, 
Subconjunctival, Intrastromal, Intracameral)).TW. 
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Collagen cross linking; ((Fungal Corneal Ulcer OR Fungal Keratitis OR Fungal Corneal abscess 
OR Fungal Infective Keratitis OR Fungal Corneal abscess OR fungal corneal abscess OR Mycotic 
keratitis OR Mycotic corneal ulcer) AND (Collagen Cross linking OR CCL OR CXL OR X-Linking OR 
Corneal Cross linking OR Collagen Corneal cross linking OR riboflavin OR Ultraviolet-A OR PACK-
CXL)). TW. 
 
Surgery; ((Fungal Corneal Ulcer OR Fungal Keratitis OR Fungal Corneal abscess OR Fungal 
Infective Keratitis OR Fungal Corneal abscess OR fungal corneal abscess OR Mycotic keratitis OR 
Mycotic corneal ulcer) AND (surgery OR surgical OR corneal allograft OR corneal transplant OR 
Keratoplasty OR Therapeutic Keratoplasty OR TPK OR PK OR Conjunctival flap OR Flap OR 
Gunderson flap OR debridement OR gluing OR Keratectomy OR amniotic membrane graft)).TW. 
 
Argon laser; ((Fungal Corneal Ulcer OR Fungal Keratitis OR Fungal Corneal abscess OR Fungal 
Infective Keratitis OR Fungal Corneal abscess OR fungal corneal abscess OR Mycotic keratitis OR 
Mycotic corneal ulcer) AND (argon laser OR laser)).TW. 
 
A separate PubMed search was made specifically for topical treatment for candida keratitis using 
the search terms Candida Keratitis. 
 
Inclusion criteria: 
• Participants: Patients of any age with fungal keratitis 
• Interventions: Topical antifungal treatment, antifungal injections, systemic antifungal 
treatment, surgical treatment (conjunctival flap, amniotic membrane flap, lamellar 
keratoplasty, therapeutic penetrating keratoplasty), corneal cross linking, or argon laser 
treatment (any of these) 
• Comparisons: Topical antifungal treatments, Topical vs injections, or Topical vs surgery (any 
of these) 
• Outcomes: Best Corrected Visual Acuity (BCVA), improvement in vision, complication rate, 
recurrence rate, time to heal, or residual scar size (any of these) 
• Type of study: Randomised controlled trials, case series with at least 10 cases and published 
audits. For topical and oral treatments, we only included randomised clinical trials. 
• Language: English 
• Publication status: Published 
 
Study selection: 
One author assessed all the studies identified in the search for eligibility. Initial selection was made 
by reviewing title and abstract; full texts were retrieved for studies considered to possibly meet 
inclusion criteria. The full text was reviewed and assessed against the inclusion criteria. Studies 
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meeting inclusion criteria were included in the review. These were independently verified by a 
second author. 
 
Data collection: 
We extracted the following data: Author and year of publication, study design, participants, inclusion 
criteria, fungal diagnosis, severity, fungal species, intervention (drug or surgery), indication for 
surgery, follow-up period, main outcome variables (BCVA, time to heal, complications, recurrence, 
scar size) 
 
Risk of bias: 
The risk of bias in clinical trials was assessed using the Cochrane risk of bias tool.16 Parameters 
assessed included: random sequence generation, allocation concealment, masking of participants 
and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting. In 
addition, all studies were allocated a general score of strength of evidence using the Scottish 
Intercollegiate Guidelines Network (SIGN 50) criteria as shown in Table 1.17 
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RESULTS: 
 
1) TOPICAL TREATMENT 
The search returned 426 articles on topical and oral anti-fungal treatment. Among these were 8 
randomised controlled trials comparing topical antifungal agents. The key features of the study 
designs and the main findings from these trials are presented in detail in Table 2. All the trials were 
conducted in South Asian countries (India, Bangladesh and Nepal), where there are enough FK 
cases for clinical trials. Many cases enrolled in these trials had filamentous fungi (Fusarium spp. and 
Aspergillus spp. being most frequent), rather than yeasts. All trials included topical natamycin as one 
of the treatments being compared. Where the Risk Ratio (RR) is presented in Table 2, natamycin is 
considered the reference treatment. The methodologies were varied in terms of treatment used, 
follow-up schedules and outcome measures, which limits potential meta-analysis. The studies are 
considered in chronological order. 
 
Two trials (Rahman et al 1997, 1998) compared topical natamycin and chlorhexidine.18,19 These 
were relatively small, with a combined size of 130 participants. In the first, three different 
concentrations of chlorhexidine (0.05%, 0.1%, 0.2%) were compared to natamycin 5%.20 There were 
trends towards more favourable responses by five days and “cure” at 21 days with increasing 
chlorhexidine concentration. The authors concluded that a chlorhexidine concentration of 0.2% was 
required. In the second trial, chlorhexidine 0.2% was compared to natamycin 2.5% (half the standard 
concentration).21 Chlorhexidine 0.2% was associated with more favourable responses at 5 days (RR 
of a bad outcome 0.23, 95%CI 0.08 – 0.63, p=0.004) and no significant difference in healed ulcers 
at 21 days (RR of a bad outcome 0.78, 95%CI 0.54 – 1.14, p=0.200). In a meta-analysis of these 
two studies, combining the chlorhexidine and natamycin groups with different concentrations, there 
was a non-significant trend favouring chlorhexidine over natamycin for cure / healing at 21 days 
(Figure 2). 
 
One trial (Prajna et al 2003) compared topical natamycin 5% to econazole 2%, in 116 participants.22 
The primary outcome measure was healed or healing ulcers at the final visit. No difference was 
found between the two arms (RR 1.04, 95% CI 0.64-1.72, p=0.86).  
 
Four studies have compared topical natamycin 5% and voriconazole 1%. The first trial (Prajna et al 
2010) used a factorial design with 120 patients randomised to natamycin or voriconazole, with or 
without repeated corneal scrapping.23 The primary outcome was best spectacle-corrected visual 
acuity (BSCVA) at 3 months: there was a non-significant trend in favour of voriconazole (0.98 
logMAR better, 95%CI: -0.28 to 0.83, p=0.29). In the second trial (Arora et al 2011) 30 patients were 
randomised to natamycin or voriconazole.24 There was a non-significant trend in favour of natamycin. 
In the third trial (Prajna et al 2013), 323 patients were randomised to natamycin or voriconazole. This 
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found strong evidence for the superiority of natamycin for the primary outcome of BSCVA at 3 
months. The fourth trial (Sharma et al 2015) randomised 119 patients to natamycin or voriconazole. 
The overall final visual acuity was better in the natamycin group.25 Meta-analysis of the 3-month, 
final visual acuity for these four trials indicates that natamycin is associated with a more favourable 
visual acuity outcome than voriconazole (Figure 3).  
 
Three of the studies reported perforation rates.26-28 Overall, there was evidence that this was lower 
in natamycin treated patients (Figure 4). Two trials reported a subgroup analysis comparing fungal 
keratitis due to Fusarium spp compared to non-Fusarium spp (Aspergillus spp and others).25,28 In 
the larger trial (Prajna et al 2013), the Fusarium spp results were better with natamycin for BSCVA 
at 3 months, perforation rates, infection resolution at 6 days and the scar size at 3 months.28 Sharma 
et al also reported that the final visual acuity was better in patients with Fusarium keratitis but not 
with Aspergillus keratitis.25 
 
Topical Treatment for Candida spp. 
The search returned 479 papers were returned from which 30 were selected for abstract review, 
most were dropped for being case reports and finally 5 articles were considered for full text review. 
29-33 These included 1 case series and 4 audits. Overall, the most commonly reported drugs were 
topical Amphotericin B, topical fluconazole and oral azoles.33 An earlier case series had reported 6 
eyes with Candida Keratitis which all improved on topical fluconazole.31 In one audit from Japan, 10 
patients with Candida Keratitis were initially treated with fluconazole (topical and oral), then 
miconazole or natamycin eyedrops if they showed no improvement. Of the 10, 7 responded well and 
3 with recalcitrant Candida parapsilosis had to be managed with 0.1% Mucafungin.30 In another audit 
of 29 patients, topical amphotericin B (17 eyes), natamycin (4 eyes), and miconazole (2 eyes) ± oral 
ketoconazole or itraconazole were used to successfully manage the cases.33 In a more recent audit 
of 128 patients with fungal keratitis all the 16 patients with Candida Keratitis were treated with topical 
amphotericin B (0.15%). In addition, those with deep infiltrate, increase in hypopyon, or size of 
infiltrate received additional intracameral injection of amphotericin B (10 mg in 0.1 mL). All patients 
received oral itraconazole as adjunctive systemic therapy.32 Good outcomes were noted in 14/16 
with only 2 patients needing TPK.32 In an earlier audit, 4 cases with had been successfully treated 
with topical antifungal therapy (amphotericin B 0.7%, 5-fluorocytosine 1%, one drop every hour) and 
oral itraconazole (400 mg daily).29 
 
2) ORAL TREATMENT 
Oral treatments are sometimes used in addition to topical therapy for cases with deep invasive 
disease (Table 3). There is limited trial data to guide practice in this area. We identified three 
randomised trials for oral treatments. In the first trial (Agrawal et al 2001) 54 patients with fungal 
keratitis, who were all treated with topical itraconazole, were randomised to receive oral itraconazole 
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or no oral treatment (no placebo).34 Oral itraconazole was not found to provide additional benefit of 
healing by 6 weeks (RR 1.0, 95%CI 0.37 – 2.71). 
 
In a second trial (Prajna et al 2016) 240 patients with particularly severe fungal keratitis were all 
treated with topical voriconazole ± topical natamycin.35 They were randomised to oral voriconazole 
or placebo. There was no additional benefit from oral voriconazole for the primary outcome measure 
of corneal perforation (RR 1.2, 95%CI 0.78 – 1.80). 
 
In the third trial (Sharma et al 2017), 50 patients with severe fungal keratitis were randomised to 
receive oral voriconazole or oral ketoconazole as adjunct treatment to topical natamycin.36 Patients 
who received oral voriconazole had better BSCVA at 3 months (primary outcome) compared to the 
ones who received oral ketoconazole (mean Log MAR 1.3 ± 0.07 Vs 1.5 ± 0.07, p=0.02). In this trial, 
3/25 patients in the voriconazole group and 5/25 in the ketoconazole group developed corneal 
perforation (RR 0.6 95% CI 0.2-2.2, p=0.45) 
 
3) INJECTED TREATMENT 
Several types of ocular injection have been reported: subconjunctival, intrastromal and intracameral 
injections (Table 4). Indications for this treatment tend to be severe and/or unresponsive fungal 
keratitis. The reported injected agents include fluconazole, voriconazole and amphotericin B.  
 
Fluconazole Injection 
The search for fluconazole injections returned a total of 2550 articles. Following title and abstract 
review, we identified 12 papers for full article review. We eliminated seven articles that did not meet 
the inclusion criteria. Five articles were included: 1 RCT, 3 case series and 1 retrospective audit. 
The route of injection was subconjunctival in four studies and intrastromal in one report. These 
studies are summarised in detail in Table 4. 
 
Subconjunctival Fluconazole: In the RCT from Egypt (Mahdy et al 2010), 48 patients were 
randomised into two arms: (1) topical amphotericin B 0.05% eye drops and 1mL of sub-conjunctival 
fluconazole 2mg/mL, injected daily for 10 days and then every 48 hours for a further 10 injections; 
(2) topical amphotericin B 0.05% eye drops.37 The main outcome measures were the proportion 
healed at 3 months (“healing rate”) and the time to being healed. In the combination treatment group, 
the 3-month healing rate was 83% and the mean time to healing was 31 days. However, this trial 
had several methodological limitations with respect to randomization and masking. In the topical only 
group the healing rate was 67% and time to healing was 37 days (p <0.05). 
 
In the three prospective case series (Yilmaz et al 2005, Dev et al 2006, Mahdy et al 2010), 
subconjunctival fluconazole was found to have no local toxicity.38-40 Outcomes in terms of healing, 
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improvement in visual acuity and ulcer/infiltrate resolution, were variable (Table 4). Healing or 
resolution was variable and was reported in 54-100% of the patients. Outcomes were not separately 
analysed by species for significance.38,41 
 
Amphotericin B injection 
The search returned 3071 articles for amphotericin B injection. After title and abstract review, we 
identified 23 papers for full review. We eliminated 17 studies which did not meet the inclusion criteria, 
leaving five articles (Table 5): one RCT, two non-randomised trials, two case series that reported 
intracameral use of amphotericin B; one audit reported use of intrastromal amphotericin B.  
 
Intracameral Amphotericin B (ICAMB): One RCT (Sharma et al 2015) of 45 patients with fungal 
keratitis examined the effect of intracameral amphotericin B, in addition to topical and systemic 
treatments; there was no additional benefit in terms of healing or BCVA.42  
 
In the first non-randomised prospective study (Sharma et al 2015) 104 patients were allocated to 
groups depending on how they responded to conventional topical antifungal treatment by day 7.43 
Those who seemed to be responding were maintained on the same treatment, while those who 
showed no response received additional intracameral amphotericin injection. The two groups were 
compared for healing time, time of hypopyon resolution, complication rate and improvement in final 
BCVA. The group which received the additional amphotericin injection had a non-significant trend to 
slightly better outcomes in all parameters compared to the group that did not. Another more recent 
non-randomised study (Gupta et al 2019) enrolled patients with recalcitrant fungal keratitis and 
allocated one group to early ICAMB (at 2 weeks) intervention and another to late ICAMB (at 4 
weeks). Patients in the early ICAMB intervention group had a quicker healing time compared to the 
ones in the late intervention group.44 
 
Among the case series, one report (Yoon et al 2007) audited the outcomes of two groups, one was 
treated with conventional antifungal drops and intracameral amphotericin B while the other was 
treated with only conventional antifungal treatment. Both groups were compared for final visual 
acuity, time to healing, hypopyon resolution, time for epithelial defect resolution and overall treatment 
success. Although overall treatment success was comparable in the two groups, the group that 
received intracameral amphotericin B had a better final vision and shorter healing times.45 The 
second prospective series (Yilmaz et al 2007) of 14 eyes of 12 patients that had not responded to 
initial topical and systemic therapy, were treated with repeated doses of ICAMB. Healing was 
reported in 12 out of 14 eyes, cataract was also reported as a complication in this series.46  
 
There were mild differences in the doses used in these studies (5-10 µg/0.1ml given up to 3 times 
1-10 days apart). Favourable outcomes for ICAMB were reported in other studies, however, these 
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had a low level of evidence. Overall, literature on the use of intracameral amphotericin is 
inconclusive, some have reported favourable outcomes and others not. However, there appear to 
be specific situations where there may be advantages, such as unresponsive deep filamentary 
fungal keratitis with hypopyon. The literature on this was too scanty and the level of evidence too 
weak to draw any firm conclusions. A fully powered RCT for ICAMB for deep, recalcitrant intraocular 
fungal infections is needed. 
 
Intrastromal Amphotericin B: An audit from Egypt (Nada et al 2017) reviewed 68 cases of 
unilateral fungal keratitis.47 Forty-one cases that had not responded to the initial topical antifungal 
therapy were treated with a single intrastromal injection of amphotericin B + topical fluconazole 2%. 
These were then compared to 27 cases treated with only topical amphotericin B 0.3% monotherapy. 
Healing was reported to be faster in the amphotericin injection group. However, the overall evidence 
level was quite weak. 
 
Voriconazole Injection 
The search returned a total of 3911 articles for voriconazole injection. After title and abstract review, 
we identified 34 papers for full article review. We eliminated 27 papers for not meeting the inclusion 
criteria. The 7 studies that we included were: 2 RCT and 5 case series. Use of voriconazole was 
intrastromal in 5 studies (2 RCTs and 3 case series); intracameral in one case series; and 
intracameral combined with intrastromal in one case series. Details of these studies are in Table 6. 
 
Intrastromal Voriconazole: The one RCT (Sharma et al 2013) randomised 40 patients into two 
groups.48 One group received topical Voriconazole 1% and Natamycin 5% while the other group 
received intrastromal Voriconazole and topical Natamycin 5%. For all outcome measures of 
treatment success, BCVA at 3 months, time to heal, complications and scar size, the group that 
received topical Voriconazole had a better outcome than the group that received intrastromal 
Voriconazole.49 In a more recent RCT (Narayana et al) 70 patients were randomised to two groups 
comparing topical Natamycin and Intrastromal Voriconazole (ISV) vs topical Natamycin alone. For 
all the outcome measures of microbiological cure, BSCVA, scar size, perforation rate, there was no 
evidence of benefit in adding ISV injections to topical natamycin in the primary treatment of moderate 
to severe filamentous fungal ulcers. Meta-analysis of these 2 trials shows that ISV is associated with 
more perforation rates and a worse vision at 3 months than topical treatment alone (figure 5 and 6). 
However, in the three case series (Sharma et al 2011, Kalaiselvi et al 2015, Nagar et al 2015), 
intrastromal voriconazole was found to be effective in treating deep seated fungal infiltrates/stromal 
abscesses unresponsive to 5% topical natamycin and 1% voriconazole, and oral itraconazole.48,50-52  
 
Intracameral Voriconazole: Intracameral voriconazole injection have been reported in a few case 
series.53,54 In a study from China (Shen et al 2010), 10 patients with fungal keratitis progressing to 
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endophthalmitis were given treated with intracameral voriconazole once daily until resolution of the 
endothelial infiltrate.53 The injections varied from 1-8 (median 5). Patients were followed up for 4 
months. The infiltrates resolved in 6 out of 10 patients and there was no reported intra or 
postoperative complications.  
 
Intrastromal and intracameral Voriconazole: This combination has been reported in a study from 
India (Killani et al 2015); 30 patients with proven fungal corneal ulcers with deep stromal infiltrates 
and endothelial plaque not responding to routine antifungal drugs (5% natamycin, 1% voriconazole, 
oral itraconazole) were given 1-2 intrastromal and intracameral voriconazole injection 48 hours apart 
in addition to the topical treatment. Infection resolved in 25 patients, without significant 
complications. 
 
4. SURGICAL TREATMENT 
Medical treatment alone is sometimes insufficient to successfully manage severe cases of fungal 
keratitis. Surgical interventions may be required, including: therapeutic penetrating keratoplasty, 
lamellar keratoplasty, keratectomy, amniotic membrane graft, and conjunctival flaps. The main aims 
are to eliminate the infection and maintain the integrity of the globe. Indications usually include 
progressive or unresponsive keratitis, perforations, impending perforations, posterior corneal 
involvement, and persistent epithelial defects. 
 
The search returned 3387 articles on the surgical treatment of fungal keratitis. After reviewing titles 
and abstracts, we identified 201 papers for full review. We eliminated 181 papers which did not meet 
the inclusion criteria. The surgical interventions described in the 20 studies included were: 
Therapeutic Penetrating Keratoplasty (11 studies), Lamellar Keratoplasty (5 studies), conjunctival 
flap (2 studies) and amniotic membrane graft (2 studies). Details of these studies are in Table 7. 
 
Therapeutic Penetrating Keratoplasty (TPK): Eleven audit studies looked at the outcomes of 
fungal keratitis in patients who had undergone TPK (Table 7).55-65 These studies were mostly from 
Asian countries. Follow-up ranged from 2 weeks to 5 years. The indications for TPK included 
perforations, impending perforations, non-healing ulcers despite medical treatment, infiltrates 
progressing to involve deep corneal layers or limbus. Figure 6 shows a summary of the indications. 
 
The studies reported several different outcome measures: anatomical integrity, graft clarity, “cure”, 
recurrence of infection, vision and complications.  
• Anatomical integrity was reported in 5 studies and ranged from 64-92%.55-58,61 
• Graft clarity was reported in 7 studies as 26-94%.55,56,58,59,61,63,65 
• Recurrence rate was reported in 9 studies from 0-47%.55,56,58-63,65 
• Improvement in vision was reported in 3 studies.56,57,60 One study in India (Sharma et al 2014) 
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reported it as 5.66% (6/106 patients with a BCVA>6/60).57 However, it was reported as high 
as 88% in two other studies (Palakash et al 2015, Xie et al).56,60 It was not clear whether the 
improvement was after the primary TPK or a secondary optical keratoplasty. Vision data in 
these studies was not disaggregated by the main vision categories. 
• Complications reported included glaucoma 2-64% and cataract 5-20%.55,56,60,62,63 
 
Lamellar Keratoplasty (LK): Five studies (3 retrospective audits and 2 case series), all from China, 
examined the outcomes of fungal keratitis in patients who had undergone LK (Table 7).66-70 Follow-
up ranged from 1-20 months. The main indication for LK was non-healing ulcers despite medical 
treatment. However, only infiltrates limited to anterior and middle cornea, where vision less than 6/60 
were considered. Some of the main outcome measures reported were: 
• Graft clarity was reported as 100% by Gao et al and at 92% by Xie et al. 70 66 
• Cure of disease was reported study at 92% and 93% by xie et al in 2 separate audits. 70 69 
• Recurrence rate was reported at 7% and 8% in 2 audits 66,69. However, it was reported at 
0% in a case series of 47 fungal keratitis patients in China by Zhang et al where porcine 
corneas were used. 68 
• Improvement in vision was reported at 72% using porcine corneas 66 while Gao et al 
reported it at 100% in a smaller series of 14 patients. 68 
• Complications: corneal neo-vascularisation was reported in 15%. 68 
 
Amniotic Membrane Graft (AMG): We found one 8-year audit of 23 cases from China (Chen et al 
2006) meeting our inclusion criteria.71 Indications for AMG included: corneal perforation (35%), 
descemetocele (35%), and deep ulcer (95% stromal loss with poor reepithelialisation, 30%). In this 
audit, immediate improvement in visual acuity was reported at 61%. The main complications 
reported were; secondary glaucoma (17%) and graft failure (13%). In a separate head to head RCT 
from Egypt (Abdulhalim et al 2015) comparing AMG with conjunctival flap (CF) for keratitis, AMG 
and CF were all comparable for re-epithelialisation time, persistence of infection, improvement in 
visual acuity and complications.72 
 
Conjunctival flaps: These are frequently used for microbial keratitis which is failing to respond to 
treatment in a resource limited setting. The introduction of a vascular bed over the ulcer is thought 
to help control infection and promote healing. Literature on this method is generally scanty. In a 
recent series from China (Zhong et al 2018), 17 patients with recalcitrant fungal keratitis underwent 
conjunctival flap. The globe was preserved in 15/17(88%) and none developed raised Intra Ocular 
Pressure (IOP).73 
 
5. COLLAGEN CROSS LINKING 
The search returned 886 articles related to corneal cross linking (CXL). After title and abstract review, 
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we identified 45 articles for full paper review. We eliminated 42 papers for not meeting the inclusion 
criteria. The 3 selected studies were exclusively fungal keratitis cases, one was a randomised trial, 
one a retrospective comparative study and the third a case series. Details of these studies are in 
Table 8. 
 
In the RCT (Udaraju et al 2015), patients with severe fungal keratitis not responding to topical 
antifungal therapy after 2 weeks of treatment were randomised to either receive CXL treatment in 
addition to the topical treatment or continue with the antifungal topical treatments only.74 The main 
outcome was treatment failure at 6 weeks, defined as a composite score of perforation and/or 
increase in the infiltrate by 2mm or more; other secondary outcomes included uncorrected vision at 
6 weeks. This study was prematurely stopped after only 13 patients had been enrolled as there was 
already a significantly higher rate of perforation among the CXL group compared to the non CXL 
group (p=0.02). This trial only enrolled patients with severe, extensive, and deep ulcers.  
 
In a more recent trial (Wei et al 2019) 41 patients with fungal ulcerative keratitis were randomised to 
CXL combined with antifungal medications (CXL-M) or antifungal medications alone (M).75 Patients 
were followed up for 6 months. In the cured patients the area of corneal ulcers, the duration of ulcer 
healing, the time to non-observed fungal hyphae by In Vivo Confocal Microscopy (IVCM), the number 
of antifungal medications, the frequency of administered medications, and the maximum ulcer depth 
decreased significantly after CXL compared with the M group. 
 
Vajpayee et al conducted a retrospective audit of 41 eyes with moderate fungal keratitis, 21 whom 
had received CXL on admission and continued with 5% Natamycin and 20 who only received 5% 
Natamycin. CXL was performed on the day of presentation using a standard surgical technique. 
Medical management was continued after the CXL. Main outcome measures were resolution of 
infection, BCVA at 3 months, rate of corneal perforation and size of residual scar. There was no 
difference in all the outcome variables between the two groups, CXL was not particularly associated 
with any adverse events.76 
 
One case series of 8 patients with culture proven fungal keratitis not responding or worsening on 
topical antifungal treatment were treated with CXL in addition to 5% natamycin. The main outcome 
measure was resolution of the infiltrate. After the CXL treatment, in all patients, re-epithelialisation 
occurred within 3 to 8 days. Hypopyon had resolved in 8—11 days, vision improved in 6 patients, 
remained unchanged in 1 and worsened in 1. None of the patients required a corneal transplant. 
The times of review were not specified in this study.77 
 
Another recent small series treated 13 fungal Keratitis patients who were unresponsive to topical 
voriconazole with CXL.78 Seven patients (54%) were healed with topical voriconazole and CXL 
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adjuvant treatment while the remaining six patients did not respond to CXL treatment. Those who 
responded had small and superficial mycotic ulcers. 
 
6. ARGON LASER FOR FUNGAL KERATITIS TREATMENT 
The search returned a total of 165 articles on laser treatment. After title and abstract review, we 
identified 11 articles for full paper review. We eliminated 9 papers for not meeting the inclusion 
criteria. Two RCTs: Argon laser Vs intrastromal voriconazole, and argon laser Vs Amniotic 
Membrane Graft (AMG) were included. Details of these papers are in Table 9.79 
 
Argon laser Vs intrastromal voriconazole: In this RCT (Khater et al, 2016), 40 patients with culture 
proven mycotic keratitis not improving on topical treatment of 0.15% amphotericin, or 5% natamycin, 
or 1% voriconazole, or 1% itraconazole or 0.2% fluconazole were randomised into two groups to 
receive Argon laser or intrastromal voriconazole.80 Argon laser was applied as follows: After 
application of surface anaesthesia and a drop of fluorescein sodium 0.25%. Argon laser therapy was 
done using argon green wavelength (Carl Zeiss LSL 532s AG; Meditec, Inc.). A spot size of 500 m, 
pulse duration of 0.2s, and power of 900 mW were used. Number of shots varied from one case to 
another depending on the size of ulcer. The bed and edge of the ulcer were targeted during argon 
laser therapy with laser shots. Argon laser was found to have a significantly quicker healing time of 
2-4 weeks and fewer patients needing AMG. More patients in the voriconazole group had 
improvement in vision but this was not significant. This RCT had a relatively weak design in 
randomisation, masking, allocation concealment and reporting.80 
 
Argon laser and AMG Vs AMG: In this RCT (Kharter et al,2016) 40 patients with culture proven 
mycotic keratitis not improving on topical treatment with 0.15% amphotericin, or  5% natamycin, or 
1% voriconazole, or 1% itraconazole or 0.2% fluconazole were randomised into two groups to 
receive AMG or Argon laser. Argon laser therapy was done using a similar machine and protocol as 
in the previous study. AMG was done in all cases of the study, after argon laser therapy in the laser 
treatment group and after tissue debridement in the AMG group. The multilayer amniotic membrane 
was sutured to the cornea using nylon 10/0 suture (Ethilon, Ethicon Inc.) under general anaesthesia 
(inlay technique). The amniotic membrane was sewn in with the epithelium/basement membrane 
side facing outwards so that neighbouring epithelial cells of the recipient would migrate over the 
amniotic membrane, allowing ulcer healing. Topical drops were continued after either intervention.  
Argon laser was found to be comparable to AMG in improving vision. However, patients in the argon 
laser arm had a significantly faster healing time compared to those in the AMG arm. 79 
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Figure 1: Flow diagram of the search results 
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Figure 2: Metanalysis of a healed outcome by 21 days in randomised trials of Natamycin Vs 
Chlorohexidine: RR > 1 favours Natamycin 
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Figure 3: Metanalysis of mean difference in final best corrected visual acuity of randomised 
trials comparing Natamycin to Voriconazole: A difference of >0 favours Natamycin 
 
SMD: Standardised Mean Difference in Log MAR units. 
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Figure 4: Metanalysis perforation rates in randomised trials comparing Natamycin to 
Voriconazole: RR > 1 favours Natamycin 
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Figure 5: Metanalysis perforation rates in randomised trials comparing topical Natamycin 
±Voriconazole to Intrastromal Voriconazole: RR > 1 favours Topical treatment alone 
 
 
 
Figure 6: Metanalysis of mean difference in final best corrected visual acuity of randomised 
trials comparing Intrastromal Voriconazole to topical Natamycin ± topical Voriconazole. 
 
SMD: Standardised Mean Difference in Log MAR units.   
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Figure 7: Indications of Therapeutic Penetrating Keratoplasty 
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Table 1: Evidence grading using the SIGN 50 criteria.17 
Evidence 
Grade 
Description 
1++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low 
risk of bias 
1+ Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low 
risk of bias 
1- Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias 
2++ High-quality systematic reviews of case–control or cohort studies 
High-quality case–control or cohort studies with a very low risk of confounding, 
bias or chance and a high probability that the relationship is causal 
2+ Well-conducted case–control or cohort studies with a low risk of confounding, bias 
or chance and a moderate probability that the relationship is causal 
2- Case–control or cohort studies with a high risk of confounding, bias, or chance 
and a significant risk that the relationship is not causal 
3 Non-analytic studies (for example, case reports, case series) 
4 Expert opinion, formal consensus 
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Table 2: Topical Treatment 
STUDY DESIGN RESULTS COMMENTS 
 
NATAMYCIN VS CHLORHEXIDINE 
Rahman et al 
1997 
India 
18 
 
RCT with 4 parallel arms: 
• g-Natamycin 5% 
• g-chlorhexidine 0.05% 
• g-chlorhexidine 0.1% 
• g-chlorhexidine 0.2% 
 
Drop Frequency 
• Day 1: Half hourly for the 1st 3 hours, 
hourly rest of the day 
• Day 2: 2 hourly during day 
• Day 5 onwards: 3 hourly 
 
Inclusion: 
• suppurative corneal ulcers 
• fungal elements on microscopy 
 
Exclusion: 
• Patients with only one eye 
• Patients with diabetes mellitus 
• Patients with mixed infections 
• Unwilling to come for follow up 
• Less than 1 year of age 
• Perforated 
• Lived far away 
 
Outcome Measures (primary not designated): 
• Favourable response at 5 days 
• Healed ulcer by 21 days 
• Toxicity 
N=60 
•  16 patients in g-Natamycin 5% arm 
• 17 patients in g-chlorhexidine 0.05% arm 
• 17 patients in g-chlorhexidine 0.1% arm 
• 8 patients in g-chlorhexidine 0.2% arm 
 
Fungal species: 22 Fusarium, 10 Aspergillus, 3 
Curvularia, 6 other, 19 unidentified. 
 
1) Favourable response at 5 days: 
• g-Natamycin 5% - 7 / 16 (43.8%) 
• g-chlorhexidine 0.05% - 8 / 17 (47.1%) 
• g-chlorhexidine 0.1% - 10 / 17 (58.5%) 
• g-chlorhexidine 0.2% - 6 / 8 (75.0%) 
 
2) Healed ulcer by 21 days: 
• g-Natamycin 5% - 7 / 14 (50.0%) 
• g-chlorhexidine 0.05% - 7 / 12 (58.3%) 
• g-chlorhexidine 0.1% - 8 / 14 (57.1%) 
• g-chlorhexidine 0.2% - 5 / 6 (83.3%) 
 
If the data from all three chlorhexidine arms are 
combined the following results are obtained (RR>1 
favours Natamycin): 
• Favourable response at 5 days; RR 0.76, 
95%CI: 0.44-1.33; p=0.3) 
• Healed ulcer at 21 days; RR 0.73, 95%CI: 
0.36-1.45, p=0.4 
• Toxicity: no toxic effects observed. 
Pilot trial to compare three concentrations of 
chlorhexidine.  
 
The sample size is small and insufficient for a 
comparison with natamycin 5%. 
 
Masking examiner to natamycin is difficult as it can 
leave a white precipitate on ocular surface. Masking 
may not have been possible for treatment failures 
after 5 days. 
 
Data on 12 severe cases is excluded from the 
analysis, because none were cured in 21 days. 
 
Level of evidence: 1- 
 
. 
 
Rahman et al 
1998 
Bangladesh 
19 
 
RCT with 2 parallel arms: 
• g-Natamycin 2.5% 
• g-chlorhexidine 0.2% 
 
Drop Frequency 
• Day 1: Half hourly for the 1st 3 hours, 
hourly for 2 days 
• Day 3-7: 2 hourly 
• Day 7-21: 3 hourly 
 
N=71  
• 36 patients in g-Natamycin arm 
• 35 patients in g-Chlorhexidine arm 
 
Fungal species: 22 Fusarium, 22 Aspergillus, 5 
Curvularia, 10 other, 19 unidentified. 
 
Primary outcome: (RR>1 favours Natamycin): 
• Healed ulcer at 21 days: RR 0.78, 95%CI: 
0.54-1.14, p=0.2  
This study used natamycin of half the usual (2.5% 
instead of 5%). 
 
Masking nurses and ophthalmologists was not 
possible due to appearance differences of the 
formulations 
 
Level of evidence: 1- 
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Inclusion: 
• suppurative corneal ulcers 
• fungal elements on microscopy 
 
Exclusion: 
• Patients with only one eye 
• Patients with diabetes mellitus 
• Patients with mixed infections 
• Unwilling to come for follow up 
• Less than 1 year of age 
• Perforated 
 
Outcome Measures (primary not designated): 
• Favourable response at 5 days 
• Healed ulcer by 21 days (Primary) 
• Toxicity 
• g-chlorohexidine 0.2%-14/32 (43.8%) 
• g-Natamycin 2.5%-9/32 (28.1%) 
 
Secondary outcomes: 
• Favourable response at 5 days: RR 0.24, 
95%CI: 0.09 – 0.63, p=0.0039 
• g-Chlorohexidine 0.2%-31/35 (88.6%) 
• g-Natamycin 2.5% 18/35 (51.4%) 
• Toxicity: 1 patient receiving chlorhexidine 
developed temporary punctate 
epitheliopathy 
 
  
NATAMYCIN VS ECONAZOLE   
Prajna et al 
2003 
India 
22 
RCT with 2 parallel arms: 
(1) g-Natamycin 5% 
(2) g-econazole 2% 
 
Drop frequency 
• Day 1-7: Hourly 7am-9pm 
• Day 7 onwards: 2 hourly 7am-9pm 
 
Inclusion: 
• suppurative corneal ulcers 
• fungal elements on microscopy 
• Ulcer size 2 – 60 mm2 
 
Exclusion: 
• Unwilling to participate 
 
Outcome Measures ( primary not designated) 
• Healed ulcer 
• Time to heal 
N=116 
• 53 patients in g-Natamycin arm 
• 59 patients in g-Econazole arm 
 
Fungal species: 64 Fusarium, 30 Aspergillus, 6 
Curvularia, 12 other, 4 unidentified. 
 
Outcomes: 
Healed ulcer by four weeks (RR>1 favours 
Natamycin):  
• Natamycin 36 / 55 (65.5%) 
• Econazole 39 / 61 (63.4%) 
• RR 1.04, 95% CI 0.64-1.72, p=0.86. 
 
Time to heal: 
• No difference: log rank 0.52, p=0.47 
Randomisation not clear 
 
Masking examiner to NATA is problematic as can 
leave a white precipitate on ocular surface. 
 
Patients were followed up for 4 weeks 
 
Level of evidence: 1- 
 
NATAMYCIN VS VORICONAZOLE 
Prajna et al 
2010 
India  
23 
 
RCT with a 4-arm factorial design: 
• g-Natamycin 5% with scraping 
• g-Natamycin 5% no scraping 
• g-Voriconazole 1% with scraping 
• g-Voriconazole no scraping 
N=120 
• 60 patients in each arm 
 
Fungal species: 44 Fusarium, 19 Aspergillus, 39 
other, 8 unidentified 
Double masking done by using identical opaque 
bottles and having a study nurse wipe the 
natamycin residue before examination 
 
primary and secondary outcomes assessed. 
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Scrapping was done at baseline for all ulcers and 
then repeated in the scraping arms at one and two 
weeks. 
 
Drop frequency 
• Day 1-7: Hourly while awake 
• Day 7-21: 2 hourly while awake 
 
Inclusion: 
• Corneal ulcer 
• fungal elements on microscopy 
 
Exclusion: 
• Mixed infections 
• Younger than 16 years 
• Bilateral disease 
• Live >200km away 
• Pregnant 
• VA <6/60 in fellow eye 
• Allergy to antifungal medication 
• Previous corneal transplant 
• Epithelial defect < 0.5mm 
 
Follow-up was 3 months 
Outcome Measures: 
• BSCVA at 3 months ( Primary) 
• Scar size 
• Perforations  
• Time to re-epithelialize  
 
Primary outcome: 
• After adjusting for scraping, voriconazole 
treatment was associated with a non-
significant trend towards a slightly better 
logMAR visual acuity at 3 months: 0.98 
logMAR better, 95%CI: -0.28 to 0.83, 
p=0.29. 
• Eyes that had repeated scraping showed a 
non-significant trend towards having a 
worse logMAR visual acuity at 3 months: 
0.71 worse, 95%CI: -0.007 to 0.35, p=0.06 
 
Secondary outcomes: 
• Scar size; voriconazole treatment was 
associated with 0.17 mm larger infiltrate / 
scar size diameter (95% CI, 0.20 mm 
smaller to 0.53 mm larger; p=0.37) 
• Time to re-epithelialization; no difference 
in the time to re-epithelialization between 
the NATA and VOR groups. Voriconazole 
associated with a hazard ratio of −0.05 
(95% CI, −0.13 to 0.14; =.61) 
 
Level of evidence: 1- 
 
Arora et al 
2011 
India 
24 
RCT with 2 parallel arms: 
• g-Natamycin 5%  
• g-Voriconazole 1% 
 
Drop frequency: 
• Day 1-14: Hourly 
• Day 14: Titrated as per response 
 
Inclusion: 
• Positive fungal KOH scraping 
 
Exclusion 
• Prior use of antifungal drugs 
• History of herpetic keratitis 
N=30 
• 15 patients in each arm 
 
Fungal species: 3 Fusarium, 12 Aspergillus, 9 
Curvularia, 1 other, 5 not identified 
 
Primary Outcome: 
• Non-significant difference in the time to 
resolution, which was shorter in the NATA 
Vs the VOR groups: 24 Vs 27 days 
(p>0.05) 
 
Secondary outcome (s): RR>1 favours Natamycin 
• Healing rate NATA 15/15, VOR 14/15.  
Sample size small and insufficient for a comparison 
 
Randomisation by lottery 
 
Double masking by using identical opaque bottles 
and having a nurse wipe any white residue from the 
patient’s eye before examination 
 
Level of evidence: 1+ 
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• Previous corneal scars 
• Impending perforation 
• NPL 
 
Follow-up 2 months or until complete resolution 
Outcome measure: 
• Time to healing of ulcer ( Primary) 
• Best Corrected Visual Acuity ( BCVA) at 
3/12 
• Proportion of healed cases 
• Scar size 
 
• Scar size: Not significant 
• Final BCVA: NATA: 1.368 +/-0.887 Vs 
VOR 1.775 +/-1.036 (P = 0.227). 
• RR 3, 95% CI 0.13-68.2, p=0.49 
 
Prajna et al 
2013 
India 
81 
 
RCT with 2 parallel arms: 
• g-Natamycin 5%  
• g-Voriconazole 1% 
 
Drops frequency 
• Hourly until re-epithelialisation.  
• Then QID for at least 3 further weeks. 
 
Inclusion 
• Corneal ulcer 
• fungal elements on microscopy  
• Visual acuity: 6/12 to 6/120 
 
Exclusion 
• Mixed infections 
• Younger than 16 years 
• Bilateral disease 
• Unwilling follow-up 
• Pregnant 
• VA <6/60 in fellow eye 
• Allergy to antifungal medication 
• Previous corneal transplant 
• Epithelial defect < 0.5mm 
 
Follow-up was 3 months 
 
Outcome Measures 
• BCVA at 3/12 ( Primary) 
• Corneal perforation 
• TPK 
N=323 
• 162 patients in each arm 
 
Fungus speciated in 255 cases:  
128 Fusarium, 54 Aspergillus, 20 Curvularia, 56 
other, 68 not identified 
 
Primary Outcome: 
• logMAR BSCVA at 3 months: VOR 1.8 
lines poorer, p=0.006 
 
Secondary Outcomes: 
• logMAR BSCVA at 3 weeks: VOR 1.1 lines 
poorer, p=0.03 
• Fusarium Cases Only: logMAR BSCVA at 
3 months: VOR 4.1 lines poorer, p<0.001 
• Day 6 re-culture positive: NATA 15% Vs 
VOR 48%, p<0.001. 
• Re-epithelialization: faster in Fusarium 
cases with NATA: hazard ration 1.89, 
p=0.005 
• Scar size: Fusarium cases had 
significantly smaller scars at 3 months if 
treated with NATA, -1.02mm, 95%CI: -1.46 
to -0.58. 
• Perforations and /or Therapeutic 
Penetrating Keratoplasty: 18 NATA Vs 34 
VOR. All OR 0.42, 95%CI: 0.22 – 0.80, 
p=0.009.  Fusarium only: OR 0.06, 95%CI: 
0.01 – 0.28, p<0.001. 
The arms were well balanced in terms of the 
demographic, baseline clinical signs and organisms 
cultured.  
 
Randomisation code autogenerated 
 
Double masking done by using identical opaque 
bottles and having a study nurse wipe the 
natamycin residue before examination 
 
Primary and secondary outcomes reported 
 
Level of evidence: 1+ 
 
 
 
Sharma et al 
2015 
RCT with 2 parallel arms: 
• g-Natamycin 5%  
N=118.  
• 60 patients in g-Natamycin arm 
The arms were well balanced in terms of the 
demographic, baseline clinical signs and organisms 
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India 
25 
 
• g-Voriconazole 1% 
 
Drops frequency 
• Day 1-3: Hourly day and night 
• Day 4: Hourly during day, 3 hourly at night 
• Day 5: 2 Hourly while awake until cured 
 
 
Inclusion: 
• above 18 years old 
• symptoms < 14 days 
• epithelial defect (2-6mm) + stromal 
infiltrate +/- hypopyon 
• corneal scrapping +ve 
 
Exclusion: 
• allergy to Natamycin/ Voriconazole 
• Scleral involvement 
• Posterior 1/3 corneal involvement 
• Perforation/ impending perforation 
• Mixed infection 
• Comorbidities 
 
Outcome Measures  
• Healing 
• Final VA at last follow-up (Primary) 
• VA on day 7 
• 58 patients in g-Voriconazole arm 
 
Fungal species: 29 Fusarium, 15 Aspergillus, 46 
other , 28 no growth. 
 
Primary outcome (s): RR>1 favours Natamycin 
• % of patients with healed or resolving 
ulcer; NATA (50/56) Vs VOR (34/51) 
P<0.005 
 
• Final VA at last follow-up; NATA LogMar 
0.6 (CI 0.4-0.8) Vs VOR LogMar 1.1 (CI 
0.9-1.2) P=0.01 
• RR 3.1, 95% CI 1.3-7.2, p=0.009 
 
Secondary outcome 
• Visual acuity on day 7; VA in NATA 
marginally better than VOR (p=0.04) 
 
cultured.  
 
Randomisation code autogenerated 
 
Double masking done by using identical opaque 
bottles and having a study nurse wipe the 
natamycin residue before examination 
 
Primary and secondary outcomes reported 
Shorter incubation time for fungus- 2 weeks instead 
of 3 
 
It was not clear when the final review date was. 
 
Level of evidence: 1+ 
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Table 3: Oral Treatment 
STUDY DESIGN / INTERVENTION RESULTS COMMENT 
 
TOPICAL ITRACONAZOLE VS TOPICAL ITRACONAZOLE + ORAL ITRACONAZOLE 
Agrawal et al 
2001 
India 
34 
 
RCT Arms: 
• g-itraconazole 1% 
• g-itraconazole 1% + itraconazole 
100mg,  
 
Drug frequency: 
• Hourly drops 
• 100mg PO BD*3/52 
 
Inclusion: 
• Suspected fungal keratitis 
Exclusion: 
• Unclear 
 
Follow-up 6 weeks 
 
Outcome measures: (primary not designated) 
• Therapeutic effect 
• Healing of the ulcer by 6 weeks 
 
N=54 
• 27 patients in each arm 
 
Fungal species: 4 Fusarium, 28 Aspergillus, 6 Penicillium, 2 
Candida, 4 Other fungi, 10 No growth  
 
Outcome measure: 
• Healing of ulcer by 6 weeks. 
 
No added benefit found of using an oral anti-fungal in addition to 
topical treatment. RR 1.0, 95%CI: 0.37 – 2.71 
• Fusarium was unresponsive to itraconazole 
 
Method of randomisation unclear 
Inclusion and exclusion not clear 
Not placebo-controlled 
Concerns over blinding as treatment different  
Topical treatment was continued for 6 weeks 
after the resolution of keratitis 
 
Level of evidence: 1- 
 
 
Oral Voriconazole + g-Voriconazole or g-natamycin Vs Placebo + g-Voriconazole or g-natamycin 
Prajna et al 
2016 
India / Nepal 
35 
RCT Arms 
• Tablets Voriconazole 400mg BD then 
200mg BD + g-Natamycin or g-
Voriconazole 
• Placebo+ g-Natamycin or g-
Voriconazole 
 
Drug frequency: 
• Oral Voriconazole; 400mg BD *24hrs 
then 200mg BD* 20/7 
• Drops; week 1-Houlry while patient 
awake; week 2-3-2 hourly while patient 
awake 
 
Inclusion 
N=240 
• 119 patients in the oral voriconazole arm 
• 121 patients in the placebo group 
 
Fungal species: 72 Fusarium, 63 Aspergillus, 8 Culvuralia, 4 
Bipolaris, 12 Unidentified hyaline, 18 unidentified dematiaceous, 16 
Other spp,  44 No growth 
 
Primary outcome 
• There was no difference in rate of perforation or need for 
TPK: HR 0.82 (CI 0.57 to 1.18) P=0.29, HR<1 favours oral 
Voriconazole 
 
Secondary outcome (s) 
• BCVA at 3 weeks and 3 months: no difference in the two 
groups  
Randomisation 
Masking by having identical placebo and 
Voriconazole tablets 
Primary and secondary outcomes reported 
No benefit seen in adding oral voriconazole to 
topical antifungal treatment for severe fungal 
keratitis. 
 
Level of evidence: 1+ 
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• Confirmed fungal keratitis 
(KOH/culture) 
• Severe keratitis VA 3/60 or worse 
 
Exclusion 
• Mixed infections 
• Younger than 16 years 
• Bilateral disease 
• Pregnant 
• Liver disease 
• Allergy to antifungal medication 
• VA <6/60 in the fellow eye 
 
Follow-up was for 3 months 
 
Outcome measures 
• Perforation rate/need for TPK at 3/12 
(primary) 
• (BSCVA) at 3/52 & 3/12 
• Infiltrate and/or scar size at 3/52 & 
3/12 
• Time to re-epithelialization 
• Microbiologic cure at6days (±1day) 
• Complications such as endophthalmitis 
and evisceration. 
• Infiltrate/scar size at 3 weeks and 3 months: no difference 
in the two groups 
• Time to re-epithelialization: no difference in the two groups 
• Cure rate at 6 days: no difference in the two groups 
• Rate of adverse events: statistically significant increase 
among the oral voriconazole Vs placebo group (58/120 Vs 
28/120; P = .001) 
 
Oral Voriconazole Vs Oral Ketoconazole 
Sharma et al 
2017 India36 
RCT Arms 
• Tablets Voriconazole (VCZ) 200mg BD 
+ g-Natamycin 5% 
• Tablets Ketoconazole (KCZ) 200mg 
BD+ g-Natamycin or g-Voriconazole 
 
Drug frequency: 
• Oral Voriconazole or Ketoconazole 
200mg BD (duration not specified) 
• Drops; g-Natamycin 5% every 1 hour, 
for the first 48 hours, every 2 hours 
during waking hours until epithelial 
healing, and then every 4 hours for 3 
weeks. 
 
Inclusion 
N=50 
• 25 patients in the oral voriconazole arm 
• 25 patients in the placebo group 
 
Fungal species: 8 Fusarium, 6 Aspergillus, 1 Culvuralia, 1 
Alternaria, 1 Helminthosporium spp, 33 No growth 
 
Primary outcome 
• BSCVA at 3 months; oral VCZ mean Log MAR 1.3 ± 0.07 
oral KCZ mean log MAR 1.5 ± 0.07, p=0.02 
 
Secondary outcome (s) 
• Re-epithelialisation time VCZ 41± 11 Vs KCZ 43± 12 
days, p=0.71. 
• Final scar size VCZ 4.47 6± 0.11 Vs KCZ 4.79 6 ± 
0.11mm, p=0.03 
•  
Randomisation by computer 
Double masking, all tablets were wrapped in 
uniformly coloured paper 
Primary and secondary outcomes reported 
Oral VCZ more effective than oral KCZ in 
cases of severe fungal keratitis, 
Level of evidence: 1+ 
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• Confirmed fungal keratitis 
(KOH/culture) 
• Maximum diameter >5mm 
• Involving >4mm of the centre of the 
cornea 
• >50% stromal diameter 
 
Exclusion 
• Mixed infections 
• Evidence of herpetic Keratitis 
(history/examination) 
• Perforation/impending 
• Younger than 18 years 
• Bilateral disease 
• Pregnant/Lactating 
• Unwilling for follow-up 
• Previous antifungal treatment 
• Diabetes 
 
Follow-up was for 3 months 
 
Outcome measures 
• BSCVA at 3 months (primary) 
• Percentage of healed cases 
• Scar size 
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Table 4: Results of studies on Fluconazole injection for treatment of fungal keratitis 
STUDY DESIGN RESULTS COMMENT 
Sub conjunctival Fluconazole RCT 
Mahdy et al 
2010 Egypt  
37 
RCT Arms. 
•  g-Amphotericin B and sub conjunctival Fluconazole 
• g-Amphotericin B alone.  
 
Drug frequency: 
• Fluconazole was injected daily for 10 injections and after 
every 48 hours for another 10 injections 
• Drops 2 hourly * 21/7 
 
Inclusion:  
• Clinical presentation of Fungal Keratitis 
 
Exclusion: 
• Not clear 
 
Follow-up: 3 months 
 
Outcome measures: (primary not designated) 
• Healing time 
• Healing rate at 3/12  
N=48 
• 24 patients in g-Amphotericin B and sub 
conjunctival Fluconazole arm 
• 24 patients in g-Amphotericin B alone arm 
 
Fungal species: 0 Fusarium, 20 Aspergillus, 14 
Candida, 4 Penicillium, 10 No growth 
 
Outcomes:  
• Healing time: Fluconazole group 31 days Vs 
Amphotericin B alone 37 days (p<0.05). 
Fluconazole had a faster healing time 
• Healing rate at 3/12. Fluconazole 20/24 
(83%), Amphotericin B only 16/24 (67%) 
(p<0.05) 
• RR 1.2, 95% CI 0.9-1.7, p=0.2. RR> 1 
favours Fluconazole 
  
Methodologically this is a weak study. 
Inclusion and exclusion not clear 
Method of randomisation unclear. May not have 
been completely random allocation – as the two 
groups appear matched for fungal species. 
Observers were not masked to allocation. 
Randomisation and blinding protocol unclear 
Outcome measures not clear 
 
Level of evidence: 1-  
Case series 
Yilmaz et al 
2005 
Turkey 38 
Case series 
• Sub conjunctival fluconazole. 
 
Drug frequency 
• Sub conjunctival fluconazole 2% up to 1ml BD, for at least 
5/7. If necessary, therapy was continued OD for a 
maximum of 14/7 after 5/7 of injections. 
 
Inclusion:  
• Severe microscopy confirmed fungal keratitis, not 
responding to initial treatment (Topical fluconazole 2% 
hourly, Intravenous fluconazole and oral itraconazole) at 
10/7.  
 
Exclusion: 
• Negative culture result 
 
Outcomes: (primary not designated) 
N=13 
 
Fungal species: 1 Fusarium, 1 Aspergillus, 4 Candida, 
7 No growth 
 
Outcome (s):  
• Healed 13/13 
• Time to heal, 6 healed in 5/7, 4 in 10/7 and 3 
in 14/7 
• Improvement in Visual acuity (11/13), 
• Hypopyon clearance time (mean 5.06 days 
SD 2.06 days) 
• Corneal ulcer resolution (mean 28.40 days 
SD 11.66 days) 
• Recurrence rate (3/13) 
• Complications (0%)  
This series included only severe fungal keratitis 
cases 
Sub conjunctival fluconazole given as second 
line treatment 
Dose of fluconazole was not the same for all 
patients 
Follow-up time for the patients not clear 
Small series 
 
Level of evidence: 3  
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• Healed  
• Healing time 
• Improvement in VA 
• Hypopyon clearance time 
• Corneal ulcer resolution 
• Recurrence rate 
• complications 
Dev et al 
2006 India 
40 
Case series 
• Sub conjunctival Fluconazole 
 
Drug frequency 
• Fluconazole Injection given for 5-40 days 
 
Inclusion: 
• Culture proven fungal keratitis 
• Not responding to topical (5% natamycin, 2% Econazole, 
1% clotrimazole, 1% Itraconazole) and Oral Ketoconazole 
200mg BD 
 
Exclusion: 
• Not clear 
 
Outcomes ( primary not designated) 
• Eradication of the infection 
• Toxicity  
 
N=33 
 
Fungal species: 22 Fusarium, 10 Aspergillus, 
Curvularia 
 
Outcomes:  
• Eradication of infection 18/33 (54.05%) 
• Toxicity 0/33 
•  
 
Letter to the Editor 
All fungal species in this series were filamentous 
 
Level of evidence: 3 
 
 
Mahdy et al 
2010 Egypt  
41 
Case series. 
• Topical Amphotericin B and sub conjunctival Fluconazole 
 
Drug frequency 
 
• 0.5-mL sub-conjunctival injection of fluconazole 2 mg/mL 
was injected daily for 10 injections and then every 48 
hours for another 10 injections 
• Drops 2 hourly * 21/7 
 
Inclusion:  
• Clinical fungal keratitis (elevated slough, feathery edges, 
gutter formation),  
• Not responding to topical treatment after 7 days 
 
Exclusion:   
• No clear 
 
N= 12 
 
Fungal species: 0 Fusarium, 2 Aspergillus, 5 Candida, 
1 Penicillium, 4 No growth 
  
• Healing at 21 days; 9/12 (75%) 
• Complications; conjunctival haemorrhage 
3/12 ( 25%)  
Case series was mainly to assess safety and 
efficacy of a combination therapy of topical 
amphotericin B and sub conjunctival fluconazole 
for the treatment of fungal keratitis 
Pre-trial pilot 
Exclusion criteria not clear 
Included clinical fungal cases 
 
Level of evidence: 3  
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Follow-up 3 months 
Outcome measures (primary not designated) 
•  
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Table 5: Results of studies on Amphotericin B injection for treatment of fungal keratitis 
STUDY DESIGN RESULTS COMMENT 
Intracameral Amphotericin B RCT 
Sharma 
2015 India 
42 
RCT 3 Arms 
• Topical 5% Natamycin and 0.15% topical amphotericin B + 
oral ketoconazole 
• Topical 5% Natamycin and 0.15% topical amphotericin B + 
Intracameral amphotericin B (ICAMB)+oral Ketoconazole 
• Topical 5% Natamycin and 0.15% topical amphotericin B + 
Intracameral amphotericin B (ICAMB)+oral Ketoconazole+ 
drainage of hypopyon 
 
Drug frequency 
• g-Natamycin 5% hourly during day and 2 hourly at night 
• g-Amphotericin B 0.15% 2 hourly 
• ICAMB 0.5µg in 0.1ml 5% dextrose repeated 72hours if no 
improvement to a maximum of 3 injections. 
• PO ketoconazole BD 
 
Inclusion:  
• Smear positive fungal keratitis 
• Involvement of anterior one-third or more with concomitant 
hypopyon. 
Exclusion: 
• One-eyed patients 
• children <12 years of age 
• Cases with keratitis limited to anterior third of the stroma, 
• corneal thinning (<300 mm) on anterior segment OCT 
•  concurrent sclera involvement were excluded. 
 
Follow-up time  not clear 
 
Outcomes ( Primary not designated) 
• Treatment success 
• Time to disappearance of hypopyon 
• Time to healing 
• Final BCVA 
• Cataract 
• Hyphema 
N=45 
• 15 patients in each arm 
 
Fungal species: 2 Fusarium, 7 Aspergillus, 30 No 
growth 
 
Outcomes:  
• Treatment success rate (resolution of 
stromal infiltrates, healing of epithelial defect 
and disappearance of endothelial plaque).  
Topical treatment alone  (11/15) Vs ICAMB  
(9/15), Vs  ICAMB + draining of hypopyon 
(11/15) P=0.66 
 
Secondary Outcomes:  
• Tine to disappearance of hypopyon P=0.7 
• Time to heal P=0.18 
• Final visual acuity P=0.8 
• Presence of complications, Cataract P=0.1, 
Hyphema P= 0.5 
 
Occurrence of cataract as a complication was more 
commonly seen in ICAMB and hypopyon wash 
+ICAMB groups compared to topical treatment group 
 
Sample might have been small for the 
comparisons 
A big proportion of the fungal cases were not 
culture positive 
Randomisation done using tables 
It was not feasible to mask  
Primary and secondary outcomes not 
designated 
3 arms might be difficult to compare 
 
Level of evidence: 1- 
 
 
Sharma 
2015 India 
43 
Non-randomised clinical trial, 2 arms. All patients were started on 
topical natamycin or fluconazole. They were evaluated at one week 
N=104,  
• 49 patients in the good response arm ( 
topical treatment alone) 
Non-randomization, selective bias per response. 
Group allocation was per response or no 
response to topical treatment at 7/7 
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and additional intra cameral AMB was injected if there had been no 
response by one week. 
• Arm I showed good response at one week to topical 5% 
Natamycin or 0.3% fluconazole or topical itraconazole and 
tablets fluconazole  
• Arm II showed No response at one week  to topical 5% 
Natamycin or 0.3% fluconazole or topical itraconazole and 
tablets fluconazole 
 
Drug frequency 
• Drops- Hourly during day and 2 hourly at night 
• ICAMB 5-10µg in 1ml of 5% dextrose repeated 3-6 days 
depending on the response 
 
Inclusion: 
• smear-positive deep fungal keratitis; 
• corneal ulcers presenting with history of trauma from 
organic matter; 
• ulcers not responding to topical and systemic antifungal 
• medications for 7 days (with history of trauma from organic 
matter) 
• abscess at presentation (with history of trauma from 
organic matter 
 
Exclusion: (not clear) 
 
Follow-up for 4 weeks 
 
Outcomes 
• Time for epithelialization/decrease in infiltrates and ulcer 
resolution ( Primary) 
• Improvement in BCVA 
• Time for hypopyon disappearance 
• Scars 
• Complications  
 
• 55 patients in the No response arm ( ICAMB) 
 
Fungal species: Not reported 
 
Primary outcome: (no significant difference) 
• Time for epithelialization with a decrease in 
infiltrates and ulcer resolution. Topical 
treatment 13.08 ± 4.33 days Vs ICAMB arm 
12.37 ± 5.50 days (p value not given but 
calculated as p=0.15 ) 
 
Secondary outcomes:  
• Improvement in best-corrected visual acuity 
(BCVA). Topical treatment 0.55 ± 0.30 
logMAR Vs ICAMB arm 1.40 ± 0.2 logMAR. 
(Calculated p<0.01) 
• Mean time for hypopyon disappearance: 
Topical treatment 17.12 ± 8.7 days Vs 
ICAMB 13.4 ± 8.0 days (calculated p<0.01) 
• More scars in Topical treatment Vs ICAMB  
(P<0.05) 
• Less complications in ICAMB Vs Topical 
treatment (p<0.05) 
 
 
 
No masking 
Primary and secondary outcomes reported 
 
Level of evidence: 1- 
 
 
Gupta 
2019 
India44 
Non-randomised clinical trial 2 arms of cases that were not 
responding to standard treatment. All patients received Intracameral 
Injection of Liposomal Amphotericin B (ICAMB) 10 micrograms/0.1 
mL + g-Natamycin 5% + Oral Itraconazole 200mg BD. However, the 
timing of the ICAMB injection was different between the arms.  
• Arm I early at 2 weeks 
• Arm II late  at 4 weeks 
 
Drug frequency 
N=50,  
• 25 patients in the early arm (Group I) 
• 25 patients in the late arm (Group II) 
 
Fungal species: 4 Fusarium, 11 Aspergillus, 1 
Curvularia, 1 Bipolaris, 32 No growth 
 
Outcome: 
• The mean healing time in Group I was 17.5± 
Non-randomization 
 
No masking 
Primary and secondary outcomes reported 
 
Level of evidence: 1- 
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• 0.1ml of 10µg of ICAMB repeated every 48-72 hours until a 
maximum cumulative dose of 50µg or resolution of 
infiltrates 
• g-Natamycin 5% hourly for 2 weeks 
• Oral Itraconazole 200mg BD 
• g-Moxiflocxacin tds 
• g-Atropine 1% tds 
 
Inclusion: 
• Confirmed fungal keratitis (Microscopy/culture) 
• >18 years old 
• infiltrates more than 5 mm in size and involving more than 
2/3rd of the corneal thickness 
• ulcers not responding to conventional antifungal for 2 
weeks 
 
Exclusion:  
• Not willing for follow-up 
• Perforation/impending 
• Scleral involvement 
• Endophthalmitis 
• Mixed infection 
• Antifungal allergy 
• Immune compromised 
• Renal disease 
• Liver disease 
 
Follow-up:  3 months 
 
Outcomes (Primary not designated) 
• Treatment success defined as resolution of the corneal 
infiltrate with scarring, disappearance of the corneal 
endothelial plaque and hypopyon, and healing of the 
epithelial defect 
• Final visual acuity 
• Corneal opacity 
Complications 
• Cataract, hyphema, increased inflammation, pain 
3.64 days and 32.2± 8.89 days in Group II 
(p<0.001) 
• Maculo-leucomatous corneal opacity in 12 
(48%) eyes in Group I versus 4 (16%) eyes 
in Group II (p=0.03) 
• leucomatous corneal opacity in 13 (52%) 
eyes in Group I versus 16 (64%) eyes in 
Group II (p=0.56) 
• Adherent leucoma in none of the eyes in 
Group A versus 5 (20%) eyes in Group II 
(p=0.05). 
• None of the eyes in Group I required 
additional surgical intervention while 10 eyes 
in Group II developed corneal perforation, 
thus requiring surgical intervention 
(p=0.006). 
 
 
Intracameral Amphotericin B Case series 
Yoon et al 
2007 China 
45 
Audit 
• Conventional topical antifungal + Intra Cameral 
Amphotericin B (ICAMB) 
• Conventional topical antifungal alone (0.15% amphotericin 
B and 1% fluconazole and PO fluconazole 200 mg/d. 
N=32 
• 14 ICAMB 
• 17 topical alone 
 
Non randomised-topical antifungal group was 
treated July-Dec 2005, ICAMB Jan-June 2006 
 
Primary and secondary outcomes not 
designated 
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Drug frequency 
• 10 µg of amphotericin B in 0.1 mL into the anterior 
chamber single dose 
Inclusion 
• Fungal keratitis 
• Minimum follow-up of 3/12 
 
Exclusion: 
• Not clear 
Outcomes (primary not designated) 
• Time to heal of epithelial defect 
• Time to disappearance of hypopyon 
• Final VA 
• Time to final improvement 
• Final outcome 
• Side effects 
 
Fungal species: 10 Fusarium, 7 Aspergillus, 3 
Alternaria, 1 Curvularia, 6 Candida, 4 Not identified  
 
Outcomes:  
• Mean final visual acuity (log MAR) ICAMB 
1.6 ± 1.1 Vs Topical alone 1.3 ± 1.4 (P = 
0.24) 
• Time to hypopyon disappearance, Group 
ICAMB 9.4+/-9.4 Vs Topical alone 26.7± 
21.3 (P=0.03) 
• Time to epithelial defect closure, ICAMB 
19.8± 10.4 Vs Topical alone 32.6 +/-22.8 (P 
= 0.08) 
• Time to final improvement, ICAMB 26.6 ± 9.2 
Vs Topical alone 52.8 ± 38.2 days (P = 0.04) 
• Treatment success, ICAMB 92.9% Vs 
Topical alone 82.4% (P = 0.38) 
 
ICAMB had a significantly better time to final 
improvement and faster hypopyon clearance 
compared to topical alone 
 
Study not powered to test differences 
Level of evidence: 2- 
 
 
 
Yilmaz 
2007 
Turkey 82 
Case series 
• Intracameral Amphotericin B 
Drug frequency 
• ICAMB 0.5µg in 0.1ml 5% dextrose repeated PRN 1-10 
days apart 
 
Inclusion 
• Fungal keratitis not responding to 0.3% topical and 
intravenous fluconazole and oral itraconazole for 14/7 
 
Exclusion: Not clear 
 
Follow-up: 6 months 
 
Outcomes ( Primary not designated) 
• Treatment success defined as resolution of the corneal 
infiltrate, disappearance of the endothelial plaque, and 
healing of the epithelial defect 
• Complications  
N=14 eyes of 12 patients 
 
Fungal species: 2 Fusarium, 4 Aspergillus,  2 
Candida, 7 No growth 
 
Outcomes 
•  Treatment success; 12/14 
• Complications rate; 4/14 (cataract) 
 
This study had a small sample size 
Included only severe cases 
 
Level of evidence: 3 
 
Intracameral & Intrastromal Amphotericin B Case series 
Hu 2016 
China 83 
Case series 
• Intracameral Amphotericin B 
 
N=9 
 
Small sample size 
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Drug frequency 
• ICAMB 50µg/0.1ml + Intrastromal 25µg/0.1ml Injections 
were repeated PRN until resolution.  
• Intrastromal injections were repeated after more than 5/7, 
and intracameral after more than 3/7 
 
Inclusion 
• Fungal keratitis not responding to 0.5% topical fluconazole 
combined with 5% natamycin or 0.25 topical amphotericin 
B and oral itraconazole for 7/7 
• Fungal keratitis presenting with serious corneal damage 
and intraocular extension 
 
Exclusion 
• Cases that had some involvement of adjacent sclera, frank 
corneal perforation, shallow anterior chamber, and 
presence of intravitreal fungal mass by B- ultrasound 
scanning were excluded 
 
Follow-up 2-4 months 
 
Outcomes ( primary not designated) 
• Treatment success defined as resolution of the corneal 
infiltrate, disappearance of the anterior chamber 
inflammation, and healing of the epithelial defect 
• Complications rate 
• Recurrence rate 
 
Fungal species: 3 Fusarium, 1 Aspergillus, 1 
Alternaria, 1 Unidentified, 2 No growth  
 
Outcomes: 
• Treatment success. 9/9 
• Complications rate: Bleeding 2/9, uveitis 9/9, 
secondary glaucoma 6/9, cataract 9/9 
• Recurrence rate: 0/9 
 
Mixed routes for amphotericin injection 
(intrastromal and intracameral) 
 
Difficult to conclude on which route had the most 
effect 
 
A significant number of complications were 
reported in this study 
 
Level of evidence: 3 
 
Intrastromal Amphotericin B 
Nada et al 
2017 Egypt 
47  
2-year Audit (2015-2016) 
• Group A: Intrastromal Amphotericin +g-Fluconazole 2%. 
47 cases resistant to topical treatment (g-Natamycin 2.5% 
(12), g-Amphotericin B 0.3 mg/mL (11), g-Itraconazole 2% 
(13), and g-fluconazole 2% (5) 
 
• Group B: treated with topical amphotericin B (Fungizone 
50 mg vial) 0.3 mg/mL in 5% dextrose five times daily, in 
addition + regular debridement of the ulcer every 48 hours 
to facilitate penetration of the drug. 
 
Drug frequency: 
• Intrastromal Amphotericin B 2–3 mid stromal injection sites 
around the ulcer with 0.1–0.15 mL containing 2–3 μg of 
amphotericin B (single dose) 
N=68 
• 41 patients received Intrastromal 
Amphotericin B (Group A)  
• 27 patients received g-Amphotericin B ( 
Group B) 
 
Fungal species: 11 Fusarium, 17 Aspergillus, 31 
Candida, 5 Alternaria, 4 Penicillium 
 
Outcome (s) RR > 1 favours intrastromal 
Amphotericin 
• Complete healing: Group A 34/41 (82.9%), 
Group B 16/27 (59.3%). RR 1.4 95% CI 0.7-
3.1, p=0.3 
No randomisation was done 
 
Patients were allocated depending on their 
response rate  
 
Level of evidence: 2- 
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• Topical drops; five times daily 
 
Inclusion 
• Culture positive fungal keratitis 
 
Exclusion not clear 
 
Follow-up 2 months 
 
Outcomes ( primary not designated) 
• Complete healing 
• Mean duration of healing 
• Burning sensation  
 
 
 
• Mean duration of healing: Group A 24± 6.42 
days, Group B 39.66± 13.6 days, (calculated 
p<0.01) 
• Burning sensation: Group A 4/41 ( 9.8%), 
Group B 11/27 (40.7%). RR 5.6 95% 2.0-
15.4 p<0.01 
 
Intrastromal Amphotericin B had a significantly better 
healing rate, faster healing time and less burning 
effect than topical amphotericin B) 
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Table 6: Results of studies on Voriconazole injection for treatment of fungal keratitis 
STUDY DESIGN RESULTS COMMENT 
Intrastromal Voriconazole RCT 
Sharma 
2013 India 
48 
RCT 2 Arms 
• Arm I: g- Voriconazole 1% + g-Natamycin 5% 
• Arm II: Intrastromal Voriconazole injections + g-Natamycin 
5% 
 
Drug frequency 
• Drops 2 hourly while awake for 72 hours then 4 hourly 
• Five injection spots of intrastromal voriconazole (50µg/0.1 
ml). At least 3 injections were given 72 hours apart 
 
Inclusion:  
• Smear- or culture-proven fungal ulcers + 
• Larger than 2mm + 
• Involving up to 2/3 of the stromal thickness + 
• Not showing any signs of clinical improvement after 2 
weeks of topical natamycin therapy. (Increase in size of 
epithelial defect, a decrease of less than 20% of stromal 
infiltrate or scar complex, or increasing hypopyon) 
 
Exclusion: 
• Mixed infection on smear or culture analysis 
• Evidence of herpetic keratitis in history or upon 
examination 
• Impending perforation 
• Bilateral ulcers 
• Those with vision less than 6/60 in the fellow eye 
• Patients younger than 18 years 
 
Follow-up 3 months 
Outcomes 
• BSCVA at 3 months (primary) 
• Time to healing 
• Size of scar 
• Perforation rate 
 
N=40 
• 20 patients in each arm 
 
Fungal species: 7 Fusarium, 12 Aspergillus, 5 
Curvularia, 1 Alternaria, 15 No growth 
 
Primary outcome:  
• Best spectacle-corrected visual acuity 
(BSCVA) at 3 months. It was significantly 
better in the topical arm: Mean BSCVA g-
VOR 1.295 ± 0.5 log MAR Vs intrastromal 
VOR 1.692 ± 0.29 log MAR (p=0.008) 
 
Secondary Outcomes:  
• Time to healing. g-VOR 28.9 ± 19.1 days Vs 
intrastromal VOR 36.1 ± 20.0 days (p=0.38) 
• Size of the scar. g-VOR 4.36 ± 1.38 mm Vs 
intrastromal VOR 5.3 ± 1.4 mm (p=0.06) 
• Perforation rate. g-VOR (1/20) Vs 
intrastromal VOR (4/20) (p=0.22). RR >1 
favours g-VOR. RR=4, 95% CI 0.4-32.7, 
p=0.2 
 
Randomisation done by variable block 
Masking was impossible 
Primary and secondary outcomes clearly 
reported 
Sample size may not have been adequate for 
some of the secondary outcomes 
 
Level of evidence: 1+ 
 
Narayana 
2019 
India84 
RCT 2 Arms 
• Arm I: Intrastromal Voriconazole (ISV) + g-Natamycin 5% 
• Arm II: g-Natamycin 5% alone 
 
N=70 
• 35 patients in each arm 
 
Randomisation done by 1:1 fashion 
Outcome masking possible for examining 
physicians, microbiologist, optometrist at 
3months, 
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Drug frequency 
• 3-5 injection spots of intrastromal voriconazole (50µg/0.1 
ml) repeated on day 3 and 5 
• Frequency of g-Natamycin not mentioned 
 
Inclusion:  
• Smear- or culture-proven fungal ulcers + 
• Visual acuity worse than 20/70 (Log MAR 0.54) 
 
Exclusion: 
• Mixed infection  
• Impending or perforation 
• Limbal involvement 
• NPL in affected eye 
• Those with vision less than 20/200 (6/60) in the fellow eye 
• Patients younger than 18 years or older than 70 years 
• Patients who were cognitively impaired 
• Patients unable to complete follow-up 
 
Follow-up 3 months 
Outcomes 
• Microbiological cure at 3 days (primary) 
• BSCVA at 3 weeks & 3months 
• Size of infiltrate/scar at 3 weeks & 3months 
• Perforation rate/need for TPK 
• Microbiological cure at 7 days 
 
Fungal species: 19 Fusarium, 17 Aspergillus, 4 
Curvularia, 15 Others, 13 No growth 
 
Primary outcome:  
• Microbiological cure at 3 days. Culture 
negative results 21/35 (60%) in g-Natamyicn 
+ ISV Vs 23/35 (68%) in g-Natamycin only 
group. aOR of a culture positive result in the 
ISV arm Vs g-Natamycin only arm was 1.82 
(95% CI 0.65-5.83; p=0.26) 
 
Secondary Outcomes:  
• BSCVA at 3 weeks. Those randomized to 
ISV injection showed 1.6 log MAR 
(approximately 1.5 Snellen lines) worse 
visual acuity at 3 weeks after controlling for 
baseline visual acuity (95% CI, -1.2 to 4.4 
log MAR; p=0.25) 
• Size of the infiltrate/scar was 0.69 mm larger 
among those who were randomized to ISV 
injection after controlling for baseline 
measurements (95% CI, 0.04-1.33 mm; 
p=0.04). 
• Perforation rate. ISV (8/35) Vs intrastromal 
VOR (3/35) aHR=2.85 (95% CI 0.76-10.75, 
p=0.12) 
• Microbiological cure at 7 days; aOR of a 
culture positive result in the ISV arm Vs g-
Natamycin only arm was 1.98 (95% CI 0.69-
5.91; p=0.20) 
 
Primary and secondary outcomes clearly 
reported 
Sample size may not have been adequate for 
some of the secondary outcomes 
 
Level of evidence: 1+ 
 
    
Intrastromal Voriconazole Case series 
Sharma 
2011 India 
85 
Case series 
• Intrastromal Voriconazole (50µg/0.1ml)  
 
Drug frequency 
• Week 1-2: g-Natamycin 5%  2 hourly, if no improvement, 
• Week 2-4: g-Natamycin 5% + g-Voriconazole 1% 2 hourly 
+ PO Voriconazole 200mg BD, if no improvement,  
• Week 4:  Five injection spots of intrastromal voriconazole 
(50µg/0.1 ml) repeated 72hours if no improvement. In 
addition topical and PO treatment 
 
N= 12 
 
Fungal species: 3 Fusarium, 8 Aspergillus, 1 
Curvularia 
 
 
Outcomes 
• Healing at 3 months (10/12) 
• Improvement in BCVA at 3 months (10/12) 
 
Included only fungal cases resistant to g-
Natamycin and Voriconazole + PO Voriconazole 
 
Level of evidence: 3 
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Inclusion 
• Proven fungal keratitis non-responsive on 4 weeks of 
topical Natamycin (5%) and 2 weeks of topical 
Voriconazole (1%) and oral Voriconazole (200 mg BD) 
  
Exclusion 
• Involvement of adjacent sclera 
• Impending or frank corneal perforation 
• Presence of descemetocele 
• Concomitant endophthalmitis 
 
Follow-up: Follow-up 3 months 
 
Outcomes 
• Healing at 3 months 
• Improvement in BCVA at 3 months 
Intrastromal Voriconazole had good response to 
fungal cases resistant to g-Natamycin, g-Voriconazole 
and oral Voriconazole. 
Kalaiselvi 
2015 India 
51 
Case series 
• Intrastromal Voriconazole (50 µg/0.1 mL) 
 
Drugs frequency: 
• Week 1-2: g-Natamycin 5%  2 hourly, if no improvement, 
• Week 2-4: g-Natamycin 5% + g-Voriconazole 1% 2 hourly 
+ PO Voriconazole 200mg BD, if no improvement,  
• Week 4:  Five injection spots of intrastromal voriconazole 
(50µg/0.1 ml), repeated within 1 week if no imprvement 
 
Inclusion 
•  Proven fungal keratitis non-responsive on 4 weeks of 
topical Natamycin (5%) and 2 weeks of topical 
Voriconazole (1%)  
Exclusion 
• Mixed corneal infections 
• Perforated corneal ulcers or those with impending 
perforation 
• Presence of descemetocele 
• Involvement of the adjacent sclera 
• Ulcers with clinical features of non-infective and 
autoimmune conditions 
• Fungal ulcer associated with endophthalmitis 
• Patients <16 years and beyond 80 years 
• Patients with one eye. 
 
Follow-up: 3 months 
 
N=25 
 
Fungal species: 13 Fusarium , 4 Aspergillus, 1 
Curvularia, 2 Exserohilum, 2 Unidentified hyaline 
fungus,  3 Unidentified 
 
Outcomes 
• Healing at 3 months (18/25) 
• Improvement in BCVA (16/25) 
 
Intrastromal Voriconazole had good response to 
fungal cases resistant to g-Natamycin, g-Voriconazole  
Included only fungal cases resistant to g-
Natamycin and Voriconazole + PO Voriconazole 
 
Level of evidence: 3 
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Outcomes ( primary not designated) 
• Treatment success-healing with scar, improvement in 
vision 
• Treatment failure-non healing, progression, perforation 
 
Nagar 
2015 India  
52 
Case series 
• Intrastromal Voriconazole (50 µg/0.1 mL) 
 
Drug frequency 
• Week 1-2: g-natamycin 5% 2 hourly and PO itraconazole 
100mg BD 
• Week 2: Five injection spots of intrastromal voriconazole 
(50µg/0.1 ml) as one time dose 
 
Inclusion 
• Fungal keratitis involving deep corneal stroma not 
responding to 5% topical natamycin and oral itraconazole 
 
Exclusion 
• Perforated corneal ulcer 
• Anaesthetic cornea 
• Lagophthalmos  
 
Follow up: variable 
 
Outcomes (primary not designated) 
• Improvement in visual acuity at 4 months (20/30) 
• Resolution of the infection (26/30) 
• Healing time, Mean 5 weeks +/-1 week 
 
 
N=30 
 
Fungal species: 7 Fusarium, 7 Aspergillus, 2 Candida 
14 No growth 
 
Outcomes 
• Improvement in visual acuity at 4 months 
(20/30) 
• Resolution of the infection (26/30) 
• Healing time, Mean 5 weeks ± 1 week 
 
Not sure if this was peer reviewed 
 
Level of evidence: 3 
 
Intracameral Voriconazole 
Shen 2010 
China 53 
Case series 
• Intracameral Voriconazole 100µg/0.1ml 
 
Drug frequency 
• Intracameral Voriconazole 100µg/0.1ml OD until resolution 
( 1-8 injections) 
 
Inclusion 
• Proven fungal keratitis progressing to endophthalmitis on 
5% topical Natamycin, 0.15% topical Amphotericin B, 1% 
Voriconazole, 200mg Itraconazole 
N=10 
 
Fungal species: 6 Fusarium, 2 Aspergillus, 1 
Alternaria, 1 Acremonium 
 
Outcomes 
• Resolution (6/10) 
 
Included patients with severe fungal keratitis 
with AC spread 
 
Level of evidence: 3 
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Exclusion  
• Not clear 
 
Follow-up 4 months 
 
Outcomes  
• Resolution 
• TPK 
 
Injection given OD until resolution of the AC fungal infiltrate 
Intracameral + Intrastromal Voriconazole  
Killani 2015 
India 86 
Case series 
• Intracameral and intrastromal voriconazole (50 µg/0.1 mL) 
 
Drug frequency 
• Week 1-3, g-Natamycin 5% & g-Voriconazole 1% 2 hourly, 
+ PO itraconazole 100mg BD 
• Week 2-3 if no improvement, ring intrastromal voriconazole 
50µg/0.1ml and intracameral 50µg/0.1ml. A second 
injection was given 48 hours later if no clinical response. 
Not more than 2 injections of intracameral and intrastromal 
Voriconazole were given. 
 
Inclusion 
• Proven fungal corneal ulcers with deep stromal infiltrates 
and endothelial plaque not responding to routine antifungal 
drugs (5% Natamycin, 1% Voriconazole, oral Itraconazole) 
 
Exclusion 
• Perforated ulcers 
• Children < 10 
 
Follow-up not given 
Outcomes ( primary not designated) 
•  Time of healing after the injection 
• Clinical outcome-scar formation, perforation 
• Improvement in visual acuity 
N=30 
 
Fungal species: 15 Fusarium, 12 Aspergillus, 3 
Candida 
 
Primary Outcome 
• Resolution of infection (25/30) 
• Perforation (5/30) 
• Time of healing 4-12 weeks 
•  
This study has combined interventions, 
intrastromal and AC voriconazole 
 
Level of evidence: 3 
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Table 7: Results of studies on surgical options for fungal keratitis 
STUDY DESIGN RESULTS COMMENT 
TPK-AUDIT 
Bajrachary
a 2015 
Nepal 55 
5-year audit study, 2006-2010 
 
Inclusion:  
• All infectious MK that underwent TPK 
Exclusion: 
• Patients with <2 months follow-up 
 
Patients who had a second TPK, only their first was considered for 
outcome assessment 
 
Follow-up: variable ( 2months minimum) 
 
Outcomes ( primary not designated) 
• Anatomical stability 
• Recurrence 
• Graft Clarity 
• Development of glaucoma 
N=180, Culture proven Fungal (n)=49 
 
Fungal species: 13 Fusarium, 23 Aspergillus, 5 
Cladosporium, 8 Unidentified 
 
Indications: 
• Perforation (128/180) 
• Impending 
• Non-healing 
 
Outcome (s):  
• Anatomic stability (34/44) 
• Recurrence (13/49) 
• Graft clarity (9/34) 
• Development of glaucoma (22/34) 
 
All aetiologies of MK were included but was 
disaggregated by aetiology. 
 
We restricted outcome data to fungal proven 
cases 
 
5 fungal keratitis patients were not analysed for 
anatomical success because they had < 2 
months’ follow-up. 
 
Level of evidence: 3 
 
Palaksha 
2015 India 
56 
2-year audit study, 2012-2014 
 
Inclusion: 
• Non-healing fungal keratitis 
 
Exclusion: 
• Posterior segment disease 
• Glaucoma  
 
Follow-up 6 months 
 
Outcomes ( primary not designated) 
• Anatomical integrity 
• Recurrence 
• Visual acuity improvement 
• Graft clarity 
• Complications rate 
N=25 
 
Fungual species: Culture not done, cases were 
identified by KOH 
 
Indication: 
• Perforation (7/25) 
• Non-healing (14/25) 
 
Outcome (s): 
• Anatomical integrity (23/25) 
• Recurrence (7/25) 
• Visual acuity improvement (22/25) 
• Graft clarity (9/25) 
• Complication (epithelial defect 10/25, 
glaucoma 7/25, cataract 2/25, scleral 
abscess 2/25) 
 
Level of evidence: 3 
 
Sharma 
2014 India 
57 
10-year audit 1999-2009 
 
Inclusion 
• All patients > 14 years who underwent TPK 
• Patients with at least 1 year follow-up 
N= 506, fungal cases n=106 
 
Fungal species: 42 Aspergillus, 64 other fungal 
species 
 
All aetiologies of MK were included but was 
disaggregated by aetiology. 
 
Different fungal species not mentioned 
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Exclusion 
• Patients with follow-up < 1 year 
• Patients < 14 years 
 
Follow-up mean 26.7 months 
 
Outcomes: (primary not designated) 
• Anatomical success 
• Visual success 
• complications 
Indication: 
• Infiltrates progressing to deeper 
stroma/limbus or sclera despite appropriate 
treatment 
• cases of impending perforation/perforation. 
 
Outcome (s): 
• Anatomical success; 94/106 
• Visual success (VA>6/60), 6/106 
 
We restricted outcome data only to fungal cases. 
Data on complications was not disaggregated 
 
Proportions of indication not mentioned 
 
Level of evidence: 3 
 
Barut 2014 
Turkey 58 
7-year audit study, 2006-2013 
 
Inclusion: 
• All culture proven fungal keratitis that underwent TPK 
Exclusion: 
• Not mentioned 
 
Mean follow-up was 14 months 
 
Outcomes (primary not designated) 
• Anatomical stability 
• Recurrence rate 
• Graft clarity 
• Evisceration 
• Phtisis Bulbi 
N=17 
 
Fungal species: 6 Fusarium, 4 Aspergillus, 4 
Acremonium, 1 Candida, 1 Penicillium, 1 
Colletotrichum 
 
Indications: 
• Corneal perforation (4/17) 
• Severe disease (13/17) 
 
Outcome (s) 
• Anatomical stability (11/17) 
• Recurrence rate (8/17) 
• Graft clarity (5/17) 
• Evisceration (4/17) 
• Pthisis Bulbi (2/17) 
  
Level of evidence: 3 
 
Lui 2013 
China 59 
2-year audit study, 2007-2009 
 
Inclusion: 
• All culture proven fungal MK who underwent PKP 
Exclusion: 
• Not mentioned 
•  
Mean follow-up 28 months 
Outcomes (primary not designated) 
• Graft clarity 
• Recurrence 
 
 
N= 19 
 
Fungal species: 4 Fusarium, 14 Aspergillus, 1 
Candida 
 
Indications 
• Ulceration deteriorated or did not improve 
after intensified antifungal 
 
Outcome (s) 
• Graft clarity (18/19) 
• Recurrence (1/19) 
 
Minimal trephination technique used 
 
Level of evidence: 3 
 
Xie 2007 
China 60 
5-year audit study, 1999-2004 
 
Inclusion 
• Fungal keratitis that underwent TPK 
N= 52 
 
Fungal species: 35 Fusarium, 3 Aspergillus, 8 other 
filamentous, 2 Candida, 4 No growth 
Level of evidence: 3 
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Exclusion 
• Not mentioned 
 
Follow-up: 2 weeks-24 months (mean 12 months 
 
Outcomes (primary not designated) 
• Complications: graft rejection, recurrence, cataract, 
glaucoma, graft ulcer 
• Improvement in visual acuity 
 
Indications: 
• Not mentioned 
 
Outcome (s) 
• Complications; immune graft rejection 
(20/52), fungal recurrence (8/52), Cataract 
(10/52), glaucoma (7/52), graft ulcer (3/52) 
• Improvement in visual acuity; 46/52 
 
Chen 2003 
Taiwan 61 
14-year audit study, 1987-2001 
 
Inclusion: 
• All patients who underwent TPK 
 
Exclusion: 
• Herpetic 
• Re-grafts for surgically uncontrolled microbial keratitis 
within 3 months after first therapeutic PKP were excluded 
• Patients with <1month’s follow-up 
 
Follow-up variable (minimum 1 month) 
 
Outcomes ( primary not designated) 
• Graft clarity at 1 month and 1 year post op 
• Cure rate 
• Anatomical success rate 
• Recurrence rate 
 
 
N= 108, Culture proven fungal (n)=52 
 
Fungal species: 13 Fusarium ,  21 Aspergillus, 5 
Candida, 4 Acremonium, 4 Paecilomyces, 3 
Cephalosporum, 2 Mycelium, 
 
Indications 
• Perforation or impending perforation 
• Unresponsiveness and progression of 
• the infection after extensive medical 
treatment 
• Impending scleral involvement of the 
infection 
 
Outcome (s) 
• Graft clarity rate at 1 year postoperative 
(20/39) 
• Cure (36/52) 
• Anatomical success rate (44/52) 
• Recurrence (20/52) 
All aetiologies of MK were included but was 
disaggregated by aetiology. 
 
We restricted outcome data only to fungal cases 
 
Patients who had a second TPK, only their first 
was considered for outcome assessment 
 
Specific proportions of the indications were not 
given 
 
Level of evidence: 3 
 
Yao 2003 
China 62 
6-year audit study, 1995-2001 
 
Inclusion: 
• Post TPK with cryo-preserved donor cornea 
• Culture proven fungal keratitis 
 
Exclusion: 
• <6/12 follow-up 
 
Follow-up:  7-37 months 
 
Outcomes (primary not designated) 
• Control of infection 
• Glaucoma 
N=45 
 
Fungal species: 14 Fusarium, 12 Aspergillus, 7 
Verticillium, 5 Microsporum, 7 Others 
 
Indication (s) 
• AC collapse by fibrinoid membrane formation 
post hypopyon resorption (29/45) 
• Perforation (14/45) 
• Extensive suppuration (1/45) 
• Large infiltrate >8mm (3/45) 
 
Outcome (s) 
• Infection control (39/45) 
No explanation on why all the 39/45 did not 
receive optical PKP 
 
Some of the eyes had more than 1 indication for 
TPK 
 
Level of evidence: 3 
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• Enucleation 
• Optical PKP 
• Glaucoma (4/45) 
• Enucleation (2/45) 
• Optical PKP (23/45) 
 
Xie 2001 
China 63 
3-year audit study, 1996-1999 
 
Inclusion: 
• All fungal keratitis who underwent TPK 
 
Exclusion: 
• Not clear 
 
Follow-up 12-24 months 
 
Outcomes ( Primary not desgniated) 
• Graft clarity 
• Recurrence 
• Failure 
• Enucleation 
• Cataract 
• Glaucoma 
N=108 
 
Fungal species: 63 Fusarium, 14 Aspergillus, 9 
Candida, 4 Penicillium, 7 Unidentified, 11 No growth 
 
Indication: 
• Ulcer < 6 mm & not cured on intensive 
medical treatment  
• Ulcer was 6–8mm & the infection continued 
to progress during 72 hours of intensive 
medical treatment 
• Ulcer > 8 mm or corneal 
perforation/impending perforation 
 
Outcome (s) 
• Graft clarity (86/108) 
• Recurrence (8/108) 
• Failed grafts (15/108) 
• Enucleation (4/108) 
• Cataract (5/108) 
• Glaucoma (2/108) 
 
Specific proportions of the indications were not 
given  
 
Level of evidence: 3 
 
Cristol 
1996 USA 
64 
8-year audit study, 1979-1987 
 
Inclusion 
• All patients who underwent PKP in the study period 
Exclusion 
• Non-MK patients 
 
Follow-up: mean was 13.6 months (3 weeks-5 years) 
 
Outcomes ( primary not designated) 
• Final visual acuity 
• Graft survival time 
• Failure rate 
 
 
N=21, fungal cases n=10 
 
Fungal species: 9 Fusarium, 1 Aspergillus 
 
Indications 
• Perforation (21) 
• Impending perforation (5) 
 
Outcome (s) 
• VA on the last visit; 3/60-NPL 
• Time to graft failure: Median was 4 weeks 
• Graft failure rate (9/10) 
 
Bacterial and fungal aetiologies of MK were 
included but results were disaggregated by 
aetiology. 
 
We restricted outcome data only to fungal cases 
Indications were more than N because some 
patients had more than 1 graft 
 
Level of evidence: 3 
 
Killingswort
h 1993 
USA  65 
9-year audit study, 1980-1989 
 
Inclusion 
N= 70 fungal cases n=15 
 
All aetiologies of MK were included but results 
were disaggregated by aetiology. 
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• All cases who underwent PK 
 
Exclusion  
• Patients whose follow-up was <1month 
 
Follow-up: mean 9.2 months  
 
Outcomes ( primary not designated) 
• Graft clarity 
• Cure of the disease 
Fungal cases: 6 Fusarium, 3 Candida, 6 Other 
filamentous fungi 
 
Indications: 
• Advanced infections not responding to 
medical treatment (15/15) 
 
Outcome (s) 
• Graft clarity (9/15) 
• Cure of the disease (15/15) 
 
We restricted outcome data only to fungal cases 
 
Level of evidence: 3 
 
 
THERAPEUTIC KERATOPLASTY (TPK) VS LAMELLAR KERATOPLASTY (LKP) 
Singh 1972 
India 67  
5-year audit study, 1964-1969 
 
• Group I: 10 patients TPK 
• Group II: 7 patients Lamellar KP (LKP) 
 
Inclusion: 
• Not clear 
Exclusion: 
• Not clear 
 
Follow-up not clear 
 
Outcomes (primary not designated) 
• Improvement in VA 
• Recurrence of infection 
• Graft clarity 
N=17,  
 
10 patients underwent TPK  
7 patients underwent LKP 
 
Fungal species: 2 Fusarium, 7 Aspergillus, 5 Candida, 
2 Penicillium 
 
Indications 
• Massive hypopyon 
• Perforation 
 
Outcomes: RR > 1 favours TPK 
• Improvement in VA (TPK: 3/10 Vs LKP 2/7), 
RR 1, 95% CI 0.5-1.8, p=0.9 
• Recurrence of Infection (TPK: 4/10 Vs LKP 
6/7) RR 2.1 95% CI 0.9-4.8, p=0.06 
• Graft clarity (TPK: 3/10 Vs LKP: 1/7), RR 1.2 
95% CI 0.7-2.0, p=0.4 
•  
TPK has significantly less recurrence of infection 
compared to LKP. TPK also had better outcomes on 
improvement in VA and graft clarity although not 
significant 
 
This was a non-randomised study that compared 
two keratoplasty options 
 
Specific proportions of the indications were not 
given 
 
Level of evidence: 2- 
 
 
 
LAMELLAR KERATOPLASTY (LK) FOR FUNGAL KERATITIS 
Xie 2008  
China 70 
7-year audit study, 1998-2005 
 
Inclusion 
• Patients with fungal keratitis who underwent LK 
 
Exclusion 
N=218 
 
Fungal species: 142 Fusarium, 26 Aspergillus, 9 
Alternaria, 8 Candida, 5 Penicillium,  28 Unidentified, 
23 No growth 
 
A large number of patients were reviewed in this 
audit 
 
Level of evidence: 3 
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• Not clear 
 
Follow-up: 20 months 
 
Outcomes  
• Successful treatment ( clear graft, no recurrence, improved 
vision) 
Indication 
• Uncontrolled infection with intensive 
antifungal therapy but did not penetrate into 
the anterior chamber (218/218) 
 
Outcome (s) 
• Successful treatment (201/218) 
 
 
Xie 2007  
China 87 
6-year audit study, 2000-2006 
 
Inclusion 
• Culture +ve fungal infection 
• Post Lamellar keratoplasty (LK) 
 
Exclusion 
• Mixed infection 
 
Follow-up: 1 month 
 
Outcome 
• Recurrence rate 
 
N=174 
 
Fungal species: 148 Fusarium, 11 Aspergillus, 8 
Alternaria, 4 Penicillium, 3 Candida 
 
Indication (s) 
• Only the upper or middle corneal stroma was 
infected, 
• Not improving after 1 week of antifungal 
medications 
• Uncorrected VA less than 20/200 
 
Outcome 
• Recurrence rate (15/174) 
 
 
Level of evidence: 3 
 
Xie 2001 
China 69 
1-year audit 1998-1999 
 
Inclusion 
• Post LK fungal keratitis 
 
Exclusion 
• Infection already spread into the AC 
 
Follow-up: 8-18 months 
 
Outcome  (Primary not designated) 
• Curing fungal keratitis 
• Surgical complication rate  
 
N=55 
 
Fungal species: 33 Fusarium, 6 Aspergillus, 3 
Candida, 1 Penicillium, 9 No growth 
 
Indication (s) 
• Fungal keratitis not controlled in 7 days on 
antifungal medication (55/55) 
 
Outcomes 
• Curing fungal keratitis (51/55) 
• Surgical complication rate (0/55) 
 
46/55 were culture positive for fungus. Other 
diagnosis was made clinically and with confocal 
microscopy 
 
Level of evidence: 3 
 
 
LKP CASE SERIES 
Gao 2013 
China 66 
Case series 
 
Inclusion 
• Deep infectious purulent Keratitis 
• Infiltrate >4/5 of corneal thickness 
N= 17, fungal cases n=14 
 
Fungal species:  
 
Indications 
Cases of fungal and bacterial keratitis were 
included but results were disaggregated 
 
DALK assisted by big bubble technique was 
used 
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Exclusion 
• Not mentioned 
 
Follow-up: 9 months 
 
Outcomes (primary not designated) 
• Perioperative complications 
• Recurrence 
• Graft status transparency 
• Visual recovery 
 
Outcome (s) 
• Perioperative complications 
• Recurrence (1/14) 
• Graft status transparent (14/14) 
• Visual recovery (14/14) 
 
 
We restricted outcome data only to fungal cases 
 
Level of evidence: 3 
 
  
LAMELLAR KERATOPLASTY WITH PORCINE CORNEA 
Zhang 
2015 China 
68 
Case series study: TPK using acellular porcine corneas 
 
Inclusion: 
• Proven fungal keratitis 
• Not responding to antifungal medications 
• At risk of perforation 
Exclusion: 
• Not indicated 
 
Follow-up: 6 months 
 
Outcomes 
• Improvement of BCVA by 2 lines 
• Recurrence 
• Severe neo-vascularisation 
N=47 
 
Fungal species: Not reported 
 
Indications 
• Unresponsive to antifungal medication 
• At risk of perforation 
 
Outcome (s) 
• Improvement of BCVA by 2 lines (34/47) 
• Recurrence (0/47) 
• Severe neo-vascularisation (7/47) 
Diagnosis was by microscopy and confocal. No 
culture results were reported 
 
Level of evidence: 3 
 
AMNIOTIC MEMBRANE GRAFT (AMG) 
Chen 2006  
China 71 
8-year audit study, 1994-2002 
 
Inclusion: 
• Culture confirmed fungal keratitis who received AMG 
 
Exclusion: 
• Not mentioned 
 
 
Follow-up was 6-65 months 
 
Outcomes 
• Immediate improvement in visual acuity  
• Epithelial healing rate in days  
• Treatment failure necessitating therapeutic penetrating 
keratoplasty (TPK);  
N=23 
 
Fungal species: 10 Fusarium, 3 Aspergillus, 4 
Candida, 6 other  
 
Indications: 
• Corneal perforation (8/23) 
• Descemetocele (8/23) 
• Deep ulcer (95% stromal loss with poor 
reepithelialisation) (7/23) 
 
Outcome (s): 
• Immediate improvement in visual acuity 
(14/23) 
• Epithelial healing rate in days (6-26 days) 
• Treatment failure necessitating therapeutic 
Individuals who had concomitant bacterial 
infections were treated and included 
Final visual acuity improved in 17/23 cases. 
However, other surgeries were preformed to 
improve vision in 3 cases 
 
All cases who developed glaucoma had corneal 
perforation with AC collapse on presentation 
  
Double layered AMG was done with people who 
had collapsed AC, the rest had single layer AMG 
 
Level of evidence: 3 
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• The persistence of infection  
• Subsequent surgeries necessary for visual recovery  
• Other complications such as secondary glaucoma., graft 
failure  
 
penetrating keratoplasty (TPK); (3/23) 
• The persistence of infection (2/23) 
• Subsequent surgeries necessary for visual 
recovery (11/23) 
• Other complications such as secondary 
glaucoma. (4/23), graft failure (3/23) 
 
AMNIOTIC MEMBRANE GRAFT (AMG) VS BIPEDICLE CONJUNCTIVAL FLAP (CF) 
Abdulahim
m 2015 
Egypt 72 
RCT arms 
• AMG 
• CF 
 
Inclusion 
• Culture positive non-viral cases 
 
Exclusion 
• Not clear 
 
Follow-up 6 months 
 
Outcome 
• Primary: location, size and depth of the lesion, 
epithelialisation time and persistence of infection. 
• Secondary outcome measures included visual acuity and 
other complications 
 
N=40 
• 20 patients had AMG, 13 were fungal cases 
13 
• 20 patients had CF, 12 were fungal cases 
 
Fungal species: 9 Fusarium, 5 Aspergillus, 6 Candida 
(6), 5 Other filamentous 
 
Indications: 
• >50% stromal loss with poor re-
epithelialisation) 
• Descemetocele or corneal perforation 
• Medical treatment failure (no improvement 
after 2 weeks from intensive medical 
therapy). 
 
Outcome (s) specific outcome data was not 
disaggregated 
 
Primary 
• Epithelialisation time; No difference 
• Persistence of infection; No difference 
 
Secondary 
• Visual acuity; No difference 
• Complication; No difference 
 
Cases of fungal and bacterial keratitis were 
included but some of the results were 
disaggregated 
 
Computer generated randomisation was done 
 
Masking was not done 
 
Primary and secondary outcomes clearly stated 
 
Specific proportions of the indications were not 
given 
 
Level of evidence: 1- 
 
CONJUNCTIVAL FLAP 
Zhong 
2018 
China73 
Case series 
• Full Thickness Conjunctival flap Covering Surgery (FCCS) 
Inclusion 
• Culture positive FK 
• Poor response to topical therapy at 1 month (g-Natamycin, 
g-Fluconazole, occ-Fluconazole, PO Voriconazole 300mg 
BD) 
• Increasingly large lesion an increasingly large lesion 
N=17 
 
Fungal species: 6 Fusarium, 4 Aspergillus, 1 
Curvularia, 4 Other filamentous, 2 No growth 
 
Indications: 
• Poor response to medical treatment 
 
Prospective design used 
Small numbers 
Moderate follow-up period 
 
 
Evidence level: 3 
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involving the entire cornea 
• Gradual thinning of the cornea with no observable 
perforation by fluorescein staining 
• No endophthalmitis according to B‑scan ultrasounds 
 
Exclusion 
• Corneal perforation was present 
• Endophthalmitis detected by B‑scan ultrasound 
• Hypopyon present in the eye 
• Good response with antifungal medication 
 
Follow-up 12 months 
 
Outcome (Primary not desginated) 
• BCVA 
• Raised IOP 
• Eye loss 
 
7 patients received sclerokeratoplasty 3 months after 
FCCS 8 patients received conservative medication 
 
Outcome (s) specific outcome data was not 
disaggregated 
• Raised IOP 0/15 
• Eye loss 2/17 
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Table 8: Results of studies on corneal cross linking for treatment of fungal keratitis 
STUDY DESIGN RESULTS COMMENT 
CXL RCT 
Uddaraju  
2015 India 
74 
RCT 2 arms 
 
• CXL + topical antifungal 
• Topical antifungal 
Procedure 
• Dresden protocol followed. 
• Aseptic precautions followed 
• Topical anaesthesia with 0.5% proparacaine (Aurocaine; 
Aurolab, Madurai, India). 
• For the first 30 minutes the cornea was soaked with 0.1% 
riboflavin drops (riboflavin dextran solution; Intacs XL, 
Dorset, UK) every 2 minutes. Over the next 30 minutes the 
cornea was exposed to ultraviolet-A radiation of 370 nm 
with 3 mW/cm2 (IROC-UVX, Zurich,Switzerland) along 
with continued instillation of riboflavin drops. 
• Topical antifungal therapy was restarted 1 hour after the 
procedure. 
 
Inclusion:  
• Culture positive fungal keratitis +, 
• Not improved after 2 weeks of medical treatment + 
• Infiltrate 5mm or more in diameter + 
• Infiltrate involving posterior 2/3 of the cornea 
 
Exclusion: 
• Not clear 
Outcomes 
• Treatment failure at 6 weeks ( primary) 
• Perforation rate  (primary) 
• Uncorrected VA (secondary) 
 
Follow-up: 6 weeks 
N=13,  
 
• 6 patients received CXL + topical antifungal 
• 7 patients received topical only 
 
Fungal species: 3 Fusarium, 4 Aspergillus  
4 Unidentified hyaline, 2 Unidentified dematiaceous 
 
Primary outcome: (RR> favours CXL) 
• Treatment failure at 6 weeks (perforation 
and/or increase in infiltrate by more than 
2mm). CXL 5 Vs Topical 4 (p=0.56). RR 0.6 
95% CI 0.3-1.4, p=0.3 
• Perforation rate CXL 4 Vs Topical 0 (p=0.02) 
RR 0.1 95% CI 0.0-1.5, p=0.09 
 
Secondary Outcomes:  
• Uncorrected VA at 6 weeks CXL HM (6/60-
LP) Vs Topical 2/60 (6/12-HM) (p=.08) 
 
Computer generated randomisation was done 
 
Allocation concealment done 
 
The trial was stopped prematurely due to the 
perforation rate in the CXL group. 
 
Primary and secondary outcomes were reported 
 
This study included only deep severe 
unresponsive cases 
 
Level of evidence: 1+ 
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Wei  2019 
China75 
RCT 2 arms 
• CXL combined with antifungal medications (CXL-M) group 
• Antifungal medication alone (M) group 
 
Procedure 
• Aseptic technique 
• A topical anesthetic (oxybuprocaine hydrochloride 
• 0.4%, Santen Pharmaceutical Co., Ltd.) was instilled three 
times 
• The epithelium and the necrotic tissue of the ulcer were 
removed with a hockey knife;  
• Riboflavin drops (Medio-Cross riboflavin/dextran solution, 
0.1%) were instilled on the ulcer of corneal every 3 min for 
30 min. 
• The cornea was irradiated for 30 min using a Phoenix UV-
A system (Peschke Meditrade GmbH, Huenenberg, 
Switzerland) at 365 nm with an irradiance of 3 mW/cm2 
and a dose of 5.4 J/cm2. During the period of UV-A 
exposure, riboflavin was dropped onto the cornea every 
1.5 min. 
• Topical antifungal (g-Natamycin + g-Voriconazole) therapy 
was restarted 2 hours after the procedure. 
 
Inclusion:  
• Culture/IVCM positive fungal keratitis  
 
Exclusion: 
• Perforated corneal ulcer 
• Corneal melting or perforation 
• Endophthalmitis 
• Collagen vascular disease 
• Corneal descemetocele 
• Immune diseases 
• Diabetes 
• Pregnancy 
 
Outcomes (Primary not designated) 
• Visual acuity 
• Area of the ulcer 
• Duration of the ulcer 
• Time to non-observed fungal hyphae by IVCM 
• The number of antifungal medications, 
• The frequency of medication administration 
• Hypopyon 
N=41 
 
• 21 CXL-M 
• 20 M 
 
Fungal species: 9 Fusarium, 17 Aspergillus 14 No 
growth 
 
Time to healing 
• CXL-M group (1.30 ± 0.93 months) Vs M 
group (2.21 ± 1.35 months; P = 0.036). 
Depth of Ulcers 
• CXL-M group (37.62 ± 4.79 μm) Vs M group 
(68.57 ± 5.52 μm, P = 0.049) 
 
Corneal thicknesses of ulcers after healing 
• No difference 
Randomisation process not clear 
 
Masking not done 
 
Primary and secondary outcomes not 
designated  
 
This study had many outcomes and a small 
sample 
 
Level of evidence: 1- 
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• The maximum depth of the ulcer 
• Corneal thickness and epithelial thickness of the ulcer after 
healing 
 
Follow-up: 6 months 
CXL case series 
Li 2013 
China 88 
Case series 
• CXL + topical antifungal 
 
Procedure 
• Under topical anaesthesia, the epithelium surrounding the 
infiltrate was removed. Riboflavin (Medio-Cross 
riboflavin/dextran solution, 0.1%) was administered 
topically for 30 min at intervals of 2 min. The cornea was 
illuminated for 30 min using a UV light lamp (UV-X 1000 
system, IROC Innocross AG Co, Switzerland; wavelength 
365 nm, irradiance 3 mW/cm2, total dose 5.4 J/cm2). 
Riboflavin administration was continued during UV 
illumination at the same intervals. 
• Topical 5% natamycin was continued after CXL treatment. 
 
Inclusion: 
• Microbiologically proven fungal keratitis + 
• No response to topical treatment OR 
• Exacerbation of infection 
 
Exclusion: 
• Not clear 
Follow-up daily until resolution (variable) 
 
Outcomes (primary not designated) 
N=8 
 
Fungal species: 6 Fusarium, 2 Aspergillus 
 
Outcomes 
• Time to epithelial healing, 3-8 days in all 
patients 
• Time to complete healing, 3-11 days in all 
patients 
• Improvement in Visual acuity, CXL visual 
acuity improved in 6 cases, remained 
unchanged in 1 case, and deteriorated in 1 
case 
• Need for keratoplasty, 0/8 
A decision was made to include this study 
although it had less than 10 participants. 
 
Level of evidence: 3 
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• Time to epithelial healing 
• Time to complete healing 
• Improvement in VA 
• Need for TPK 
CXL Retrospective Audit  
Vajpayee 
2015 India  
89 
Comparative audit-2 arms 
• CXL + topical antifungal 
• Topical antifungal 
Procedure: 
• Topical anaesthesia with 0.5% proparacaine hydrochloride 
(Paracaine; Sunways, Mumbai, India) was used before the 
surgery. The corneal epithelium was debrided over the 
area of infiltrate. One drop of isotonic riboflavin phosphate 
0.1% (10 mg of riboflavin-5-phosphate in 10 mLof dextran-
T-50020%solution,Medio-cross GmbH, Neudorf, Germany) 
was applied every 3 min for 30 min before irradiation and 
every 3 min during irradiation. Ultraviolet A (UVA) radiation 
(365 nm with the desired irradiance of 3 mW/cm2; UV-X, 
IROC, Zurich, Switzerland) was applied at 5 cm from the 
cornea for 30 min. 
 
Inclusion 
• Moderate fungal keratitis: largest diameter < 6mm + 
• Involving <60% of corneal thickness 
Exclusion 
• Diabetes 
• Immunosuppression 
• Collagen vascular disorders 
• Impending perforation 
• Endothelial plaque 
• Hypopyon 
 
Follow-up 3months 
 
Outcomes 
• Resolution of infection (primary) 
• Healing time 
• Final BCVA 
N=41,  
• 20 patients received CXL & topical treatment 
• 21 patients received topical treatment only 
 
Fungal species:  5 Fusarium, 10 Aspergillus, 1 
Curvularia, 25 No growth 
 
Primary outcome: RR > 1 favours CXL 
• Resolution of infection CXL 18/20 Vs topical 
18/21, RR 1.4 95% CI 0.4-7.6, p=0.7 
 
Secondary outcomes: 
• Healing time CXL 30.85+/- 26.6 days Vs 
topical 31.28+/-19.97 days (p=0.94) 
• Final BCVA at 3 months CXL 1.13+/-0.55 Vs 
topical 1.25+/-0.46 (p=0.46) 
 
No randomisation 
 
This study included moderate cases 
 
Level of evidence: 2- 
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Erdem 
2018 
Turkey78 
Audit 
 
Procedure 
• Dresden protocol 
• gutt-Voriconazole 
 
Inclusion 
• Fungal Keratitis in one eye 
• Poor response to conventional therapy/progression of 
infection 
Exclusion 
•  
Follow-up 
• 3-months 
Outcomes 
• Cure rate 
N=13 
Fungal species: 5 Fusarium, 3 Aspergillus, 6 No 
growth 
 
Primary outcomes 
• 7/13 (54%) cured 
• 6 of the 7 cured cases had superficial 
infection 
Small audit 
Cases had mixed infection which was initially 
controlled 
Level of evidence: 3 
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Table 9: Results of studies on Argon laser for treatment of fungal keratitis 
STUDY DESIGN RESULTS COMMENT 
RCT: ARGON Vs INTRASTROMAL VORICONAZOLE 
Khater 
2016 Egypt 
80 
RCT 2 arms 
• Argon laser 
• Intrastromal Voriconazole  
 
Procedure: 
• A spot size of 500 um, pulse duration of 0.2 seconds, and 
power of 900-1400 mW were used. Argon laser therapy 
was done using argon green wavelength (Carl Zeiss LSL 
532s AG; Meditec, Inc). A spot size of 500 um, pulse 
duration of 0.2 seconds, and power of 900-1400 mW were 
used. The number of shots varied from one case to 
another, depending on the size of the ulcer where we 
targeted its bed and edge during argon laser therapy with 
laser shots 
 
Inclusion:  
• Fungal keratitis not responding to topical treatment of 
0.15% Amphotericin, or  5% Natamycin, or 1% 
Voriconazole, or 1% Itraconazole or 0.2% Fluconazole    at 
day 7 
 
Exclusion: 
• Improvement on medical treatment 
 
Follow-up  3 months 
 
Outcomes (primary not designated) 
• Healing time 
• Need for AMG 
• Improvement in vision 
N=40,  
• 20 patients received Argon laser, 
• 20 patients received Intrastromal 
Voriconazole 
 
Fungal species: Not mentioned 
 
Outcome (s): RR > 1 favours Argon laser 
• Healing time: Argon group 2-4 weeks Vs 
VOR group 2-6 weeks P=0.001 
• Need for AMG: Argon group 2/20 Vs VOR 
group 4/20, P=0.047, RR 2 95% CI 0.4-9.7, 
p=0.3 
• Improvement in vision: Argon 11/20 Vs VOR 
group 13/20, P=0.011, RR 0.8 95%CI 0.3-
1.7, p=0.6 
 
Argon laser had a faster healing time, fewer cases 
needed AMG. Intrastromal Voriconazole had better 
improvement in vision 
28 cases were pure fungal, 12 were mixed 
fungal and bacterial. 
Inclusion and exclusion not clear 
Randomisation not clear 
Masking not possible 
Primary and secondary outcomes not clearly 
stated 
 
 
Level of evidence: 1- 
 
RCT: ARGON VS AMNIOTIC MEMBRANE GRAFT (AMG) 
Khater 
Egypt 2016 
79 
RCT 2 arms 
• Argon laser 
• AMG 
 
Inclusion 
• Fungal keratitis not responding to topical treatment of 
0.15% Amphotericin, or  5% Natamycin, or 1% 
Voriconazole, or 1% Itraconazole or 0.2% Fluconazole  at 
day 7 
N= 40, 
• 20 patients received Argon laser 
• 20 patients received AMG 
 
Fungal species: Not mentioned 
 
Outcome (s): RR > 1 favours Argon 
• Healing time: Argon 2-3 weeks Vs AMG 3-5 
weeks P=0.001 
28 cases were pure fungal, 12 were mixed 
fungal and bacterial. 
Inclusion and exclusion not clear 
Randomisation not clear 
Masking not possible 
Primary and secondary outcomes not clearly 
stated 
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Exclusion 
• Improvement on medical treatment 
 
Follow-up 3 months 
 
Outcomes 
• Healing time 
• Improvement in vision 
• Improvement in vision: Argon 8/20 Vs AMG 
6/20 P=0.138, RR 1.2 95% CI 0.7-1.8, p=0.5 
 
Argon laser had a significant faster healing time 
compared to AMG 
Level of evidence: 1- 
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DISCUSSION AND RECOMMENDATION: 
This review examined the evidence for the main reported options for fungal keratitis. Overall, the 
strength of the evidence was low in a significant proportion of studies: many of the studies were 
observational and few clinical trials had a low risk of bias. 
Medical interventions for fungal keratitis 
Topical treatments: While the evidence for topical antifungal treatment has been previously 
reported, including a Cochrane review in 2015, this current review also included a recent RCT by 
Sharma et al comparing 5% natamycin and 1% Voriconazole eye drops.90 25 We conducted 
metanalyses of natamycin vs chlorohexidine (2 trials) and natamycin Vs voriconazole (4 trials). The 
natamycin Vs chlorohexidine metanalysis had a non-significant trend for healing by day 21 in favour 
of chlorohexidine.20,21 However, the concentrations natamycin were 2.5% in one trial and 5% in the 
other.21 natamycin Vs voriconazole metanalysis compared two outcome measures: Best Corrected 
Visual Acuity at 3 months in 4 RCTs and perforation rates in 3 RCTs.25-28 natamycin had a significant 
trend for less perforations compared to Voriconazole. Unlike in the Cochrane metanalysis, where 
natamycin had a non-significant trend towards better BCVA at 3 months (p=0.20), our metanalysis 
that included the recent trial (Sharma et al, 2015) showed a significant trend (p<0.01) for better 3 
months BCVA with natamycin figure 3). Evidence from the other 2 trials that compared topical 
natamycin Vs econazole and natamycin Vs itraconazole was inconclusive.91,92 In all these trials, 
majority of the fungal species were filamentary. 
 
 
 
 
 
Oral treatments: Evidence from the three trials that compared adding an oral antifungal (oral 
itraconazole or oral voriconazole) to topical treatment did not show any benefit.34,35 However, a 
smaller trial that compared oral voriconazole Vs oral ketoconazole showed a benefit in terms of 
BSCVA at 3 months in the oral voriconazole arm.36 
 
Injections for fungal Keratitis 
In view of the results from our review, our current recommendation is that filamentary fungal 
keratitis should be initially treated with topical natamycin 5%, rather than topical voriconazole. 
The caveat to this is that there is limited data on the variation between geographical regions in 
the sensitivity of fungi to the various alternative drugs. This is the best available evidence to guide 
our practice. More work is needed on use of chlorohexidine for fungal Keratitis. This is ongoing 
in Nepal and East Africa studies. Although it is widely used, particularly for candida, amphotericin 
has received little attention in formal studies and no RCTs  
 
The evidence for oral treatment is still too scanty to utilise in making recommendations. In 
addition, patients on these oral treatments required frequent liver function tests which might not 
be ideal in resource limited settings, they should be avoided. 
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Injection Fluconazole: Although the use of subconjunctival fluconazole was found to be safe, the 
outcomes were variable and evidence too weak to draw a conclusion.38-40 The only RCT included in 
this review although showed some benefit of using injection fluconazole as an adjuvant to topical 
amphotericin B compared to topical amphotericin B monotherapy, it had several methodological 
limitations with respect to randomization and masking.37 
 
Injection Amphotericin B: This was described as an intracameral injection (ICAMB), intrastromal 
injection and mixed (intracameral and intrastromal). The most commonly described was ICAMB 
given in dosages ranging from 0.5-50 µg/0.1ml given 1 up to 3 times 1-10 days apart. 42,46,82,83 Our 
review reported data on 2 trials which used ICAMB. We were unable to summarise these two trials 
in a pooled measure because they were methodologically different. One RCT from India compared 
ICAMB across 3 arms did not report any difference in the main outcome measures. However, the 
numbers in each arm were small (n=15).42 Another RCT from China reported favourable outcomes 
for ICAMB Vs normal saline placebo by: time of hypopyon resolution and healing.46 
Favourable outcomes for ICAMB were also reported in other studies.42,44 However, these had a low 
level of evidence. For instance, a non-randomised trial from India compared ICAMB in patients who 
had not responded at 7 days to antifungal treatment (topical Natamycin or topical fluconazole or 
topical itraconazole and tablets fluconazole) to those who responded. Non responders were given 
ICAMB while the responders were not given ICAMB.43 ICAMB had significantly favourable outcomes 
on improvement in BCVA, time of hypopyon disappearance, less scars and less complications. 
Patients in the ICAMB arm could have responded better just because they had “more” treatment. 
Another more recent non-randomised study among patients with recalcitrant fungal keratitis 
allocated (one group to early ICAMB at 2 weeks and another to late ICAMB at 4 weeks) found that 
patients in the early ICAMB intervention group had a quicker healing time compared to the ones in 
the late intervention group.44 Again this may not necessarily be because of the drug but the timing.  
Other encouraging results were reported one audit from China that compared ICAMB Vs topical 
antifungal alone and in another small series which reported good outcomes of use of ICAMB in 
patients with recalcitrant fungal keratitis.45,82 Majority of fungal species in all these studies were 
filamentary fungi. 
 
 
  
The evidence for injection fluconazole is still scanty to utilise in making recommendations. 
 
Overall, literature on the use of ICAMB is inconclusive. However, there seems to be context 
specific advantages of using ICAMB such as unresponsive deep filamentary fungal keratitis with 
hypopyon. A large RCT to determine the role of ICAMB in treatment of deep fungal keratitis may 
be warranted. 
 
152
 Simon Arunga PhD Thesis 2019 
 
Other routes of administration reported for Amphotericin B were intrastromal and a mixed 
intrastromal and ICAMB.47,83 Intrastromal injection dose ranged from  2-25µg/0.1ml. A more recent 
audit in Egypt reported a significantly faster healing time and less burning sensation in the 
intrastromal Amphotericin B injection group. Majority of the fungal species in this study were yeasts 
at 45%.47 A separate series reported on combined ICAMB and intrastromal Amphotericin B in 
recalcitrant cases. 83 Treatment success was reported at 100% but also complications such as uveitis 
at 100%.83 
 
 
Injection Voriconazole: Use was described as intrastromal (IVS), intracameral and mixed routes. 
Majority of the papers reported intrastromal use. In many studies, it was given as 5 injection spots 
of intrastromal voriconazole (50µg/0.1 ml) at least 3 injections given 72 hours apart.48,51,52,85 In two 
RCTs from India, Intrastromal Voriconazole injections + topical treatment was compared to topical 
treatment (Natamycin 5% ± Voriconazole 1%) as adjuvant therapy or first line treatment in fungal 
keratitis patients, there was no evidence of benefit for IVS in healing time, scar size, vision at 3 
months.48,84 Pooled data from the two trials showed strong evidence of increased perforation and a 
worse vision at 3 months among the IVS arms. 
Some series documented use of ISV in patients with recalcitrant keratitis.51,52,85 Healing at 3-4 
months ranged from 76-87% and improvement in vision ranged from 64-83%. In all these studies, 
all fungal species were filamentary. The conclusion of the authors that ISV had good response to 
filamentary fungal cases resistant to topical Natamycin and Voriconazole.  
 
 
 
Surgical Interventions for fungal keratitis 
TPK: The major challenge in reviewing TPK data was that most studies reported TPK outcomes for 
mixed aetiologies. Two previous review articles have looked at the role of TPK in management of all 
cause MK in general.93,94 In addition, most of the reports were audits with an average SIGN evidence 
level of 3 (weak evidence).  
We restricted our outcome reporting to only cases of fungal aetiology. Majority of the fungal species 
were filamentary and the most common indications for TPK in these cases were perforation/ 
impending perforation and non-healing ulcers/infiltrates. These audits had variable follow-up (1 
The evidence for intrastromal Amphotericin B is still scanty to utilise in making recommendations. 
 
Metanalysis of the two RCTs indicates that IVS has no additional benefit in treatment of fungal 
Keratitis and is associated with worse outcomes and increased perforation rates. Our 
recommendation is that IVS should be avoided. 
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month to years) and variable outcomes: Based on pooled data, anatomical stability was at 84%, 
recurrence 20%, graft clarity 60%, cure rate 80%.55,56,58-61,63 Glaucoma was the most reported 
complication at 15%.55,56,60,62,63 
Post-operative care especially use of steroids was not systematically described in almost all these 
audits. 
 
 
Lamellar Keratoplasty (LK). Most of the studies which reported LK were audits and case 
series.66,68-70,87 Majority of the fungal species were filamentary and the most common indications 
were under controlled infection but not very deep/extending into the anterior chamber. Follow up 
ranged from 1 month to 20 months. Generally favourable outcomes were reported in many studies: 
successful treatment/ cure/ non recurrence was reported in 5 studies at 471/498 combined patients 
(95%: ranging from 91-100%).66,68-70,87 One study retrospectively analysed a small set of patients 
who had had LK compared to those who had received TPK.67 TPK had a non-significant trend to 
improvement in VA, graft clarity and less recurrence.  
 
 
Amniotic Membrane Graft (AMG): Literature on AMGs was scanty to draw any conclusions, we 
found only 3 papers in our inclusion that systematically documented use of AMGs in fungal 
keratitis.71,72,95 One audit in China recorded 23 culture proven fungal keratitis patients who had 
undergone AMG, the distribution of indications; perforation ( 35%), descemetocele ( 35%) and poor 
re-epithelialisation (30%) were similar to TPK.71 In this audit, there was a high recovery rate in vision 
and control of infection. Many of the patients with high vision recovery had presented with perforation 
and flat anterior chambers. Like TPK, glaucoma was the most commonly reported complication at 
18%. 
 
Conjunctival Flap (CF): Although conjunctival flap is frequently used in most parts in SSA, literature 
on outcomes was scanty. We only found one recent series from China that fit into the inclusion 
criteria. The globe was preserved in majority of cases and none developed raised Intra Ocular 
Pressure (IOP).73 
 
Overall, TPK has an important role in management of severe MK by being able to provide eye 
salvage and infection control options. More efforts are needed to optimise outcomes. 
 
Although promising, indications for LK among patients with fungal keratitis need to be carefully 
considered since most of the fungal infections tend to be deep. 
 
The evidence for Amniotic Membrane Graft is still scanty to utilise in making recommendations. 
 
The evidence for Conjunctival Flap is still scanty to utilise in making recommendations. However, 
Due to lack of corneal tissue in many Low- and Middle-Income Countries, Conjunctival Flap has 
a role in salvaging eyes with severe infection. 
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AMG Vs Conjunctival Flap: On which of the two is better, one RCT compared outcomes of AMG 
Vs bipedicle conjunctival flap with 20 patients in each arm. Although this trial included some bacterial 
keratitis cases, it was included because majority of the cases (63%) in each arm were fungal 
keratitis.72 In this trial, primary outcome measures were: epithelialisation time and persistence of 
infection. Secondary outcome measures included visual acuity and other complications. There were 
no differences in primary or secondary outcomes. The sample size was small. 
 
 
Corneal Cross Linking (CXL): Our search included 3 papers that used fairly similar CXL protocols: 
2RCTs, 2 series and 1 audit.74,75,78,88,89 The trial in India compared use of CXL+ topical antifungal 
treatment (CXL-M) Vs topical antifungal treatment only (M) in severe recalcitrant fungal keratitis 
patients.74 The trial was prematurely stopped because of futility: there were more patients in the CXL 
arm that perforated than in the topical arm. In a more recent trial (Wei et al 2019), Forty-one patients 
with fungal ulcerative keratitis were randomised to (CXL-M)or (M).75 Patients were followed up for 6 
months. In the cured patients, the area of corneal ulcers, the duration of ulcer healing, the time to 
non-observed fungal hyphae by In Vivo Confocal Microscopy (IVCM), the number of antifungal 
medications, the frequency of administered medications, and the maximum ulcer depth decreased 
significantly after CXL compared with the M group. The severity grades of the patients in this trial 
were not reported. 
A separate case series in China that used CXL-M did not report any perforation incident.88 Again, 
the severity grade of the cases in this series was not reported. Another audit that compared two 
groups: CXL-M and M only did not report any significant differences in the outcomes of resolution of 
infection, healing time and final BCVA.74 This audit excluded severe cases and did not report 
perforation rates. Another recent small series  treated 13 fungal Keratitis patients who were 
unresponsive to topical Voriconazole with CXL.78 Seven patients (54%) were healed with topical 
voriconazole and CXL adjuvant treatment while the remaining six patients did not respond to CXL 
treatment. Those who responded had small and superficial mycotic ulcers. 
 
 
 
 
Argon laser: One interesting finding in our review was reports on the use of argon laser in treatment 
of keratitis. Although not well understood, it is thought that the thermal energy is fungicidal and 
The evidence for Amniotic Membrane Graft Vs Conjunctival Flap is still scanty to utilise in making 
recommendations. 
 
The evidence shows that although CXL might be dangerous for deep seated corneal infiltrates in 
causing perforation, it may not be dangerous in superficial infiltrates. The evidence on the 
beneficial effects of CXL on superficial infiltrates not responding to topical antifungal medicine is 
still inconclusive and more studies are warranted 
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mimics epithelial debridement in facilitating penetration of topical medication.96 Although literature 
on Argon laser was insufficient, the two RCTs considered in our review showed some minimal 
evidence of the role of Argon laser in fungal keratitis not responding to medical treatment. One RCT 
compared Argon laser Vs intrastromal Voriconazole for treatment of fungal keratitis not responding 
to topical treatment at day 7.80 Argon laser had a significantly faster healing time and fewer cases 
needed AMG. However, the Intrastromal Voriconazole arm had better improvement in vision. 
Another RCT compared Argon laser Vs AMG for the treatment of fungal keratitis not responding to 
topical treatment at day 7.79 Argon laser had a significant faster healing time compared to AMG. 
However, these 2 RCTs had significant methodological weaknesses. 
 
CONCLUSION 
Our review systematically looked at all the evidence on treatment options for fungal keratitis. For 
some options such as topical Natamycin, it is becoming apparent that it is the first line treatment of 
choice for filamentary fungi. However, although there are trends, evidence on other options is still 
inconclusive. No apparent benefit has been documented for oral treatments (Voriconazole and 
Itraconazole). Among the injections, there is modest evidence against use of intrastromal 
Voriconazole and modest evidence for the use of Intra cameral Amphotericin B (ICAMB) especially 
for deep seated/anterior segment fungal Keratitis. A large RCT would be useful. Evidence for surgical 
techniques (TPK, LK, AMG, CF) was inconclusive, however, there is a role of all these procedures 
in salvaging the eye and controlling infection. There is need to optimise results. CXL is gaining 
ground especially in superficial keratitis that are not responding to medical treatment, however, there 
is strong evidence that it might be dangerous for deep seated corneal infiltrates in causing 
perforation. Argon laser may have a role but more studies are needed to generate more evidence. 
  
The evidence for Argon laser is still scanty to utilise in making recommendations. More studies 
are needed 
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Chapter 3. Research setting 
Uganda: An introduction into the research setting 
Geography of Uganda 
Figure 1 Political map of Africa showing the different countries in the continent, 
including Uganda 
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Figure 2 Political Map of Uganda 
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Uganda is a land locked country located in East Africa. It is bordered by five countries, Kenya 
in the east, South Sudan in the north, Tanzania in the south, Rwanda in the southwest and 
Democratic Republic of Congo in the west. Uganda is located on the Equator and thus has a 
tropical climate. The wet months are March to May and September to November. The country 
mainly experiences two dry seasons (December to February and June to August).1
Demography of Uganda 
According to the National Census of 2014, the total population of Uganda was 34.6 million 
people. This represented an increase of 10.4 million from the census in 2002 with an annual 
growth rate averaging of 3%.2 The population was 49.3% male and 50.7% female. Using this 
growth rate, the estimated population for Uganda as of June 2019 is 44.4 million. 
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Figure 3: The population pyramid. The majority of the population is youthful. 
Uganda Health system 
Table 1 gives a summary of the health system in Uganda; it is a tier-based system divided into 
7 levels with the lowest point of care being at the village level. However, physically, a HC II is 
the lowest unit and is located at a parish level. These units have different staffing and capacity 
in terms of service provision. Patients are referred along the tier system depending on the 
complexity of their condition. Special Clinics are facilities which provide specialised services 
only such as HIV treatment services. 
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Table 1: Structure of the Uganda health system 
Level Status Population Staffing Services Provided 
One Health Centre 1 
(HCI) Village 
Level 
1,000 Health Volunteer Community Based preventive 
health services 
Two Health Centre II 
(HCII) Parish 
level 
5,000 Enrolled nurse Outpatient curative health 
services and outreach care 
Three Health Centre III 
(HCIII) sub-
county level 
20,000 Registered nurse, 
midwife, Clinical 
Officer 
Outpatient curative health 
services, maternity, in patients 
and laboratory services 
Four Health Centre IV 
(HC IV) County 
level 
100,000 Medical Officer 
plus HC III cadre 
HC III plus emergency surgery, 
blood transfusion 
Five District hospital 500,000 Registrars plus HC 
IV cadre 
HC IV plus in service training, 
consultation, research, 
community based organisms 
Nation
al 
Regional Referral 
Hospital 
2,000,000 Consultant 
specialists plus 
District hospital 
cadre 
District hospital plus 
specialised services (REC and 
MURHEC are at this level) 
National Referral 
Hospital 
25,000,000 Consultant 
specialists plus 
Regional referral 
Hospital cadre 
Regional referral plus 
Comprehensive sub-specialist 
care 
According to the National Health Facility Master list of 2017 (source, Ministry of Health 
Uganda), there are a total of 6,404 health facilities in Uganda. Most health facilities (48%) are 
public (exclusively government owned and aided), 15.0% (947) are Private and Not-For-Profit 
(PNFP) while the remaining 37.0% (2,373) are Private-For-Profit (PFP) facilities. The 
Government and PNFPs are mostly higher levels of health facilities while the Private-For-Profit 
facilities are largely lower level facilities (HC IIs and clinics). 
The South Western Region where this study was based has 786 health facilities (2 Blood 
Collection and Distribution Points, 49 Clinics, 492 HC IIs, 174 HC IIIs, 41 HC IVs, 20 Hospitals, 
2 Regional Referral Hospitals and 5 Special Clinics). 
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Eye care services are integrated within the general health service system. However, eye care 
providers (ophthalmologists, Ophthalmic Clinical Officers [OCOs], Ophthalmic Assistants 
[OAs] and refractionists) are few and mainly deployed at the regional referral hospital. Uganda 
still has a huge Human Resources for Eye Health gap. 3,4 According to the Uganda Medical 
and Dental Practitioners’ Council specialist register of 2019 
(https://www.umdpc.com/registers.php), there are 51 Ophthalmologists in Uganda for a 
population of 44 million people.2 Out of these, 33 (63%) practice in the capital city Kampala, 7 
(14%) in the second city Mbarara where referral eye hospitals for South western Uganda are 
located. Patients that need specialized eye care attention are referred to one of the 15 regional 
hospitals with ophthalmic services. Although ophthalmic outreach programme is organized by 
regional ophthalmic centres, they don’t reach the rural community adequately. 
According to several Rapid Assessment of Avoidable Blindness studies (RAABs) done in 
Uganda, the general population prevalence of blindness ranges from 1.5%-3.9% in people 
over 50 years.5 Table 2 shows summary findings from the three RAABs conducted in different 
parts of Uganda. The causes of blindness have been reported to be Cataract, Glaucoma and 
Corneal Opacities (Table 3). In these RAABs, the non-Trachomatous Corneal opacities were 
responsible for 3.2-11.1% of all cause blindness. Among children aged below 16 years, two 
studies have been done in Uganda; one study was done in Eastern Uganda ( prevalence 
0.07%) and another in western Uganda (prevalence 0.02%).6,7 The main causes of blindness 
in children were found to be cornea and lens pathologies. 
Table 2: Extrapolated population estimates of prevalence of Blindness in Uganda 
District/Region Mubende (Western) Karamoja (Northern) Hoima (Central) 
n (%) (95%CI) n (%) (95%CI) n (%) (95%CI) 
Blindness - 1.9 (1.5-2.4) 1075 3.1 (2.3-3.9) 858 2.0 (1.5-2.4) 
SVI - 1.1 (0.7-1.4) 498 1.5 (0.8-2.1) 778 1.8 (1.3-2.2) 
MVI - 5.5 (4.8-6.2) 2369 6.9 (5.6-8.2) 2309 5.2 (4.5-6.0) 
FLV - - - 878 2.6 (1.6-3.5) 679 1.5 (1.1-2.0) 
Table extracted from the RAAB reports with permission from the Principal Investigator. SVI 
“Severe Visual Impairment” MVI “Moderate Visual Impairment” FLV “Functional Low Vision”. 
Mubende report did not show the actual numbers but reported extrapolated percentages 
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District Mubende
N=3729 
Karamoja
N=3727 
Hoima
N=3862 
Table 3: Causes of Blindness in Uganda 
n (%) n (%) n (%) 
Cataract untreated 36 57.5% 95 43.8% 31 49.20% 
Cataract surgical complications 1 1.6% 4 1.80% 3 4.80% 
Trachomatous corneal opacity 1 1.6% 57 26.3% 3 4.80% 
Non-Trachomatous corneal opacity 7 11.1% 20 9.20% 2 3.20%
Phthisis - 2 0.90% 3 4.80%
Onchocerciasis - 0 0.00% 0 0.00%
Glaucoma 5 7.9% 18 8.30% 4 6.30%
Diabetic retinopathy - 0 0.00% 0 0.00%
ARMD 1 1.6% 2 0.90% 1 1.60%
Table extracted from the RAAB reports with permission from the Principal Investigator. 
Mubende RAAB report had missing information  
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Research Partners 
Study sites 
Patients were recruited from two sites: 
 Mbarara University and Regional referral Eye hospital (MURHEC) 
 Ruharo Eye Centre (REC). 
MURHEC is a tertiary eye hospital of Mbarara University of Science and Technology (MUST) 
Department of Ophthalmology. It is a government owned hospital providing free service and 
treats about 10,000 patients/year. MURHEC has a staffing of 4 consultant ophthalmologists, 
22 ophthalmology residents, 3 ophthalmic clinical officers, 1 optometrist, 7 nurses. The 
hospital has a daily outpatient consultation schedule that includes a side microbiology 
laboratory, imaging facilities (fundus camera, Optical Coherence Tomography, ultrasound, 
visual fields) laser (YAG capsulotomy, Argon laser for retina, Argon laser trabeculoplasty), an 
admission ward and two theatres. 
REC is a church based fee-paying tertiary eye hospital that has been in existence since the 
1960s. REC sees about 25,000 patients/year. REC has a staffing of 2 consultant 
ophthalmologists, 10 ophthalmic clinical officers, 1 optometrist, 25 nurses. The hospital has a 
daily outpatient consultation schedule and a high-volume cataract surgery service. The 
ophthalmology residents from MURHEC do some of their rotations at REC. 
Both hospitals are in Mbarara Municipality, South-western Uganda approximately four hours’ 
drive from the capital Kampala. The two units are about 5km apart and work closely together. 
They receive patients mainly from south-western Uganda, parts of north western Tanzania, 
Rwanda and eastern Congo.  
Laboratories 
I. Mbarara University of Science and Technology, department of Microbiology-Ocular 
microbiology (Microscopy, culture and sensitivity) 
II. Kilimanjaro Christian Medical College Laboratory-Pan fungal PCR DNA sequencing 
References 
1. Uganda_Wildlife_Authority. The Geography of Uganda. In: Tourism, ed. Kampala: UWA; 2019. 
2. UBOS. The National Population and Housing Census 2014 – Main Report. In: Statistics UBo, ed. 
Kampala: UBOS; 2014. 
3. Palmer JJ, Chinanayi F, Gilbert A, et al. Mapping human resources for eye health in 21 countries of sub-
Saharan Africa: current progress towards VISION 2020. Hum Resour Health. 2014;12(1):44. 
4. Palmer JJ, Chinanayi F, Gilbert A, et al. Trends and implications for achieving VISION 2020 human 
resources for eye health targets in 16 countries of sub-Saharan Africa by the year 2020. Human resources 
for health. 2014;12(1):45. 
5. Kikira S. KARAMOJA RAAB NOV–DEC 2015 REPORT. 
169
Simon Arunga PhD Thesis 2019 
6. Arunga S, Onyango J, Ruvuma S, Twinamasiko A. Prevalence and causes of blindness and severe visual 
impairment (BL/SVI) among children in Ntungamo district, Southwestern Uganda: A key informant cross-
sectional population survey. JOECSA. 2016;20(1). 
7. Dan B. Childhood blindness and its impact: Key informant method in Bulambuli district, Eastern Uganda. 
London: Msc CEH, London School of Hygiene and Tropical Medicine; 2011. 
170
Simon Arunga PhD Thesis 2019 
Chapter 4. Overview of the project design 
Ruharo Eye Centre, Uganda. One of the project participant recruitment sites 
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Rationale for the study 
Microbial keratitis is a common and serious eye problem that leads to loss of sight and a high 
morbidity for affected individuals. Currently, there is very little information on MK in Sub-Saharan 
Africa; it has been a neglected area of research.  
The overall purpose of this research programme was to make a major contribution to the 
development of strategies to reduce blindness from microbial keratitis (MK) in East Africa. This would 
be achieved by carrying out detailed studies of the epidemiology, aetiology, microbiology and clinical 
presentation of microbial keratitis cases presenting to Mbarara University and Referral Hospital Eye 
Centre (MURHEC) and Ruharo Eye Centre (REC), south western Uganda. 
The things learned through this project will help us to improve the management and outcomes for 
people with MK in Uganda and the wider East African region in several ways: 
1. Identification of predisposing factors to corneal infections will help us to develop prevention 
strategies. 
2. Understanding the barriers to timely presentation of patients with MK in Uganda will help us 
to design well-informed public health interventions to encourage early presentation. 
3. A better understanding of the capacity of lower health centres in managing MK will enable us 
to design a training module for mid-cadre health workers, and also make recommendation to the 
Ugandan MOH stocking of medication in lower health centres. 
4. Knowledge of the causative organisms and local antibiotic sensitivity patterns will help us 
make rational decisions on the choice of empirical treatment and to recommend to the MOH the 
choice of drugs. 
5. The evaluation of specific clinical signs in relation to the underlying causative agent will help 
us develop a protocol for clinicians in settings where microbiological support is not available.  
6. An understanding of the use and impact of TEM will help us to better engage with the wider 
community about the potential risks and develop health education messages to discourage its use 
(if it turns out to be detrimental). 
7. A detailed understanding of the determinants of a poor outcome from MK will help clinicians 
to plan management accordingly such as whether to admit or not, and what the likely outcome of the 
treatment will be. 
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Theory of Change 
We used a theory of change conceptual thinking process of the issues around MK that lead to poor 
outcomes. We used this model to narrow down to specific research aims. This was based on 
extensive literature which has been discussed in the background chapter, review of the local data in 
Uganda, knowledge of the disease process as well as discussion with fellow clinicians involved in 
managing eye conditions. 
Our overall vision was to explore how to prevent vision impairment and vision loss due to MK. We 
explored reasons that contribute to poor outcomes among patients with MK. Figure 2 shows a logical 
cascade of events along this pathway. For one to get a severe MK infection, first there must be an 
epithelial breach, secondly, this becomes an infected epithelial breach which if not treated results in 
severe MK and ultimately poor outcome resulting in vision loss.  
Broadly, there are “risk factors” that make one susceptible to developing MK. These could include, 
Traditional Eye Medicine use, Trauma, existing Ocular surface disease, environment contextual 
factors such as poverty, farming occupation, Immunological susceptibility (diabetes and HIV). 1-6
Next are factors which exacerbate the disease such as delay starting treatment, lack of 
microbiological support in identifying the causative organisms and poor clinical management. 7-10
There is overlap and some of the pre-existing factors also contribute not only in susceptibility but in 
worsening the condition. Efforts to prevent blindness from MK can address to primary prevention 
against corneal epithelial breach (for example prevention of ocular trauma), secondary prevention 
against this breach becoming infected (antibiotic prophylaxis, avoiding TEM use) and once it gets 
infected, prompt treatment with effective antimicrobial agents. 
Although this was logically clear, there were underlying questions along this though process that 
needed to be answered. This formed our basis for the aims and objectives mentioned below. 
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Figure 1 Theory of change model showing factors that lead to poor outcomes for Microbial Keratitis 
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Research Aims
1. To describe the epidemiology of MK; patient presentation, causative organisms and 
their anti-microbial sensitivity; outcome and its determinants among MK cases in 
south western Uganda. 
2. To investigate risk factors for MK in Uganda including HIV infection, Diabetes Mellitus, 
Traditional Eye Medicine and Occupation.  
3. To understand the patient perspective on the effect of MK on quality of life 
4. To investigate the role of the health system particularly lower health centres in care of 
MK, and the barriers that need to be overcome. 
5. To explore the contribution of Traditional Eye Medicine (TEM) to MK in Uganda 
Table 1 Specific research objectives 
Study Specific objectives Design 
Epidemiology of MK 
in Uganda 
1. To describe the phenotypic presentation of 
MK patients in Uganda. 
2. To describe the microbiological spectrum of 
MK in Uganda. 
3. To describe the 3 months outcomes among 
MK patients in Uganda. 
4. To determine the factors associated with 
poor outcomes among MK patients in 
Uganda 
Cohort 
Risk factors of MK 
in Uganda 
1. To determine if HIV infection, Diabetes 
Mellitus, Traditional Eye Medicine use and 
farming occupation are risk factors for MK in 
Uganda? 
Nested matched 
case-control 
Effect of MK on 
Quality of Life (QoL)
1. To compare QoL amongst MK patients 
before and after treatment (at 3 months). 
2. To compare QoL at 3 months among MK 
patients with individually matched healthy 
individuals without MK. 
Cross sectional 
comparative 
study 
Role of the healthy 
system in 
management of MK 
in Uganda 
1. To determine the knowledge of mid-level 
health workers in managing MK. 
2. To determine the capacity of different tiers in 
the health system in managing MK. 
3. To determine the level of training given to 
mid-level health workers in eye health. 
4. To describe the presentation pathways of 
MK patients through the different tiers of the 
health system in Uganda. 
Cross sectional 
survey 
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Role of Traditional 
Eye Medicine 
(TEM) 
1. To determine the proportion of people with 
MK who use TEM. 
2. To determine the effect of TEM on the 
presentation and outcomes of MK in 
Uganda. 
3. To determine factors associated with TEM 
use in Uganda 
4. To explore reasons why people, use TEM 
for treatment of MK in Uganda. 
Mixed methods 
Methods Overview: 
The overall design was a prospective cohort study of individuals presenting with MK to 
investigate their pattern of presentation, clinical features, microbiology and outcomes. We then 
conducted a nested case-control study, recruiting community controls matched to a subset 
of the MK cases, to investigate the impact of MK on Quality of Life and identify addressable 
risk factors for this disease. In parallel, we explored in a qualitative study through one-to-one 
interviews and small group discussions reasons of use of TEM. A separate situation analysis 
survey was conducted to understand how patients with MK are currently cared for within the 
formal Health System in Uganda. Figure 3 shows the general schematic of how these studies 
were conducted. 
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Figure 2 Flow of studies 
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Chapter 5. Factors Associated with Poor Presenting Vision 
Among Patients with Microbial Keratitis in Uganda 
A study patient undergoes a smart phone-based peek visual acuity examination at 
Ruharo Eye Centre 
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Abstract 
Purpose: To determine factors associated with poor presenting vision among patients with 
microbial keratitis in Uganda. 
Methods: Retrospective audit of patients presenting with microbial keratitis at the two main 
eye units in Southern Uganda in 2015. We collected information on time to presentation, 
treatment history, use of traditional eye medicine, trauma and presenting final visual acuity. 
We analysed factors associated with a poor presenting vision in a regression model. 
Results: There were 273 cases during 2015. The median presentation time was 7 days from 
onset (IQR 2-21, total range 0-366 days). Trauma was reported in 59/88 (67%) patients and 
69/162 (43%) reported using traditional eye medicine. Visual acuity was reported in only 
216/273 cases at presention. Visual acuity at presentation of less than 6/60 (severe visual 
impairment) was strongly associated with the use of traditional eye medicine (OR 5.13, 95%CI 
2.17–12.1, p=0.001). 
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Conclusion: This audit highlighted the role of use of traditional eye medicine in causing poor 
presentation among patients with microbial keratitis in Uganda. 
Keywords 
Microbial Keratitis, Bacterial keratitis, Fungal keratitis, Keratitis, Traditional Eye Medicine, 
Uganda 
Text 
Introduction: Microbial keratitis (MK) can be caused by a range of pathogens including 
bacteria, viruses, protozoa and fungi. MK frequently leads to sight-loss from dense corneal 
scarring, or even loss of the eye, especially when the infection is severe and/or appropriate 
treatment is delayed.1 MK has been described as a “silent epidemic”, which leads to 
substantial morbidity, related to blindness and other consequences such as pain and stigma.2 
It is the leading cause of unilateral blindness after cataract in Tropical regions and is 
responsible for about 2 million cases of monocular blindness per year.3 
A good outcome depends on early appropriate treatment, correct identification of the causative 
organism, and careful follow-up.4, 5 In Low and Middle-Income Countries (LMIC), MK presents 
major challenges: Majority of patients present with advanced disease when little can be done. 
Ultimately, outcomes tend to be poor.6, 7 Outcome data from SSA have reported overall cure 
rates with and without scarring of about 50% and the majority of patients end up with vision of 
less than 6/60.6, 8-13  
The purpose of our audit was to determine factors associated with poor presentation among 
patients with MK in rural South-Western Region of Uganda. 
Methods 
We conducted a retrospective audit of all patients with MK that presented to Ruharo Eye 
Centre (REC) and Mbarara University and Referral Hospital Eye Centre (MURHEC) during the 
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whole of 2015. MURHEC is a government owned tertiary eye unit established in 2013. It 
provides mostly free services and sees about 6,000 - 10,000 patients/year. REC is a church-
based fee-paying tertiary eye hospital founded in the 1960s. It sees about 20,000 - 25,000 
patients/year. Both hospitals are located in Mbarara Municipality, South-Western Region, 
Uganda, approximately four hours drive from Kampala. The two units are about 5km apart and 
work closely together. 
This study adhered to the tenets of Declaration of Helsinki. It was approved by the London 
School of Hygiene & Tropical Medicine Ethics Committee (Ref:10647). It was approved as an 
audit study by both MURHEC and REC. All data were anonymized after extraction from clinical 
notes. 
We included all patients who were recorded to have a clinical diagnosis of either clinically 
diagnosed fungal or bacterial keratitis presenting between 1st January and 31st December 
2015. Patients with other forms of keratitis were excluded. We reviewed and extracted 
information from the case records. This included patient demographics, history, recorded risk 
factors, presenting visual acuity, treatment and outcome.  
Data were analysed in STATA v14. The main study variables were presentation time, use of 
traditional eye medicine, use of “other eye medicine”, history of trauma, presenting vision, 
follow-up rate, final visual acuity and loss of the eye. Visual acuity was categorised according 
to the WHO classification system.14 Presentation time was classified as early (1-3 days) or late 
(4 days and above).15. For the purposes of this analysis we categorised poor presenting vision 
to be worse than 6/60.6 Logistic regression analysis was used to identify factors associated 
with poor presenting vision. 
Results 
We enrolled 273 patient records with clinically diagnosed bacterial or fungal keratitis. Figure 
one shows the enrolment process. 
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Of the 273 individuals with bacterial or fungal keratitis, 178 (65%) were male (Table 1). Their 
median age was 36 years (IQR 19–55 years, Total Range 1–104 years). The time between 
the onset of symptoms and presentation was skewed: median 7 days, IQR 0–21 days, total 
range 0–366 days. Seventy three patients (30%) presented early (≤3 days) and 166 patients 
(70%) presented late (≥ 4 days). Patients had to travel considerable distances to reach the 
eye units: median 80 km, IQR 45-99 km, total range 1-378 km. There was no microbiology 
data recorded. At presentation, visual acuity was documented in 220 out of 273 patients (81%) 
of which 80/220 had a vision worse than 6/60. 
We analysed the factors associated with a poor presenting vision (<6/60). The univariable and 
multivariable logistic regression models for these outcomes are presented in a table 3. Poor 
vision at presentation (<6/60) was associated with increasing distance from home to hospital 
(OR 1.02, 95%CI 1.01-1.03, p=0.002) and TEM use (OR 5.13, 95% CI 2.17-12.1, p=0.001). 
Discussion 
This audit highlights factors associated with a poor presenting vision. Multiple factors were 
hypothesised to contribute to poor outcomes. These included large distances from the eye 
hospital, delayed presentation, trauma and Traditional Eye Medicine (TEM). 
In this audit, almost half of the patients with recorded information on TEM use reported having 
used TEM and this was strongly associated with worse presenting vision, even after controlling 
for delay in presentation. Many people probably choose to try TEM for several days before 
attending hospital as it can be easily obtained within or close to home. Its use appears to 
contribute to poor outcomes, substantially adding to the risk of poorer presenting vision. In 
Uganda, TEM is usually made from plant products. This is concerning, as such substances 
may be toxic or harbour infectious agents, such as fungal spores.16, 17  
A large distance to the eye hospital was strongly associated with poor presenting vision. The 
units included in this audit constitute the referral centres for the whole region and many of the 
187
Simon Arunga PhD Thesis 2019 
 
patients came from substantial distances to seek treatment. While the evidence from our data 
was limited, distance is probably an important factor in the presentation, course and outcome 
of MK in our setting. 
This retrospective audit had several limitations. Visual acuity was not recorded consistently for 
all patients at presentation and follow-up. Presenting vision was available in about 81% of the 
patients. From a clinical management point of view this is an important audit learning point. 
We have already introduced new procedures that ensure the consistent recording of vision 
data for all patients. It is possible that this might have introduced some systematic bias, with 
people with poorer vision being less likely to have this documented than those with better 
vision. 
Loss to follow-up is generally a significant challenge in this region and makes it difficult to 
evaluate outcomes. Follow-up data was largely missing and so the analysis was based on 
presenting vision as a proxy of outcome.18  
During 2015, samples were not sent for microbiological investigations, therefore, diagnosis 
and treatment choices were based purely on clinical evaluation. In the absence of a 
microbiological diagnosis, diagnostic uncertainty remains high, likely resulting in failure to treat 
appropriately.19, 20 Following this audit, we have started a routine ocular microbiology service 
for all patients with MK. 
Conclusion 
This audit reflects the factors associated with a poor presentation among patients with MK. 
Delayed presentation, traditional eye medicine use, lack of laboratory support are all factors 
which need to be addressed in the effort to reduce avoidable blindness. Good quality data 
collection and research into strategies to manage MK are clearly needed.  
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Figure 1 Patient chart evaluation for enrolment 
 
 
Table 1: Baseline characteristics of all 273 individuals with microbial keratitis.  
Variable Median IQR (Total Range) 
Age (years) 36 19-55 (1-104) 
Distance from Eye Hospital (km) 80 45-99 (1-378) 
Time to presentation (days) 7 0-21 (0-295) 
Variable N Count (%) 
Sex 
• Male 
• Female 
273  
178 
95 
 
(65%) 
(35%) 
Trauma* 88 59 (67%) 
Prior Treatment Ɨ 154 147 (96%) 
Traditional Eye Medicine use ǂ 162 69 (43%) 
Hypopyon 271 42 (15%) 
Visual acuity at presentation § 216   
6/5-6/18  107 (48%) 
6/24-6/60  33 (15%) 
5/60-3/60  8 (4%) 
2/60-1/60  13 (6%) 
0.5/60-PL  48 (22%) 
NPL  11 (5%) 
*Data not recorded in all clinical notes, denominator (N) indicates the number of records where reference to this 
variable was made. Out of the 273 patients, 88 had data on whether there was trauma or not (59/88, 67%, positive). 
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Ɨ 147/154 (95%) patients reported prior use of some other eye medicine other than TEM, but the specific type was 
not recorded. ǂ 162 patients had data on whether they had used Traditional Eye Medicine (TEM) or not (69/162, 
43%, positive). The different types of traditional medicine were not recorded in the charts. § only 216 out of 273 
patients had recorded presenting vision. PL = Perception of Light; NPL = No Perception of Light
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Table 2: Logistic regression for factors associated with a poor presenting vision among patients with Microbial Keratitis 1 
Variable 
Univariate analysis Multivariate analysis 
Crude OR (95% CI) p-value Adjusted OR (95% CI) p-value 
Age 1.02 (1.01-1.03) 0.016    
Sex (being female) 1.19 (0.66-2.13) 0.564    
Distance (for every 1Km increase) 1.02 (1.01-1.03) 0.001 1.02 (1.01-1.03) 0.002 
TEM use 4.66 (2.18-9.95) 0.001 5.13 (2.17-12.1) 0.001 
    5.19 (2.24-12.0) 0.001 Ɨ 
Trauma 1.28 (0.44-3.75) 0.645    
Delayed presentation 1.49 (0.75-2.92) 0.247    
In this model, there was a lot of missing data in the patient charts that not all the patients with reported baseline vision could be used for the analysis. The final model had 120 2 
observations.  Ɨ TEM adjusted for delayed presentation 3 
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Chapter 6. Epidemiology of Microbial Keratitis in Uganda 
A patient undergoes review at Mbarara University and Referral Hospital Eye Centre 
(MURHEC) 
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ABSTRACT
Purpose: To describe the epidemiology of Microbial Keratitis (MK) in Uganda.
Methods: We prospectively recruited patients presenting with MK at two main eye units in
Southern Uganda between December 2016 and March 2018. We collected information on
clinical history and presentation, microbiology and 3-month outcomes. Poor vision was
defined as vision < 6/60).
Results: 313 individuals were enrolled. Median age was 47 years (range 18–96) and 174 (56%)
were male. Median presentation time was 17 days from onset (IQR 8–32). Trauma was reported by
29% and use of Traditional Eye Medicine by 60%. Majority presented with severe infections
(median infiltrate size 5.2 mm); 47% were blind in the affected eye (vision < 3/60). Microbiology
was available from 270 cases: 62% were fungal, 7% mixed (bacterial and fungal), 7% bacterial and
24% no organism detected. At 3 months, 30% of the participants were blind in the affected eye,
while 9% had lost their eye from the infection. Delayed presentation (overall p = .007) and prior
use of Traditional Eye Medicine (aOR 1.58 [95% CI 1.04–2.42], p = .033) were responsible for poor
presentation. Predictors of poor vision at 3 months were: baseline vision (aOR 2.98 [95%CI
2.12–4.19], p < .0001), infiltrate size (aOR 1.19 [95%CI 1.03–1.36], p < .020) and perforation at
presentation (aOR 9.93 [95% CI 3.70–26.6], p < .0001).
Conclusion: The most important outcome predictor was the state of the eye at presentation,
facilitated by prior use of Traditional Eye Medicine and delayed presentation. In order to improve
outcomes, we need effective early interventions.
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Background
Microbial keratitis (MK) can be caused by a range of
pathogens including, bacteria, viruses, protozoa, and
fungi. It is characterized by acute or sub-acute onset
of pain, conjunctival hyperemia, and corneal ulceration
with a stromal inflammatory cell infiltrate.1
MK has been described as a “silent epidemic”, which
leads to substantial morbidity, related to blindness, pain,
and stigma.2 It is the leading cause of unilateral blindness
after cataract in Tropical regions estimated at 2 million
cases of monocular blindness per year.3 In 2017,
1.3 million individuals were bilaterally blind from corneal
opacity globally (excluding trachoma and vitamin
A deficiency), accounting for 3.2% of the binocular
blindness.4 In Sub-Saharan Africa (SSA), MK is an impor-
tant cause of binocular blindness and is responsible for
about 15% of the monocular blindness (Nigeria National
Survey).5,6 The only report of the incidence in SSA is from
Malawi in 1994, which suggested a rate of around 180/
100,000/year.7 Rates in high-income settings are lower at
5–10/100,000.8–10
MK frequently leads to sight-loss from dense corneal
scarring, or even loss of the eye, especially when the
infection is severe and/or appropriate treatment is
delayed. A good outcome depends on early appropriate
treatment, supported by correct identification of the cau-
sative organism, and careful follow-up.11,12 In low and
middle-income countries (LMIC), these resources are not
readily available and outcomes tend to be poor.13
Literature on MK in SSA is extremely sparse, only
one audit from an LMIC setting (Tanzania) has pre-
viously reported outcomes of MK at discharge in
SSA.13 Here, in this large prospective cohort study
CONTACT Simon Arunga Simon.Arunga@lshtm.ac.uk International Centre for Eye Health, Clinical Research Department, Faculty of Infectious and
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from South-Western Uganda, we describe patient pre-
sentation, causative organisms, 3-month outcomes,
and investigate their determinants.
Methods
Ethical statement
This study followed the tenets of the Declaration of
Helsinki. It was approved by the London School of
Hygiene & Tropical Medicine Ethics Committee (Ref
10647), Mbarara University Research Ethics Committee
(Ref 10/04-16) and Uganda National Council for
Science and Technology (Ref HS-2303). Written
informed consent in the local language was obtained
before enrolment. If the patient was unable to read, the
information was read to them, and they were asked to
indicate their consent by application of their thumb-
print, which was independently witnessed.
Study design and setting
In this cohort, we prospectively enrolled patients with
MK that presented to Ruharo Eye Centre (REC) and
Mbarara University and Referral Hospital Eye Centre
(MURHEC) from December 2016 to March 2018.
MURHEC is a government-owned tertiary eye unit
established in 2013. It provides mostly free services and
sees about 6,000–10,000 patients/year. REC is a church-
run fee-paying tertiary eye hospital founded in the 1960s.
It sees about 20,000–25,000 patients/year. Both hospitals
are located in Mbarara Municipality, South-Western
Region, Uganda. In order to investigate the seasonal
variation in the presentation of MK, we aimed to recruit
all MK cases presenting during at least one year.13
Study participants
MK was defined as loss of corneal epithelium (of at least
1-mm diameter) with underlying stromal infiltrate,
associated with any or all signs of inflammation (conjunc-
tival hyperemia, anterior chamber inflammatory cells, ±
hypopyon).14 We also included patients presenting with
a deep corneal abscess (of at least 1 mm), defined as
having all the features of MK, but without an epithelial
defect. We excluded those not willing to participate, those
not willing to return for follow-up, pregnant women,
lactating mothers and those aged below 18 years.
Assessment
We documented basic demographic information and
their ophthalmic history. This included the circumstances
in which their eye became infected, predisposing factors,
treatment received, and their “health care journey” before
reaching the eye hospital. Presenting Log MAR
(Logarithm of Minimum Angle of Resolution) visual
acuity at 2 m in a dark room was measured using Peek
Acuity software.15 Participants were examined with a slit
lamp to assess the anterior segment using a structured
protocol, including eyelid assessment, corneal ulcer fea-
tures, anterior chamber (flare, cells, hypopyon shape, and
size) and perforation status. Infiltrate size was determined
from the greatest diameter of the infiltrate (major axis)
and the widest perpendicular diameter (minor axis).14
The final infiltrate size was then derived as the geometric
mean of these two diameters.14 The same was repeated
after fluorescein staining of the ulcer to determine epithe-
lial defect sizes. High-resolution digital photographs with
and without fluorescein staining were taken with a Nikon
SLR 7200 digital camera with Macro lens.
Corneal scrape specimens were collected from the
ulcer at a slit lamp or an operating microscope, using
21G needles after application of a proxymetacaine
(minims) anesthetic eye drops. Samples underwent
processing for the Gram stain, Potassium Hydroxide
[KOH] stain, Calcofluor White [CFW] stain and direct
inoculation on culture media (Sheep’s Blood Agar
[BA], Chocolate Agar [HBA], Potato Dextrose Agar
[PDA] and Brain Heart Infusion broth [BHI]). Two
sterile corneal swab samples were taken for pan fungal
gene sequencing. The number of corneal samples was
dependent on how much material could be safely
scraped from the cornea. The order was samples for
microscopy, agar, broth, and finally corneal swabs.
In addition, a random blood sugar test and HIV
counseling and testing were offered, as per the Uganda
Ministry of Health HIV testing protocol. For those who
were confirmed as HIV positive, a CD4 test was per-
formed to determine the level of immune suppression
and they were referred to the HIV care center, which is
on the hospital site.
Microscopy, culture, and antimicrobial sensitivity
work were done at the Mbarara University Department
of Microbiology. The technician underwent initial train-
ing in ocular microbiology at the Aravind Eye Hospital
System, department of ocular Microbiology in Madurai,
India and had a site supervision visit by amycologist from
the London School of Hygiene & Tropical Medicine.
Immediate CFW staining was also done in the side lab at
MURHEC on a fluorescein microscope (Zeiss Primostar
ILED) by the attending ophthalmologist. Agar plates and
broths were incubated and read daily at 35–37°C for
bacteria for up to 7 days and at 25°C for up to 21 days
for fungi. Organism identification and sensitivity testing
(MIC/zone of inhibition) were performed using standard
2 S. ARUNGA ET AL.
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microbiological techniques. We followed a previously
described approach for reporting positive microbiology
results.16 Briefly, bacteria were identified using routine
biochemical identification tests. Identification of fungi
was according to the macroscopic appearance of cultures
on potato dextrose andmicroscopic appearance of conidia
and spore-bearing structures. Positive culture was growth
at the site of inoculation or growth on one solid medium
consistent with microscopy; or semiconfluent growth at
the site of inoculation on one solid medium (if bacteria);
or growth of the same organism on repeated scraping. If,
by microscopy, hyphae were observed in corneal tissue,
but failed to grow in culture, the causative organism was
reported as fungal.
Treatment and follow-up
Patients were treated empirically at presentation and
the treatment choice was reviewed when the micro-
biology results became available. Patients with fungal
keratitis were treated with Natamycin 5% eyedrops
(Zonat Sunways India), those with bacterial
keratitis were treated with Ofloxacin 0.3% eyedrops
(Biomedica Remedies-India). Patients with fungal
infection were treated hourly day and night for the
first 3 days and then hourly while the patient was
awake for 2 weeks. This was changed to 2-hourly for
another 2 weeks and then tapered to 4 times a day
until healed. For bacterial infections, patients were
treated hourly day and night for the first 3 days and
then reduced to 6 times a day for a further week. All
patients with fungal MK were also given Ofloxacin
0.3% eye-drops four times a day as prophylaxis until
all epithelial defects were healed. In addition, those in
pain were treated with Atropine 1% eye-drops (locally
formulated) and oral Paracetamol tablets. Raised
intraocular pressure was treated with Timolol 0.5%
eye-drops (locally formulated). Those with presumed
viral keratitis were treated with Acyclovir 3% eye
ointment (CIPLA India) five times a day for 3
weeks. Most patients were admitted during the first
week.
After the initial assessment patients were seen
on day 2, day 7, day 21, and day 90 (3 months).
Additional assessments were conducted as clinically
indicated. The main outcome measures were final best-
corrected vision at 3 months, blindness (<3/60 in the
affected eye) at 3 months, and loss of the eye at 3
months. Scar density was also graded as “no scar”
(clear cornea), “mild scar” (anterior chamber structures
clearly visible through the scar), “moderate scar” (ante-
rior chamber structures vaguely visible through the
scar) and “dense scar” (anterior chamber structures
completely obscured by the scar).
Analysis
Data were analyzed in STATA v14. To describe the
presentation of MK, summary frequency tables of
demographics, presentation time, clinical history and
clinical features were generated. Presentation time was
classified as prompt (0–3 days), early (4–7 days), inter-
mediate (8–14 days), late (15–30 days) and very late
(more than 30 days).17 In addition, a summary tally of
patients that presented by month across one year
(2017) was generated to describe the presentation pat-
tern. This was compared to local rainfall, humidity and
temperature patterns. Local weather data were obtained
from the weather and climate repository.18 For presen-
tation purposes, Log MAR visual acuity measurements
were converted to the Snellen scale and categorized
according to the WHO classification system.19
We used two different analytical approaches. We first
took a causal modeling approach to explore the associa-
tion of six risk factors of interest with visual acuity at
presentation. These six factors were (Traditional Eye
Medicine) TEM use, history of trauma, delayed presenta-
tion, distance from hospital, distance from nearest health
center (HC), and organism type. In order to inform our
modeling choices, we first drew Direct Acyclic Graphs
(DAGs), using www.daggity.net v2.3 software, to identify
relevant variables to adjust for in the multivariable logistic
regression model.20 A DAG is a representation of the
hypothesized order of events from the exposure to the
outcome. It allows the researcher to logically map out
relationships between different variables and identify
those to adjust for to determine the overall effect of the
exposure on the outcome. A change in point estimate
criteria was used to assess for confounding and multi-
collinearity. Each main exposure was separately adjusted
for confounding factors and final adjusted odds ratios
(aOR) recorded.
The second modeling approach was to build
a predictive model for visual acuity outcomes at 3
months, using baseline clinical features. Patients with-
out 3-month data were excluded from the analysis.
Ordinal logistic regression analysis of the WHO
Snellen visual acuity categories was used to identify
factors associated with visual acuity at 3 months.
Univariable regression was performed to generate
OPHTHALMIC EPIDEMIOLOGY 3
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crude odds ratios (cOR). Variables with a p-value less
than 0.1 were initially included in the multivariable
model. A backward stepwise approach was then used
until only the variables with a p-value of less than 0.05
were retained. Adjusted ORs were reported for the final
model.
Results
Participants
Patient enrolment is illustrated in Figure 1. The baseline
characteristics of the patients are shown in Table 1.
Median age was 47 years (IQR 35–60, total range 18–96
years), and the majority (56%) were male. Over a quarter
had never had any formal education. Most (70%) were
married and most (70%) were the heads of households.
Median distance from home to the eye hospital was 79 km
(IQR 52–128, total range 0.2–378 km). Median distance
from home to their nearest HC was 3 km (IQR 1–4, total
range 0–45 km). The main occupation was farming
(70%). The baseline characteristics of the patients who
were lost to follow-up and those who completed 3months
were similar (Supplementary Table 1).
Presentation pattern
Figure 2 illustrates the number presenting per month
throughout 2017, compared to rainfall, temperature and
humidity patterns. Patients presented throughout the year,
with peaks inMay to July andOctober toNovember, which
corresponded with the harvest seasons. April and
November had the greatest rainfall. Temperature and
humidity were constant throughout the year.
Figure 1. Flow diagram of participants who were enrolled in the cohort study.
Table 1. Demographic characteristics of the study participants.
Variable n/313 (%)
Age (median = 47, IQR 35–60) in years
< 30 years 54 (17%)
30–40 years 63 (20%)
40–50 years 59 (19%)
50–60 years 66 (21%)
> 60 years 71 (23%)
Gender
Female 139 (44%)
Male 174 (56%)
Occupation
Farmer 220 (70%)
Non-farmer 93 (30%)
Education
None 84 (27%)
Primary level 162 (52%)
Secondary level 45 (14%)
Tertiary level 22 (7%)
Marital status
Unmarrieda 95 (30%)
Married 218 (70%)
Economic statusb
Lower 85 (28%)
Middle 189 (63%)
Upper 26 (9%)
Being head of household
Yes 212 (68%)
No 101 (32%)
Distance from the eye hospital (median = 79 km
IQR 52–128)
0–50 km 77 (25%)
50–100 km 111 (35%)
100–150 km 75 (24%)
>150 km 50 (16%)
Nearest health center (Median 3 km, IQR
1–4 km)c
Clinic 10 (3%)
HC II 103 (33%)
HC III 96 (31%)
HC IV 43 (14%)
Hospital 32 (10%)
Don’t know 29 (9%)
aUnmarried included single divorced and widowed.
bEconomic status was self-reported where participants compared them-
selves with their neighborhood as “poor”, “neither poor nor rich” or
“rich”, n was 300 with 13 non-reported values.
cThe nearest health center was the health center that the patients con-
sidered nearest to them regardless of the level of that health center
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Presenting history
The median time from onset of symptoms to presenta-
tion time at the eye unit was 17 days (IQR 8–32, total
range 0–370 days), Table 2. Only 7% of the participants
presented “promptly” (within 3 days). Only 29% of the
participants reported a history of trauma, and most
(74%) of these were classified as organic in nature.
Many patients (60%) reported use of TEM.
Clinical features and microbiology
Table 3 shows the clinical features at presentation,
including detailed characteristics of the ulcers and
microbiology results. Specimen for microbiology was
collected in 270 patients. Due to limited amounts of
sample material, it was not possible to perform all tests
on all those sampled. Almost half of the participants
(47%) had a visual acuity of less than 3/60 (blind) in the
affected eye at presentation. Microbiology results were
available in 270/313 (86.3%) participants. Corneal
scrapping was not performed on 43 participants who
either did not consent, had deep-seated infiltrates, or
small infiltrates (less than 0.5 mm). Overall, most infec-
tions were fungal (62%), 7% were bacterial and 7% were
mixed (fungal and bacterial). Fifty-seven (20%) of the
corneal scrapping samples were negative on both
microscopy and culture.
Outcomes
Table 4 shows the outcomes of the 260 participants seen
at the 3-month follow-up. At 3 months, the visual acuity
was better than baseline vision. Median final visual acuity
(Log MAR) was 0.4 (IQR 0–1.5) compared to a baseline
Figure 2. Presentation of patients with MK, by month in 2017 (n = 261). Monthly average minimum and maximum
temperatures, average humidity and the number of days with rain are overlaid. Humidity was in percentage but was scaled
to tens (divided by 10) to fit on the plot scale.
Table 2. Clinical history.
Variable n/313 (%)
Presenting time (median = 17 days, IQR 8–32)a
Prompt 0–3 days 23 (7%)
Early 4–7 days 46 (15%)
Intermediate 8–14 days 72 (23%)
Late 15–30 days 79 (26%)
Very late >30 days 90 (29%)
Most important symptom (self-reported)
Pain 144 (46%)
Reduced vision 137 (44%)
Other 32 (10%)
History of trauma
Yes 91 (29%)
No 220 (71%)
Used traditional eye medicine
Yes 188 (60%)
No 125 (40%)
Used other treatmentb
Yes 275 (88%)
No 38 (12%)
Diabetic (n = 280)c 22 (8%)
HIV positive (n = 284)c 37 (13%)
an was 310. For 3 patients the date of onset could not be well ascertained.
Some patients had used other forms of eye drops prior to presentation and
there was some overlap among those who used TEM and other eye drops.
bIt was not possible to ascertain the forms of other treatment used.
cSome patients declined to be tested for HIV and diabetes
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median of 1.3 (IQR 0.3–2.5). Visual acuity at 3 months
improved in 139 participants, worsened in 66 partici-
pants and remained unchanged in 56 (sign rank test
p < .0001). Visual acuity was categorized according to
the WHO classification system and poor outcome was
considered as vision < 6/60.19 Thirty percent of the
participants were blind in the affected eye (vision less
than 3/60) and 9% had lost their eye to infection due to
evisceration following endophthalmitis.
Causal modeling for poor presentation
Figure 3 shows the overall model for several variables of
interest that we considered in the causal analysis for poor
presenting vision. The results are summarized in Table 5
and their corresponding outputs from the DAGitty soft-
ware in Supplementary Figures 1–5. Those who reported
TEM were estimated to have overall 1.6 times the odds of
being in a poorer vision category compared to those who
did not use TEM (aOR 1.62 [95%CI 1.04–2.54], p = .033).
It was considered plausible that some of this effect was
mediated through delayed presentation and/or organism
type, and after adjusting for these factors as well, the aOR
was 1.47 [95%CI 0.91–2.38], p = .11. There was some
evidence (p = .033) of an association between the cate-
gory of presentation time and presenting vision, with the
lowest odds of poorer vision being in those that present
earliest and increasing odds as delay increases. No evi-
dence (p = .609) was found of an association between
trauma and presenting visual acuity, but strong evidence
was found of an association between presenting visual
acuity and both distance from the eye hospital (p < .001)
and distance from the nearest HC (p = .007).
Table 3. Clinical features and diagnosis at presentation (n = 313).
Variable Median
(IQR [Total
Range])
Infiltrate size (mm)a 5.2 (3.3–7.7 [0.5–13])
Epithelial defect size (mm)a 3.9 (2.4–6.5 [0–14])
Variable n/313 (%)
Snellen Visual Acuity in affected eye
(n = 312)
6/5–6/18 102 (33%)
6/24–6/60 42 (12%)
5/60–3/60 24 (8%)
2/60–1/60 33 (11%)
Counting fingers-light perception 103 (33%)
No light perception 9 (3%)
Snellen visual acuity in non-affected
eye (n = 312)
6/5–6/18 278 (89%)
6/24–6/60 16 (5%)
5/60–3/60 2 (1%)
2/60–1/60 4 (1.2%)
Counting fingers-light perception 6 (2%)
No light perception 6 (1.8%)
Slough (n = 312)b
No slough 62 (20%)
Flat 124 (40%)
Raised 126 (40%)
Infiltrate edge (n = 293)
Defined 35 (12%)
Serrated 258 (82%)
Not visible 20 (6%)
Satellite lesions present (n = 304)
Yes 178 (57%)
No 126 (40%)
Infiltrate colour (n = 288)
White 148 (47%)
Cream 106 (34%)
Other colour 34 (11%)
Hypopyon (median height 1.3mm IQR
0.9–2.9, n = 301)
Yes 94 (30%)
No 217 (69%)
Site of ulcer (n = 310)c
Peripheral 27 (9%)
Paracentral 64 (21%)
Central 219 (70%)
Perforation status
Not perforated 237 (76%)
Impending 31 (10%)
Perforated 48 (12%)
Perforated & sealed 7 (2%)
Overall Laboratory diagnosis (n = 270)d
Unknown 65 (21%)
Bacterial 20 (6%)
Fungal 168 (54%)
Mixed (bacteria/fungal) 17 (5%)
Where n < 313 was due to some missing data: percentages calculated for
313 and rounded off to the nearest whole number.
aThese were calculated as the geometrical means using the MUTT protocol.
The upper limits exceeded normal corneal diameter for some lesions,
which extended up to the sclera.
bRaised slough was when the corneal infiltrate profile was raised, flat
slough was when the profile was flat while no slough is when there
was no debris noted.
cSite of ulcer was peripheral when the ulcer was marginal, paracentral was
when the ulcer was not marginal but not within 4 mm of the center of
the cornea, central was when the ulcer was within the central 4 mm of
the cornea.
Impending perforation is when the clinicians felt the ulcer would perforate
in the next 48 h.
dSpecimen for microbiology was collected in 270 patients. Due to limited
amounts of sample material, it was not possible to perform all tests on all
those sampled. The order of material collection was 3 slide smears (gram,
KOH, CFW), 3 agar inoculations (blood, chocolate, PDA) and 1 broth (BHI)
depending on available material.
Table 4. Outcomes at 3 months.
Variable n/260 (%)
Visual acuity in the affected eye (Snellen)
6/5–6/18 138 (53%)
6/24–6/60 37 (14%)
5/60–3/60 7 (3%)
2/60–1/60 14 (5%)
Counting fingers-light perception 31 (12%)
No light perception 33 (13%)
Visual acuity in the non-affected eye
6/5–6/18 229 (90%)
6/24–6/60 11 (4%)
5/60–3/60 2 (1%)
2/60–1/60 0 (0%)
Counting fingers-light perception 6 (2%)
No light perception 7 (3%)
Outcome
Healed no scar 34 (12%)
Healed mild scar 83 (30%)
Healed moderate scar 65 (24%)
Healed dense scar 46 (17%)
Eviscerated 24 (9%)
Not healed 20 (7%)
Staphyloma 4 (1%)
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Interestingly, even after adjusting for delayed presenta-
tion there remained strong evidence of an association
(p < .0001 and p = .009).
Predictors of outcome
In the final multivariable model, worse visual acuity
outcome at 3 months was associated with baseline
vision, size of the infiltrate and perforation status at
presentation Table 6.
Discussion
This study describes the clinical history, signs, micro-
biological etiology, causes, and outcomes of MK in
Uganda. Most patients presented with poor vision. At
3 months, 30% had monocular blindness in the affected
eye and 1 in 10 lost their eye to infection.
Delayed presentation was common. Very few (7%)
presented within 3 days of symptom onset and this had
a direct impact on outcomes, as previously reported.13
In this study, delayed presentation after adjusting for
being a farmer, distance, economic status, education
status, trauma, TEM and previous use of other treat-
ment was associated with poor presenting vision.
Earlier studies indicate that prompt prophylactic anti-
biotic can prevent simple corneal abrasions developing
into MK, leading to much better outcomes.17,21,22 Most
late presenters had advanced ulcers, where treatment
could do little. We know from prior literature that once
an ulcer is advanced, treatment does relatively little to
change its course.23 From previous studies, it is recom-
mended that treatment of MK should be started as early
as possible to achieve optimal outcomes.17
Another important cause of poor vision at presenta-
tion was Traditional Eye Medicine use. In this study, 60%
of the patients reported TEM use. TEM increased the
Figure 3. A DAG framework showing the causal pathways for poor presenting vision. This diagram is adjusted to illustrate the role of
TEM. The solid lines indicate hypothesized direct relationships and the dashed lines indicate hypothesized indirect relationships.
OPHTHALMIC EPIDEMIOLOGY 7
207
odds of poor presentation by 60% after adjusting for age,
sex, being a farmer, economic status, education level, and
distance. In our model, some of the effects of TEM
seemed to be mediated through delay and organism
type. But after adjusting for these, there was still an
estimated 40% increase in odds of poor presentation,
Table 5. Causal modeling for poor presenting vision (n = 313).
Variable
Univariable Analysis Multivariable Analysis
Multivariable analysis for
direct effect
Crude
ORa (95% CI) p-value
Adj.
OR (95% CI) p-value OR (95% CI) p-value
Model 1: Used Traditional Eye Medicine (TEM) as the main exposure of interestb
Used traditional eye medicine (TEM) 1.78 (1.17–2.70) 0.007 1.62 (1.04–2.54) 0.033 1.47 0.91–2.38 0.11
Model 2: Delayed presentation as the main exposure of interestc
Prompt 0–3 days 1 0.0004 1 0.033
Early 4–7 days 2.78 (1.07–7.20) 1.94 (0.70–5.39)
Intermediate 8–14 days 4.45 (1.84–10.7) 3.02 (1.17–7.79)
Late 15–30 days 5.58 (2.33–13.3) 3.57 (1.40–9.07)
Very late > 30 days 2.63 (1.11–6.25) 1.87 (0.74–4.72)
Model 3: Trauma as the main exposure of interestd
Positive history of trauma 0.94 (0.60–1.48) 0.810 1.13 (0.70–1.83) 0.609
Model 4: Distance from the eye hospital in km as the main exposure of intereste
0–50 km 1 < 0.0001 1 < 0.0001 1 < 0.0001
50–100 km 1.27 (0.73–2.21) 1.27 (0.73–2.21) 1.26 (0.71–2.21)
100–150 km 2.90 (1.60–5.23) 2.90 (1.60–5.23) 2.63 (1.45–4.80)
> 150 km 5.60 (2.87–10.9) 5.60 (2.87–10.9) 5.06 (2.58–9.92)
Model 5: Distance from nearest health center (for every km increase)e
Distance from nearest health center (for every km
increase)
1.22 (1.05–1.41) 0.007 1.22 (1.05–1.41) 0.007 1.21 (1.05–1.41) 0.09
Model 6: Type of organismf
No organism detected 1 0.105 1 0.101
Bacteria 1.25 (0.50–3.15) 1.43 (0.55–3.66)
Fungal 1.80 (1.05–3.07) 1.82 (1.06–3.13)
Mixed 2.49 (0.93–6.62) 2.71 (1.07–2.79)
aAll crude estimates were adjusted for age and sex. bUse of TEM was adjusted for age, sex, being a farmer, economic status, education level, distance from the
eye hospital, and distance from the nearest health center (n = 298). After adjusting for delay and organism type, the effect of TEM was OR 1.47 95% CI
0.91–2.38, p = 0.11. cDelayed presentation was adjusted for age, sex, being a farmer, distance, economic status, education level, TEM, trauma, and previous
use of prior treatment before presentation (n = 295). dHistory of trauma was a priori based on literature from previous studies. It was adjusted for age, sex,
being a farmer, TEM, distance, and prior treatment (n = 306). eLong distance from the eye hospital and long distance from the nearest health center were
only adjusted for age and sex (n = 309). Their crude and adjusted point estimates are the same. However, the direct effect of distance to eye hospital and
distance to nearest health center after adjusting for delay was still highly significant, p < 0.0001 and = 0.009. fType of organism was a forced priori and was
adjusted for trauma and use of TEM (n = 267).
Table 6. Factors at presentation predictive of a poor final visual acuity (WHO snellen ordinal scale) at 3 months (n = 260).
Variable
Univariate Analysis Multivariable Analysis
Crude ORa (95% CI) p-value Adjusted ORb (95% CI) p-value
Baseline visual acuity (for every line decrease in vision) 4.78 (3.59–6.35) < 0.0001 2.98 (2.12–4.19) < 0.0001
Presence of slough
None 1 0.007
Flat 1.91 (0.95–3.83)
Raised 2.95 (1.46–5.95)
Infiltrate edge being serrated 0.84 (0.58–1.24) 0.393
Satellite lesions being present 0.64 (0.40–1.03) 0.068 0.51 (0.28–0.90) 0.021
Infiltrate color
White 1 < 0.0001
Cream 2.70 (1.56–4.63)
Colored 6.37 (3.10–13.2)
Hypopyon present 2.16 (1.38–3.55) 0.002
Infiltrate size (for every 1 mm increase) 1.60 (1.44–1.79) < 0.0001 1.19 (1.03–1.36) 0.020
Perforation status at presentation
Not perforated 1 < 0.0001 1 < 0.0001
Impending perforation 11.9 (5.27–26.9) 2.86 (1.11–7.37)
Perforated and sealed 5.60 (1.44–21.8) 1.57 (0.31–7.76)
Perforated 41.0 (17.3–97) 9.93 (3.70–26.6)
HIV status being positive 0.85 (0.39–1.85) 0.683
Diabetes status being positive 0.81 (0.34–1.92) 0.630
Microbiology
No organism detected 1 0.063
Bacteria 1.48 (0.53–4.14)
Fungal 2.25 (1.19–4.26)
Mixed 2.80 (0.86–9.01)
aAll crude estimates were adjusted for age and sex. bFinal predictive model adjusted for age and sex.
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although the evidence for this associationwas weak.Many
people probably try TEM before attending hospital, as it
can be easily obtained within or close to home. In
Uganda, TEM is usually made from plant products. This
is concerning, as such substances may be toxic or harbor
infectious agents, such as fungal spores.7,24 Importantly,
our patients were open in admitting use of TEM, a widely
acceptable practice for treating MK.
Distance was an important cause of poor presenting
vision. This included distance to the eye hospital and
distance to the nearest HC. This highlighted a major
underlying problem of access to health services: the
further the HC, the lower the chances of promptly
starting appropriate treatment. In our model, even
after adjusting for delay, distance was still highly asso-
ciated with poor presenting vision meaning that there
were still other unexplained factors in this relationship.
As reported previously, severity of infection at pre-
sentation (vision, perforation status, and infiltrate size)
was the strongest predictor of outcome.23,25,26 Poor
vision at presentation (WHO Snellen categories) was
strongly associated with a worse visual outcome. Vision
is an easily measurable and reliable prognostic measure
that can support lower and mid-level cadres to make
the right clinical decisions. A perforated eye at presen-
tation had 10 times greater odds while an eye with an
impending perforation had 3 times greater odds of
a worse visual outcome compared to a non-perforated
eye. This was not surprising because keratoplasty ser-
vices are currently not available in Uganda. People who
presented with threatened or full perforation under-
went conjunctival flap or evisceration surgery depend-
ing on the extent of the perforation.
Most of our patients presented with large infiltrate
and epithelial defect sizes. Such median sizes would be
considered severe ulcers in a high-income setting. The
epithelial defect size was not included in the analysis
because it was highly correlated to the infiltrate size.
A large infiltrate size was associated with increased
odds of a worse final visual outcome.25,26
Most of the affected patients were aged between 31
and 60 years, which are the prime years for economic
productivity.13 About 70% of the affected people were
heads of households and sole breadwinners in their
home. Prolonged morbidity due to MK meant that
they could not provide for their dependents. In an
ongoing study, we have been exploring how MK affects
the quality of life and household incomes (unpublished).
The prevalence of HIV among our cohort was almost
double the national prevalence and diabetes was 4 times
the reported prevalence.27,28 A high prevalence of HIV
has been previously reported in people with MK.13,29
HIV and diabetes predispose to MK through immune
suppression: we conducted a nested case-control to test
for risk factors of MK including HIV and diabetes which
have been reported separately.
Understanding the seasonal pattern of presentation
is important to prepare a surveillance mechanism and
for hospitals to have expectant management. We found
that the presentation of MK tended to follow rainfall
patterns linked to agricultural activity. This was not
surprising since the majority (70%) of patients were
farmers. There was little variation in humidity and
temperature throughout the year. This region of
Uganda has two planting and harvesting seasons, one
in each half of the year following rains. Harvesting time
is May–July and November–January. These were the
periods when we recorded increased numbers of pre-
sentations. Farming (especially harvesting) has been
linked to ocular trauma which predisposes to MK.30
These corresponded with peak presentation to hospital.
April has modest farming activity, as people are waiting
for the harvesting season and it usually corresponds to
Easter holiday. August usually has almost no farming
activity since it comes at the end of the harvesting
season before the rains come again in September.
December had fewer patients presenting, possibly due
to the Christmas season.
It remains unclear if this seasonal variation was related
to trauma, as there were no clear seasonal differences in
the pattern of presentation among patients who reported
trauma and those who did not. We were surprised that
relatively few patients (29%) reported trauma, although
this is consistent with other studies from sub-Saharan
Africa (SSA). In an older study from Ghana, 39% of the
MK cases reported some form of eye injury prior to
onset.31 In two separate studies from Tanzania, 24% and
39% of the cases were associated with trauma.13,32 These
levels are somewhat lower than those from South Asia,
where around 75% are associated with an injury.31,33–36
The reason for this difference is not apparent.
Ocular microbiology is not performed in many set-
tings in SSA. As part of this study, we undertook to
build the capacity of the hospital to provide this service.
The overall microbiology yield was 80%. This was
a composite of all the microscopy and culture results.
Overall culture positive results were 55% similar to the
expected yield reported in literature.16,31
Strengths/limitations
This is the first large prospective cohort study in SSA to
describe outcomes of MK. Most of the reports have
described etiology and presentation.16,29,31,32 Only one
audit had attempted to describe outcomes.13 The large
number of patients gave sufficient power to analyze
OPHTHALMIC EPIDEMIOLOGY 9
209
several factors associated with the main outcome mea-
sures. It was not possible to follow-up all the patients,
with around 20% not having 3-month outcome data;
however, no systematic differences were found between
those with and without final follow-up data.
Conclusion
This study provides an understanding of MK epide-
miology in Uganda. Majority of patients presented
late after having traveled large distances to seek spe-
cialist care. Most patients presented with severe
ulcers. The outcomes for many were poor, although
around half had some improvement of vision with
treatment. Predictive factors for these poor outcomes
were the state of the eye at presentation. There is
need to work on early interventions to prevent
patients reaching such a stage where little can be
done.
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Supplimentary Figure 1: DAG for a causal effect of TEM on presenting vision 
In this DAG, it was necessary to adjust for being a farmer, distance from the eye hospital 
and distance to the nearest health centre, economic status and education level to be able to 
correctly estimate the overall effect of using TEM on poor presenting vision. We also 
separately adjusted for delay and organism type to estimate a direct effect of TEM on poor 
presenting vision. 
KEY: In the DAGiity software, Green with a black arrow represents exposure of interest, 
Green without an arrow represents ancestor of the exposure, Pink is ancestor of the 
exposure and outcome, Blue is ancestor of the outcome. 
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Supplimentary Figure 2: DAG for a causal effect of delayed presentation on presenting vision 
In this DAG, it was necessary to adjust for being a farmer, distance, Economic status, 
Education status, trauma, TEM and previous use of other treatment to estimate the overall 
causal effect of delayed presentation on presenting vision 
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Supplimentary Figure 3: DAG for a causal effect of Trauma on presenting vision 
In this DAG, it was necessary to adjust for being a farmer, delay, distance, TEM and prior 
treatment to estimate the overall effect of Trauma on presenting vision 
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Supplimentary Figure 4: DAG for a causal effect of distance from the eye hospital on presenting vision 
In this DAG, it was not necessary to adjust for anything apart from age and sex to estimate 
the overall causal effect of distance from the eye hospital on presenting vision. However, we 
separately for delay to estimate a direct effect of distance to the eye hospital on presenting 
vision. 
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Supplimentary Figure 5: DAG for a causal effect of distance from the nearest health centre on presenting 
vision 
In this DAG, it was not necessary to adjust for anything apart from age and sex to estimate 
the overall causal effect of distance from the nearest health centre on presenting vision. 
However, we separately adjusted for delay to estimate a direct effect of distance to nearest 
Health Centre on presenting vision. 
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Supplimentary Figure 6: DAG for a causal effect of organism type on presenting vision 
In this DAG, it was necessary to adjust for Trauma and use of TEM to estimate the overall 
causal effect of organism type on presenting vision 
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Microbiology results from patients with microbial Keratitis in Uganda (n=313) 
Variable Category Count (%)
Gram microscopy Unknown 141 57% 
Bacteria 33 13% 
Fungal 73 30% 
Mixed 0 0 
KOH Unknown 158 67% 
Fungal 77 33% 
Calcofluor white/KOH stain Unknown 79 33% 
Fungal 163 67% 
BHI microscopy Unknown 126 57% 
Bacteria 22 10% 
Fungal 72 33% 
BHI culture Unknown 120 55% 
Bacteria 23 11% 
Fungal 74 34% 
Blood agar culture Unknown 109 51.5% 
Bacteria 21 10% 
Fungal 80 38% 
Mixed 1 0.5% 
Chocolate agar culture Unknown 101 52% 
Bacteria 20 10% 
Fungal 75 38% 
Potato dextrose agar culture Unknown 133 60% 
Fungal 90 40 
Overall Laboratory diagnosis (n=257, 
74 were not tested)
Unknown 56 22% 
Bacterial 21 8% 
Fungal 162 63% 
Mixed (Bacteria/Fungal) 18 7% 
Cultured organisms Staph Aureus (2 mixed) 8 3% 
Strep Pneumonae 8 3% 
Pseudomonas 6 2.5% 
Klebsiella 4 2% 
Norcadia 1 0.5% 
Fusarium (2mixed) 45 19% 
Aspegillus 18 8% 
Acremonium 13 6% 
Bipolaris 6 2.5% 
Scedospovium 1 0.5% 
Candida 3 1.5% 
Lasiodiplodia 2 1% 
Unidentified fungi 9 3.5% 
No growth 110 47% 
Yield rates Gram 106/247 43% 
KOH 77/235 33% 
CFW/KOH 163/242 67% 
BHI Gram 94/220 43% 
BHI culture 97/217 45% 
Blood agar 102/211 48% 
Chocolate agar 95/196 48% 
Potato dextrose agar 92/223 41% 
Composite 201/257 78% 
Bacterial sensitivity Ciprofloxacin 22/23 96% 
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Ofloxacin 14/14 100% 
Levofloxacin 23/23 100% 
Amikacin  5/5 100% 
Ceftriaxone 23/23 100% 
Gentamycin 20/22 91% 
Chloramphenicol 0/23 0% 
Tetracycline 0/23 0% 
This table shows the preliminary microbiology results and bacterial sensitivity results of the 
313 patients with MK who were enrolled into the study. Of these, 74 microbiology specimens 
were not collected from 74 patients due to various reasons (small ulcers, deep ulcers, 
uncooperative patients). Corneal swabs were collected and shipped for pan fungal 
sequencing at a regional reference laboratory in Tanzania. A final microbiology profile will be 
published once these results are verified. 
219
Simon Arunga PhD Thesis 2019 
Chapter 7. Risk factors of Microbial Keratitis in Uganda 
A traditional healer presents some of the common herbs used in the community for 
treating common eye conditions. Photo taken by Terry Cooper 
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ABSTRACT
Purpose: Microbial keratitis (MK), is a frequent cause of sight loss worldwide, particularly in low
and middle-income countries. This study aimed to investigate the risk factors of MK in Uganda.
Methods: Using a nested case control, we recruited healthy community controls for patients
presenting with MK at the two main eye units in Southern Uganda between December 2016 and
March 2018. Controls were individually matched for age, gender and village of the cases on a 1:1
ratio. We collected information on demographics, occupation, HIV and Diabetes Mellitus status. In
STATA version 14.1, multivariable conditional logistic regression was used to generate odds ratios
for risk factors of MK and a likelihood ratio test used to assess statistical significance of
associations.
Results: Two hundred and fifteen case-control pairs were enrolled. The HIV positive patients
among the cases was 9% versus 1% among the controls, p = .0003. Diabetes 7% among the cases
versus 1.4% among the controls, p = .012. Eye trauma was 29% versus 0% among the cases and
controls. In the multivariable model adjusted for age, sex and village, HIV (OR 83.5, 95%CI
2.01–3456, p = .020), Diabetes (OR 9.38, 95% CI 1.48–59.3, p = .017) and a farming occupation
(OR 2.60, 95%CI 1.21–5.57, p = .014) were associated with MK. Compared to a low socio-economic
status, a middle status was less likely to be associated with MK (OR 0.29, 95%CI 0.09–0.89,
p < .0001).
Conclusion: MK was associated with HIV, Diabetes, being poor and farming as the main occupa-
tion. More studies are needed to explore how these factors predispose to MK.
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Background
Microbial keratitis (MK), or infection of the cornea, can
be caused by a range of pathogens. The causative organ-
isms include bacteria, viruses, protozoa (e.g. acantha-
moeba), and fungi (yeasts, moulds and microsporidia).
It is characterised by acute or sub-acute onset of pain,
conjunctival hyperemia and corneal ulceration with
a stromal inflammatory cell infiltrate. MK frequently
leads to sight-loss from dense corneal scarring, or even
loss of the eye, especially when the infection is severe
and/or appropriate treatment is delayed.1
MK in low and middle-income countries (LMIC)
has been described as a “silent epidemic”, which leads
to substantial morbidity, related to blindness and other
consequences such as pain and stigma.2 It is the leading
cause of unilateral blindness after cataract in Tropical
regions and is responsible for about 2 million cases of
monocular blindness per year.3 The World Health
Organization (WHO) estimated (2017) that
1.3 million individuals are bilaterally blind from cor-
neal opacity globally (excluding trachoma and vitamin
A deficiency), accounting for 3.2% of binocular
blindness.4 In Sub-Saharan Africa (SSA), MK is an
important cause of binocular blindness and is respon-
sible for about 15% of monocular blindness (Nigeria
National Survey).5,6 The incidence of MK in South
India was estimated at 113/100,000/year and in Nepal
799/100,000/year.7,8 There is only one older report of
the incidence of MK in SSA from Malawi, which sug-
gested a rate of around 180/100,000/year.9 Rates in
high-income settings are lower.10
There are many potential risk factors that may pre-
dispose a person to developing MK with some risk
factors being more specific to settings (region, income
status and organism) and some being ubiquitous. Risk
factors such as trauma especially with vegetative matter
have been associated with fungal keratitis compared to
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a pre-existing ocular disease for bacterial keratitis.11,12
Injury with mud is strongly linked to Acanthamoeba
keratitis.12 In addition, agricultural work and foreign
body in the eye have been implicated.11,13,14 Risk fac-
tors that are more setting specific include the use of
contact lenses, which affects more people in high-
income countries as opposed to the use of traditional
eye medicines (TEM), which is more of a problem in
Low and Middle-Income Countries (LMIC).9,15–18
Other identified risk factors include age (trauma being
common in the lower age groups versus ocular surface
diseases in older folk), gender (males engaging more in
outdoor activities than females) and poverty (MK
mostly is more prevalent in among the poor).11–13
Diabetes Mellitus (DM) has been the most commonly
reported systemic risk factor, especially following kera-
toplasty or corneal trauma.19–21
In the few studies from SSA on the risk factors for
MK, suggested factors include trauma and use of
TEM.22–24 The other risk factors reported in the litera-
ture are steroid use, severe staphylococcal eyelid infec-
tions and the HIV positive cases.17,22–25 However, all
previous studies from Africa, had a limited extrapola-
tion of outcome due to the lack of controls.
The aim of this study, therefore, was to investigate
the role of multiple risk factors (HIV infection, DM,
farming) which are preventable or modifiable by com-
paring MK cases to disease free community controls,
matched for age, sex and village in Uganda.
Methods
Ethical statement
This study followed the tenets of the Declaration of
Helsinki. It was approved by the London School of
Hygiene & Tropical Medicine Ethics Committee (Ref
10647), Mbarara University Research Ethics Committee
(Ref 10/04-16) and Uganda National Council for
Science and Technology (Ref HS-2303). Written
informed consent in Runyankore, the local language,
was obtained before enrolment. If the patient was
unable to read, the information was read to them, and
they were asked to consent by application of the
thumbprint which was independently witnessed.
Study design and setting
A pair-matched case control study was used with a 1:1
case-to-control ratio. The cases were recruited during
the main cohort study that prospectively enrolled
patients with MK that presented to Ruharo Eye
Centre (REC) and Mbarara University and Referral
Hospital Eye Centre (MURHEC) from
December 2016 to March 2018. MURHEC is
a government owned tertiary eye unit established in
2013. It provides mostly free services and attends to
about 6,000–10,000 patients/year. REC is a church-
based fee-paying tertiary eye hospital founded in the
1960s. Attendance is about 20,000–25,000 patients/year.
Both hospitals are in Mbarara Municipality, South-
Western Region, Uganda, approximately four hours’
drive far from Kampala. The two units are about 5km
apart and work closely. Controls were enrolled in com-
munities where the cases came from.
Study participants
For the purpose of this study microbial keratitis was
defined as the loss of corneal epithelium (of at least
1mm diameter) with underlying stromal infiltrate, asso-
ciated with any or all signs of inflammation (conjunc-
tival injection, anterior chamber inflammatory cells, ±
hypopyon).26 Controls were healthy individuals (with-
out any current eye complaint) matched for gender and
address. For cases and controls, we excluded those not
willing to participate, those not willing to return for
follow-up, pregnant women, lactating mothers and
those aged below 18 years.
Sample size
The prevalence of HIV in the general population in
Uganda is 6%. A sample of 200 case-control pairs
would have 80% power and 95% confidence to detect
an odds Ratio of three between cases and controls.
From Tanzanian data we expected that perhaps more
than 10% of MK cases in our cohort would have HIV
infection.17,27
Assessment
Cases
We documented baseline demographic information
and ophthalmic history including how the eye became
infected, predisposing factors such as trauma, prior
use of Traditional Eye Medicine (TEM), treatment
received, and their “health care seeking journey”
before reaching to the eye hospital. In summary,
cases underwent a detailed anterior and posterior seg-
ment examination on a slit lamp. Corneal scrapes were
collected for microscopy, culture and sensitivity and
molecular diagnosis. HIV counselling and testing were
offered, as per the Uganda Ministry of Health HIV
testing protocol where three rapid tests (Determine
HIV-1/2/O [Abbott Laboratories, Abbott Park, IL],
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HIV 1/2 Stat-Pak Ultra-Fast [Chembio Diagnostic
Systems, Medford, NY] and Uni-Gold Recombinant
HIV-1/2 [Trinity Biotech, Bray, Ireland]) were used to
screen participants.28 For those who were confirmed
as HIV positive, a CD4 test was performed for level of
immune suppression. They were referred to the HIV
care centre, which is on the hospital site. If a patient
refused the HIV test, they were still enrolled for the
main cohort but were censored for the nested study.
A peripheral prick for blood sugar was taken and
WHO guidelines were used to make a diagnosis of
Diabetes (random glucose >11.1mmol/L or fasting
glucose of >7.0mmol/L).29 Cases were treated empiri-
cally at presentation; the treatment choice was
reviewed after microbiology results according to the
hospital protocol. The study follow-up assessment was
on day 2, day 7, day 21 and at day 90 to determine
their outcome. Additional assessments were con-
ducted as clinically indicated.
Controls
At 3 months, the cases were followed-up in their homes
for a final assessment at which point healthy commu-
nity controls were enrolled. Enrolment followed
a similar method as previously used in Ethiopia.30 The
research team visited the villages (100–200 households),
the local village head was asked to write down all the
eligible controls in that village. They were people of the
same gender and in a similar age bracket (decade) as
the case. One person was randomly selected from this
list using a lottery method, explained to the details of
the study and invited to participate if eligible. If
a selected control refused or was ineligible, another
was randomly selected by lottery. Demographic data
was collected as well as a detailed history of exposure
to trauma, TEM use, DM and HIV status. A random
blood sugar and HIV counselling and testing were
offered, as per the Uganda Ministry of Health HIV
testing protocol. Home testing for HIV is widely prac-
tised in Uganda. For those who were confirmed as HIV
positive, a CD4 test was performed for the level of
immune suppression. They were referred to the nearest
HIV centre for appropriate care. Cases and controls
were asked to self-report their wealth status compared
to their neighbours using a scale of 1 “very poor” 2
“poor” 3 “neither poor nor rich” 4 “rich” 5 “very
rich”.31
Analysis
Data were analysed in STATA v14. All cases and con-
trols were individually matched by age, gender and
village. However, we noticed in the analysis that all
the pairs had not been correctly matched on age
because the village heads had subjectively guessed the
ages of the controls. We thus adjusted for age through-
out the analysis. We compared the proportions of
potential risk factor exposures among cases and control
and performed a Mcnemar’s chi2 test (binary expo-
sures) and a univariable conditional logistic regression
(categorical exposures) for significance of the differ-
ences. The main exposures of interest were HIV posi-
tive patients, DM patients, farmers and participants
with a positive history of trauma and or TEM use.
Multivariable conditional logistic regression analysis
was used to estimate odds ratios (ORs) and 95% CI’s of
risk factors of MK. The likelihood ratio test was used to
assess statistical significance of associations. Variables
with a p-value less than 0.1 were introduced in the
multivariable model. For variables with a high colli-
nearity, the variable of most interest was included in
the model. A backward stepwise approach was then
used until only the variables with a p-value of less
than 0.05 were retained.
Because it was not possible to enrol controls for all
the cases in the cohort, a separate analysis was per-
formed to compare the baseline characteristics of the
cases who had controls and those who did not to look
for any systematic bias. A Pearson Chi test (categorical
variables) or a Wilcoxon rank sum test (continuous
variables) was used to test for significance of the
differences.
Results
A total of 215 controls were enrolled out of 260 eligible
cases who had 3-months outcome data. It was not possi-
ble to enrol controls for 45 cases because of several rea-
sons. These included: not at home at the agreed time of
the home visit (11), wrong home address (4), died (1),
uncooperative village members (20), case address too far
(9). The cases without controls were dropped from the
matched risk factor analysis. We compared the baseline
characteristics and exposure proportions between the
cases for whom we were able to enrol controls versus
the patients without controls (Table 1). Overall, these
two groups were comparable across most of the charac-
teristics. However, there was a significant difference in the
proportion of HIV (22%) among the cases without con-
trols versus the cases with controls (8%), (Chi-square test
10.7, p = .001, df 1). The overall prevalence of HIV was
12% and DMwas 7%. Out of all the 37 HIV positive cases,
14 (38%) were newly diagnosed after presenting withMK.
They were unaware of their current HIV status or had
previously tested negative. The median CD4 count was
358 cells/µL (IQR 267–533, total range 154–1,053). Out of
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the 22 DM patients, 11 (50%) were diagnosed after pre-
senting with MK.
Table 2 shows exposure comparison among the cases
and controls matched for age, sex and village. The
proportion of HIV positive patients among the cases
was 9% versus 1% among the controls (p = .0003). DM
was 7% among the cases versus 1.4% among the con-
trols (p = .012). Sixty-one (29%) of the cases reported
eye trauma before onset of symptoms, none of the
controls reported any trauma in the previous 3 months.
One hundred and twenty-eight (61%) of the cases
reported having used TEM versus only one control
who had recently used TEM. Cases more than controls
had more people in the poor social economic bracket
(p = .0001) and lived further from the nearest village
health centre, median distance 3km (IQR 1–4, total
Table 1. Comparison of people who were enrolled into the nested case-control and those who were not (n = 313).
Enrolled into the case-control (n = 215) Not enrolled (n = 98) ǂ
Variable Median (IQR) (Total range) Median (IQR) (Total range) P value
Age 50 (37–60) (18–96) 42 (33–59) (18–87) .040
Distance 78 (53–120) (1.5–286) 85 (48–183) (0.2–378) .171
Household population 7 (5–8) (1–28) 6 (3–8) (1–18) .030
Distance to nearest Health Centre in KM 3 (1–4) (0–45) 2 (1–4) (0–35) .215
Variable Category count (%) count (%) P value
Gender Female 101 (47) 38 (39) .176
Male 114 (53) 60 (61)
Occupation Farmer 157 (73) 63 (64) .117
Non-farmer 58 (27) 35 (36)
Marital status Not married* 61 (28) 34 (35) .259
Married 154 (72) 64 (65)
Education status None 60 (28) 24 (25) .896
Primary 110 (51) 52 (53)
Secondary 31 (14) 14 (14)
Tertiary 14 (7) 8 (8)
Being head of household Yes 146 (68) 66 (67) .922
No 69 (32) 32 (33)
Being HIV positive (overall 12%) Ɨ Yes 18 (8%) 19 (22%) .001
No 197 (92%) 67 (78%)
Being a Diabetic patient (overall 7%) Ɨ Yes 14 (7%) 8 (9%) .385
No 201 (93%) 77 (91%)
*Not married refers to single, separated, divorced or widowed. Ɨ missing results for HIV and diabetes, it was not possible to test everyone for HIV and
Diabetes. ǂ These 98 include the 53 that were lost to follow up and the 45 cases with follow-up data at 3 months but to whom controls could not be
enrolled.
Table 2. A matched comparison of exposures among 215 case-control pairs. (gender and village and adjusted for age).
Cases (215) Controls (215) P-value
Exposure n (%) n (%)
Married 154 (72) 143 (67) .215
Head of household 146 (68) 140 (65) .441
Education status
None 60 (28) 48 (22) .148
Primary 110 (51) 114 (53)
Secondary 31 (14) 32 (15)
Tertiary 14 (7) 21 (10)
Farming occupation (if yes) 157 (73) 168 (78) .144
Trauma (if yes, n = 214) 63 (29) 0 (0) <.0001
Traditional Eye Medicine (if yes) 133 (62) 1 (0.5) <.0001
HIV (being positive) * 18 (9) 2 (1) .0001
Diabetes Mellitus (being positive) Ɨ 14 (7) 3 (1.4) .012
Size of the household
Small (1–4 people) 50 (23) 109 (51)
Medium (5–10 people) 115 (54) 94 (44)
Large (>11 people) 50 (23) 12 (5)
Self-reported wealth status ǂ
Poor 36 (18) 20 (9) .003
Middle 158 (74) 188 (89)
Upper 21 (8) 6 (2)
Type of water source
Well 103 (50) 107 (52)
Tap 85 (41) 74 (36)
Other 17 (9) 25 (12)
median (IQR) median (IQR)
Distance to nearest Health centre 3 (1–4) 2 (1–3) <.0001
*Twelve cases had missing HIV results, however, all the controls had HIV results reported. Ɨ Nineteen Cases had missing Diabetes test results. self-reported
wealth status was classified as poor (1” very poor” 2” poor”), middle (3 “neither poor nor rich”) upper (4 “rich” 5 “very rich”)
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range 0–45) versus 2km (IQR 1–3, total range 1–15)
among the controls (p < .0001).
Table 3 shows the univariable and multivariable
analysis for risk factors of MK adjusted for age, sex
and village. These were all adjusted for age, sex and
village. In the final model, important risk factors were
HIV (OR 83.5, 95%CI 2.01–3456, p = .020), DM (OR
9.38, 95% CI 1.48–59.3, p = .017), a farming occupation
(OR 2.60, 95%CI 1.21–5.57, p = .014) and living far
from a health facility (OR 1.39, 95%CI 1.14–1.67,
p = .001) were strongly associated with MK. On the
other hand, a middle compared to a low social eco-
nomic status was less associated with MK (OR 0.29,
95%CI 0.09–0.89), p < .0001).
Discussion
This was the first case control study in SSA to investigate
the risk factors of MK. We found that the significant risk
factors were trauma, HIV, DM, farming, living far from
a health facility and poverty.
The odds of being HIV-positive was higher among MK
cases than in the controls, suggesting HIV is a risk factor
for MK. HIV affects the immune system making its host
susceptible to a range of opportunistic infections. Two
previous studies, both from Tanzania, suggested
a possible relationship between HIV and Keratitis.17,25 In
the first study in 1999, the proportion of HIV among MK
cases was 40% with a statistically significant trend towards
fungal Keratitis.25 In the second study in 2003, the propor-
tion of HIV among MK cases was 16%.17 Even though
anti-retroviral therapy (ART) is now widely available in
most parts of SSA, the findings of our study confirmed that
HIV is still an independent risk factor for MK. The pro-
portion ofHIV positive cases in our cohort was 12%, which
was about double the national average of 6.3%.27 In the
group that was considered for the case control analysis, the
proportion ofHIVwasmuch lower among the cases (9% as
opposed to 12%) and controls (1% as opposed to 6%
national average). We speculate that this might have been
due to “healthy user bias” where people who thought they
were HIV negative were more likely to consent as controls.
Although HIV counselling and testing is widely practised
in Uganda, almost 40% of the HIV positive patients in this
study were identified after presenting with MK. They were
unaware their HIV status or previously thought that they
were negative.
We found that the possibility of MK is higher in DM.
Although this had been suggested from other regions, there
have not been any previous studies in SSA that described
this association.32,33 The proportion of DM among theMK
cases was 7%, about thrice the national urban average and
seven times the rural average.34 DM also affects the
immune system making the host susceptible to infection.
Additionally, hyperglycaemia provides essential nutrients
for the pathogens to thrive. This makes treatment more
challenging as these patients tend to respond slowly. The
prevalence of DM is on the rise globally due to lifestyle
changes, In Uganda, there has been a three fold rise over
the last decade.34 We have since started offering routine
HIV and Diabetes screening for all patients presenting
with MK
A farming occupation was another identified risk factor;
our hypothesis is that this was linked to trauma. However,
trauma could not be tested in the model because of none of
the controls reported trauma in the last 3 months. We
found that even among the MK cases, trauma rates were
lower than anticipated (29%). This is consistent with other
studies from sub-Saharan Africa (SSA). In an older study
from Ghana, 39% of MK cases reported some form of eye
injury prior to onset.22 In two separate studies from
Tanzania 24% and 39% of cases were associated with
trauma.17,35 These levels appear to be lower than those
reported from South Asia, where the proportion of MK
Table 3. A matched univariable and multivariable analysis of risk factors of Microbial Keratitis among 215 case-control pairs
(matched for sex, village and adjusted for age).
Univariate Analysis Multivariable Analysis
Variable Crude OR (95% CI) p-value Adjusted OR (95% CI) p-value
Farming occupation (if yes) 2.10 (1.12–3.92) .021 2.60 (1.21–5.57) .014
HIV (being positive) 18.3 (2.41–139) .005 83.5 (2.01–3456) .020
Diabetes Mellitus (being positive) 4.75 (1.29–17.6) .019 9.38 (1.48–59.3) .017
Size of the household*
Small (1–4 people) 1 (reference) <.0001
Medium (5–10 people) 5.09 (2.89–8.94)
Large (>11 people) 1.88 (0.69–5.12)
Social economic status
Poor 1 (reference) <.0001 1 (reference) <.0001
Middle or upper Ɨ 0.21 (0.08–0.56) 0.29 (0.09–0.89)
Upper 1.14 (0.23–5.58) 1.96 (0.34–10.9)
Distance to the nearest Health Centre (increase/km) 1.32 (1.14–1.53) <.0001 1.39 (1.14–1.67) .001
*Family size was highly correlated with wealth status (p = 0.02) and was not included in the model. All analysis was adjusted for age
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cases associated with an injury is typically around
75%.11,36,37 The reason for this difference is not immedi-
ately apparent. Perhaps eye trauma was either not as com-
mon in SSA as SouthAsia or it was too subtle to be recalled.
This might explain why there were even much less recall
among the controls. As one intervention, farmers could be
sensitized and encouraged to use eye protection while
working.
Poverty and health are intricately related. It is linked
to decisions and practises which predisposes indivi-
duals to disease, limit access to care and determine
choices of treatment options (such as use of TEM). In
our study, the odds of MK among individuals of
a “low” economic status were about four times more
than individuals over a “middle” economic status.
According to the latest Uganda household survey,
about 30% of the population is poor.38 This translates
into 12 million who are at an increased risk of MK. In
this study, we noticed that cases were more likely to be
poorer and live further from the nearest health centre.
Strengths and limitations
We were not able to enrol controls for all the MK cases in
the cohort. However, the sample size was enough to
detect important risk factors and enrolling all the con-
trols may have provided minimal addition. Trauma could
not be tested as risk factors because there was no reported
episode among the controls. Although we were interested
in TEM as a risk factor, it was not feasible to test this: we
could not ascertain whether it had been applied before or
after onset of MK. Before this study, HIV had been
suggested as a potential risk factor. This study provided
strong evidence of HIV as an independent risk factor for
MK, and although the confidence interval is wide, the
estimated effect is large. This was the first case control
design to investigate risk factors of MK in SSA.
Conclusion
HIV, DM, a farming occupation and poverty were
important risk factors for MK in Uganda. There is
need for more work to be done to explore mechanisms
of interaction and how these can inform prevention
strategies against MK. Patients with MK should be
offered HIV and diabetic screening.
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ABSTRACT
Purpose: To describe the care seeking journey and causes of delay among patients with Microbial
Keratitis in Uganda.
Methods: A prospective cohort of patients presenting with microbial keratitis at the two main eye
units in Southern Uganda (2016–2018). We collected information on demographics, home
address, clinical history, and presentation pathway including, order of facilities where patients
went to seek care, treatment advice, cost of care, and use of Traditional Eye Medicine.
Presentation time was noted. We compared “direct” presenters versus “indirect” presenters and
analysed predictors of delay.
Results: About 313 patients were enrolled. All were self-referred. Only 19% of the patients
presented directly to the eye hospital. Majority (52%) visited one facility before presenting, 19%
visited two facilities, 9% visited three facilities, and 2% visited four facilities. The cost of care
increased with increase in the number of facilities visited. People in a large household, further
distance from the eye hospital and those who used Traditional Eye Medicine were less likely to
come directly to the eye hospital. Visiting another facility prior to the eye hospital and use of
Traditional Eye Medicine aOR 1.58 (95%CI 1.03–2.43), p = .038 were associated with delayed
presentation to the eye hospital.
Conclusion: This study provided information on patient journeys to seek care. Delay was largely
attributable to having visited another health facility: a referral mechanism for microbial keratitis
was non-existent. There is need to explore how these health system gaps can be strengthened.
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Introduction
Microbial keratitis (MK) can be caused by a range of
pathogens, including bacteria, viruses, protozoa (e.g.
acanthamoeba), and fungi (yeasts, moulds, andmicrospor-
idia). It is characterised by an acute or sub-acute onset of
pain, conjunctival hyperaemia, and corneal ulceration with
a stromal inflammatory cell infiltrate. MK frequently leads
to sight-loss fromdense corneal scarring, or even loss of the
eye, especially when the infection is severe and/or appro-
priate treatment is delayed.1 MK is important because it is
a leading causes of uniocular blindness worldwide.2,3
In Sub Saharan Africa, the incidence of MK has been
suggested to be around 180/100,000/year.4 Bacterial
(staphylococcus, streptococcus and pseudomonas) and
fungal (fusarium and aspergillus) are the most common
with an almost 50:50 proportion.5–11
In Low and Middle-Income Countries (LMIC), MK
management is often more challenging because of late
presentation, use of Traditional Eye Medicine (TEM),
insufficient diagnostic support, lack of effective drugs
and keratoplasty services.11,12
A critical step in effectively managing MK is ensuring
that patients start appropriate treatment as early as pos-
sible. This is because once the infection is well established,
there is little that can be done to change its course.13 It is
believed that many MK start following corneal abrasions.
Studies in Burma and Bhutan showed that if people with
a simple corneal abrasion applied antibacterial or anti-
fungal medication within the first 24–48 hours, there was
full recovery without any infectious sequalae.14,15
Delayed presentation of patients is a key determinant of
outcomes.12 Patients typically present at least two weeks
after the onset of the first symptoms.12 There are a number
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of factors that could contribute to this delay such as: dis-
tance from the hospital, transportation costs, poverty, self-
medication, and tortuous referral pathways through the
health system.16–18 Prior visit to a non-specialist health
facility has been implicated as a cause of delay in other
eye conditions.17,19
In Uganda, the public health system has six levels,
with the lowest point of care being at the village level
(Village Health Committee).20 However, physically,
a Health Centre II (HC II) is the lowest unit and is
located at a parish level, HC III at sub-county level, HC
IV at county level, district hospital (HC V), and referral
hospital (HC VI). These units have quite different staff-
ing and capacity in terms of service provision. There
are several different levels of private health care provi-
ders as well. Patients are referred up this tier system
depending on the complexity of their condition.
Therefore, to investigate the role of the health system
in providing care and onward referral of people with
MK, here we describe the presentation pathway and
factors associated with delayed presentation, among
patients with microbial keratitis in Uganda.
Methods
Ethical statement
This study followed the tenets of the Declaration of
Helsinki. It was approved by the London School of
Hygiene & Tropical Medicine Ethics Committee (Ref
10647), Mbarara University Research Ethics Committee
(Ref 10/04–16) and Uganda National Council for Science
and Technology (Ref HS-2303). Written informed consent
in “Runyankore” the local language was obtained before
enrolment. If the participant was unable to read, the infor-
mation was read to them by the research assistant. The
participant was then asked to place a thumbprint on the
consent form which was independently witnessed.
Study design and setting
This was part of a study where we prospectively enrolled
patients with MK that presented to Ruharo Eye Centre
(REC) and Mbarara University and Referral Hospital Eye
Centre (MURHEC) from December 2016 to March 2018.
MURHEC is a government owned tertiary eye unit estab-
lished in 2013. It provides mostly free services and sees
about 6,000–10,000 patients/year. REC is a church-based,
fee-paying tertiary eye hospital founded in the 1960s. It sees
about 20,000–25,000 patients/year. Both hospitals are in
Mbarara Municipality, South-Western Region, Uganda,
approximately 4 hours’ drive from Kampala. The two
units are about 5 km apart and work closely together.
Participants
All patients that were enrolled into the cohort study
were included. In that cohort study, we aimed to recruit
all MK cases presenting during a year in order to have
a powerful sample set to answer detailed questions
around the seasonal microbiological patterns. It was
important to recruit for a full year as MK had been
shown in other parts of the world to have seasonal
variations in its’ epidemiology.21
Study participants
The inclusion criteria for the bigger prospective study was
the presence of acute MK at presentation to the hospital
defined as EITHER (i) corneal epithelial ulceration
(≥1 mm diameter) AND corneal stromal infiltrate AND
evidence of acute ocular inflammation (e.g. Conjunctival
injection/anterior chamber inflammatory cells/hypop-
yon); OR (ii) a corneal abscess (≥1 mm diameter) AND
evidence of acute ocular inflammation. We excluded
those not willing to participate, those not willing to return
for follow-up, pregnant women, lactating mothers, those
aged below 18 years.
Data collection procedures
Patients presenting with MK were introduced to the
study and the informed consent processes followed.
They were assigned a unique study number and their
age, sex, occupation, and place of residence recorded.
A history was taken of the circumstances in which their
eye became infected, the predisposing factors (such as
trauma and use of Traditional Eye Medicine [TEM]).
A meticulous “journey” history was taken to document
the date when they developed symptoms, where and
when they sought treatment (name and level of the
health centre), what medical advice and treatment was
given (including whether they were referred to the eye
hospital or not), how much each step cost them in
Uganda shillings (transportation, consultation fees,
medicines). The total amount of money recorded was
for all the costs incurred before patients were enrolled
into the study.
The place where they first received any form of
treatment was denoted as “Facility 1”, the second
place visited (either as a result of formal referral or self-
initiated referral) was denoted “Facility 2” and so on.
GPS coordinates were generated for the patients’
addresses (to the nearest village, parish, county school,
or health centre depending on what was available on
Google maps). Presenting Log MAR (Logarithm of
Minimum Angle of Resolution) visual acuity at 2 m
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in a dark room was measured using Peek Acuity
software.22 For visual acuities of counting fingers or
less, Log MAR values were attributed as follows: count-
ing fingers, 2.0; hand movements, 2.5; perception of
light, 3.0; and no perception of light, 4.0.23 The patients
were then examined on a slit lamp and clinical signs
carefully recorded. Infiltrate size was measured as the
greatest diameter of the infiltrate (dimension 1) and
the diameter of an imaginary line perpendicular to the
widest axis (dimension 2). The final infiltrate size was
then derived as the geometrical mean of the two
diameters.24 The same was repeated after fluorescein
staining of the ulcer to measure the epithelial defect
sizes. Corneal specimens were obtained for microbio-
logical testing at Mbarara University Microbiology
Department. Patients were treated as per the hospital
treatment protocol and followed up periodically for up
to 3 months to determine their outcome.
Analysis
Data were analysed in STATA v14. “direct” presenters
were defined as participants whose first point of care
was the eye hospital (MURHEC or REC). “Indirect”
presenters are those who first went to other health
centres before presenting to the eye hospital.
Summary frequency tables of demographics and clinical
presentation of “direct” versus “indirect” presenters
were generated with appropriate statistical tests for
each variable (Wilcoxon rank sum for the continuous
variables and χ2 test for the categorical variables). To
determine where the participants came from, Google
maps was used to pinpoint to the addresses of the
participants. The presentation journey was described
using interval times in days from home to Facility 1
or from Facility 1 to Facility 2 and so on (presented as
median time in days with Inter Quartile Ranges
[IQRs]). To describe the cost of care, the total patient
expenditure at different facilities were summarised and
cumulative expenditure derived depending on how
many facilities an individual visited. Costs are pre-
sented as median expenditure in Uganda shillings
with IQRs.
Presentation time was defined as the time in days it
took a patient to come to the eye hospital after onset of
symptoms. For analysis of delay, presentation time was
divided into quartiles as “early” (0–7 days), “intermedi-
ate” (8–14 days), “late “(15–30 days), and “very late”
(>30 days). Ordinal logistic regression was performed
to determine the factors associated with these four
quartiles of “delay”, while logistic regression was per-
formed to determine factors associated with direct pre-
sentation. Univariable regression was performed to
generate crude Odds Ratios (OR). After assessing for
collinearity, variables with a p value less than 0.1 were
introduced in the multivariable model. A backward
stepwise approach was then used, until only the vari-
ables with a p value <0.05 were retained. Adjusted OR
were reported for the final model.
Results
Demographic features
During the study period, 313 patients were enrolled
into this study. The baseline characteristics of direct
versus direct presenters are shown in Table 1. Overall,
Table 1. Baseline characteristics of direct versus indirect presenters (n = 313).
Direct presenters (n = 58) Indirect presenters (n = 255)
Variable Median (IQR) (Total range) Median (IQR) (Total range) p value
Age 47 (35–60) (18–96) 47 (35–60) (18–87) 0.772
Distance to eye units 58 (16–85) (0.2–244) 87 (57–131) (2–378) 0.0001
Household population 5 (3–7) (1–14) 7 (4–8) (1–28) 0.006
Distance to nearest health centre in km* 2 (1–3) (0–14) 3 (1–4) (0–45) 0.174
Variable Category Count (%) Count (%) p value
Gender Female 22 (38%) 117 (46%) 0.271
Male 36 (62%) 138 (54%)
Occupation Farmer 34 (59%) 186 (73%) 0.031
Nonfarmer 24 (41%) 69 (27%)
Marital status Unmarried Ɨ 18 (31%) 77 (30%) 0.900
Married 40 (69%) 178 (70%)
Education status None 15 (26%) 69 (27%) 0.407
Primary 29 (50%) 133 (52%)
Secondary 7 (12%) 38 (15%)
Tertiary 7 (12%) 15 (6%)
Being head of household Yes 42 (72%) 170 (67%) 0.398
No 16 (28%) 85 (33%)
Needed an escort to hospital* Yes 24 (41%) 49 (20) <0.0001
No 34 (59%) 202 (80)
*Variables with some missing data: distance to nearest health centre was measured in km (n = 312, [direct 57]) needed an escort (n = 309, [direct 58]). Ɨ Unmarried
included single, divorced, and widowed,
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the direct and indirect presenters were similar for many
variables. However, the direct presenters lived closer to
the eye hospital (median 58 km vs. 87 km; p = .0001),
had fewer household members (median 5 people vs. 7
people; p = .006) and fewer were farmers (59% vs. 73%,
p = .031).
Table 2 shows some select clinical history and signs of
direct versus indirect presenters. Compared to indirect
presenters, direct presenters had a shorter presentation
time (median 8 days vs. 17 days; p < .0001), had slightly
better presenting vision (median Log MAR 0.65 vs. 1.3;
p = .075), a smaller infiltrate size (median 4.2 mm vs.
5.5 mm; p = .025) and a smaller epithelial defect (median
3.5 mm vs. 4.1 mm; p = .048). The proportion of people
who had used TEM was higher among the indirect (63%)
versus direct presenters (46%), p = .020. The direct and
indirect presenters had similar proportions with a history
of trauma, hypopyon, an opaque stromal opacity and
perforation.
Factors associated with direct presentation
On univariable and multivariable analysis summarised
in Table 3. People who lived far from the eye hospital
(overall p = .003), those from large households OR 0.53
(95%CI 0.32–0.85), p = .0080 and those who had used
TEM OR 0.48 (95% CI 0.25–0.90), p = .020 were less
likely to be direct presenters.
Table 2. Clinical history and clinical signs of direct versus indirect presenters (n = 313).
Direct presenters (n = 58) Indirect presenters (n = 255)
Variable Median (IQR) (Total range) Median (IQR) (Total range) p value
Presentation time in days* 8 (2–18) (0–116) 17 (8–32) (0–370) <0.0001
Presenting vision (Log MAR) 0.65 (0.1–2.5) (0–4) 1.3 (0.3–2.5) (0–4) 0.072
Infiltrate size in mm Ɨ 4.2 (2.5–7.1) (0.9–11) 5.5 (3.5–8) (0.5–13) 0.025
Epithelial defect size in mm Ɨ 3.5 (1.8–5.8) (0–11) 4.1 (2.5–6.9) (0–13) 0.048
Variable Category Count (%) Count (%) p value
History of trauma (overall 29%) ǂ Yes 14 (25%) 77 (30) 0.388
No 43 (75) 177 (70)
Used traditional eye medicine (overall 61%) Yes 27 (46) 161 (63) 0.020
No 31 (53) 94 (37)
Pain being the main complaint Yes 26 (45%) 112 44 0.121
No 32 55 143 56
Opaque stromal opacity ǂ Yes 25 (43) 107 (44) 0.918
No 33 (57) 137 (56)
Hypopyon ǂ Yes 13 (22) 81 (32) 0.151
No 45 (78) 172 (68)
Perforated at admission Yes 10 (17) 66 (26) 0.166
No 48 (83) 189 (74)
*Presentation time was measured as duration in days it took to come to the eye hospital after onset of symptoms. Ɨ geometrical of the largest diameter and
the diameter perpendicular to the largest diameter. ǂ variables that had less than 313 observations due to missing data (trauma n = 311 [direct57], opaque
stromal opacity n = 302 [direct 58], hypopyon n = 311 [direct 58]).
Table 3. Univariable and multivariable logistic regression analysis of factors associated with direct presentation to the eye hospital
(n = 309).
Variable
Univariable analysis Multivariable analysis
cOR (95% CI) p value aOR (95% CI) p value
Age in years 1.004 (0.987–1.022) 0.576
Sex (being male) 1.38 (0.77–2.48) 0.273
Marital status (being married) 0.96 (0.52–1.78) 0.900
Occupation (being a farmer) 0.52 (0.29–0.94) 0.033
Being head of household 1.31 (0.69–2.46) 0.399
Number of people in household (increase/one person) 0.59 (0.38–0.90) 0.015 0.53 (0.32–0.85) 0.008
Distance to the eye hospital
0–50 km 1 0.001 0.003
50–100 km 0.52 (0.26–1.01) 0.62 (0.30–1.27)
100–150 km 0.16 (0.05–0.44) 0.16 (0.06–0.48)
>150 km 0.42 (0.17–1.03) 0.52 (0.19–1.34)
Distance from nearest health centre (increase per 1 km) 0.92 (0.822–1.029) 0.146
Positive history of trauma 0.74 (0.38–1.44) 0.389
Positive history of TEM Use 0.50 (0.28–0.90) 0.021 0.48 (0.25–0.90) 0.020
Education status
None 1 0.462
Primary 1.00 (0.50-1.99)
Secondary 0.84 (0.31–2.25)
Tertiary 2.14 (0.74–6.17)
*patients with missing data were dropped from the model. OR less than 1 means they were less likely to come directly to the eye hospital
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Care seeking pathway
Figure 1 shows where the patients came from in rela-
tion to the eye hospital (MURHEC or REC). Most came
from the South Western region of Uganda and
a handful from Northern Tanzania. Figure 2 shows
the place where patients were first treated. Majority
(46%) sought treatment at a nearby clinic/pharmacy/
drug shop, 19% presented directly to the eye hospital,
15% were initially treated at home (either used TEM or
an old eye drop) and 17% were treated at various levels
of the health system (HC II, HC III, HC IV, and district
hospital). Some patients (2%) did not know the type of
facility where they first sought care and only 1% went
to a traditional healer’s shrine for treatment.
Figure 3 illustrates the pathway patients took to come
to the eye hospital and the different times spent on each
stage. Only 55 (20%) patients presented directly to the eye
hospital, majority (134, 51%) visited one facility before
presenting to the eye hospital, another 43 (19%) visited
two facilities, 24 (9%) visited three facilities, and 5 (2%)
visited four facilities. On average, patients took about
a week to move from one facility to the next. The shortest
response time was from onset of symptoms to Facility 1
and was even shorter among indirect presenters, median
2 days (IQR 0–5) versus direct presenters, median 8 (IQR
2–18), p < .0001. The longest interval time was from
Facility 4 to the eye hospital, median 13 (IQR 10–33).
The choice of the first facility did not affect overall pre-
sentation time. All the patients were self-referred.
Figure 1. A map of Uganda showing patients homes.
Each point represents a patient. The red circle is the eye hospital where these patients presented.
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We found in our study that most patients used TEM
after having been to a health facility (secondary use).
Out of the 188 who used TEM, only 51 used TEM as
primary treatment (47 at home and 4 at the traditional
healers’ shrine). The rest (137/188) had secondary
TEM application.
Cost of care
The cost of care in Uganda shillings (UGX) is presented in
Table 4. The cost of care increased with increase in the
number of facilities visited. There was evidence (Cuzick test
for trend p < .0001), of an association between expenditure
and number of facilities visited prior to presentation. The
lowest spend was for direct presenters where the median
expenditure was UGX 30,000 (IQR 7,000–63,000, total
range 0–385,000) and the largest spend was among patients
who had visited 4 facilities before presentation with
a median expenditure of UGX 284,000 (IQR 118,000–-
439,500, total range 96,000–864,000). Across the different
expenditure lines, medicines were the most expensive fol-
lowed by transportation, consultation fees were the least
expensive.
Factors associated with delay
We tested for associations with delay in presenting to the
eye hospital (Table 5). After adjusting for distance, visit-
ing another facility prior to the eye hospital was strongly
associated with delay but no obvious trend. Previous use
of TEM was also found to be associated with delay OR
1.58 (IQR 1.03–2.43), p = .038
Discussion
This study aimed to describe the presentation journey and
factors associated with delay. Factors associated with delay
were having visited another health facility and prior use of
Traditional Eye Medicine (TEM). This supported our
hypothesis that an initial visit to a health facility introduced
delay as had been reported previously for other eye
conditions.17,19,25 After onset of symptoms, the majority
of patients quickly visited a health facility to seek treatment.
This was an impressive median response time (within
48 hours). Although we did not explicitly ask their reasons
for presenting early to these facilities, the painful nature of
MK, proximity of the facilities and trauma (for those who
had it) could have played a role. Perhaps, if appropriate
treatment had been given or rapid referral made at this
stage, the outcomes might have been better.13,14
At the first point of contact with the health system,
there were three missed opportunities that we identified
in our study, these were: to promptly initiate appropriate
treatment; to triage and urgently refer; and health educa-
tion advice against TEM use. We discuss these below.
Firstly, the health facility where most patients presented
first were usually a nearby pharmacy/clinic. These are
mostly private clinics that have sprouted up in many parts
of Uganda. They are loosely regulated, manned by primary
healthworkers and do not require a doctor’s prescription to
dispense treatment. Effective anti-microbial medication
such as Natamycin and Ciprofloxacin eye drops are not
available in such units. These could be potential stake-
holders to target in promotion of triage and referral
mechanisms for MK. We found that there was no referral
Figure 2. showing where patients first accessed treatment (n = 309).
Key: Clinic refers to clinic/pharmacy/drug shop, District is district hospital, MURHEC is the main eye hospital (Mbarara University and Referral
Hospital Eye Centre and Ruharo Eye Centre).
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mechanism for MK: all patients who came to the eye
hospital were self-referred.
Secondly, all the patients who visited a health facility we
given some treatment but none of the patients was ever
referred for specialist care. Most of the health centres
(II and III) are managed by mid-level cadres, who may
not have the necessary skills and tools to appreciate the
urgency and seriousness ofMK.General eye health training
has been previously reported to be limited amongmid-level
cadres in the region.26 In addition, Uganda is still grappling
with a major shortage of human resources for eye health.
An eye specialist is found at some level six facilities and
a mid-level ophthalmic cadre might be available in some
level IV onwards.27We plan to conduct a study into factors
around the health system that could be developed to
strengthen treatment, triage and referral.
Figure 3. The care seeking journey of patients with microbial keratitis and the time taken at each step (n = 276).
In this analysis, only patients with complete data were included. START refers to when the symptoms started. Facility refers to a health
centre or clinic/pharmacy and not necessarily the hierarchy of the health centres.
Table 4. Money spent by patients per number of facilities visited before coming to the eye hospital.
Cost of care median (IQR) in Uganda Shillings*
Facility n (%) Transportation Consultation Medicine Total expenditure
0 58 (18.5%) 11,000 (4,000–20,000) 15,000 (0–15,000) 0 (0–27,000) 30,000 (7,000–63,000)
1 147 (52%) 19,500 (10,000–33,000) 15,000 (15,000–15,000) 19,800 (2,750–99,500) 52,000 (31,000–142,000)
2 58 (18.5%) 22,000 (15,000–37,000) 15,000 (0–15,000) 25,750 (6,000–80,000) 67,750 (34,250–142,500)
3 29 (9%) 30,000 (19,000–51,000) 15,000 (0-15,000) 28,500 (3,000–70,000) 78,250 (32,000–209,000)
4 6 (2%) 62,500 (33,000–143,000) 12,500 (10,000–30,000) 170,500 (78,000–343,500) 284,000 (118,000–439,500)
p value of test for trend <0.0001
*All money is quoted in Uganda shillings. The US $ exchange rate was US $1: Uganda shillings 3,700 (2017). Ɨ0-direct presenters who did not visit any other
facility before coming to the eye hospital. Patients with incomplete data were not included in this analysis
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Thirdly, we found in our study that most patients used
TEM after having been to a health facility (secondary use).
This is worrying because these were patients who could
have been sensitised against TEM use at the health facil-
ities where they first presented. This was a missed oppor-
tunity that needs to be addressed.
Fifty-eight (19%) of the patients were direct presen-
ters. As expected, people who had large households,
those who lived far from the eye hospital and those
who used TEM were less likely to present directly to
the eye hospital. Understandably, use of TEM and
having a large household were negative predictors for
being a direct presenter. Most of the people who used
TEM used it at home and this was marked as
a treatment event in our study design. Many patients
in our cohort were heads of households and the sole
bread winners, they might have preferred to first seek
treatment at a place near home.
The cost of care was variable depending on the num-
ber of facilities visited. Most of the money was spent on
drugs, and transportation. The public health system in
Uganda is largely free or highly subsided. Expenses are
incurred on transportation and sometimes medicines
when they are out of stock. For the case of MK, drugs
such as Natamycin have only been erratically and expen-
sively supplied by select private pharmacies and not
available in the public health system. We anticipate this
to change as Natamycin was recently added on the
WHO essential medicines list.28
Strengths/limitations
This study was the first in SSA to systematically collect
information on howMK patients seek care and what influ-
ences their pattern. It provides useful information on key
health system gaps that need strengthening. Before this
study, it had been thought that patients had poor health
seeking behaviour, however, what we found was that
majority of people presented to a health facility quite early
after the onset of symptoms. Secondly, although TEM use
was a known problem, this study showed that the bigger
problem was secondary TEM use, that is patients who
opted to use TEM even after they had been to a health
facility.
Although we collected information on distance cov-
ered and treatment given at each level, it was difficult
to analyse for these because most patients did not come
to the eye hospital with their medicine and could not
recall the names. There were many circular move-
ments that made it complicated to analyse total dis-
tance covered by each patient. A qualitative approach
in discussing with patients what informed their choice
of self-referral or direct presentation would have
strengthened the evidence in this study.
Conclusion
Delayed presentation to a specialist eye hospital is
a problem in the care of MK, and that this appears to be
largely attributable to slow referral through the health
system. There are opportunities for health education,
early referral, appropriate treatment and sensitization
against TEM use that could be utilized to improve care of
MK.More needs to be done to understand what goes on in
the health system and how this can be strengthened.
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Table 5. Univariable and multivariable ordinal logistic regression analysis of factors associated with delay among patients with
microbial keratitis (n = 309).
Variable
Univariable analysis Multivariable analysis
cOR (95% CI) p value aOR (95% CI) p value
Age in years 1.009 (0.994–1.019) 0.140
Sex (being male) 1.06 (0.71–1.58) 0.792
Marital status (being married) 0.86 (0.55–1.33) 0.316
Occupation (being a farmer) 1.24 (0.80–1.93) 0.339
Being head of household 0.83 (0.54–1.27) 0.394
Number of people in household (increase/one person) 1.14 (0.85–1.51) 0.365
Distance to the eye hospital (every 10km increase) 1.036 (1.003–1.) 0.034
Distance from nearest health centre (increase per 1km) 1.01 (0.97–1.06) 0.501
Positive history of trauma 0.96 (0.62–1.49) 0.860
Positive history of TEM Use 1.73 (1.14–2.62) 0.010 1.58 (1.03–2.43) 0.038
Other facilities visited before eye hospital
Nil (direct presenters) 1 0.0002 1 0.001
One facility 2.95 (1.63–5.38) 2.74 (1.53–4.92)
Two facilities 3.62 (1.74–7.52) 2.58 (1.30–5.15)
Three facilities 4.12 (1.82–9.34) 3.26 (1.42–7.45)
Four facilities* 15.5 (2.65–90) 14.3 (2.45–83.7)
*two patients had visited five facilities and one patient six facilities, these were dropped from the analysis
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Abstract
: Traditional eye medicine (TEM) is frequently used to treatBackground
microbial keratitis (MK) in many parts of Africa. Few reports have
suggested that this is associated with a worse outcome. We undertook this
large prospective study to determine how TEM use impacts presentation
and outcome of MK and to explore reasons why people use TEM for
treatment in Uganda.
 
: In a mixed method prospective cohort study, we enrolledMethods
patients presenting with MK at the two main eye units in Southern Uganda
between December 2016 and March 2018 and collected information on
history, TEM use, microbiology and 3-month outcomes. We conducted
qualitative interviews with patients, carers traditional healers on reasons
why people use TEM. Outcome measures included presenting vision and at
3-months, comparing TEM Users versus Non-Users. A thematic coding
framework was deployed to explore reasons for use of TEM.
 
: Out of 313 participants enrolled, 188 reported TEM use. TEMResults
Users had a delayed presentation; median presenting time 18 days versus
14 days, p= 0.005; had larger ulcers 5.6 mm versus 4.3 mm p=0.0005; a
worse presenting visual acuity median logarithm of the minimum angle of
resolution (Log MAR) 1.5 versus 0.6, p=0.005; and, a worse visual acuity at
3 months median Log MAR 0.6 versus 0.2, p=0.010. In a multivariable
logistic regression model, distance from the eye hospital  and delayed
presentation were associated with TEM use. Reasons for TEM use
included lack of confidence in conventional medicine, health system
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 included lack of confidence in conventional medicine, health system
breakdown, poverty, fear of the eye hospital, cultural belief in TEM,
influence from traditional healers, personal circumstances and ignorance.
 
: TEM users had poorer clinical presentation and outcomes.Conclusion
Capacity building of the primary health centres to improve access to eye
care and community behavioural change initiatives against TEM use should
be encouraged.
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Introduction
Microbial keratitis (MK) frequently leads to sight-loss from dense 
corneal scarring, or even loss of the eye, especially when the 
infection is severe and/or appropriate treatment is delayed1. MK 
has been described as a “silent epidemic”, which leads to sub-
stantial morbidity, related to blindness and other consequences 
such as pain and stigma2. It is the leading cause of unilateral 
blindness after cataract in tropical regions and is responsible 
for about 2 million cases of monocular blindness per year3.
In Low and Middle-Income Countries (LMIC), use of 
Traditional Eye Medicine (TEM) for treatment of many eye 
conditions is a common practise4–6. In the few reported studies, 
TEM has been found to lead to complications such as corneal 
scarring and delayed presentation of patients to hospital resulting 
in poor outcomes7,8.
Literature on TEM use for MK is scanty. However, among the 
three papers from Sub-Saharan Africa (SSA), TEM use among 
patients with MK was reported to be associated with a severe 
presentation. These studies did not report clinical outcomes9–11. 
In addition, since most of the TEM involves plant products such 
as fresh leaves, it could have a major role in the pathogenesis of 
fungal keratitis, which has been associated with  injuries involv-
ing vegetative matter12,13. Our experience in Uganda is that TEM 
is widely used to treat a number of eye conditions including 
MK. However, the drivers of this practice are not well understood.
The aim of this study therefore was to determine how TEM 
use impacts presentation and outcome of MK and to explore 
reasons why people use TEM for treatment of MK in Uganda.
Methods
Ethical statement
This study adhered to the Declaration of Helsinki. It was 
approved by the London School of Hygiene & Tropical Medi-
cine Ethics Committee (Ref 10647), Mbarara University Research 
Ethics Committee (Ref 10/04-16) and Uganda National Coun-
cil for Science and Technology (Ref HS-2303). Written informed 
consent in Runyankore, the local language, was obtained 
before enrolment. If the patient was unable to read, the 
information was read to them, and they were asked to indi-
cate their consent by application of their thumbprint. The col-
lected source data is stored in a secure database at Mbarara 
University of Science and Technology. An anonymised digital 
version was also uploaded in a secure server. The data will be 
kept for 7 years according to institutional policy.
Participants
Due to the cultural complexity of TEM usage, we used a mixed 
methods approach. We prospectively enrolled patients with 
MK that consecutively presented to two tertiary eye hospi-
tals in South-Western Uganda from December 2016 to March 
2018. The case definition of MK was the presence of a corneal 
epithelial defect (of at least 1mm diameter) with an underly-
ing stromal infiltrate, associated with signs of inflammation 
(conjunctival hyperaemia, anterior chamber inflammatory cells, 
+/- hypopyon). We excluded those not willing to participate, those 
not willing to return for follow-up, pregnant women, lactating 
mothers, those aged below 18 years.
Quantitative assessment
We documented basic demographic information and ophthal-
mic history using ophthalmic nurses as part of the routine hos-
pital work up. This included treatment received including prior 
use of TEM. For those who reported use of TEM, a detailed 
structured history was taken on what they had applied, source 
of the medicines, cost, how it was prepared, duration of use and 
any complications experienced. A detailed description of the 
cases evaluation has been previously presented. In summary, 
after measurement of the presenting visual acuity (Logarithm 
of Minimum Angle of Resolution), cases underwent a detailed 
clinical examination on a slit lamp using a structured proto-
col, including eyelid assessment, corneal ulcer features, anterior 
chamber (flare, cells, hypopyon shape and size) and perforation 
status. Corneal scrapes were collected for microscopy, culture 
(blood agar, chocolate agar, potato dextrose agar) and molecular 
diagnosis. HIV, Diabetes counselling and testing were offered, 
as per the Uganda Ministry of Health HIV testing protocol. 
Cases were treated according to the hospital protocol, which 
usually involved a brief admission for the first few days. The 
study follow-up assessment schedule was days 2, 7, 21 and 
90, to determine outcome. Patients were asked to return to the 
eye hospital for these reviews where their follow up data was 
collected as before. Additional assessments were conducted 
as clinically indicated. The primary outcome measure was 
final best corrected vision at 3 months. See extended data14 for 
questionnaire used.
Qualitative assessment
All interviews and discussion groups were conducted by AA. 
They were audio recorded and summarised. Additional contex-
tual information provided such as patient emotions, environment 
and any other aspect the interviewer found noteworthy.
Firstly, at presentation, patients who reported to have used TEM 
were asked if they would be willing to discuss their experi-
ences. For such patients, an interviewer would return later that 
evening or the next day when the patient was more relaxed. 
Interviews were conducted in the local language by a social 
            Amendments from Version 1
In this revised version, we have addressed all the reviewer 
comments in a point by point format. The main differences are:
On lines 339–341, we have added a comment on why economic 
status was not significant in the multivariate analysis.
Data in Table 2 had been interchanged to show that TEM users 
had better presenting acuity than non TEM users, this has been 
corrected to show that TEM users had a worse vision.
On lines 364–365, we have acknowledged a limitation in not being 
able to enroll children and provided an explanation for this.
On Lines Line 48–55, we have provided a description on clinical 
examination and microbiological methods for the patients.
Typos in the abstract and in line 291 have been corrected.
Any further responses from the reviewers can be found at the 
end of the article
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scientist either at the hospital bedside (when quiet) or in the hos-
pital compound depending on the patient’s preference. The focus 
of the interview was to explore reasons why they had used TEM.
Secondly, we conducted informal group discussions (IGDs) with 
a sample of the MK patients involved in the study and relatives 
of people with MK on the practise and reasons why people use 
TEM. This was an opportunistic approach to allow flexible data 
collection. For example, a patient might present escorted by 
many family members and friends (common in this setting), 
such a group would then be invited to discuss issues around 
TEM. Such a naturally composed group was to result in a more 
relaxed discussion than a group of people who did not know each 
other who are brought together solely for the discussion.
Finally, we conducted in-depth interviews with traditional heal-
ers to learn about what they would usually do for people pre-
senting with a problem like MK and why people go to them for 
treatment. Healers were identified from a traditional healers’ 
registry at the local council headquarters. A random sample of 
15 traditional healers were contacted through their coordinator. 
Those willing to share their knowledge and practise in treating 
eye problems particularly MK were visited and interviewed at 
their home or shrine.
For all the groups, topic guides were developed using available 
literature and experiences of the local ophthalmologists treat-
ing patients with MK (see extended data14). They included 
local understanding of MK, causes, treatment and experiences 
of using TEM. The guides were piloted among a few patients 
and modified accordingly. The final version was approved 
by all the authors who included senior social scientists (AA) 
and a professor (JS). In this report, our focus is on reasons why 
people use/do not use TEM. These were reviewed by one of the 
authors. They were then piloted among MK patients and revised 
accordingly. All interviews lasted about 30–45 minutes.
Analysis
Quantitative data were analysed using STATA v14. We com-
pared demographic data, baseline clinical presentation and 
final vision outcomes at 3-months of patients who reported to 
have used TEM versus those who had not. Appropriate tests of 
significance (chi2 for categorical data and Wilcoxon rank sum for 
continuous data) were employed. Multivariable logistic regression 
analysis was used to identify factors associated with TEM use. 
Initially, univariable regression was performed to generate 
crude odds ratios (OR). Variables with a p-value less than 0.1 
were introduced in the multivariable model. A back stepwise 
approach was then used, until only the variables with a p-value 
of less than 0.05 were retained. Adjusted OR were reported for 
the final model. Summary tables of proportions were constructed 
to describe the source, cost, complications and duration of use 
of TM.
For the qualitative data, all interviews were recorded with an 
audio recorder (Olympus WS-853 Digital Stereo Voice Recorder) 
and transcribed into summaries. These were independently 
reviewed several times by two of the authors (SA and JS). A 
coding framework was developed, and data were then manually 
coded. Emerging themes around reasons why people used/did 
not use TEM are presented. Specific conversation response clips 
from the respondents that supported the generated themes were 
extracted from the audio recordings and used as illustrative 
statements.
Results
We enrolled 313 people with MK, of whom 188 (60%) reported 
TEM use (“TEM Users”) and 125 said they did not use TEM 
(“TEM Non-Users”). The demographic characteristics of both 
groups are shown in Table 1 (see underlying data14). There were 
some differences between TEM Users and Non-Users. TEM 
Users lived further from the eye unit, were more frequently 
farmers, were less likely to be married and had progressed less in 
formal education.
The clinical characteristics of both groups are shown in 
Table 2. There was evidence that the condition of TEM Users 
was worse than TEM Non-Users at presentation. The TEM Users 
presented later, had larger corneal ulcers (both infiltrate and 
epithelial defect), more frequent hypopyons and poorer vision.
We modelled factors associated with TEM use (Table 3). After 
adjusting for potential confounders, distance from the eye 
hospital and delayed presentation were associated with TEM 
use. Whereas, there was less TEM use among those who were 
married, had a history of trauma and a high education level.
At 3-months, 260 patients completed their follow-up. There was 
no systematic baseline difference between patients who were seen 
at 3-months and those that were not. The final LogMAR visual 
acuity was worse among TEM Users, median 0.6 (IQR 0-2.5), 
compared to TEM Non-Users, 0.2 (IQR 0-1.5), p=0.010.
Among the 188 patients who reported TEM use, 137 (73%) 
used TEM after they had been to a government health facil-
ity (secondary TEM use). TEM was mostly made from fresh 
leaves [154, (82%)]; the commonest preparation method was to 
freshly squeeze them [145, (77%)]. Most patients obtained TEM 
either from their home garden (40%) or from a neighbour (54%), 
only 5 patients (3%) obtained TEM from a traditional healer. 
TEM was generally free, 169 (90%) reported not to have spent 
any money to obtain it.
The qualitative study involved a total of 38 participants: 11 
traditional healers, 21 MK patients who had used TEM and 6 
MK patients who had not used TEM. The baseline character-
istics of these individuals are presented in Table 4. Overall, it 
was a mix of male and female, young and old, not educated 
and highly educated. In addition, three informal group discus-
sions (IGDs) were conducted, each with around 15 partici-
pants (these were naturally composed groups of patients who 
had used or not used TEM, relatives and friends).
The major factors coming out as the reasons for using TEM 
included lack of consumer confidence in conventional medi-
cine, health system breakdown, poverty, fear, cultural belief in 
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Table 2. Baseline clinical characteristics of participants (n=313), comparing traditional eye medicine (TEM) users to 
non-users.
Variable
TEM Users (188) TEM Non-Users (125)
Median (IQR) (Total range) Median (IQR) (Total range) P value
Presentation time in days 18 (12–35) (1–274) 14 (5–32) (0–370) 0.005
Infiltrate size in mm* 5.6 (3.8–8.1) (0.5–11) 4.3 (2.4–6.8) (0.6–12) 0.0005
Epithelial defect size in mm* 4.2 (2.5–11) (0–14) 3.6 (2.2–5.1) (0–11) 0.0105
Presenting Vision (Log MAR) 1.5 (0.3–2.5) (0–4) 0.6 (0.2–2.5) (0–4) 0.005
Count (%) count (%) P value
Visual Acuity > 6/18 50 (27) 52 (42) 0.011
6/18 – 6/60 24 (13) 18 (14)
< 6/60 113 (60) 55 (44)
Eye discharge Yes 107 (57) 60 (48) 0.122
History of Trauma Yes 42 (22) 49 (39) 0.001
Presence of lid swelling Yes 85 (46) 45 (36) 0.097
Slough Ɨ None 31 (17) 30 (24) 0.246
Flat 77 (41) 47 (38)
Raised 78 (42) 46 (37)
Infiltrate colour White 77 (44) 71 (63) 0.005
Cream 76 (43) 30 (27)
Other 23 (13) 11 (10)
Table 1. Baseline demographics characteristics of participants (n=313), comparing traditional eye medicine (TEM) 
users to non-users.
Variable
TEM Users (188) TEM Non-Users (125)
Median (IQR) (Total range) Median (IQR) (Total range) P value
Age 48 (34–60) (18–87) 45 (35–60) (18–96) 0.651
Distance to eye hospital (km) 87 (59–132) (1.5–378) 67 (42–121) (0.2–316) 0.003
Distance to nearest Health Centre in (km) 3 (1–5) (0–45) 2 (1–4) (0–35) 0.528
Count (%) count (%) P value
Gender Male 101 (54) 73 (58) 0.415
Occupation Farmer 140 (75) 80 (64) 0.047
Non-farmer 48 (25) 45 (34)
Education None 59 (31) 25 (20) 0.016
Primary Level 98 (52) 64 (51)
Secondary Level 23 (12) 22 (18)
Tertiary Level 8 (5) 14 (11)
Marital status Unmarried* 66 (35) 29 (23) 0.025
Married 122 (65) 96 (77)
Household SES Ɨ Poor 51 (28) 34 (29) 0.520
Middle 116 (64) 72 (60)
Upper 13 (7) 13 (11)
SES: Socioeconomic status.
*Unmarried included-single, divorced, widowed. Ɨ This was relative self-reported economic status compared to the neighbours.
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Table 3. Univariable and multivariable logistic regression for factors associated with traditional eye medicine use (n=313).
Variable Univariable Analysis Multivariable Analysis
Crude OR (95% CI) p-value Adjusted OR (95% CI) p-value
Age in years 1.002 (0.988-1.016) 0.699
Distance to Eye hospital (for every km) 1.005 (1.001-1.0090 0.009 1.004 (1.001-1.008) 0.035
Distance to the nearest Health Centre (for every km) 1.028 (0.971-1.089) 0.332
Sex (Being male) 0.82 (0.52-1.30) 0.415
Occupation (Being a farmer) 1.64 (1.01-2.68) 0.048
Married 0.55 (0.33-0.93) 0.026 0.54 (0.31-0.95) 0.035
Education level
None 1 0.016 1 0.059
Primary 0.64 (0.36-1.14) 0.71 (0.38-1.30)
Secondary 0.44 (0.20-0.93) 0.44 (0.20-1.00)
Tertiary 0.24 (0.09-0.65) 0.28 (0.09-0.83)
Household economic status
Low 1 0.526
Middle 1.07 (0.63-1.81)
Upper 0.66 (0.27-1.61)
Presentation time
0–3 days 1 <0.001 1 0.002
4–7 days 2.17 (0.72-6.53) 1.50 (0.46-4.83)
8–14 days 6.03 (2.10-17.3) 4.76 (1.55-14.6)
15–30 days 5.77 (2.03-16.4) 4.37 (1.44-13.2)
>30 days 4.89 (1.75-13.6) 3.74 (1.27-11.1)
History of trauma 0.44 (0.26-0.72) 0.001 0.43 (0.25-0.74) 0.003
Variable
TEM Users (188) TEM Non-Users (125)
Median (IQR) (Total range) Median (IQR) (Total range) P value
Hypopyon Yes 66 (35) 28 (22) 0.014
Perforated at admission Yes 29 (15) 16 (13) 0.517
Microbiology Unknown 38 (23) 27 (25) 0.089
Bacteria 10 (6) 10 (10)
Fungus 108 (67) 60 (55)
Mixed 6 (4) 11 (10)
Log MAR: Logarithm of the minimum angle of resolution.
*These were calculated as the geometrical means using the MUTT protocol15. The upper limits exceeded normal corneal diameter for some 
lesions, which extended up to the sclera. Ɨ Raised slough was when the corneal infiltrate profile was raised, flat slough was when the profile 
was flat while no slough is when there was no debris noted. The difference in presenting vision and infiltrate sizes remained significant even 
after adjusting for delayed presentation.
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Table 4. Baseline characteristics of people who participated in the in-depth interviews, including 
traditional healers and patients with microbial keratitis (both traditional eye medicine (TEM) users 
and non-users).
Participant Age Sex Marital status Occupation Household size Education Religion
Traditional Healers (n=11)
1 70 Male Divorced Farmer 1 None Christian
2 56 Female Married Farmer 4 None Christian
3 52 Female Widowed Farmer 3 None Christian
4 76 Female Married Farmer 8 Primary Christian
5 78 Female Married Farmer 5 - -
6 53 Female Widowed Farmer 2 - Christian
7 72 Female Widowed TBA 4 Primary Christian
8 82 Male Divorced Farmer 8 None Christian
9 59 Male Married Carpenter 18 Secondary Christian
10 69 Female Married TBA 6 Primary Christian
11 60 Female Widowed TBA 5 Primary Christian
TEM Users (n=21)
1 42 Male Married Farmer 7 Primary Christian
2 46 Male Married Charcoal maker 8 Primary Christian
3 26 Male Married Mechanic 4 Primary Christian
4 53 Female Married Farmer 5 Primary Christian
5 38 Female Married Farmer 3 Primary Christian
6 26 Male Single Graduate 5 Tertiary Christian
7 18 Female Single Farmer 6 Secondary Christian
8 39 Male Married Farmer 5 None Muslim
9 85 Female Widowed Farmer 18 None Christian
10 60 Female Married Business 5 None Christian
11 72 Female Married Farmer 8 None Christian
12 29 Male Married Teacher 3 Tertiary Christian
13 60 Male Married Farmer 6 Primary Muslim
14 39 Female Married Farmer 5 Primary Christian
15 54 Male Married Guard 4 Primary Christian
16 58 Female Married Farmer 4 Primary Christian
17 30 Female Divorced Farmer 4 Primary Christian
18 81 Male Married Farmer 9 None Christian
19 81 Male Married Farmer 5 Primary Christian
20 69 Male Married Farmer 17 Primary Christian
21 20 Male Single Shop keeper 20 Primary Muslim
TEM Non-Users (n=6)
1 56 Male Married Teacher 6 Tertiary Christian
2 25 Male Married Bike rider 6 Primary Christian
3 39 Male Married Accountant 1 Tertiary Christian
4 30 Female Single Hairdresser 1 Primary Christian
5 20 Male Single Farmer 10 Secondary Christian
6 19 Female Single Student 4 Tertiary Muslim
TBA: Traditional Birth Attendant;
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TEM, Role of Traditional Healers, personal circumstances and 
Ignorance.
Lack of confidence in conventional medicine
While some participants reported visiting health centres for 
treatment, many talked of resorting to TEM with the persist-
ence in pain after use of conventional medicine. A 26-year male 
mechanic said “At first, I got some relief when I put the eye 
drop, but later, it pained me severely and I was advised to use 
herbs. Having seen no great improvement, I started using herbs.” 
A participant in an IGD told us “We are using western medi-
cine to no avail. You can use western medicine for a week or a 
month but don’t get healed.” A 75-year male traditional healer 
reported that “many people with eye problems come to me 
because some even fail to get cured from Mbarara hospital and 
are referred to me. I then put my traditional eye medicine like 
twice and they gain or enjoy life again.” These statements sup-
ported the observation above that the majority (73%) of the TEM 
users had applied it after they had visited a health facility.
Lack of service in health facilities
Inadequate care including lack of medicines, rude health work-
ers, unskilled health workers and poorly equipped health 
facilities, especially government owned ones, were reported as 
major drivers to use of TEM by a majority of patients. “There 
are no experts or doctors experienced in treating eye diseases 
in Health Centres within our vicinities. When you find a 
doctor at a Health Centre, they say that they don’t know such an 
eye disease you are suffering from” (a 28-year unemployed man). 
The majority of primary health facilities do not have trained 
primary eye care workers. Eye patients are reviewed by 
general health workers who may have limited experience with 
managing ophthalmic condition. Eye care workers are nurses 
who have received an ophthalmic certificate course in examina-
tion and management of common eye conditions. In addition, 
as an 81-year-old farmer put it “Health facilities within our 
areas don’t have eye medicine, examination machines and they 
are also unwelcoming to a person who has gone there. One just 
looks at the eye, prescribes the medicine and start treating the 
illness. Or, you hear medicine has been brought but when you 
go there the next day, you are told there is no medicine.” 
Poverty as a barrier to access care
With subsistence farmers constituting the major part of the pop-
ulation, poverty was reported as a key barrier to accessing eye 
care, encouraging people to opt for TEM. This was expressed 
as being unable to afford transport to eye hospitals and treat-
ment. In an IGD1, one respondent told us “Those of us who are 
able to afford treatment are very few you can count them; many 
people who have the same problem have turned blind because 
they cannot afford treatment.” Another person added “It’s a result 
of poverty! Many people in the village have no money. Even 
sometimes you don’t have money in the pocket, so you pick the 
herb and apply it to the sick eye. You get to come here at the 
facility when you can’t count the types of herbs you have tried 
just because of poverty.” Compared to going to hospital and the 
costs involved, TEM was a far cheaper option: the majority of 
the patients had obtained it from within their homesteads and had 
not spent any money on it.
Fear of the eye hospital
Most people lived far from the eye hospital and fear of travel-
ling long distances, which was reported as a constraint. “One 
can be having money but chooses not come to the hospital 
fearing how he will reach. Not all people are poor, but one just 
wonders where he is to pass and continue to Mbarara eye 
hospital. There are reluctant for example one says he won’t be 
able to reach the place he has never gone to” (an 81-year old male 
farmer from a distant village). We found that most of the 
patients travelled l distances (about 90 km) to reach the only 
referral eye hospitals in Mbarara town. Another form of fear 
was of what treatment would be offered; some people thought 
that this would make them go blind. For example, a participant 
in IGD2 told us “What stops them from going to the hospital is 
that one is told they are going to operate your eye and after that 
it means that it is damaged completely you will never see again. 
That is the reason many people fear coming to the hospital, 
they say when you are operated the eye ends up getting dam-
aged. They say when you reach in the hospital and get operated, 
it doesn’t get well” 
Cultural understanding of MK and its treatment
Use of TEM in general is viewed as an acceptable practice 
and as part of culture in the community. It was revealed by 
several participants that MK is culturally understood as a disease 
to be treated locally. Almost all participants talked of receiving 
advice to use TEM from fellow community members who 
attest that it cured them. An 81-year old female farmer told us 
“People in communities don’t know that MK as an eye disease 
is treated in hospitals or that there are hospitals that can treat 
it. People say it is cured by traditional eye medicine.” Another 
42-year old farmer said “The old people we live with know 
those medicines and they testify that they cured them. Therefore, 
they encourage one who is suffering from an eye disease to keep 
using them saying he too will get well.” Most of the people came 
from rural settings where there is a strong sense of community.
Belief in TEM
From the experience of previous TEM users and personal 
experience of use, it was not surprising that almost all par-
ticipants who had used TEM believed it was effective. They 
attributed their failure to heal to their body makeup. “The old 
people believe and know that traditional eye medicine cures eye 
diseases. There are people, they identified for me who used the 
same medicine and got well. Even themselves, they told me that 
they used it and got cured” (a 42-year male farmer). “The 
person who gave me traditional eye medicine told me she too 
suffered from the same disease and got healed by the same 
herbs” (a 60-year old butter maker). On being asked why it had 
not worked for them, a 53-year old female farmer responded 
“those who don’t heal I think the condition of the eye might 
have needed medical attention from doctors as genetically 
people are different. There is one who heals by traditional 
eye medicine and another who doesn’t and is only treated by 
modern medicine from hospitals.” 
Role of traditional healers
With the belief and acceptance that use of TEM is within 
their culture, many had confidence in traditional healers. The 
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traditional healers themselves also had a strong confidence in 
their medicine and reported remarkable cure rates. One 56-year 
old traditional healer said: “They go to the hospitals and 
come back to me when they have failed to heal with modern 
medicine. I give them traditional eye medicine and they get healed, 
none that I have treated or given my medicine has failed to get 
well” Another 75-year old male healer reported “There are 
many people I have treated; none I gave my medicine has 
ever complained that it failed to heal her or him. Whoever I 
meet just praises God and prays for me to be blessed. I treat 
people with faith in God.” 
Personal circumstances
Desperation due to the pain of the condition and the view of 
TEM as a form of first aid was mentioned as a prompt to use 
traditional medicine. This was mostly reported among patients 
who used TEM before presenting to health facilities. Participants 
explained that with the pain, one can use anything recommended 
to him or her to the extent of accepting TEM containing needle 
prick blood from another person without being afraid of con-
tracting HIV. A 42-year male farmer told us “This disease is so 
painful. No one should suffer from it because, with pain you 
can use anything given to you. You are not mindful of HIV, you 
only want the pain gone”. A 85-year female farmer wondered, 
“Can anyone who has been found in pain and recommended an 
herb fail to use it? Pain can make you do anything”.
Lack of awareness to the dangers of TEM
Interestingly, most participants did not think using TEM could 
be dangerous. “Traditional eye medicine doesn’t damage the 
eye, it just rinses or cleanses it” (a 46-year old male charcoal 
burner). “There are no risks of using traditional eye medicine 
because when one fails to get healed, she or he goes somewhere 
else or to hospitals” (an 85-year female farmer). In addition, 
some thought it was better than conventional medicine and did 
not have any side effects like most conventional medicines. 
A 59-year old traditional healer said, “Our herbal medicine 
is fresh not preserved.” 
Discussion
This study investigated the extent of TEM use by people with 
microbial keratitis, and how this impacts their clinical presenta-
tion and outcome. We went on to explore more deeply the spe-
cific practices and the reasons and beliefs behind using TEM. 
The use of TEM in Southern Uganda in the treatment of MK is 
common (60%), and more frequent than that previously reported 
from Malawi (34%) and Tanzania (25%)9,10. Importantly, we 
found that people who used TEM presented later with a more 
severe clinical picture and they ended up with worse final 
visual acuity outcomes at 3-months, compared to those who 
had not used TEM.
Our findings are similar to previous reports from Malawi, which 
found that patients who had used TEM presented later than 
those who had not used TEM9,16. The previous studies, how-
ever, did not examine final outcomes, after the infection had 
been treated. MK is a disease where prompt treatment is critical 
if one is to improve the likelihood of a good outcome. We know 
from prior literature that once an infection is advanced, treat-
ment does relatively little to change its course17. The clear 
conclusion from earlier studies from South Asia and East 
Africa is that effective treatment of MK should be started as 
early as possible to save the eye and achieve the best possible 
outcomes18,19.
In this study we combined both quantitative modelling 
approaches and complementary qualitative approaches to inves-
tigate not only “what” but also “why” people use TEM. In the 
explanatory multivariable model, increasing distance to the eye 
hospital, lower education level, an onset not linked to trauma and 
not being married were associated with TEM use. These were 
explored further in the informal group discussions (IGDs). 
These discussions the major reported reasons for using TEM 
were around consumer confidence in the health system, access, 
poverty and cultural influence.
Importantly, we found that most people who used TEM did so 
after first visiting a government health facility. This is consistent 
with the IGDs, in which people felt that conventional medicine 
was not helping, leading them to resort to alternative approaches. 
This conclusion could be a result of inappropriate treatment. 
However, even with appropriate treatment, the clinical response 
can be slow, especially for fungal keratitis. Patients need to 
be properly counselled to manage expectations. Another impor-
tant aspect is good pain management on top of the anti-microbial 
treatment. Patients reported that desperation due to pain made 
them more likely to try many options to find relief. This initial 
early contact point with the formal health system represents 
an opportunity to improve the diagnosis and treatment of 
people with MK, through providing enhanced training, diagnostic 
tools and medication in the primary care setting.
Lack of appropriate ophthalmic medicines is a major challenge. 
For example, the best current evidence indicates that topical 
natamycin is the treatment of choice for filamentous fungal 
keratitis20. However, this is currently not readily available in 
the main ophthalmic units Uganda or elsewhere in SSA. It is 
certainly not available in more isolated locations. Therefore, 
patients with a fungal MK will not access effective treatment 
until they arrive in a major eye unit. Natamycin was added 
to the WHO Essential Medicines List in 2018, which will 
hopefully result in greater availability soon.
Limited access to eye care was a major driver of TEM use. This 
was evident in the regression modelling, with increasing TEM 
use with increasing distance to the eye hospitals. The majority of 
TEM users came from districts relatively far away where no eye 
care facilities were situated. This was a strong and frequently 
articulated theme in the interviews and discussions. Multiple 
people commented on the lack of eye health services in the 
nearby health facilities, the long distances to the eye hospi-
tal and poverty is a major barrier to access (because of the high 
transport and other direct costs). Several people also highlighted 
that government health centres near to them have no eye spe-
cialists or treatment and do not treat eye conditions. Pharmacies 
simply sell available eye drop medication, with no examination; 
frequently these are steroid and antibiotic combinations which may 
result in more harm than good in fungal keratitis. Unfortunately, 
Uganda still grapples with a severe shortage of human resources 
and infrastructure for eye health21.
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Although the regression model did not demonstrate a relation-
ship between economic status and TEM Use, during the IGDs 
poverty was reported to be a major driver for using TEM. In the 
model, there were only a handful of people in the upper eco-
nomic status which may have obscured this relationship. The 
majority of the patients were subsistence farmers and therefore 
not able to readily afford the cost of medicines and transpor-
tation. In contrast, TEM could be accessed closer to home at 
almost no cost. Most of the patients used got the TEM from their 
nearby gardens or from the neighbour and applied it freshly 
squeezed into the eye. People who are married may have 
access to greater household financial resources, possibly 
explaining why being married was associated with less TEM use.
We found that TEM use was linked to strong cultural beliefs 
and this seemed related to the level of education. In the model, 
people with no or little education were more likely to use 
TEM. It was worrying that people did not perceive TEM use as 
potentially dangerous. This was also reinforced by messages 
from traditional healers and older members of the commu-
nity who carry a high level of respect. Public health orientated 
messaging and health education need to particularly focus on and 
work with these groups. There is some evidence from Malawi 
and Nigeria, where ophthalmologists worked with traditional 
healers to lower the use of TEM, that changes are possible7,16. 
Although, in our context, only 3% of TEM users consulted a tra-
ditional healer, their place in society cannot be underestimated 
and it would be in our best interest to bring them on board.
Strengths/limitations
The use of a mixed methods approach provided a more inform-
ative data on reasons for using TEM for MK in Uganda. To the 
best of our knowledge, this was the first study in SSA that 
looked at 3-month outcomes of people who had used TEM 
for treatment of MK. Although a sensitive topic, it was noted 
that participants and traditional healers were willing to talk 
about their TEM experiences. We did not have any evidence that 
people withheld information. The large numbers were enough 
to have a well powered study to explore factors associated 
with TEM use. Inclusion of children would have provided a 
more overall understanding of this topic, however, this was 
not practical in out setting.
Conclusion
TEM use is an important factor in the presentation and out-
come of MK in Uganda, leading to delayed presentation to hos-
pital, a poor presentation and a worse outcome. Cultural beliefs, 
access to the health system (due to poverty and long distances) 
and inherent challenges in the primary health centres (lack of 
knowledge, medicines, equipment and supplies) are major 
drivers of TEM use. Sensitisation of the people and capacity 
building in the primary health centres will be a step in the right 
direction to mitigate these effects.
Data availability
Underlying data
Havard dataverse: Traditional Eye Medicine use in Microbial 
Keratitis in Uganda. https://doi.org/10.7910/DVN/5GOPKZ14.
This project contains the following underlying data:
•    tem_data_descriptive_5May2019.tab (quantitative underly-
ing data)
•    tem_coding_framework_May2019.tab (codes of qualitative 
data responses)
Extended data
Havard dataverse: “Topic guides for exploring Traditional 
Eye Medicine Use for treatment of Microbial Keratitis in 
Uganda.docx”, Traditional Eye Medicine use in Microbial 
Keratitis in Uganda, https://doi.org/10.7910/DVN/5GOPKZ14.
This project contains the following underlying data
•    Topic guides for exploring Traditional Eye Medicine 
Use for treatment of Microbial Keratitis in Uganda.docx 
(Topic guides that were used to probe respondents to 
talk about their understanding, opinions and experiences 
of using Traditional Eye Medicine)
•    Quantitative questionnaire on use of Traditional Eye 
Medicine.docx (A of a quantitative questionnaire that was 
used to collect information from all the patients with MK 
on their history of use of Traditional Eye Medicine)
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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 This is a useful addition to the mounting evidence that improving the early treatment of microbial keratitis
should be a priority for prevention of blindness programmes.
The authors conclude that TEM is more likely to be used if patients have less access to effective
eye care facilities. Although poverty was cited by many participants as a driver for TEM use, it was
not significant in the multivariate analysis. This may be explained by the paucity of higher SES
patients in both groups. I think it is likely that poverty does contribute to TEM use, alongside the
other factors.
 
Although the text of the results section states that TEM users had worse presenting acuity than non
TEM users, the data in Table 2 appears to contradict this, and I suspect there may be an error in
the table.
 
This study confirms the finding of previous authors who noted that TEM use is associated with a
greater risk of hypopyon. The underlying assumption of this article is that all patients had microbial
keratitis prior to TEM use. However, it is possible that some may have had self-limiting, or minor
conditions, such as a corneal abrasion or conjunctivitis. The introduction of unsterile preparations
on to a compromised ocular surface may have led to   development of microbial keratitis.de novo
 
An unexpected finding is that TEM use in this population was usually independent of traditional
healers. I have always assumed that TEM use is partly driven by a desire for answers that western
medicine is not good at providing, particularly "Why has this happened to me?". This study would
seem to indicate that the main motivation for most patients was a simple desire for faster and
greater improvement in their symptoms.
 
A less surprising finding is that outcomes were significantly worse for patients using TEM. Previous
studies have not been able to obtain outcome data, as it can be difficult for these patients to return
for review. It is valuable to have clear evidence that TEM use is harmful.
 
One significant weakness in the study is the exclusion of children. In Tanzania we found that 50%
of TEM users were aged 11 or younger. I suspect that the findings would be similar in children and
adults, but the authors should acknowledge this weakness in the discussion.
 
The ready availability of TEM in people's homes and gardens means that campaigns to reduce the
use of TEM are unlikely to be successful. Prevention of blindness programmes would be better to
focus on improving the delivery of eyecare, and raising the quality of the care delivered.
Anecdotally, I can report that TEM use was widespread in a poor part of rural Tanzania, but almost
non-existent in the relatively developed Central Province of Kenya. My experience would appear to
support the authors' conclusion that improving rural eye care will lead to a decline in the harms
caused by TEM.
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
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 If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
 No competing interests were disclosed.Competing Interests:
Reviewer Expertise: Vitreoretinal surgery, public health ophthalmology in developing countries
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
Author Response 02 Sep 2019
, London School of Hygiene & Tropical Medicine, London, UKSIMON ARUNGA
 The authors conclude that TEM is more likely to be used if patients have less access toComment:
effective eye care facilities. Although poverty was cited by many participants as a driver for TEM
use, it was not significant in the multivariate analysis. This may be explained by the paucity of
higher SES patients in both groups. I think it is likely that poverty does contribute to TEM use,
alongside the other factors.
Response: We agree with the reviewer that poverty does contribute to TEM use and was
indeed reported by many participants. In the multivariable model, there were only a
handful of people in the upper economic status which may have obscured this
relationship. We have added this comment in lines 339-341. Also to note is that
SES/Access/poverty are all on a similar/same causal path and do not function
independently of each other.
Although the text of the results section states that TEM users had worse presentingComment: 
acuity than non TEM users, the data in Table 2 appears to contradict this, and I suspect there may
be an error in the table.
Response: We thank the reviewer for spotting this. We noticed that the data had been
accidentally interchanged. It has been corrected in table 2.
: This study confirms the finding of previous authors who noted that TEM use isComment
associated with a greater risk of hypopyon. The underlying assumption of this article is that all
patients had microbial keratitis prior to TEM use. However, it is possible that some may have had
self-limiting, or minor conditions, such as a corneal abrasion or conjunctivitis. The introduction of
unsterile preparations on to a compromised ocular surface may have led to de novo development
of microbial keratitis.
Response: We agree with the reviewer and feel the same way. However, there was no way
of objectively ascertaining this fact. We intend to explore this in our future studies.
: An unexpected finding is that TEM use in this population was usually independent ofComment
traditional healers. I have always assumed that TEM use is partly driven by a desire for answers
that western medicine is not good at providing, particularly "Why has this happened to me?". This
study would seem to indicate that the main motivation for most patients was a simple desire for
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 study would seem to indicate that the main motivation for most patients was a simple desire for
faster and greater improvement in their symptoms.
Response: Indeed, this was surprising. Only 3% of the participants visited a traditional
healer to obtain TEM. From our further exploration of this in the qualitative studies, our
impression is that  since the“everyone in the community is a traditional healer”
knowledge of the herbs is common among the community members. However, this does
not negate the role of the healers since they are strong advocates for TEM use.
: A less surprising finding is that outcomes were significantly worse for patients usingComment
TEM. Previous studies have not been able to obtain outcome data, as it can be difficult for these
patients to return for review. It is valuable to have clear evidence that TEM use is harmful.
Response: We thank the reviewer for acknowledging this new contribution.
: One significant weakness in the study is the exclusion of children. In Tanzania weComment
found that 50% of TEM users were aged 11 or younger. I suspect that the findings would be similar
in children and adults, but the authors should acknowledge this weakness in the discussion.
Response: We thank the author for this comment. Although we provided care for children
who presented with Microbial Keratitis, the design of our study enrolled only adults due to
pragmatic reasons such as being able to test people for HIV, subjecting children under
general anaesthesia for corneal scrapping and ethical approvals for a vulnerable group. In
addition, we found out during the pilot phase that microbial keratitis was not very
common among children in our setting, accounting for only about 3% of all microbial
keratitis cases. However, this point has been acknowledged in the limitation. lines
364-365.
: The ready availability of TEM in people's homes and gardens means that campaigns toComment
reduce the use of TEM are unlikely to be successful. Prevention of blindness programmes would
be better to focus on improving the delivery of eyecare, and raising the quality of the care
delivered. Anecdotally, I can report that TEM use was widespread in a poor part of rural Tanzania,
but almost non-existent in the relatively developed Central Province of Kenya. My experience
would appear to support the authors' conclusion that improving rural eye care will lead to a decline
in the harms caused by TEM.
 Response: We thank the reviewer for this comment.
 n/aCompeting Interests:
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© 2019 Sharma S. This is an open access peer review report distributed under the terms of the Creative Commons
, which permits unrestricted use, distribution, and reproduction in any medium, provided the originalAttribution License
work is properly cited.
   Savitri Sharma
Jhaveri Microbiology Center, Brien Holden Eye Research Centre (BHERC), L V Prasad Eye Institute
(LVPEI), Hyderabad, Telangana, India
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 1.  
2.  
3.  
4.  
5.  
This report gives an account of the "mystery" surrounding the traditional eye medicine usage in the
treatment of microbial keratitis. The practice is rampant in some of the developing and underdeveloped
countries and the more we know and understand this practice better we can get at influencing people to
make a distance from them. Social, cultural, economical and emotional factors - all seem to be
responsible for continued presence of this unwanted practice. This reviewer appreciates the efforts of the
authors in putting up this paper together which is very well written. Following are minor comments that
may help make the paper even better:
Abstract: Results begins with digits which in good writing should be avoided and replaced with
words.
 
Methods: Clinical examination and microbiological methods are not described at all. A description
would allow better understanding of how the data was collected.
 
Analysis, Page 4, results, last but one line: The word farmer is spelt wrongly with one "r" missing.
 
There is no data on what type of organisms were involved in the microbial keratitis in the two study
groups. If microbiology was done, as is claimed in methods, there should be results of the same.
Similarly, how were the patients treated in the control group that did not receive traditional eye
medicine? These are important determinants of the outcome in the two groups that have been
compared. My comments of "partly satisfied" are related to these issues.
 
Discussion: Para 2, line 6: “...if one is improve the likelihood of a good outcome.” This sentence is
incorrect with a missing word "to".
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Partly
Are the conclusions drawn adequately supported by the results?
Yes
 No competing interests were disclosed.Competing Interests:
Reviewer Expertise: I am a clinical microbiologist in an academic tertiary care eye centre with over 25
years experience in diagnosing and researching microbial keratitis cases in India. I have published
extensively and written book chapters in the area of ocular infections including microbial keratitis. My
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 extensively and written book chapters in the area of ocular infections including microbial keratitis. My
research areas include fungal keratitis, Acanthamoeba keratitis, antibiotic susceptibility, infection control,
molecular diagnosis of eye infections, infectious endophthalmitis etc.
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard, however I have significant
reservations, as outlined above.
Author Response 02 Sep 2019
, London School of Hygiene & Tropical Medicine, London, UKSIMON ARUNGA
: Abstract: Results begins with digits which in good writing should be avoided andComment
replaced with words.
Response: We thank the reviewer for spotting this. We have revised this sentence to read
“Out of 313 participants enrolled, 188 reported TEM use”.
 Methods: Clinical examination and microbiological methods are not described at all. AComment:
description would allow better understanding of how the data was collected.
Response: We thank the reviewer for this comment. The detailed assessment of the
patients has been described in a different report (under review), however, we have
revised the manuscript and summarised patient assessment. Line 48-55.
 Analysis, Page 4, results, last but one line: The word farmer is spelt wrongly with oneComment:
"r" missing.
Response: We thank the author for spotting this. It has been corrected. Line 115.
 There is no data on what type of organisms were involved in the microbial keratitis inComment:
the two study groups. If microbiology was done, as is claimed in methods, there should be results
of the same. Similarly, how were the patients treated in the control group that did not receive
traditional eye medicine? These are important determinants of the outcome in the two groups that
have been compared. My comments of "partly satisfied" are related to these issues.
Response: We would like to draw the attention of the reviewer to the last section of table 2
which summarises the types of organisms in the two groups. Although the proportion of
fungal keratitis was more common among the people who had used TEM, the evidence of
this difference was weak. We agree with the reviewer that treatment for people with
keratitis should consider the history of use of TEM since that could influence the
organisms involved, especially in the absence of a good microbiology support. However,
treatment of the participants in our study was dependant on the microbiological findings.
 Discussion: Para 2, line 6: “...if one is improve the likelihood of a good outcome.” ThisComment:
sentence is incorrect with a missing word "to"
 Response: We thank the author for spotting this. It has been corrected. Line 296.
 n/aCompeting Interests:
Page 17 of 17
Wellcome Open Research 2019, 4:89 Last updated: 13 OCT 2019
270
A Table showing the list of herbs used as Traditional Eye Medicine in Uganda 
LOCAL BANTU NAME PLANT FORM ENGLISH NAME BOTANICAL NAME 
Akatooma Erlangea cordifolia  
Omujaja Ocimum grattisimum 
Akanyunyambuzi Oxalis latifolia 
Omubarama ClutiaAbyssinca 
Amampera Tree Guava Psidium guajava 
Omuhukye Shrub Lantana trifolia 
Eshwinga Herb Solanum nigrum (sensu lato) 
Omufumbagesi Rumex abyssinica 
Omuyora Kahoo Leucaena leucocephala 
Ekyoganyaja Erlangea tomentosa 
Entoobo Solanum incanum 
Akajwamante Herb/shrub Lactuca capensis 
Akacumucumu Herb/shrub Leonotis nepetifolia
Enyabarashana  Herb Black jack Bidens pilosa 
Ekarwe Herb Melanthera scandens 
Akacumita Mbongo Oxygonum sinuatum 
Ekihindihindi Climbing herb Climbing bean Phaseolus lunatus 
Akajongojongo 
Omubirizi Vernonia amygdalina 
Oburabyo Bwekiko Tree Flame tree Flowers of Erythrina abysinica 
Entabee Herb Tobacco Nicotiana tabacum 
Akabindizi Herb Zehneria scabra 
Orumbungu Grass Cough grass Digitaria  abysinica 
Kanyoro 
Rukaka Aloe sp. 
Amashanda G`Omutooma Tree Sap of  Ficus natalensis  
Enkoninyabato Klanchoe tetraphylla 
Ekinami Crasocephalum bauchiense 
Obushaza Herb/crop Cow Peas Pisum sativum 
Ekijamba Crop Bean leaves Phaseolus vularis leaf 
Omwihura Climbing herb Momordica foetida 
Akayenje Euphorbia tirucali 
Omuturashonga 
Oruhingura Woody herb Triumpheta rhomboidae 
Omukogorane Pseundarthria hookeri  
Omusoroza Herb African Indigo Indigofera arrecta 
Akanyamafundo Leucas marticensis 
Omubarama ClutiaAbyssinca 
Akaitsire Nkore 
Omuziranfu Tetrorchidium didymostemon 
Nyakasambu 
Ekyoganyaja Woody herb /shrub   Erlangea tomentosa 
Akatunguru Onion Allium cepa 
271
Omuhukye Shrub Lantana trifolia 
Ekyiyondo Kalanchoe luciae 
Ekiteezi Commelina bengalensis 
Ekihabukuru Desmodium intortum 
Eteija Creeping herb Wandering jew Commelina bengalensis 
Omuherere Shrub Vernonia cistifolia 
Ekihungunga 
Orunokwo 
Omuhe Microglossa angolensis  
Bukabuka Herb Ageratum conyzoides 
Ereka Herb Kalanchoe Pinnata 
Omuzabibu Vine Cardiospermum grandifloum 
This table represents a collection of herbs reported by the patients with Microbial Keratitis MK) 
enrolled in the main cohort study who had used Traditional Eye Medicine (TEM). In this cohort, 
188/313 patients reported to have used TEM. The patients were asked to bring in a sample of 
the herbs they had used on their subsequent visits, there were then taken to the taxonomy 
department at Mbarara University of Science and Technology for identification. For some who 
were unable to bring the samples, the taxonomy department would obtain these samples from 
a local network of herbalists.  
This work is still ongoing, and a separate manuscript will be prepared to present these findings 
of the different herbs used as TEM for treatment of microbial Keratitis in South Western 
Uganda. 
272
Simon Arunga PhD Thesis 2019 
Chapter 10. Impact of Microbial Keratitis on Quality of Life 
in Uganda 
A technician fits a prosthetic eye in a post enucleation patient at Ruharo Eye Centre, 
Uganda 
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Precis 
Microbial keratitis in Uganda leads to a reduction in the quality of life in affected individuals, compared to 
unaffected individuals, matched for age, sex and location of residence. 
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ABSTRACT 
 
Background: Microbial Keratitis (MK) is a frequent cause of sight loss in sub-Saharan Africa. However, no 
studies have formally measured its impact on Quality of Life (QoL) in this context. 
 
Methods: As part of a nested case control design for risk factors of MK, we recruited patients presenting with 
MK at two eye units in Southern Uganda between December 2016 and March 2018 and unaffected individuals, 
individually matched for sex, age and location. QoL was measured using WHO Health-Related and Vision-
Related QoL tools (at presentation and 3-months after start of treatment in cases). Mean QoL scores for both 
groups were compared. Factors associated with QoL among the cases were analyzed in a linear regression 
model. 
 
Results: 215 case-controls pairs were enrolled. The presentation QoL scores for the cases ranged from 20-
65 points. The lowest QoL was visual symptom domain; mean 20.7 (95% CI 18.8-22.7) and the highest was 
psychosocial domain; mean 65.6 (95% CI 62.5-68.8). At 3-months, QoL scores for the patients ranged from 
80-90 points while scores for the controls ranged from 90-100. The mean QoL scores of the cases were lower 
than controls across all domains. Determinants of QoL among the cases at 3-months included visual acuity at 
3-months and history of eye loss. 
 
Conclusion: MK severely reduces QoL in the acute phase. With treatment and healing, QoL subsequently 
improves. Despite this improvement, QoL of someone affected by MK (even with normal vision) remains lower 
than unaffected controls. 
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Key messages 
What is already known about this subject? 
• Quality of life is affected in many bilateral ocular conditions such as cataract, glaucoma and 
trichiasis. 
• The impact of Microbial Keratitis on Quality of Life compared to unaffected individuals has not been 
previously reported. 
• Microbial Keratitis is a common cause of blindness in Sub Saharan Africa 
What are the new findings? 
• Microbial Keratitis severely reduces Quality of Life in the acute phase of the disease. 
• Quality of life improves with treatment and healing. 
• Despite improvement, QoL of someone affected by MK (even with normal vision) remains lower than 
unaffected controls. 
How might these results change the focus of research or clinical practice? 
• The focus of this study is to make the case that Microbial Keratitis, although usually a uniocular 
disease severely reduces the Quality of Life of the affected individuals. 
• Treatment strategies for Microbial Keratitis should include deliberate interventions to address Quality 
of Life. 
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BACKGROUND 
 
Microbial keratitis (MK) has been described as a “silent epidemic”, which leads to substantial morbidity, related 
to sight loss, pain and stigma.[1] It is the leading cause of unilateral blindness after cataract in tropical regions, 
estimated at 2 million cases of monocular blindness per year.[2] In 2017, 1.3 million individuals were bilaterally 
blind from corneal opacity globally (excluding trachoma and vitamin A deficiency), accounting for 3.2% of 
binocular blindness.[3]  
 
Quality of Life (QoL) is a very important consideration in the management of any disease and treatments 
should ultimately aim to maintain or restore QoL.[4] Few studies from sub-Saharan Africa (SSA) have 
examined the effect of cataract and trachomatous trichiasis on QoL.[5-7] These have generally examined both 
the general Health Related Quality of Life (HRQoL) and more specific Vision Related Quality of Life (VRQoL). 
 
However, there is no published data on the impact of MK on QoL from SSA, and very little from other World 
regions. In the Mycotic Ulcer Treatment Trial 1 (MUTT1) in India which compared topical natamycin to topical 
voriconazole for the treatment of fungal keratitis, QoL scores at 3 months were compared between the two 
treatment arms. However, there was no comparison group of unaffected individuals.[8] There is a need to 
better understand how MK and its outcomes affect people, to develop improved management, counselling and 
support. 
 
In order to investigate the impact of MK on QoL, we conducted this study in South-Western Uganda. Here we 
describe the QoL among patients with MK, at presentation and three months after presentation compared to 
the QoL of unaffected individuals recruited from the community who were individually matched for age, sex 
and location of residence. 
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METHODS 
 
Ethical Statement 
This study adhered to the tenets of the Declaration of Helsinki. It was approved by the London School of 
Hygiene & Tropical Medicine Ethics Committee (Ref 10647), Mbarara University Research Ethics Committee 
(Ref 10/04-16) and Uganda National Council for Science and Technology (Ref HS-2303). Written, informed 
consent in the local language, was obtained before enrolment. If the potential participant was unable to read, 
the information was read to them, and they were asked to indicate their consent by application of their 
thumbprint, which was independently witnessed. 
 
Study Design and Participants 
This study of the impact of MK on QoL was nested within a case-control study of MK in Uganda. We 
prospectively enrolled patients with MK that presented to Ruharo Eye Centre and Mbarara University and 
Referral Hospital Eye Centre from December 2016 to March 2018. These are the tertiary referral centres for 
South-Western Uganda. The case definition of MK was the presence of a corneal epithelial defect (of at least 
1mm diameter) with an underlying stromal infiltrate, associated with signs of inflammation (conjunctival 
hyperaemia, anterior chamber inflammatory cells, +/- hypopyon).[9] We excluded those not willing to 
participate or to return for follow-up, pregnant women, lactating mothers and those under 18 years. All the 
questions in the tools were responded to directly by the study participants. 
 
Assessment of Cases 
At presentation we documented basic demographic information and ophthalmic history. Presenting LogMAR 
(Logarithm of Minimum Angle of Resolution) visual acuity at 2 meters in a dark room was measured using the 
Peek Acuity smartphone application.[10] Cases were examined at a slit lamp to assess the anterior segment 
using a structured protocol. Corneal scrape specimens were collected from the ulcer at a slit lamp or an 
operating microscope and samples were processed in the department of microbiology laboratory at Mbarara 
University of Science and Technology. Following corneal scrapping, immediate Calcofluor White staining was 
done in the side lab at the eye hospital on a fluorescence microscope (Zeiss Primostar ILED) by the attending 
ophthalmologist to rule out fungal Keratitis. Additional microscopy (Gram staining and KOH staining) was done 
in the main University microbiology laboratory and results became available within 24 hours. Agar plates and 
broths (Blood, Chocolate, Potato Dextrose and Brain Heart) were incubated at 35-37°C for bacteria for up to 
7 days and at 25°C for up to 21 days for fungi. Organism identification and sensitivity testing were performed 
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using standard microbiological techniques. Cases were treated empirically at presentation and the treatment 
was reviewed when the microbiology results became available. Patients with fungal keratitis were treated with 
Natamycin 5% eyedrops (Zonat Sunways India), those with bacterial keratitis were treated with Ofloxacin 0.3% 
eyedrops (Biomedica Remedies-India). They were reviewed on days 2, 7, 21 and 90 (3-months). At 3-months, 
the cases were followed-up in their homes for a final assessment.  
 
Control Recruitment:  
We recruited healthy community controls during the 3-month follow-up of cases in their home village. The 
controls were individuals without any current eye complaints and with normal vision. The controls were 
individually matched to the cases. They had to be living in same village as the case, be of the same gender 
and in the same age group (+/- 5 years). Enrolment followed a similar approach to that previously used in study 
in Ethiopia.[6] The research team visited the villages (typically 50-100 households), the local village head was 
asked to write down all individuals they thought would meet the matching criteria for a particular case in that 
village. One person was randomly selected from this list using a lottery method. They were approached and 
provided with details of the study and invited to participate if eligible. If a selected individual refused or was 
ineligible, another person was randomly selected and approached. Both cases and controls were asked about 
their social economic status, this was a self-reported question compared to their neighbours on a 5-scale level 
(5 “very rich”, 4 “rich”, 3 “neither rich nor poor”, 2 “poor”, 1 “very poor”).[6, 7, 11] In this 5-point scale, participants 
were asked “Compared to your neighbours, how do you rate your household wealth status?” 
 
Quality of Life Instruments 
To measure QoL we used two instruments: the general health WHOQOL-BREF and the vision related 
WHO/PBD-VF20. These were both initially independently translated by two translators into Runyankole, the 
local language. Any discrepancies were discussed with a third party and a merged final agreed version 
produced. Both instruments were administered to cases at presentation and at the 3-month follow-up. They 
were administered to the control group only once, during the 3-month assessment of the matched case. 
 
VRQoL: the WHO/PBD-VF20 tool measures vision related quality of life. It assesses the impact of visual 
impairment in several domains including mental wellbeing, dependency and social functioning. The 
WHO/PBD-VF20 consists of 20 questions divided into four sub-scales: “General Vision” subscale (1 question); 
“Visual Symptoms” subscale (3 questions); “General Functioning” subscale (12 questions); and “Psychosocial” 
subscale (4 questions). It begins by asking the patient “Overall, how would you rate your eyesight using both 
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eyes?”; and uses a five-point scale answer option such as “very good”, “good”, “moderate”, “bad”, “very bad”. 
Each subsequent question also has a 5-point response option: one indicates the highest and five the lowest 
score. 
 
 HRQoL: the WHOQOL-BREF (WHOQOL Group, 1998) has good applicability in low and middle-income 
countries (LMIC) as it was developed simultaneously from concept across 18 countries in Africa, Asia and 
Latin America.[12] It measures 4 domains of health: Physical Health, Psychological Health, Social 
Relationships, and Environment. It asks respondents 26 questions. These include the frequency they have 
experienced issues and/or were able to do things (e.g. feel safe, able to concentrate, enjoy life) in the past 4 
weeks and how satisfied they are with certain aspects of their lives (e.g. sleep, capacity for work)[12]. 
 
Sample size 
Based on the effect sizes found in previous work on cataract and trichiasis, a sample size of 215 pairs would 
have 80% power to detect a moderate effect of MK on QoL with an effect size of 0.27 (effect size = QoL score 
difference (3) / SD 11) with a Type 1 error of 5%.[5, 7] 
 
Analysis 
Data were managed in Access (Microsoft), and transferred to Stata 14 (StataCorp) for analysis. Data were 
analysed using a previously described methodology, applied in other QoL studies.[6, 7, 13] 
 
VRQoL. All items were grouped, and scores added into their respective subscales: “General Vision” subscale 
(1 question); “Visual Symptoms” subscale (3 questions); “General Functioning” subscale (12 questions); and 
“Psychosocial” subscale (4 questions). The subscale scores were then converted into a scaled value out of 
one hundred, using the formula: ([individual score—lowest possible score]/[highest possible score—lowest 
possible score]) x 100. Therefore, the person with the lowest possible VRQoL score would receive a scaled 
value of “0” and the person with the highest possible VRQoL score receives a scaled value of “100”. 
 
HRQoL. Data were analysed following the WHOQOL-BREF protocol.[12] Three negatively framed items were 
reversed into a positive frame so higher scores denote higher QoL. To generate domain scores, questions 
were grouped into their respective domains and their scores totalled. The mean score of all items included in 
the domain was calculated and then multiplied by four. These scores then transformed to a 0 to 100 scale with 
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the formula specified in the manual to allow comparison between domains made of unequal number of 
items.[14] 
 
Psychometric property evaluation. Construct validity of the VRQoL and HRQoL data was assessed through 
known-group difference and convergence validity using a linear regression model. Cronbach’s alpha was used 
to test for internal consistency and reliability of the VRQoL and HRQoL data. 
 
Cases and controls were compared for baseline characteristics. However, we noticed that not all the pairs had 
been correctly matched for age because the village heads had subjectively guessed the ages of the controls. 
We thus adjusted for age throughout the analysis. The VRQoL and HRQoL analysis compared the cases to 
the controls at 3-months using a linear regression random effects model, which was adjusted for age and 
socio-economic status, as these factors may confound the association between MK and QoL. A linear 
regression analysis was used to determine vision related factors associated with QoL among the cases at 3 
months adjusted for baseline QoL, age, sex, education and economic status. 
 
Patient and public involvement 
Apart from helping to provide information during the piloting and data collection phase, we did not explicitly 
involve patients or the public in the designing and implementation of our work 
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RESULTS 
 
A total of 313 MK cases presented and were enrolled. We were able to follow-up 260 cases at 3-months. It 
was not possible to enrol a control for 45/260 cases. Therefore, the analysis of QoL at 3-months comprises 
215 pairs. The baseline characteristics were comparable among the cases and control group: median age was 
47 years (IQR 35-60, total range 18-96 years), and 120 (56%) were male. (Table 1) 
 
Table 2 shows the baseline and 3-month VRQoL and HRQoL scores for the cases and the scores for the 
control group. The mean baseline VRQoL scores among the cases were all low (<50) except the psychosocial 
domain which had a score of 65 points. The most affected domain was visual symptoms, with a mean score 
of 20.7 (95% CI 18.8-22.7). The mean baseline HRQoL scores among the cases were all low (<50). At 3-
months, all the case VRQoL and HRQoL scores had increased and were relatively high (between 80-91). 
Despite this increase, there was still very strong evidence (p<0.0001 in all domains) that QoL scores among 
MK cases at 3-months were lower than the controls, after adjusting for age, and economic status.  
 
Table 3 shows the presenting vision, microbiology and 3-months outcomes among the 260 cases. Majority 
(137/260) presented with vision worse than 6/60 in the affected eye. Microbiology results were available for 
226/260 participants out of which the majority (63%) showed fungal keratitis. At 3-months, 138/260 had vision 
of better than 6/18 in the affected eye. Vision had improved in 137 individuals, remained the same in 56 and 
worsened in 66 participants (sign rank p<0.0001).  
 
To investigate if the difference in QoL between the cases and controls was due to factors in addition to impaired 
vision in the MK group, a separate sub-group analysis was performed comparing only MK cases with normal 
vision in the affected eye (better than 6/18) to their paired controls (Supplementary table 1). It was observed 
that the differences in QoL was similar to that obtained when using all the cases. 
 
Tables 4 and 5 shows factors associated with a good VRQoL and HRQoL among the cases at 3 months. This 
analysis was among all the 260 MK cases who were followed up at 3 months. Analysis was restricted to 
variables related to the disease such as vision at 3 months and whether the person had lost their eye. They 
were adjusted for sex, age, education, baseline QoL and socioeconomic status. Vision and eye loss were the 
both found to be associated with VRQoL and HRQoL. 
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Validity of the data was found to be good. Satisfying the known-groups difference criteria, the cases had 
significantly lower VRQoL and HRQoL scores in all domains (p<0.0001) than the controls (Table 2). The 
VRQoL data were reliable after being assessed for internal consistency with a Cronbach’s alpha: coefficients 
of >0.80 (visual symptom 0.90, general functioning 0.98, psychosocial 0.87). The overall HRQoL data had a 
Cronbach’s alpha of 0.98 (physical health 0.96, psychological 0.89, social 0.91 and environment 0.95).  
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Table 1: Baseline characteristics among the 215 case-control pairs. (matched on gender and village and adjusted for age) 
Exposure 
Cases (215) Controls (215) P-value 
n (%) n (%)  
Married (yes) Ɨ 154 (72) 143 (67) 0.215 
Head of household (yes) ǂ 146 (68) 140 (65) 0.441 
      
Education status §      
None 60 (28) 48 (22) 0.148 
Primary 110 (51) 114 (53)  
Secondary 31 (14) 32 (15)  
Tertiary 14 (7) 21 (10)  
      
Farmer (yes) § 157 (73) 168 (78) 0.144 
      
Size of the household ǁ      
Small (1-4 people) 50 (23) 109 (51) 0.05 
Medium (5-10 people) 115 (54) 94 (44)  
Large (>11 people) 50 (23) 12 (5)  
      
Self-reported wealth status *      
Poor 36 (17) 20 (9) 0.003 
Middle 158 (73) 188 (88)  
Upper 21 (10) 6 (3)  
      
Ɨ People who were married, or cohabiting were considered as married while those who were divorced, single or widowed were considered as not married. ǂ Being head of the household 
meant people who were responsible for the overall care of the family, this was regardless of gender: among the cases and controls, 31% and 23% were female heads of households 
respectively. § Majority of the participants had no or minimal education (primary level) which is not uncommon for a predominantly rural population in Uganda. Subsistence farming is 
the main occupation for this population. ǁ Majority of the household sizes were medium to large (5 people or more). This is not uncommon since most of the living in rural Uganda is 
largely in an extended family setting. * Self-reported wealth status was classified as poor (1” very poor” 2” poor”), middle (3 “neither poor nor rich”) upper (4 “rich” 5 “very rich”). There 
was one missing value among the control group. Participants were asked to compare themselves to their neighbours and give a score of their economic status. 
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Table 2: Vision-Related (VRQoL) and general Health-Related Quality of Life (HRQoL) among cases (baseline and 3 months) and controls (215 pairs). 
Domain 
Cases at Baseline Cases at 3 Months Controls at 3 Months Adjusted mean difference at 3 months 
Mean (95%CI) Mean (95%CI) Mean (95%CI) Mean Ɨ  (95%CI) p-value ǂ 
VRQoL 
Overall Sight 32.9 (30.6-35.2) 86.3 (83.3-89.2) 98.6 (97.5-99.6) 11.6 (8.8-14.5) <0.0001 
Visual Symptom 20.7 (18.8-22.7) 88.3 (85.5-91.1) 99.4 (98.9-99.8) 10.5 (7.7-13.3) <0.0001 
General Functioning  42.8 (40.6-45.1) 89.0 (86.1-91.9) 99.6 (99.3-100) 9.9 (7.1-12.7) <0.0001 
Psychosocial 65.6 (62.5-68.8) 90.7 (88.1-93.3) 99.8 (99.4-100) 8.5 (6.0-11.0) <0.0001 
 
HRQoL 
General facet items 
Overall quality of life 40.3 (39.0-41.6) 86.6 (83.9-89.4) 97.2 (96.4-97.9) 10.2 (7.6-12.8) <0.0001 
Overall Health 31.0 (29.0-33.0) 85.6 (82.7-88.5) 98.2 (97.3-99.1) 12.0 (9.1-14.9) <0.0001 
Domains 
Physical health 28.4 (26.5-30.3) 86.1 (83.1-89.2) 98.3 (97.6-98.9) 11.5 (8.6-14.5) <0.0001 
Psychological 49.2 (47.5-50.9) 84.4 (81.9-86.9) 94.0 (93.4-94.7) 9.1 (6.7-11.5) <0.0001 
Social 48.5 (46.5-50.5) 88.2 (85.2-91.2) 98.5 (97.6-99.3) 9.9 (6.9-12.9) <0.0001 
Environment 43 (41.7-44.3) 84.8 (82.0-87.6) 96.3 (95.2-97.3) 10.9 (8.2-13.6) <0.0001 
Only the cases who had controls were included in this analysis (215 pairs).  
Ɨ mean difference between cases and controls adjusted for age, sex and wealth status.  
ǂ Linear regression random effects model was used to test for significance of the differences among the cases and controls adjusted for age, sex and wealth status. 
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Table 3: Presenting vision, microbiology and 3 months outcomes for the cases (n=260) 
Variable n/260 (%) 
Presenting Visual Acuity in the affected eye (Snellen) Ɨ 
> 6/18 86 (33%) 
6/18-6/60 36 (14%) 
< 6/60 137 (53%) 
   
Presenting Visual Acuity in the non-affected eye (Snellen) Ɨ 
> 6/18 232 (90%) 
6/18-6/60 14 (5%) 
< 6/60 13 (5%) 
   
Microbiology * 
Fungal 143 (63%) 
Bacterial 18 (8%) 
Mixed 13 (6%) 
Unknown 52 (23%) 
   
Visual Acuity in the affected eye (Snellen) at 3 months 
> 6/18 138 (53%) 
6/18-6/60 37 (14%) 
< 6/60 85 (33%) 
   
Visual acuity in the non-affected eye at 3 months 
>6/18 229 (90%) 
6/18-6/60 11 (4%) 
< 6/60 15 (6%) 
   
Outcome at 3 months 
Healed no scar 34 (12%) 
Healed Mild scar 83 (30%) 
Healed moderate scar 65 (24%) 
Healed dense scar 46 (17%) 
Eviscerated 24 (9%) 
Not healed 20 (7%) 
Staphyloma 4 (1%) 
 
   
Ɨ There was one missing value (n=259). * Corneal scrapping was performed on 226/260 participants; it was not possible to obtain corneal scrapping samples in 34 participants either 
due to uncooperative patient, declining consent, deep infiltrates with intact epithelium, such patients were treated based on clinical impression. 52 samples returned negative, no organism 
detected on microscopy or culture, these were also managed based on clinical impression.  
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Table 4: Univariable and multivariable linear regression for factors associated with Vision-Related Quality of Life (VRQoL) among cases only (n=260) seen 
at 3 months. 
Variable Overall Sight Visual symptom General functioning Psychosocial 
Mean (95%CI) Mean (95%CI) Mean (95%CI) Mean (95%CI) 
Visual acuity at 3 months 
> 6/18 89.7 (86.6-92.7) 90.9 (87.6-94.2) 93.3 (90.5-96.1) 93.3 (90.9-96.1) 
6/18 - 6/60 78.4 (69.1-87.6) 82.7 (73.5-91.8) 82.2 (73.3-91.1) 83.3 (74.9-91.7) 
< 6/60 77.4 (71.6-83.1) 82.9 (78.3-87.6) 81.3 (76-86.6) 83.8 (78.7-88.9) 
p-value a Ɨ <0.0001 0.006 <0.0001 <0.0001 
p-value b Ɨ 0.001 0.044 0.006 0.003 
 
Eye removal ǂ 
No 83.6 (80.7-86.6) 86.5 (83.5-89.3) 87.5 (84.6-90.3) 88.6 (86-91.2) 
Yes 87.5 (76.3-98.7) 93.1 (86.3-99.8) 90.8 (81.6-100) 90.8 (81.2-100) 
p-value a 0.406 0.168 0.356 0.619 
p-value b 0.030 0.025 0.054 0.111 
a P-values from univariable linear regression analysis. 
b P-values from multivariable linear regression analysis, adjusted for age, education status, wealth category and baseline QoL. 
Ɨ For visual acuity at 3 months (ordinal exposures with three categories), the p-values were calculated for trend.  
ǂ Eye removal was a priori 
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Table 5: Univariable and multivariable linear regression for factors associated with Health-Related Quality of Life (HRQoL) among cases only (n=260) seen 
at 3 months. 
Variable 
Overall QoL Overall health Physical health Psychological Social Environment 
Mean (95%CI) Mean (95%CI) Mean (95%CI) Mean (95%CI) Mean (95%CI) Mean (95%CI) 
Vision outcome at 3 months 
> 6/18 88.7 (85.5-91.9) 88.8 (85.6-91.6) 89.4 (86.2-92.5) 87.7 (85.1-90.3) 90.6 (87.4-93.7) 87.9 (84.9-90.9) 
6/18 - 6/60 82.1 (73.7-90.5) 82.0 (74.2-90.0) 81.9 (73.6-90.0) 80.9 (74.3-87.5) 84.8 (76.8-92.8) 78.8 (70.6-87) 
< 6/60 78.4 (73.3-83.3) 79.3 (74.0-84.5) 77.7 (72.0-83.5) 77.5 (72.9-82.1) 80.5 (74.6-86.3) 77.1 (71.9-82.3) 
p-value a Ɨ <0.0001 0.001 <0.0001 <0.0001 0.002 <0.0001 
p-value b Ɨ 0.008 0.011 0.007 0.003 0.015 0.013 
 
Eye removal ǂ 
No 84.0 (81.2-86.9) 84.5 (81.8-87.1) 84.0 (81.1-87) 83.0 (80.6-85.4) 86.4 (83.6-89.3) 82.5 (79.4-85.3) 
Yes 88.0 (79.2-96.9) 88.1 (79.2-96.9) 89.1 (78.9-99.4) 86.8 (78.9-94.7) 87.8 (77.8-98.1) 88.2 (79.7-96.6) 
p-value a 0.356 0.402 0.288 0.331 0.633 0.198 
p-value b 0.038 0.031 0.028 0.041 0.122 0.009 
a P-values from univariable linear regression analysis. 
b P-values from multivariable linear regression analysis, adjusted for age, sex, education status, wealth category and baseline QoL. 
Ɨ For visual acuity at 3 months (ordinal exposures with three categories), the p-values were calculated for trend. 
ǂ Eye removal was a priori  
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DISCUSSION 
This study investigated the impact of MK on QoL in Uganda. Overall, both the VRQoL and HRQoL among MK 
patients at baseline was substantially reduced. The lowest scores were in the visual symptom (most had 
reduced vision) and physical health (most were in pain) categories. The least affected domain at baseline was 
psychological, which assesses ability to attend functions, feeling ashamed, feeling like a burden to others and 
fear of losing the other eye. In the only other published QoL study in people with MK, the MUTT1 study from 
India, QoL at the time of presentation was not reported.[8] 
 
The QoL scores among the MK cases had improved greatly by 3-months. However, compared to the control 
group, there was strong evidence that MK results in a persistent reduction in QoL, with a mean difference in 
QoL scores of around 10 points. This effect remained evident even when MK cases with impaired vision were 
excluded from the analysis.  
 
In looking at factors associated with QoL among MK cases at 3-months, after adjusting for other factors that 
may affect QoL, such as age, sex, education and economic status, visual acuity was an important determinant 
for both VRQoL and HRQoL. There was evidence that a history of eye loss was also associated with both 
VRQoL and HRQoL at 3 months. It was surprising to note that the people who had undergone evisceration 
had generally better QoL scores compared to those who did not. At the time of eye removal, most of the eyes 
were too damaged and painful that the people were “demanding” for eye removal. They received socket 
prostheses (artificial eyes) after their eye removal procedures, this could have led to a marked reduction in 
pain and other unpleasant symptoms after evisceration, which led to a less impaired QoL compared to others 
who were not eviscerated where there would have been some with ongoing pain and other symptoms like 
dense corneal scars.  
 
Validity and reliability of QoL data 
These tools have been used in a number of other vision related studies to show a difference in QoL and have 
been reported to be valid and reliable in studies conducted in similar settings.[5-7] Although the WHO/PBD-
VF20 tool was designed to assess binocular vision, it has been demonstrated to be effective in detecting 
differences in monocular visual impairment in the MUTT1 trial where patients randomised to natamycin had a 
better 3-month visual related QoL outcome compared to patients randomised to variconazole.[8] In this study, 
both the VRQoL and HRQoL data measured what they were intended to measure (construct validity) by 
demonstrating evidence of differences in the scores between groups known to be different; MK cases and 
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healthy controls had lower and higher scores respectively. The VRQoL data also showed that sub-scales 
correlate well with measures of impact of MK on QoL such as visual acuity where worsening in these measures 
is associated with lower VRQoL subscale scores (construct validity). There was evidence of higher 
homogeneity among the items in each VRQoL and HRQoL subscale (internal consistency) than the generally 
accepted criteria of >0.70. Cronbach’s alpha scores ranged from 0.80-0.99 across all sub scales. 
 
Strengths/Limitations 
This was the first study to look at impact of MK on QoL and compare these with unaffected controls. The 
control selection was good and matched for age, sex and village. We used validated tools which have been 
previously applied in similar settings and the sample size was adequate to test for differences in QoL. This 
study did not collect baseline QoL information from the control group because it was not logistically possible. 
Information on other ocular comorbidities such as presence of a cataract and posterior segment disease at 3 
months was not collected as these examination were conducted at patients’ homes and it was not practical to 
perform a full eye examination in such settings.  
 
Conclusion 
This study showed that MK severely affects QoL in the acute phase. With treatment, QoL improves, with the 
highest QoL in cases who had little or no visual impairment at 3-months. Despite this impressive improvement, 
the QoL at 3-months of someone previously affected by MK (even when they have normal vision) remains 
lower than controls. 
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Abstract
: Microbial keratitis (MK) frequently leads to sight-loss,Background
especially when the infection is severe and/or appropriate treatment is
delayed. The primary health system as an entry point plays a central role in
facilitating and directing patient access to appropriate care. The purpose of
this study was to describe the capacity of primary health centres in Uganda
in managing MK.
 
: We carried out a rigorous assessment of primary health centresMethods
and mid-cadre training schools in South Western Uganda. Through
interviews, checklists and a picture quiz, we assessed capacity and
knowledge of MK management. In addition, we interviewed the heads of all
the mid-cadre training schools to determine the level of eye health training
provided in their curricula.
 
: In total, 163 health facilities and 16 training schools were enrolled.Results
Of the health facilities, only 6% had an Ophthalmic Clinical Officer. Only
12% of the health workers could make a diagnosis of MK based on the
clinical signs in the picture quiz. Although 35% of the facilities had a
microscope, none reported doing corneal scraping. None of the facilities
had a stock of the recommended first line treatment options for MK
(ciprofloxacin and natamycin eye drops). Among the training schools, 15/16
had an eye health component in the curriculum. However, the majority
(56%) of tutors had no formal expertise in eye health. In 14/16 schools,
students spent an average of two weeks in an eye unit.
 
: Knowledge among health workers and capacity of healthConclusions
facilities in diagnosis and management of MK was low. Training for eye
health within mid-cadre training schools was inadequate. More is needed to
close these gaps in training and capacity.
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Introduction
Microbial keratitis (MK) can be caused by a range of patho-
gens including, bacteria, viruses, protozoa, and fungi. It is char-
acterized by acute or sub-acute onset of pain, conjunctival 
hyperaemia and corneal ulceration with a stromal inflamma-
tory cell infiltrate1. MK frequently leads to sight-loss from dense 
corneal scarring, or even loss of the eye, especially when 
the infection is severe and/or appropriate treatment is delayed.
MK has been described as a ‘silent epidemic’, which leads to 
substantial morbidity, related to blindness, pain and stigma2. 
It is the leading cause of unilateral blindness after cataract 
in tropical regions, estimated at 2 million cases of monocu-
lar blindness per year3. In 2017, 1.3 million individuals were 
bilaterally blind from corneal opacity globally (excluding 
trachoma and vitamin A deficiency), accounting for 3.2% of 
binocular blindness4. In Sub-Saharan Africa (SSA), MK is 
an important cause of binocular blindness and is responsible 
for about 15% of monocular blindness5,6.
A good outcome depends on early appropriate treatment, sup-
ported by correct identification of the causative organism, 
and careful follow-up7,8. In low and middle-income countries 
(LMICs), these resources are not readily available and outcomes 
tend to be poor9. It is important for patients to present 
early when the infection can be more easily controlled; for 
instance, studies in Burma and Bhutan showed that if people 
responded within the first 24–48 hours to a corneal abrasion by 
applying antibacterial or antifungal medication, there would be 
100% recovery without any sequalae10,11. Once a corneal ulcer 
is fully established, there is little that can be done to change its 
course12.
The primary health system plays a central role in facilitating 
and directing patient access to appropriate care. A retrospec-
tive study from Tanzania found that having visited a health 
facility was, paradoxically, a risk factor for severe presenta-
tion among patients with MK9,13. Our previous work found 
that although the majority of patients lived within 5km of 
their nearest primary health centre (PHC) and presented early 
to those facilities, they ended up presenting very late to eye 
hospitals and with severe infection when little could be done14. 
There were several missed opportunities at this entry level into 
the health care system to diagnose, manage and or promptly 
refer these patients.
The purpose of this study was to conduct a situation analysis 
of knowledge, practise and capacity of the PHCs in manage-
ment of MK and to determine the level of training offered on 
eye health to mid-level cadres in Uganda.
Methods
Ethical statement
This study followed the tenets of the Declaration of Helsinki. It 
was approved by the London School of Hygiene & Tropical 
Medicine Ethics Committee (Ref 10647), Mbarara University 
Research Ethics Committee (Ref 10/04–16) and Uganda 
National Council for Science and Technology (Ref HS-2303). 
Permission was sought from the District Health Offices to 
approach the facilities. Then, written informed consent was 
obtained from the facility and school heads before enrolment to 
participate in the study and to allow the research assistants 
collect information about their facilities. Written informed 
consent was also obtained from each facility head, school 
head and health worker for their personal participation in 
the research.
Study design and setting
The sampling frame for this study was defined by the catch-
ment area for a related cohort study that prospectively enrolled 
all patients presenting with MK to the main tertiary refer-
ral centres for South Western Uganda (Ruharo Eye Centre 
[REC] and Mbarara University and Referral Hospital Eye 
Centre [MURHEC]) from December 2016 to March 2018. 
The districts from which these patients came from were 
identified by tallying the district data of MK patients and see-
ing which districts had large numbers of MK patients. These 
were then pooled into regions depending on their geographical 
distribution and distance from the eye hospital. One district 
was then randomly selected from each pool.
Uganda’s Health System is a tier-based system divided into 
seven levels with the lowest point of care being at the village 
level. However, physically, a Health Centre II (HC II) is the low-
est unit and is located at a parish level. These units have differ-
ent staffing and capacity in terms of service provision. Patients 
are referred along the tier system depending on the complex-
ity of their condition. Special Clinics are facilities that provide 
specialised services only, such as HIV treatment services. 
There is a total of 408 HC IIs, 152 HC IIIs, 43 HC IVs and 12 
hospitals within the 20 districts in South Western Uganda. 
We randomly selected six districts, stratified by geographical 
distribution and accessibility from the eye hospital in Mbarara. 
All the health facilities within the sampled districts were 
enrolled. In addition, all the mid-cadre training schools 
(nursing and clinical officers) within South Western Uganda 
were enrolled.
Data collection
Quantitative interviews. Research assistants administered ques-
tionnaires (File 1, Extended data)15 to facility heads and/or 
health workers who treat eye patients to ascertain the level of 
knowledge, routine practices and capacity. One health worker 
was interviewed per facility. Heads of mid-level cadre 
training schools were interviewed using questionnaires to 
ascertain the amount of eye health training provided (File 2, 
Extended data)15.
Checklists. Data were collected from the health centres we 
visited about infrastructure, equipment and supplies relevant to 
managing MK. The research assistants collected this informa-
tion from the facility health workers and directly tallied patient 
register entries to count the number of eye patients in general 
and MK cases that visited that unit, as well as diagnosis 
and treatment. A copy of the data collection tool has been provided 
as Extended data (File 1).
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Picture quiz. A photograph of an eye with classic signs of 
MK was given to the health workers (one health worker per 
facility) to test their knowledge of clinical signs and ability to 
diagnose MK (Figure 1, File 3, Extended data)15. The quiz was 
a section of the general questionnaire (File 1, Extended data)15 
that was administered. The health workers were shown a 
coloured picture of an infected eye that had clinical signs of 
MK. They were then asked to identify the clinical signs and 
suggest a diagnosis and management plan.
Analysis
Data were analysed in STATA 14 (StataCorp). Summary tables 
were used to describe knowledge, inventory, proportion of 
eye patients seen. This was stratified by level of the health 
centres. The same analysis was used for training schools to 
describe training key training areas in the identification and 
management of MK.
Results
A total of 163 health facilities were enrolled from six dis-
tricts in South Western Uganda (101 HC IIs, 45 HC IIIs, 13 HC 
IVs and four district hospitals). These were from Kamwengye 
district (27), Kisoro district (31), Ntungamo district (40), 
Sheema district (26), Lyantonde district (16) and Ssembabule 
district (23). Table 1 shows the baseline characteristics of 
the enrolled health facilities. Only five facilities had an 
Ophthalmic Clinical Officer (OCO): these included four hospi-
tals and one HC IV15. Most of the facilities (59%) were headed 
by an enrolled nurse cadre. Most (74%) facilities had less 
than 50% of the expected staffing levels. The proportion of 
patients seen at these facilities who presented with eye problems 
was 2–8%.
Figure 1 illustrates, by level of the health facility, the avail-
ability of basic diagnostic tools and treatment for MK (Sup-
plementary Table 2, File 3, Extended data)15. Overall, 14% 
of the facilities had an examination torch, 4% had fluorescein 
strips for corneal staining, 35% had laboratory microscopes and 
Gram staining facilities. When we looked at eyedrops relevant 
to MK, 29% had gentamycin eye drops available. How-
ever, none of the facilities had ciprofloxacin or natamycin 
eye drops. There was a systematic difference in this capacity 
across the level of the health centres, with higher facilities being 
better equipped.
Knowledge of clinical signs of MK was tested using a pic-
ture quiz of a patient’s eye with MK (Figure 1, File 3, Extended 
data)15. The results are presented in Supplementary Table 3 
(File 3, Extended data)15. Overall, 60% of the health workers 
identified a red eye. However, only 4% identified an epithelial 
defect, 23% a corneal infiltrate and 4% recognised a hypopyon 
(Figure 2). On being asked what the most likely diagnosis 
was, only 12% of the health workers could correctly identify 
it as MK or eye infection. There was a systematic difference 
of the knowledge by level of the facility.
Figure 3 shows knowledge of risk factors and complications of 
MK among the primary health workers (Supplementary Table 3, 
File 3, Extended data)15. Overall, 22% identified immune 
suppression, 5% identified traditional eye medicine (TEM), 
5% identified steroid eye drops, 50% identified trauma. When 
asked to name complications of MK, 95% of the health work-
ers reported blindness. However, only 33% mentioned eye 
loss. On stratifying by level, there was not much difference 
in this knowledge across the different level facilities.
Figure 1. Basic inventory of health facilities for detecting and managing microbial keratitis (n=163).
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Figure 2. Knowledge of clinical signs of microbial keratitis among primary health workers (n=163).
Table 1. Baseline characteristics of the enrolled 
health facilities (n=163).
Variable Count (%)
Level of the health centres (HCs)
HC II 101 (62%)
HC III 45 (28%)
HC IV 13 (8%)
Hospital 4 (2%)
Distance to nearest referral centre
0–5km 27 (17%)
6–10km 72 (44%)
11–20km 43 (26%)
>20km 21 (13%)
In charge cadre type
Enrolled nurse 96 (59%)
Clinical officer 39 (24%)
Medical officer 18 (11%)
Other 10 (6%)
Variable Count (%)
Staffing levels
0–25% 42 (26%)
26–50% 79 (48%)
51–75% 32 (20%)
>75% 10 (6%)
Patient registry data
Variable Median (IQR)
Number of patients seen in last three months
HC II 3421 (1350-4782)
HC III 3187 (2160-4213)
HC IV 4625 (2296-6251)
Hospital 8301 (6181-14146)
Proportion of eye patients in last three 
months in percentage (range)
HC II 1.0% (0.5-2)
HC III 2.5% (1-5)
HC IV 2.0% (1-6)
Hospital 8.0% (3-14)
161/163 had an all-weather road access and 158/163 
had a phone communication at the facility. 136/163 had a 
power supply.
Figure 4 shows the knowledge of management of MK among 
the primary health workers (Supplementary Table 3, File 3, 
Extended data)15. Overall, only 3% knew about staining of 
the cornea with fluorescein to examine for epithelial defects 
in the diagnosis of MK. None of the cadres, including the 
OCOs, showed knowledge of the role of microscopy/culture 
in management of MK. Antibiotic as a choice of treatment 
was reported in majority of the cadres across all levels. How-
ever, antifungal was reported by only the OCOs. This is not 
surprising as antifungal eye drops are not commonly available.
Page 5 of 12
Wellcome Open Research 2019, 4:141 Last updated: 06 DEC 2019
305
Figure 3. Knowledge of risk factors and complications of microbial keratitis among primary health workers (n=163).
Figure 4. Knowledge on management of microbial keratitis among primary health workers (n=163).
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There are 22 mid-cadre training schools in South Western 
Uganda. We included 16 in this study. The rest declined to par-
ticipate. The findings are summarised in Table 2. Overall, 
15/16 schools had an eye health component in their curriculum, 
14/16 schools provided eye clinic rotations for their students. 
However, the majority (56%) of the trainers/tutors had never 
had any formal training in ophthalmology. Although training 
of practical skills during eye ward attachments was excel-
lent for basic areas, critical skills for management of MK 
and other emergency conditions such as staining, removal 
of a foreign body, using loupes to examine eyes were not 
being taught.
Discussion
This study aimed to assess the capacity of the PHCs in manag-
ing MK. We found that there was a lack of essential personnel 
for eyecare at the PHCs. Human Resources for Health (HRH) 
are a huge problem for many places in SSA. This is particularly 
an issue for Human Recourses for Eye Health (HREH), 
with many countries in SSA failing to achieve the Vision 2020 
staffing targets16,17. In our study, the majority of the facili-
ties were substantially understaffed, with more than half 
having severe staffing shortages. According to the Uganda 
Ministry of Health staffing norms, each HC IV and above 
are supposed to have an Ophthalmic Clinical Officer (OCO). 
However, in our study, only 1/13 HC IVs had an OCO. 
This means that majority of the eye patients are seen by general 
health workers who have poor knowledge on eye care18,19.
One study from Tanzania reported limited knowledge and pro-
ductivity for eye care among primary health workers. In that 
study, the primary workers were found wanting in basic skills 
including measuring of visual acuity19. Another study that 
looked at knowledge of primary eye care among 343 general 
Table 2. Assessment of capacity of eye health training in mid-cadre 
schools (n=16).
Overall n=16 Certificate 
level, n=6
Diploma level, 
n=10
Variable Count (%) Count (%) Count (%)
Presence of an eye health curriculum
Yes 15 (94%) 6 (100%) 9 (90%)
Major topics covered in the curriculum (if Yes)*
Anatomy 14 (94%) 6 (100%) 8 (89%)
Blinding conditions 12 (80%) 5 (83%) 7 (78%)
Eye infections 15 (100%) 6 (100%) 9 (100%)
Pharmacology 13 (87%) 4 (67%) 9 (100%)
Ophthalmology training level of the eye health tutor
None 9 (56%) 5 (83%) 4 (40%)
Diploma 7 (44%) 1 (17%) 6 (60%)
Does hospital attachment include eye ward? (if Yes; median 2 weeks IQR 
1-2, total range 1–6 weeks)
Yes 14 (88%) 5 (83%) 9 (90%)
Practical skills learnt in the eye ward Ɨ
Taking ocular history 14 (100%) 5 (100%) 9 (100%)
Measuring visual acuity 14 (100%) 5 (100%) 9 (100%)
Instilling eye drops 14 (100%) 5 (100%) 9 (100%)
Eye exam with a torch 14 (100%) 5 (100%) 9 (100%)
Corneal staining 5 (36%) 2 (40%) 3 (33%)
Eye exam with loupes 1 (7%) 1 (20%) 0 (0%)
Ophthalmoscopy 4 (29%) 1 (20%) 3 (33%)
Foreign body removal 1 (7%) 1 (20%) 0 (0%)
*Only schools which had an eye health curriculum were analysed (n=15). Ɨ n=14, two 
schools did not have students rotate in an eye ward. Certificate level means certificate in 
nursing, diploma level means diploma in nursing or clinical medicine.
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health workers from Kenya, Tanzania and Malawi also found 
low knowledge levels for common conditions; only 8.2% of 
the workers could correctly measure visual acuity18.
Therefore, it is not unexpected that we found that the major-
ity of health workers could not correctly identify the signs 
of microbial keratitis, one of the more common ophthalmic 
emergencies, and provide a satisfactory management plan. 
This limited knowledge will most likely compromise patient 
care and lead to poor outcomes. For example, a very small 
proportion of the health workers identified use of steroids 
as a risk factor for MK, which might imply that they would 
consider treating potential MK patients with steroids, possi-
bly making it worse. Our experience in treating MK patients 
presenting to us is that the majority have used a combination of 
eye drops, most containing a steroid.
The health facilities were poorly resourced in basic items for 
eye care such as examination torches, fluorescein for corneal 
staining and drugs for treatment. We did not find a single health 
facility that had a stock of ciprofloxacin and/or natamycin 
eyedrops, which are the recommended first line agents for 
bacterial and fungal keratitis, respectively20–22.
Despite these discouraging findings, there were some posi-
tive findings that could be utilised to improve care. Most health 
workers were able to identify conjunctival hyperaemia (red 
eye) on the picture quiz. This would be a good starting point 
for a training pack on managing emergency eye conditions. 
We recently published two articles targeting primary health 
workers on how to identify MK and how to locally make fluo-
rescein for corneal staining, and a more recent version of a 
WHO primary eye care training manual for Africa has been 
made available23–25. We hope to use these resources for training 
general health workers on triage and emergency management 
of acute ocular conditions.
In addition, we found that a modest number of facilities had 
microscopes and laboratory personnel. With simple train-
ing and simple tools such as magnifying spectacles/loupes, the 
health workers could be in a good position to do corneal scrap-
ing and microscopy to differentiate between bacterial and fungal 
keratitis. Laboratory diagnosis for MK is still the most reliable 
method since some clinical presentations are equivocal and even 
corneal specialists may make the wrong clinical diagnosis26. 
However, corneal scraping requires a certain level of com-
petence and would be feasible only at a limited number of 
centres which have OCOs. The other health cadres not suit-
able to do corneal scraping can be equipped to identify 
MK and provide early referral. Simple tools such as corneal 
staining with fluorescein have been used in large studies in 
Bhutan and Burma among minimally trained health workers 
to facilitate early detection, treatment and referral of MK10,11. 
In these trials, village health workers were able to stain the cornea 
with fluorescein and examine for corneal abrasions using a blue 
light torch.
Some facilities also had a stock of gentamycin 0.3% eye 
drops available. This can be locally fortified to make a more 
potent alternative of 1.5% gentamycin, which is quite effective 
for managing some forms of bacterial keratitis27,28. In Uganda, 
both gentamycin eyedrops and parenteral gentamycin vails 
(that can be used to fortify the eye drops) are available and sup-
plied to the facilities through the free National Medical Stores. 
However, gentamycin is limited to Gram negative bacteria and 
does not cover Gram positive bacteria and fungi. Quinolones 
such as ciprofloxacin have a broader coverage. These, together 
with natamycin for fungal keratitis, are on the WHO essential 
medicines list and should be availed to lower facilties20–22.
In this study, we also assessed mid-cadre training schools to 
assess the scope of training on eye care. Overall, we found 
that most schools had an eye health component in their 
curriculum and students were getting some time (although 
little) to have hands on training rotations in an eye unit.
However, the levels of ophthalmology training among the train-
ers were low. The majority of the trainers, especially in cer-
tificate-level training schools, had never received any structured 
courses in ophthalmology except as part of the short rotations 
during their medical training. Therefore, this casts doubt 
on the quality of training they can offer on eye health.
The training of practical skills during eye ward attachments 
was reported to be excellent for basic areas such as taking ocu-
lar history, measuring visual acuity, eye examination with a torch 
and instilling eye drops. However, critical skills for manage-
ment of MK and other emergency conditions such as staining, 
removal of a foreign body and using loupes to examine 
eyes were not being taught.
Limitations and strengths
This study enrolled a large sample of health facilities and 
used multiple sources of data collection. The findings from 
the training schools were reported by the school heads and 
therefore might have a degree of bias. We were not able to 
conduct an exit assessment among the students to verify if these 
learnings reported by the school heads were accurate.
Conclusion
The findings from this study draw attention to the very lim-
ited quality of eye care at the PHC, but it also points to several 
opportunities that could be utilised to improve this. The knowl-
edge among health workers and capacity of health facilities in 
diagnosis and management of MK was low. Training for eye 
health among mid-cadre training schools was inadequate. 
More is needed to strengthen these gaps in training and capacity.
Data availability
Underlying data
Harvard Dataverse: The management of microbial keratitis 
within Uganda’s primary health system: a situational analysis. 
https://doi.org/10.7910/DVN/MSLAOS15.
This project contains the following underlying data
•    Health Facilities data.xlsx (quantitative underlying data)
•    Training schools dataset.xlsx (quantitative underlying data)
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Extended data
Harvard Dataverse: The management of microbial keratitis 
within Uganda’s primary health system: a situational analysis. 
https://doi.org/10.7910/DVN/MSLAOS15.
•    7.MAES HEALTH CENTRE data collection forms-v3-
31oct2018.docx (File 1: a copy of the data collection 
forms used on the health facilities which include 
sections on the checklist and picture quiz)
•     7.MAES SCHOOLS data collection forms-v1-25FEB2016.
docx (File 2: a copy of the data collection forms 
used on the training schools)
•    Capacity of the Health system in managment of MK sup-
plementary files.docx (File 3: a copy of supplementary 
file data showing the picture that was used for the 
quiz as well as additional tables showing more detail 
of the results)
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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Chapter 12. Further Discussion 
Beautiful mountain ranges of one of the villages in Uganda where one of the study 
participants came from. The photo was taken during a home visit. 
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This project was important in exploring foundational issues around Microbial Keratitis in 
Uganda. There was a significant amount of learning from this work which will shape the next 
steps in research to improve care of this condition and prevention of sight loss from MK. This 
chapter focuses on reiterating the key findings from each of the different studies and their 
implications to future work/practise in management of MK in Uganda and in Sub-Saharan 
Africa (SSA). 
15.1 Epidemiology of Microbial Keratitis in Uganda 
In this study, we enrolled all patients presenting with MK to the two main referral eye hospitals 
in South Western Uganda and followed them up for three months after the start of their 
treatment to determine their outcomes. To the best of our knowledge, this was the first large 
study to prospectively report on patient outcomes in this region. Despite the challenges of a 
cohort study in a resource limited setting and far distances of participants, we successfully 
followed up 83% of these in their homes at three months. 
In our setting, the most reliable tracking method in our experience was asking participants to 
detail the landmark features to their homes. Instead of just asking about the villages where 
they came from, we asked them to state in a detailed way of how to get from the eye hospital 
to their house. The assistants used this method to tack them to their homes. Although there 
was a good coverage of telephones, these quickly became unreliable due to change in 
government policy that required people to register their phones, those which were not 
registered were disconnected. Overnight, about half of our participants were unreachable by 
phone. This method had been used previously by Waddell et al to track children with 
retinoblastoma in Uganda with 94% follow-up.1 In the absence of proper street names and 
house numbers, this is a method that might be helpful in tracking people for follow up. 
We found that Fungal Keratitis was the most common agent causing MK in our setting. Of all 
our 270 patients with microbiology data, 54% were reported as fungal cases. This was similar 
to what had been reported from other studies in Africa which averaged around 50%. 2-5
However, what was interesting was that the proportion of cases with microbiologically 
confirmed bacterial keratitis was 6%, which was low. One possible explanation for this is that 
bacterial infection cases less frequently “reach” the eye hospital because they are managed 
in the lower health centres. When we evaluated the primary health facilities, we found a 
modest stock level of antibiotic eye drops like gentamycin which may be an effective 
antimicrobial agent in some types of infection.6,7 None of the health centres had any antifungal 
medicine. It is likely that the people with fungal Keratitis did not get better in the health centres 
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and ultimately ended up at the eye hospitals. However, there is a need to study the 
microbiology profile of the cases that present to the primary health facilities. 
Lack of microbiology support is a serious challenge in many places in SSA. A logical treatment 
plan depends on identifying the causative agent. At the onset of our project, an ocular 
microbiology service was non-existent in our setting. In trying to set up our microbiology 
service, one of the things we found useful was sending a laboratory technician for an ocular 
microbiology course at Aravind Eye Hospitals, India. On his return, he helped to set up this 
service which improved our culture yield to 55% and overall composite yield to 80%.This is a 
relatively comparable to published microbiology yield rates.4,8 In addition, we deployed a side 
lab at the eye hospital and equipped it with a fluorescence microscope for immediate 
microscopy to detect fungi using Calcofluor White staining. This method has been described 
previously and fungal hyphae can be readily detected even by non-experienced personnel.9,10
When starting treatment, in this context the critical question is whether or not there is evidence 
of fungal infection. 
The diagnosis was challenging for those who did not have any microbiology results. Out of the 
313 MK patients, we managed to collect samples for 270 of which a further 65 were negative 
on both microscopy and culture. In this situation, diagnosis based on phenotypic presentation 
is still useful. There has been only one large multicentre prospective study that has devised a 
clinical scoring system to help guide the clinician as to whether or not fungal infection is 
present.11 The clinical signs that were significantly indicative of fungal keratitis, as opposed to 
bacterial, are serrated margins, raised slough, dry texture, satellite lesions and colouration 
other than yellow (p<0.05).11 Conversely, bacterial infections are more frequently associated 
with a hypopyon and fibrinous exudate (p<0.05).11 A relatively recent photographic survey 
asking corneal specialists to diagnose bacterial versus fungal infection further supports the 
presence of feathery, irregular margins as indicative of fungal infection. However, the correct 
diagnosis was only arrived at in 66% of cases.12 Using these,  a probability of the causative 
infection algorithm (in a tropical environment) was proposed by some of our group in aiding 
clinical diagnosis.13
A potential solution to help improve diagnostic accuracy, especially where the microbiology is 
negative or not available, is to develop automated, computer-assisted image analysis of good 
quality digital photographs of infected corneas. Ideally this algorithm would be developed to 
be capable of running as an application on a smartphone, utilising the built-in digital camera 
with or without hardware modification. However, there would remain the need for microbiology 
support to help the clinicians investigate the cause particularly in patients who do not respond 
to treatment. Currently it is clear that no single diagnostic approach is sufficient by itself. A 
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study from Moorfields Eye Hospital found that the diagnosis of fungal keratitis required a 
number of different modalities and that it varied quite a lot as to those that were positive.14
Another possible solution would be molecular diagnosis especially where microscopy and 
culture turn out negative. Polymerase chain reaction (PCR) is useful in such settings as it can 
detect the presence of nucleic acid from small samples and even non-viable organisms. 
Previous studies employing this technique for microbial keratitis have found PCR to be 
effective in detecting organisms and often display higher overall pick up rates than culture or 
microscopy.15
A newer technology of In vivo confocal microscopy (IVCM) examines the ocular surface at the 
cellular level. Some of the colleagues from our group recently reported a large evaluation of 
IVCM for MK in India. IVCM was found to be highly sensitive and specific for fungal 
infection.16,17 Being able to see the fungal hyphae in vivo would help the ophthalmologist to 
make an immediate diagnosis and reduce the need for corneal scrapping with its challenges. 
Our hospital recently acquired one IVCM machine to use in ongoing corneal infections work, 
however, In SSA, these options may not be a realistic option yet due to the costs involved. 
15.2 Risk factors of Microbial Keratitis in Uganda 
We nested this case-control study in the main cohort described above. Briefly, at 3 months of 
follow-up, healthy community controls were enrolled. They were 1:1 matched to the cases to 
test for risk factors. These included HIV, Diabetes Mellitus (DM) and other occupational factors 
like farming, circumstantial like poverty. To the best of our knowledge, this was the first case-
control study in SSA to directly test risk factors of MK. 
There was strong evidence that indeed, HIV and DM are risk factors to MK. What this means 
for practise is that patients presenting with MK should be offered tests for HIV and DM as this 
may be the entry point into care. As a matter of fact, we found close to 40% of the people who 
tested positive were unaware of their HIV status prior to coming to the eye hospital. In Uganda 
and many parts of SSA, the HIV treatment policy was recently updated to “test and treat” 
regardless of the person’s CD4 count.18 This helps to mitigate the immune suppressive effects 
of the virus at an early stage. Therefore, people with undiagnosed HIV are at an increased 
risk of mortality stemming from many opportunistic infections associated with immune 
deficiency (AIDS). During our study, we reported a young man with undiagnosed HIV who 
developed a rapidly progressive form of Candida Keratitis that resulted in evisceration. He was 
started on Anti Retro Viral therapy (ART). A few months later, he developed Candida Keratitis 
in his remaining eye, he was promptly treated and resolved with good vision at 3 months.19
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One key thing we did not explore is how HIV and DM might influence the relative susceptibility 
to different types of infection due to the immune suppressive nature. An older study from 
Tanzania (1999) had reported a possible predisposition to fungal keratitis among HIV positive 
patients.20 In this study, 214 Corneal Ulcer patients presenting to Muhimbili Medical Centre, 
Tanzania were enrolled and corneal scrapping specimens obtained for microscopy and 
culture. Out of the 32 patients with confirmed fungal keratitis, 26 (80%) were HIV positive while 
only 33% patients with non-fungal keratitis were HIV positive. The prevalence of HIV in this 
study was 40%. In our study, we did not find strong evidence for such an association. The 
prevalence of HIV was 13% and 23/37 (62%) of the HIV positive patients had fungal Keratitis 
compared to 132/247 (53%) of the HIV negative patients (p=0.32). The microbiological profile 
of MK in HIV and DM needs to be explored in subsequent studies when sufficient patient 
numbers are enrolled. 
Farming was implicated as an occupational risk factor for MK. Our theory is that this is 
mediated through trauma. However, only relatively few patients in our study reported trauma 
(29%). This is consistent with other studies from sub-Saharan Africa (SSA) of 20-40%.3-5
However, these levels are lower than those from South Asia, where around 75% are 
associated with an injury.4,21-24 Targeting farmers and other people predisposed to eye trauma 
such as bike taxi riders is a valid intervention to prevent new cases of MK. 
In this case-control study, it was hard to elicit history of TEM use and trauma among the 
controls, perhaps due to recall bias. Because of this, it was not possible to test these factors 
in a statistical model. 
15.3 Delayed presentation/access to care 
As part of the study, we asked patients to map out the process of their journeys from the onset 
of symptoms to the point of coming to the hospital. This included, order of facilities where 
patients went to seek care, treatment advice, cost of care and use of Traditional Eye Medicine. 
Presentation time was noted, and predictors of delay were analysed. 
We found that access to eye care is a big problem. According to the model by Levesque et al, 
access to health care is defined as an opportunity to have health care needs fulfilled.25 It is an 
interaction between the supply side (health system) and demand side (patients).  
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Figure 1 Levesque's model on dimensions which influence access 
 As shown figure 2, this model has five dimensions of interaction between the demand side 
and supply side which influence access.  The supply side dimensions include 1) 
Approachability; 2) Acceptability; 3) Availability and accommodation; 4) Affordability; 5) 
Appropriateness. The demand side are the corresponding abilities of persons interact with the 
dimensions of accessibility to generate access. These include: 1) Ability to perceive; 2) Ability 
to seek; 3) Ability to reach; 4) Ability to pay; 5) and Ability to engage.25
Approachability means that people with a health condition (in this case MK) can identify a 
service and that this service can be reached, and it will have an impact on the health of the 
individual. This is complemented by ability of the patient to perceive the need for treatment. 
Contrary to our initial expectation that MK patients have poor health seeking behaviour (went 
to hospitals late), we were surprised to find that all patients who did not present directly to the 
eye hospital attended their nearest primary health care facility in good time (median presenting 
time 2 days).26 If they had received appropriate care at this point, the infection would have 
been controlled quickly. There is still much to learn about the treatment received, the 
microbiological profile at this stage, and if the “treatment” made the infection worse. However, 
what was clear from this study is that although the patients perceived the need for care and 
approached the health system early, there was little prompt recognition and appropriate 
referral of MK patients to start effective treatment quickly.  
Acceptability is factors which determine the possibility of people to accept the aspects of the 
service (social and cultural).25 Acceptability of the health system is generally not a big problem 
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in Uganda, however, the bigger problem is acceptability of use of Traditional Eye Medicine 
(TEM). Majority of the patients reported to have used TEM as one of the “services” to treat MK 
and this practise was reported as a generally acceptable one. Acceptability is also influenced 
by the ability of the patient to seek the health services due to autonomy, gender inequality and 
economic empowerment.25 Gender inequalities have been documented in other conditions 
like Trachoma, Cataract and glaucoma where females have poorer access than males.27,28 In 
our study, although majority of the patients presenting to the eye hospital were male, we could 
not conclude on this partly because we did not have gender data of patients presenting at the 
primary health facility level.  
Availability means that the health services can be reached and in a timely manner. This is 
restricted if the resources are unevenly distributed around a country such as distance to the 
facility, cost of transport, occupational flexibility.25 Uganda faces a severe shortage of human 
resource for eye health just like most countries in SSA.29,30 According to the Uganda Medical 
and Dental Practitioners’ Council (UMDPC), there are 51 Ophthalmologists in Uganda for a 
population of over 40 million people.31 Out of these, 33 (63%) practice in the capital city 
Kampala, 7 (14%) in the second city Mbarara where referral eye hospitals for South western 
Uganda are located. Patients travelled long distances to the eye hospital with a median 
distance of 79km (some up to almost 400km). 
Affordability reflects the economic capacity for people to spend resources and time to use 
appropriate services. It results from direct prices of services and related expenses in addition 
to opportunity costs related to loss of income.25 Although the public health system is free in 
Uganda, patients incurred costs on transport and cost of medicines. This was linked to several 
other factors such as delayed presentation, use of traditional eye medicine which cascaded 
into patients presenting with severe, advanced ulcers and ultimately with poor outcomes. 
These are discussed in subsequent sections of this chapter). In our observation, when patients 
presented early, response to treatment was good with total resolution of the ulcer with no or 
minimal scarring. In our future work, we plan to shift our efforts from downstream to upstream 
where we can close the gaps in access and have early interventions. 
Appropriateness denotes the fit between services and clients need, its timeliness, the amount 
of care spent in assessing health problems and determining the correct treatment and the 
technical and interpersonal quality of, ability to engage.25 Appropriate care was perceived as 
lacking at the primary health facilities. For example, out of all the patients that used Traditional 
Eye Medicine (TEM), 73% used it after they had visited their primary health facility. They did 
not feel that the care they had received would make them better. There was a missed 
opportunity for health education and counselling against TEM use. These findings were further 
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confirmed by a situational analysis of the health system where we found severe limitations in 
capacity to manage MK. This is discussed in the next section of this chapter. 
As part of the next steps, we plan a series of interventions to strengthen the health system in 
diagnosis, triage, treatment and referral. 
15.4 Primary health system 
In this study, we carried out a rigorous assessment of 163 primary health centres and 16 mid-
cadre training schools in South Western Uganda. Through interviews, checklist and picture 
quiz, we assessed capacity and knowledge of MK management. In addition, we interviewed 
the heads of all the mid-cadre training schools to determine the level of eye health training 
provided in their curricula.  
What we found was a grim picture. The health facilities did not have vital equipment and 
consumables and the health workers lacked basic knowledge in diagnosis and management 
of Microbial Keratitis. This points to an overall poor care service delivery of eye health in the 
health system. Deliberate efforts are needed to strengthen this. We recently published two 
articles targeting primary health workers on how to identify MK and how to locally make 
fluorescein for corneal staining and a more recent version of a WHO primary eye care training 
manual for Africa has been made available. 32-34 We hope to use these resources for training 
general health workers on triage and emergency management of acute ocular conditions. This 
will include development of a smart phone based clinical management algorithm using the 
WHO primary eye care guidelines. This will be hosted on the peek vision foundation platform 
(https://www.peekvision.org/). Such a resource will empower the primary health workers to 
make logical management decisions for the patients. In parallel, more efforts are needed to 
improve the overall training of health workers in eye health and to deploy designated eye 
health workers at primary health facilities.  
15.5 Role of Traditional Eye Medicine 
This study was done as a mixed methods study. In addition to prospectively collecting 
information on history, TEM use, microbiology and 3-month outcomes on all the study 
participants, we conducted qualitative interviews with patients, carers and traditional healers 
on reasons why people use TEM. Outcome measures included presenting vision and at 3-
months, comparing TEM Users versus Non-Users. A thematic coding framework was 
deployed to explore reasons for use of TEM. 
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The problem of TEM had several facets. First, TEM use was more commonly reported in our 
study (60%) than reported from Malawi (34%) and Tanzania (25%).35,36 Secondly, a smaller 
proportion of patients used it as a primary treatment for MK (30%) while more others (70%) 
used it after not observing a favourable improvement to treatment obtained from the primary 
health facilities. This was one of the findings from the qualitative survey, where lack of 
confidence in the health system was one of the main drivers of TEM use. The opportunity here 
is that once effective care is available in the primary health facilities, it can be leveraged as 
one way to influence behaviour change away from TEM use. 
Thirdly, TEM use was associated with delayed presentation to the hospital and independently 
associated with worse condition at presentation. People who used TEM had worse ulcers at 
presentation and subsequently worse vision outcomes compared to those who had not used 
TEM. Using some of these patient stories of people who used TEM and developed poor 
outcomes is one of the strategies of discourage this practise. 
In this study, although we meticulously collected a detailed history of TEM from participants, 
it was not possible to localise the contribution of TEM on the causal pathway of MK: whether 
people had used TEM for a non-MK problem and developed MK in the process or had used it 
after developing a simple form of MK which became more complicated, such as fungal 
keratitis. In our study, there was modest evidence of higher proportions of fungal Keratitis 
among people who had used TEM compared to those who had not. Future animal studies 
would be ideal to explore these hypotheses. 
15.6 Quality of Life 
Quality of Life (QoL) is a very important consideration in the management of any disease and 
treatments should ultimately aim to maintain or restore QoL.37Although there had been a 
previous report on the QoL among MK patients in the Mycotic Ulcer Treatment Trial (MUTT1) 
where patients with fungal keratitis who had received Natamycin had a better quality of life 
compared to those who had received Voriconazole, there had been no head to head 
comparison of QoL of MK cases compared to healthy normal population controls.38 As part of 
a nested case control design for risk factors of MK, we collected and compared mean QoL 
scores among MK cases and controls. 
This study showed that MK severely affects QoL in the acute phase. With treatment, QoL 
improves, with the highest QoL in cases who had little or no visual impairment at 3-months. 
Despite this impressive improvement, the QoL at 3-months of someone previously affected by 
MK (even when they have normal vision) remains lower than controls. This makes a case for 
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advocacy in the care of MK and other conditions which cause monocular blindness and visual 
impairment. 
However, one limitation was that we did not collect information from the contralateral eye of 
the cases as this could affect the QoL score if the eye had existing visual impairment or ocular 
condition. 
Conclusion: 
This PhD was a step in the right direction in providing background information about the 
epidemiology of MK in Uganda. However, more multidisciplinary work is needed to improve 
prevent new infections of MK and outcomes of people who develop MK. Specifically, there is 
need to:  
 Understand the role of TEM in causing new infections 
 Develop strategies to prevent new infections 
 Develop sensitisation packages for people groups at increased risk of MK 
 Improve diagnosis of MK 
 Improve treatment options and access to treatment of infections especially fungal 
keratitis 
 Strengthen the capacity of the primary health system to diagnose, promptly manage 
and or refer MK 
 Improve the training of mid cadre health workers in eye health 
 Develop strategies of influencing behaviour change against use of TEM 
 Develop advocacy campaigns on funding for care and rehabilitation of patients with 
MK 
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Chapter 13. Future work 
Uganda Corneal Infections Study Team. Left to right Ms Allen Asiimwe (anthropologist), 
Ms. Pauline Boonabaana Pauline (study nurse), Prof Matthew Burton (Main supervisor, 
based at LSHTM), Dr Simon Arunga (Ophthalmologist, PhD student), Mr Bernard 
Beinomughisha (research assistant), Mr Gilbert Arinda (study coordinator) 
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From ongoing work, we plan to conclude the following studies: 
1. Clinical and Microbiology Correlation. We shall complete an analysis comparing the 
correlation between the phenotypic presentation and the microbiology. The microbiology 
data available includes pan-fungal PCR detection and sequencing of the collected 
specimens. This was done at Kilimanjaro Christian Medical College laboratory. 
2. Quality of life at one year. We intend to conduct a follow up evaluation of the participants 
and controls to compare their quality of life. The data we have now is at 3 months and 
we want to compare with a longer follow up data. 
3. Evaluation of corneal scarring after Microbial Keratitis. We shall evaluate the profile of 
the corneal scarring among the participants and feasibility of corneal transplant ( anterior 
segment OCT depth of the scars, size, limbal stem cell status, endothelial integrity and 
intraocular comorbidities). 
4. Traditional medicine studies. We collected data on the different types of herbs that 
patients used to treat MK. We are working with a taxonomist to describe them and shall 
proceed to conduct pharmacological and microbiological tests on the most commonly 
reported herbs. 
5. Economic Impact of MK on household wealth comparing MK cases and healthy control 
households. We collected household asset data among cases and controls which will be 
analysed in the near future.  
In addition, Simon will continue to work with his supervisor Prof Matthew Burton on a 5-year 
Wellcome Trust funded programme on several follow up projects listed below 
(https://www.lshtm.ac.uk/newsevents/news/2018/lshtm-lead-vital-research-severe-corneal-
infections-low-and-middle-income). 
6. Randomised controlled trial of topical chlorhexidine 0.2% verses natamycin 5% for fungal 
keratitis. In a hospital-based randomised controlled trial (RCT), we will test the 
hypothesis that g-chlorhexidine 0.2% is non-inferior to g-natamycin 5% in parallel two-
arm, single-masked RCTs. We will also assess superiority of either drug. We will conduct 
two independent trials: (i) Nepal, (ii) East Africa (Uganda and Tanzania) which have 
already started. 
7. Randomised controlled trial of topical ilomastat 0.05% verses placebo in the treatment of 
microbial keratitis. We will test the hypothesis that g-ilomastat 0.08% is superior to 
placebo in preventing corneal perforation / TPK in parallel two-arm, double-masked 
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RCTs. We will conduct two independent trials: (i) Nepal, (ii) East Africa (Uganda and 
Tanzania). These trials will be conducted after Study 1 is completed. 
8. Cluster randomised controlled trial of a complex intervention to prevent severe microbial 
keratitis. We will test the hypothesis that an intervention package can prevent blindness 
from severe MK in parallel two-arm, single-masked cluster RCTs. We will conduct two 
independent trials: Nepal, Uganda. This will be the core of Simon’s post-doctoral 
research fellowship. 
9. Microbial keratitis diagnostic and pathophysiology studies. We shall conduct a 
comparative study evaluating sensitivity/specificity of diagnostic strategies for fungal vs. 
bacterial infection. This shall be on specimen collected from patients from the above 
studies. 
10. Genetics: In the previous work, we collected human genetic samples from carefully 
phenotyped cases. The participants recruited in these subsequent clinical trials would 
also be invited to contribute genetic material to a wider study of genetic risk factors in MK  
11. Immunopathology: relatively little is known about the types of immune responses at the 
site of infection at different points in the natural history of this disease in humans. It is 
plausible that some types of responses are associated with more or less favourable 
outcomes for patients, even when timely antimicrobial is provided. We shall do corneal 
gene expression and Impression cytology to describe the cell types infiltrating the cornea 
during microbial keratitis and their secreted factors, and the association of these factors 
with poor visual outcomes. This will help us to better understand the 
immunopathophysiology of Microbial Keratitis and potential for learning new 
unrecognised therapeutic targets. 
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Appendices 
Appendix 1: Mbarara Akavurugye Eye Study – Case Record Sheet: 
Demographic Data 
1. Study Number 
2. Hospital Number  
3. Hospital REC=1, MURHEC=2 
4. Sur Name 
5. First name 
6. DOB Write in this format 
DD/MM/YYYY 
7. Age (years) 
8. Sex Male = 1, Female = 2 
9. Phone number – 1
10. Whose phone 
number? 
Please state Name and 
Relationship of the owner of 
the phone number 
mentioned above. 
11. Phone number – 2
12. Whose phone 
number 
Please state Name and 
Relationship of the owner of 
the phone number 
mentioned above. 
13. Occupation 0 = No job, 1 = Mainly farmer, 
2 = Mainly employed 
(manual), 3 = Mainly 
employed (non-manual), 4 = 
Mainly self-employed (own 
business, merchant), 5 = 
Civil servant, 6 = Retired, 7 = 
Student, 8 = Other (specify) 
14. Education level 0 = No formal education, 1 = 
Lower Primary (Grade 1-4), 
2 = Upper Primary (5-7), 3 = 
Lower secondary (1-4), 4 = 
Upper secondary (5-6), 5 = 
Certificate, 6 = Diploma, 7 = 
Degree and above 
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15. Literacy level  0 = Illiterate, 1 = Able to read 
Bantu a little, 2 = Able to read 
Bantu well, 4 = Able to read 
English and Bantu, 5 = Other 
(specify) 
16. Ethnic group 1 = Munyankole,2 = Mukiga, 
3 = Mutoro, 4 = 
Mufumbira,5=Mukonzo,6=M
uganda,7 = Other (specify) 
17. Marital status 0 = Single, 1 = 
Married/cohabiting, 2 = 
Divorced, 3 = Widowed 
18. Address  Village 
Parish 
Sub-County 
County 
District 
19.  20. Household Head’s Name 
21.  22. Name of well-known Neighbour 
23.  24. Total number of household members? Write 
number  
25.  26. Members of the household under 16 years of age? 
Write number 
27.  28. Members of the household between 16 and 60 
years of age? Write number 
29.  30. Members of the household above 60 years of age? 
Write number 
31.  32. How many under 16 year’s member of the 
household went to school? Write number 
33.  34. How many adult members of the household (≥16 
years of age) are “literate”? Write number 
35.  36. The highest level of 
education achieved in 
the household 
0 = No formal 
education, 1 = Lower 
Primary (Grade 1-4), 2 
= Upper Primary (5-7), 3 
= Lower secondary (1-
4), 4 = Upper secondary 
(5-6), 5 = Certificate 
6 = Diploma, 7 = Degree 
and above 
37.  38. What is the highest 
status occupation with 
in the household 
1 = Farming, 2 = Manual 
employment, 3 = Non –
manual employment, 4 
= Self-employment, 5 = 
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Civil servant, 7 = Other 
(specify) 
39.  40. Are you the household 
head? 
0 = No, 1=Yes 
41.  42.  What is the literacy 
level of the household 
head? 
0 = Illiterate, 1 = Able to 
read Bantu a little , 2 = 
Able to read Bantu well, 
3 = Able to read English 
and Bantu 
43.  44. What is educational 
level of the household 
head? 
0 = No formal 
education, 1 = Lower 
Primary (Grade 1-4), 2 
= Upper Primary (5-7), 3 
= Lower secondary (1-
4), 4 = Upper secondary 
(5-6), 5 = Certificate, 6 = 
Diploma, 7 = Degree 
and above 
45.  46. Occupation of the 
household head?  
0 = No job, 1 = Mainly 
farmer, 2 = Mainly 
employed (manual), 3 = 
Mainly employed (non-
manual), 4 = Mainly 
self-employed (own 
business, merchant), 5 
= Civil servant, 6 = 
Retired, 7 = Student  
8 = Other (specify) 
47.  48. Distance to the nearest 
Health Centre in KM 
49.  50. Geo location of nearest 
Health Centre 
51.  52. Level of Nearest health 
Centre 
1=clinic/pharmacy, 
2=HC II, 3=HCIII, 4=HC 
IV, 5=District hospital, 
6=don’t know 
53.  54. Nearest source of water in KM 
55.  56. Type of main water 
source 
0= none, 1=Well,2 = 
Piped, 3= Roof 
collected tank, 
4=Borehole, 
5=protected spring 
Visual Acuity assessment 
57. Presentation Date Write in this format: 
DD/MM/YYYY 
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58. Presenting Visual 
Acuity  
Right eye 
Left eye 
59. Best corrected 
visual acuity 
Right eye 
Left eye 
60. Contrast 
sensitivity 
Right eye 
Left eye 
History
History of the presenting Complaint 
1. Eye affected 1=Right, 2=Left, 3=Both 
Symptoms (Ask the patient what has brought them to hospital and write 1=Yes, 
0=No) 
2.  3. Do you have eye pain? 
4.  5. Do you have Reduced/loss of vision in the affected 
eye? 
6.  7. Is there tearing? 
8.  9. Is there eye discharge? 
10.  11. Is there photophobia? 
12.  13. Is there foreign body sensation? 
14.  15. Is there any other complaint? other (specify) 
16.  17. Out of all those symptoms, which one is the most 
important to you? 
18.  19. When did the symptoms begin? (Encourage the 
patient to pinpoint the calendar date, write in this 
format: DD/MM/YYYY) 
20.  21. Is there history of trauma or something falling into 
the eye before onset of symptoms? (1=Yes, 0=No)
If Qn 5 above is YES, ask Qn 6 and 7, If Qn 5 is NO, go to question 8 
22. What was the 
traumatising 
object? 
1=vegetative matter, 
2=stick/wood, 
3=soil/sand/dust, 3=insect, 
4=Other (name), 99=Not 
applicable 
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23. What happened to 
the traumatising 
object? 
1=did not “enter” the eye, 
2=”entered” the eye and was 
removed, 3=”entered” the 
eye, was NOT removed, 
99=Not applicable 
Current medical history 
24. Have you used 
any treatment up 
to now? 
1=Yes, 0=No 
(If NO then move to 
question 11) 
25. Which topical (eye 
drop) treatment 
have you used to-
date? (Ask the 
patient to show 
you the medicine 
they have been 
using) 
Traditional Eye Medicine 
Antibiotic 
Steroid 
Antibiotic-steroid 
Anti-viral 
Anti-fungal 
Unknown name 
26. If the patient can 
remember the 
specific name or 
shows you a 
bottle, write down 
the name 
1=Chloramphenicol, 
2=Ciprofloxacin, 
3=Tetracycline, 
4=Gentamycin,5=Iodine,6=a
ntibiotic-steroid, 7=Acyclovir, 
8=clotrimazole, 
9=econazole, 
10=Natamycin, 11=other 
(specify), 99=Not able to 
ascertain 
Other ocular History
27.  28. Did you have any symptoms 
in last 3 months before onset 
of current illness? 
0=none, 
1=reduced 
vision, 2=itching, 
3=excessive 
tearing, 
4=abnormal 
discharge, 
5=feeling dry, 
6=lid swelling, 
7=foreign body 
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sensation, 
8=other (specify) 
29.  30. Were you using any eye 
medication in the last 3 
months before onset of 
current illness? 
1=antibiotic, 
2=steroid, 
3=antibiotic-
steroid, 
4=artificial tears, 
5=anaesthetic, 
6=antiviral, 
7=antifungal, 
8=glaucoma 
drug, 9=other 
31.  32. Did you have any eye 
operation in last 3 months 
before onset of current 
illness? 
0=None, 1=lid 
surgery, Probing 
and syringing=3, 
cataract=4, 
glaucoma 
surgery=5, 
DCR=6, other=7 
(specify) 
Other medical/surgical history 
33.  34. Did you have any ENT 
conditions in last 3 months 
before onset of current 
illness? 
0=none, 1=flu 
like symptoms, 
2=cough, 
3=sinus 
congestion, 
4=other 
35.  36. Did you have of any 
ENT/facial surgery in the last 
3 months? 
1=Yes, 0=No 
37.  38. Do you have a history of 
Diabetes Mellitus? 
1=Yes, 0=No, 
3=Don’t Know 
If the answer to Qn 17 is YES, proceed to ask Qn 18-20, if NO or DON’T 
KNOW, skip to Qn 21 
39.  40. How many years have you been diagnosed with 
DM? 
41.  42. Which treatment are you 
using for DM? 
0=none,1=diet, 
2= Oral, 
3=insulin, 
4=other (specify) 
43.  44. What was your Last fasting 
blood sugar check? 
45.  46. Do you have a history of HIV 
infection? 
1=Yes, 0=No, 
3=Don’t know 
If the answer to Qn 21 is YES, proceed to ask Qn 22-24, if NO or DON’T 
KNOW, skip to Qn 25
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47.  48. How many years have you been diagnosed with 
HIV? 
49.  50. Which treatment are you 
using for HIV? 
0=NA, 1=No 
treatment, 
2=Septrin/dapso
ne only, 
3=Septrin + 
HAART, 4=Other 
(specify) 
51.  52. What was your last CD4 count? 
53. Pain Impact Questionnaire 
1=Never, 2=Occasionally, 3=Often, 4=Constantly 
In the course of your current illness, How often have you experienced eye 
pain?
In the course of your current illness, how often has eye pain interfered with 
your personal care such as bathing, eating, and dressing? 
In the course of your current illness, how often has eye pain disturbed your 
sleep? 
In the course of your current illness, how often has eye pain interfered with 
your household work such as cooking, house cleaning, washing cloth, 
fetching water, fetching firewood, caring to other family members? 
In the course of your current illness, how often has eye pain affected your 
agricultural or paid work? 
In the course of your current illness, how often has eye pain affected your 
participation in social activities such as attending weddings, social 
meetings, and funerals? 
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Appendix 2: Clinical examination of cases record form 
1. Eye affected 1=Right, 2=Left 
2. Adnexa anatomy 1=Normal, 2=abnormal (specify) 
3. Presence of eye lid swelling 0=No, 1=Yes 
4. Presence of entropion 0=No, 1=Yes 
5. Presence of lagophthalmos 0=No, 1=Yes 
6. Presence of Trichiasis 0=No, 1=Yes 
7. Bell’s phenomenon 1=Normal, 2=abnormal 
8. Regurgitation test 1=Normal, 2=abnormal 
9. Conjunctival Hyperemia 1=Not present, 2=mild, 
3=moderate, Severe 
10. Corneal sensation 1=Normal, 2=Reduced, 3=Not 
done 
11. Slough - elevated  0=None, 1=Flat, 2=Raised 
12. Slough - texture 0=None, 1=Dry, 2=Wet 
13. Infiltrate edge 1=None, 1=Defined, 2=Serrated 
14. Satellite lesions? 0=None, 1=Yes 
15. Infiltrate colour? 0=None,1=White, 2=Cream, 
3=Green, 4=Yellow, 5=Dark 
brown, 6=other (specify) 
16. Immune ring? 0=No, 1=Yes 
17. Corneal vascularisation 0=No, 1=Yes 
18. Hypopyon? 0=No, 1=Yes 
19. Hypopyon height (mm) Measure from limbus mm 
20. Hypopyon shape 0=None, 1=Flattened, 2=Heaped
21. Keratic precipitates 0=No, 1=Yes 
22. Keratic precipitate age 0=none, 1=new, 2=old 
23. Keratic precipitate size 0=none, 1=small, 2=large 
24. Perineural infiltrates 0=No, 1=Yes 
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25. Fibrin 0=No, 1=Yes 
26. Flare 0=No, 1=Yes 
27. Flare grade 0=None, 1=mild, 2=moderate(iris 
and pupil seen), 3=moderate-
severe (iris and pupil hazy), 
4=severe (fibrin in AC) 
28. Cells in AC 0=No, 1=Yes 
29. Cells grade 0=None, 1=1-5 cells, 2=6-15 
cells, 3=16-25 cells,4=26-50 
cells, 5=Hypopyon  
30. Posterior corneal abscess 0=No, 1=Yes 
31. Endothelial plaque 0=No, 1=Yes 
32. Size of epithelial defect Measure max. diameter mm 
33. Size of infiltrate Measure max. diameter mm 
34. Depth of ulceration 100% minus % of remaining 
corneal thickness 
% 
35. Site of the ulcer 1=Involving the visual axis, 
2=Visual axis spared 
36. Impending perforation 0=No, 1=Yes 
37. Perforation 0=No, 1=Yes 
38. Comment on the non-affected eye (if 
normal or not, comorbidity if present) 
Clinical Examination – Day 1 Date: 
R VA L 
R Photo (0=No, 1=Yes) L 
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R L 
Microbiology 
Microbiology done 0=No, 1=Yes (reason if No) 
Gram stain result Detail: 
KOH stain result Detail: 
Blood Agar Detail 
Potato dextrose Agar Detail 
PCR Detail 
Other Investigations 
Detail 
HIV 
CD4 
Blood sugar 
Antibacterial sensitivity 
Antifungal sensitivity 
Initial Treatment: 
Drug 0=No, 1=Yes Dose Frequency 
g-Ciprofloxacin 
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g-Econazole 
g-Atropine 
g-Natamycin 
Occ-aciclovir 
Itraconazole PO 
Aciclovir PO 
Ciprofloxacin PO 
Doxycycline PO 
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Clinical Examination – Day  Date: 
R VA L 
R Photo (0=No, 1=Yes) L 
R L 
Clinical Examination – Day  Date: 
R VA L 
R Photo (0=No, 1=Yes) L 
R L 
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Outcome 
Change in treatment 0=No, 1=Yes 
Revised treatment  Detail 
Surgery Detail 
Healed 0=No, 1=Yes 
Perforation after admission 0=No, 1=Yes 
Eviscerated 0=No, 1=Yes 
Final Vision Presenting VA Right eye 
Presenting VA Left eye 
Pinhole VA Right eye 
Pinhole VA Left eye 
HIV test performed 0=No, 1=Yes 
If HIV test performed, what was 
the result? 
0=Not performed, 1=Negative, 
2=Positive 
Discharge Date 
Comments: 
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Appendix 3: Mbarara Akavurugye Eye Study – Control Record Sheet: 
Demographic Data 
61. Study Number 
62. Hospital Number  
63. Hospital REC=1, MURHEC=2 
64. Sur Name 
65. First name 
66. DOB Write in this format DD/MM/YYYY 
67. Age (years) 
68. Sex Male = 1, Female = 2 
69. Phone number – 1
70. Whose phone 
number? 
Please state Name and Relationship of the 
owner of the phone number mentioned above. 
71. Phone number – 2
72. Whose phone 
number 
Please state Name and Relationship of the 
owner of the phone number mentioned above. 
73. Occupation 0 = No job, 1 = Mainly farmer, 2 = Mainly 
employed (manual), 3 = Mainly employed (non-
manual), 4 = Mainly self-employed (own 
business, merchant), 5 = Civil servant, 6 = 
Retired, 7 = Student, 8 = Other (specify) 
74. Education level 0 = No formal education, 1 = Lower Primary 
(Grade 1-4), 2 = Upper Primary (5-7), 3 = Lower 
secondary (1-4), 4 = Upper secondary (5-6), 5 = 
Certificate, 6 = Diploma, 7 = Degree and above 
75. Literacy level  0 = Illiterate, 1 = Able to read Bantu a little, 2 = 
Able to read Bantu well, 4 = Able to read English 
and Bantu, 5 = Other (specify) 
76. Ethnic group 1 = Munyankole,2 = Mukiga, 3 = Mutoro, 4 = 
Mufumbira,5=Mukonzo,6=Muganda,7 = Other 
(specify) 
77. Marital status 0 = Single, 1 = Married/cohabiting, 2 = Divorced, 
3 = Widowed 
78. Address  Village 
Parish 
342
Study Number: 
Simon Arunga PhD Thesis 
Sub-County 
County 
District 
79. Household Head’s Name 
80. Name of well-known Neighbour 
81. Total number of household members? Write number  
82. Members of the household under 16 years of age? Write number 
83. Members of the household between 16 and 60 years of age? Write 
number 
84. Members of the household above 60 years of age? Write number 
85. How many under 16 year’s member of the household went to school? 
Write number 
86. How many adult members of the household (≥16 years of age) are 
“literate”? Write number 
87. The highest level of 
education achieved in 
the household 
0 = No formal education, 1 = Lower Primary 
(Grade 1-4), 2 = Upper Primary (5-7), 3 = 
Lower secondary (1-4), 4 = Upper 
secondary (5-6), 5 = Certificate 
6 = Diploma, 7 = Degree and above 
88. What is the highest 
status occupation with 
in the household 
1 = Farming, 2 = Manual employment, 3 = 
Non –manual employment, 4 = Self-
employment, 5 = Civil servant, 7 = Other 
(specify) 
89. Are you the household 
head? 
0 = No, 1=Yes 
90.  What is the literacy 
level of the household 
head? 
0 = Illiterate, 1 = Able to read Bantu a little 
, 2 = Able to read Bantu well, 3 = Able to 
read English and Bantu 
91. What is educational 
level of the household 
head? 
0 = No formal education, 1 = Lower Primary 
(Grade 1-4), 2 = Upper Primary (5-7), 3 = 
Lower secondary (1-4), 4 = Upper 
secondary (5-6), 5 = Certificate, 6 = 
Diploma, 7 = Degree and above 
92. Occupation of the 
household head?  
0 = No job, 1 = Mainly farmer, 2 = Mainly 
employed (manual), 3 = Mainly employed 
(non-manual), 4 = Mainly self-employed 
(own business, merchant), 5 = Civil 
servant, 6 = Retired, 7 = Student  
8 = Other (specify) 
93. Distance to the nearest 
Health Centre in KM 
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94. Geo location of nearest 
Health Centre 
95. Level of Nearest health 
Centre 
1=clinic/pharmacy, 2=HC II, 3=HCIII, 
4=HC IV, 5=District hospital, 6=don’t know 
96. Nearest source of water in KM 
97. Type of main water 
source 
0= none, 1=Well,2 = Piped, 3= Roof 
collected tank, 4=Borehole, 5=protected 
spring 
Visual Acuity assessment 
98. Presentation Date Write in this format: DD/MM/YYYY 
99. Presenting Visual 
Acuity  
Right eye 
Left eye 
100. Best corrected 
visual acuity 
Right eye 
Left eye 
101. Contrast 
sensitivity 
Right eye 
Left eye 
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Appendix 4: Quality of life tools 
1. Quality of Life Questionnaire 
The following questions ask how you feel about your quality of life, health, or other areas of your life. I will read out each 
question to you, along with the response options. Please choose the answer that appears most appropriate. If you are 
unsure about which response to give to a question, the first response you think of is often the best one.  
Please keep in mind your standards, hopes, pleasures and concerns. We ask that you think about your life in the last four 
weeks. 
Very poor Poor  Neither poor nor good Good Very good 
1.1. How would you rate your quality of life?  1  2  3  4  5  
Very 
dissatisfied  Dissatisfied 
Neither 
satisfied nor 
dissatisfied  
Satisfied Very satisfied 
1.2. How satisfied are you with your health?  1  2  3  4  5  
The following questions ask about how much you have experienced certain things in the last four weeks. 
Not at all  A little  A moderate amount  
Very 
much  
An extreme 
amount  
1.3. To what extent do you feel that physical pain 
prevents you from doing what you need to do? 5  4  3  2  1  
1.4. How much do you need any medical treatment 
to function in your daily life?  5  4  3  2  1  
1.5. How much do you enjoy life?  1  2  3  4  5  
1.6. To what extent do you feel your life to be 
meaningful?  1  2  3  4  5  
Not at all  A little  A moderate amount  
Very 
much  Extremely  
1.7. How well are you able to concentrate?  1  2  3  4  5  
1.8. How safe do you feel in your daily life?  1  2  3  4  5  
1.9. How healthy is your physical environment?  1  2  3  4  5  
The following questions ask about how completely you experience or were able to do certain things in the last four weeks. 
Not at all  A little  Moderately  Mostly  Completely  
1.10. Do you have enough energy for everyday life? 1  2  3  4  5  
1.11. Are you able to accept your bodily 
appearance?  1  2  3  4  5  
1.12. Have you enough money to meet your needs? 1  2  3  4  5  
1.13. How available to you is the information that you 
need in your day-to-day life?  1  2  3  4  5  
1.14. To what extent do you have the opportunity for 
leisure activities?  1  2  3  4  5  
Very poor  Poor  Neither poor nor good  Good  Very good  
1.15. How well are you able to get around?  1  2  3  4  5  
Very 
dissatisfied  Dissatisfied 
Neither 
satisfied nor 
dissatisfied  
Satisfied Very satisfied 
1.16. How satisfied are you with your sleep?  1  2  3  4  5  
1.17. How satisfied are you with your ability to 
perform your daily living activities?  1  2  3  4  5  
1.18. How satisfied are you with your capacity for 
work?  1  2  3  4  5  
1.19. How satisfied are you with yourself?  1  2  3  4  5  
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1.20. How satisfied are you with your personal 
relationships?  1  2  3  4  5  
1.21. How satisfied are you with your sex life?  1  2  3  4  5  
1.22. How satisfied are you with the support you get 
from your friends?  1  2  3  4  5  
1.23. How satisfied are you with the conditions of 
your living place?  1  2  3  4  5  
1.24. How satisfied are you with your access to 
health services?  1  2  3  4  5  
1.25. How satisfied are you with your transport?  1  2  3  4  5  
The following question refers to how often you have felt or experienced certain things in the last four weeks. 
Never  Seldom  Quite often  Very often  Always  
1.26. How often do you have negative feelings such 
as blue mood, despair, anxiety, depression?  5  4  3  2  1  
2.  Visual Functioning Questionnaire 
The first two questions are about your overall eyesight. I will read out a choice of five answers and you will choose the one 
that describes you best. 
Question Answer options 
(Please circle the number which corresponds to the answer) 
2.1. Overall, how would you rate your eyesight using 
both eyes – with glasses or contact lenses if you 
wear them? 
1.V.goo
d 
2. Good 3. Moderate 4. Bad 5. V.bad 
1 2 3 4 5 
2.2. How much pain or discomfort do you have in your 
eyes (e.g. burning, itching, aching)? 
1. None 2. Mild 3. Moderate 4. 
Severe 
5. Extreme 
1 2 3 4 5 
In the next section, I am going to ask you how much difficulty, if any, you have doing certain activities. I will read out choice 
of five answers and you will choose the one that describes you best.    
1. None 2. Mild 3.Moderate 4. 
Severe 
5. Extreme/ 
Cannot do 
2.3. Because of your eyesight, how much difficulty do 
you have in going down steps/stairs/ steep slopes? 1 2 3 4 5 
2.4. How much difficulty do you have in noticing 
obstacles while you are walking alone (e.g. animals 
or vehicles)? 
1 2 3 4 5 
2.5. How much difficulty do you have in seeing because 
of glare from bright lights 1 2 3 4 5 
2.6. Because of your eyesight, how much difficulty do 
you have in searching for something on a crowed 
shelf? 
1 2 3 4 5 
2.7. How much difficulty do you have in seeing 
differences in colours? 1 2 3 4 5 
2.8. Because of your eyesight, how much difficulty do 
you have in recognizing the face of a person 
standing near you? 
1 2 3 4 5 
2.9. How much difficulty do you have in seeing the level 
in a container when pouring? 1 2 3 4 5 
2.10. Because of your eyesight, how much difficulty do 
you have in going to activities outside of the house 
on your own (e.g. sporting events, shopping, 
religious events)? 
1 2 3 4 5 
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2.11. Because of your eyesight, how much difficulty do 
you have in recognizing people you know from a 
distance of 20 metres? (e.g. from that building/tree 
– give marker of 20 meters)
1 2 3 4 5 
2.12. How much difficulty do you have in seeing close 
objects (e.g. making out differences in coins or 
notes, reading newsprint)? 
1 2 3 4 5 
2.13. How much difficulty do you have in seeing 
irregularities in the path when walking (e.g. 
potholes)? 
1 2 3 4 5 
2.14. How much difficulty do you have in seeing after a 
few moments when coming inside after being in 
bright sunlight? 
1 2 3 4 5 
2.15. How much difficulty do you have in doing activities 
that require you to see well close up (e.g. sewing – 
not including threading the needle, using hand 
tools)? 
1 2 3 4 5 
2.16. Because of your eyesight, how much difficulty do 
you have in carrying out your usual work? 1 2 3 4 5 
In the next section, I am going to ask you how you feel because of your vision problem. I will read out a choice of five answers 
and you will choose the one that describes you best. 
1. Never 2. 
Rarely 
3. 
Sometimes 
4.Often 5. Very often 
2.17. Because of your eyesight, how often have you been 
hesitant to participate in social functions? 1 2 3 4 5 
2.18. Because of your eyesight, how often have you found 
that you are ashamed or embarrassed?  1 2 3 4 5 
2.19. Because of your eyesight, how often have you felt 
that you are a burden on others? 1 2 3 4 5 
2.20. Because of your eyesight, how often do you worry 
that you may lose your remaining eyesight? 1 2 3 4 5 
2.21. Does your vision problem affect your life in ways we have not mentioned? If YES, describe how 
Record as fully as 
possible the answer 
given 
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3.  Activity and Participation  
Were you 
involved in 
[activity] in the 
last week? 
Why have you not 
done [Activity]? 
0= Not able to do it 
1=There was no 
need to do the 
activity/was not 
available  
2= The activity was 
not my 
responsibility 
99=NA 
How much difficulty did 
you have in doing [Activity] 
in the last week? 
0 = Extereme /not able to 
do 
1=  A lot of difficulty  2= 
Some difficulty 
3=  Little difficulty 
4=  No difficulty   
99=NA   
Did you do this 
activity: 
1 =with no 
assistance 
2 =with some 
assistance 
3 =fully assisted
99 = NA 
0=No 1=Yes
Household/Famil
y
3.1.  
Cooking/washing 
dishes 0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
3.2.   House cleaning 0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
3.3.  Washing clothes 0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
3.4.   Shopping 0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
3.5.  
Looking after 
children 0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
3.6.  
Looking after 
elderly/sick 0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
3.7.  
Travel (any 
purpose) 0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
3.8.  
Other 
Specify:……… 0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
Paid work 
3.9.  Paid employment 0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
3.10. Commission work 0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
3.11. Daily labour  0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
3.12.
Self-
employed/own 
business 
0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 
99 
3.13.
Other paid work: 
Specify…………
………….. 
0 1 0 1 2 99 0 1 2 3 4 99 1 2 3 99 
Work for own use
3.14. Farming  0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
3.15. Animal rearing 0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
3.16.
Fetching 
firewood/charcoal 0 1 0 1 2 99 0 1 2 3 4 99 
1 2 3 
99 
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5.  Ophthalmic Questionnaire  
Question Answer option Answer 
5.1.  Do you feel ashamed or embarrassed due to the MK?  0 = No,1 = Yes 
5.2.  Do you worry that you may lose your remaining eyesight 
due to the MK? 
0 = No 
1 = Yes 
5.3.  Does your husband/wife/family member ignore you due 
to the MK?  
0 = No 
1 = Yes 
5.4.  Do you have sleeping problem? (If No, enter “99” to the 
next two questions and go to Q 5.7)  
0 = No 
1 = Yes 
5.5.  If yes, do you think your sleeping problem is related with 
the MK? 
0 = No, 1 = Yes 
3 = NA 
3.17. Fetching water 0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
3.18.
Processing 
agricultural 
products/food 
0 1 0 1 2 99 0 1 2 3 4 9
9 
1 2 3 99 
3.19.
Other production 
own 
use:Specify:……
……………….. 
0 1 0 1 2 99 0 1 2 3 4 99 1 2 3 99 
Leisure 
3.20. Social visits 0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
3.21.
Attending 
ceremonies 0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
3.22.
Attending 
meetings 0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
3.23.
Reading, listening 
to radio, watching 
TV, games etc 
0 1 0 1 2 99 0 1 2 3 4 9
9 
1 2 3 
99 
3.24.
Chatting, relaxing 
with friends/family 0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
3.25.
Other activities, 
specify  0 1 
0 1 2 99 0 1 2 3 4 9
9 1 2 3 99 
Personal 
activities 
3.26.
Eating, Bathing, 
Dressing, sleeping 
- - - - - - 0 1 2 3 4 9
9 
1 2 3 99 
4.  Self-Rated Wealth  
4.1.  How well-off do you think your household is 
in relation to the other households in the 
village?  
1 = Very poor, 2 = Poor, 3 = Average 
(neither poor nor wealthy), 4 = 
Wealthy, 5 = Very wealthy 
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5.6.  How do you think your sleeping problem is related to the 
MK? 
1 = Related to the pain 
2 = Psychological 
(frustration, low self 
esteem, poor 
functioning ...) 
3= Other (Describe) 
4= NA 
5.7.  Dose the MK restricts you from doing/participating in 
productive activities or earn an income? 
0 = No 
1 = Mildly (A little bit) 
2 = Moderately (Some 
restriction)   
3 = Severely (a lot of 
restriction) 
4 = Extremely/not able 
to do/participate) 
5.8.  Does the MK affect your life in any way? For instance in 
physical functioning, social functioning/relationship, 
marriage...etc 
0 = No 
1 = Yes 
5.9.  If yes, in what ways? describe 
6.  Peer Rated Wealth  
Please randomly select three village members of the participant and ask the 
the following question  on the wealth status of the houshold understudy  
Peer 1 Peer 2 Peer 
3 
6.1.  How well-off do you think the household of 
[Household head] in relation to the other 
households in the village?  
1 = Very poor, 2 = Poor, 3 = Average 
(neither poor nor wealthy), 4 = 
Wealthy, 5 = Very wealthy 
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7.  Asset (Wealth Indicators) 
Please observe and record the following about the main building in the household 
Question Answer options Answer 
7.1.  What is the major construction material of 
the external walls? 
1 = Brick, 2 = Concrete blocks, 3 = Sand and Cement , 4 = Wood, logs, 5 = Tin, 6 = 
Mud, 7 = Sticks and leafs, 8 = Wood and mud, 9 = Wood and animal faeces, 10 = 
Sticks and Animal faeces, 11 = Sticks and plastics, 12 = Rock, 77= Other (specify)  
7.2.  What is the major material of the roof? 1 = Concrete, 2 = Tin (metal sheets), 3 = Cereals Straw or grass, 4 = Plastic sheath, 5 
= Wood, 6 = Wood and mud, 77 = Other (specify) 
7.3.  Number of tin the house is made  Write number  
7.4.  Does the house has  a Cornish   0 = No, 1 = Yes, Plastic, 2 = Yes, Nylon, 3 = Yes, Cloth , 4 = Yes, Wood, 77 = Other 
(specify) 
7.5.  What is the primary material of the floor 1 = Tile, 2 = Concrete, 3 = clay/earthen floor, 77 = Other (specify) 
7.6.  How many rooms do the members of your 
household occupy, including bedrooms, 
living rooms and rooms used for household 
enterprises ( do not include bathrooms, 
kitchens, balconies and corridors) 
Write number of rooms 
7.7.  Location of  domestic animals dwelling 0 = No domestic animals, 1 = Within the main house 
2 = Outside the main house 
7.8.  Kitchen location  1 = Within the main house, 2 = Outside the main house 
7.9.  How many houses are there other than the 
main house (excluding, cattle dwelling and 
kitchen) 
Write number of houses  
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7.10. What is the type of toilet that is used in your 
household 
0 = No latrine, 1 = Traditional latrine, 2 = Improved pit latrine with ventilation (VIPL), 3 
= Flush toilet, 77 = Other (specify) 
7.11. Where is the toilet located 1 = Inside dwelling, 2 = Outside dwelling – in compound, 3 = Outside dwelling – outside 
compound , 99 = NA 
7.12. Is this dwelling owned or rented? 1 = Owned, 2 = Rented, If Rented, go to Qn 7.14 
7.13. Please estimate the amount of money you 
could receive as rent per month if you let this 
dwelling to another person 
Write in Shillings or NA 
7.14. If rented, what is the value paid per month? Write in Shillings or NA 
7.15. Dose the household has Electricity/solar?  0 = No 
1 = Yes  
7.16. Dose the household own the following 
materials? 
0=No, 1=Yes 
Radio/HiFi stereo 0=No, 1=Yes 
TV/VCD/DVD 0=No, 1=Yes 
Fridge/Freezer 0=No, 1=Yes 
Electric stove  0=No, 1=Yes
Telephone/Cellular Phone 0=No, 1=Yes
Cupboard 0=No, 1=Yes
Sofa set 0=No, 1=Yes
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Table small 0=No, 1=Yes
Table medium  0=No, 1=Yes
Table large  0=No, 1=Yes
Traditional Bed  0=No, 1=Yes
Metal bed 0=No, 1=Yes
Wood/spring  bed 0=No, 1=Yes
Chair  0=No, 1=Yes
Bench 0=No, 1=Yes
Stool/small chair 0=No, 1=Yes
Showcase large 0=No, 1=Yes
Showcase medium  0=No, 1=Yes
Showcase small 0=No, 1=Yes
Clock 0=No, 1=Yes
Bicycle 0=No, 1=Yes
Water pump/generator  0=No, 1=Yes
Vehicle 0=No, 1=Yes
353
Study Number: 
Simon Arunga PhD Thesis 
Motorbike 0=No, 1=Yes
7.17. Does the household own the following? 
(If Land, enter response by changing in to 
Hectar)  
Mango Tree, 0=No, 1=Yes
Avocado Tree, 0=No, 1=Yes
Guava Tree, 0=No, 1=Yes
Lemon Tree, 0=No, 1=Yes
Orange Tree, 0=No, 1=Yes
Banana Tree land in Hectar 
Sugarcane land in Hectar  
Chat land in Hectar  
Ecualiptous tree land in Hectar  
Coffee land in Hectar  
Vegtable land in Hectar  
Maize and other cereals land in Hectar  
Town land in Hectar  
7.18. How much amount of land does the family 
own?  
Write total amount of land in Hectar  
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7.19. How many cows does this household own in 
total? 
Write number 
7.20. How many goats does this household own in 
total? 
Write number 
7.21. How many sheep does this household own 
in total? 
Write number 
7.22. How many chickens/ducks does this 
household own in total? 
Write number 
7.23. How many pigs does this household own in 
total? 
Write number 
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Appendix 5: Health system survey tools 
A. Health Centre Data Tool 
Health Centre data collection tool. This tool will be used for collecting information from the health centre on 
knowledge, capacity, and practise in management of microbial keratitis. It has four parts; general 
information, knowledge on MK, capacity of the health centre and information on treatment practise for MK. 
Name of the HC write 
1. Study Number (write) 
2. Location (district) (write) 
3. Level of the HC 1=Clinic, 2=HCII, 3=HCIII, 4=HCIV, 5=District 
Hospital 
4. Geo location of HC (write) 
5. How would you describe the 
road access to your HC? 
1=Not all weather, 2=all weather 
6. What is the population 
coverage of your HC? 
Write number 
7. Is there a latrine? 0 = No, 1 = Yes 
8. Is there a water source at the 
HC? 
0 = No, 1 = Yes 
9. What type of water source 
do you have at the HC? 
0= none, 1=Well, 2, 3 = Piped, 4= Roof collected 
tank, 5=Borehole, 6=protected spring 
10. How far is the nearest water 
source? 
0= water at HC, distance in metres 
11. What is your main type of 
electricity supply? 
0 = None, 1 = solar, 2=Hydro, 4=Generator 
12. Is there mobile phone 
network? 
0 = No, 1 = Yes 
13. What is the distance in KM of 
the next referral centre 
14. Geo-location of the next 
referral centre 
15. What is the Level of the next 
referral HC 
1=Clinic, 2=HCII, 3=HCIII, 4=HCIV, 5=District 
Hospital 
HC Capacity 
16. What is the total number 
of staff at your HC? 
Write  
17. What is the total number 
of staff supposed to be at 
your HC? 
18. What is the total number 
of the following types of 
staff cadre available at 
your HC? If none write 0 
1=VHT 
2=Nursing Aid 
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3=Ophthalmic assistant 
4=Enrolled Nurse 
5=Registered Nurse 
6=Midwife 
7=Laboratory officer 
8=Nursing officer 
9=Clinical Officer 
10=Ophthalmic clinical officer 
11=Medical officer 
12=Ophthalmologist 
13=Other (specify) 
19. What is the cadre level of 
the HC in charge? 
Use reference numbers above 
20. What eye equipment is 
available to you: (If 
available, ask about 
condition and number) 
Item Available 
0=No, 1=Yes 
Condition 
0=N/A, 
1=Not 
working, 
2=Workin
g 
Number  
Direct Ophthalmoscope  
Magnifying loupes 
Torch 
Blue Light Torch 
Eye lid retractors 
Microscope 
Slit lamp 
Lab running water source 
Staining rack 
Bunsen burner/fire source 
set up 
21. Which of the following 
diagnostic consumables 
do you have currently? 
Fluorescein  0=No, 1=Yes 
21 Gauge Needles 0=No, 1=Yes 
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Microscope slides 0=No, 1=Yes 
Amethocaine eye drops 0=No, 1=Yes 
Sterile gloves 0=No, 1=Yes 
Cover slips 0=No, 1=Yes 
KOH 0=No, 1=Yes 
Crystal Violet 0=No, 1=Yes 
Grams iodine 0=No, 1=Yes 
Acetone 0=No, 1=Yes 
Carbolfuschin 0=No, 1=Yes 
Blotting paper/cotton 0=No, 1=Yes 
22. Which of the following 
treatment stocks do you 
have currently? 
Tetracycline ointment 0=No, 1=Yes 
Chloramphenicol ointment 0=No, 1=Yes 
Chloramphenicol eye 
drops 
0=No, 1=Yes 
Gentamycin eye drops 0=No, 1=Yes 
Gentamycin IV vails 0=No, 1=Yes 
Ciprofloxacin eye drops 0=No, 1=Yes 
Steroid eye drops 0=No, 1=Yes 
Steroid/antibiotic eye 
drops 
0=No, 1=Yes 
Iodine 0=No, 1=Yes 
Chlorohexidine 0=No, 1=Yes 
Antifungal eye drops 
(write) 
0=No, 1=Yes 
Antifungal tablets (write) 0=No, 1=Yes 
Practise (Information to be collected from the In charge/person who sees eye patients and 
patient/dispensing logs 
22. Total number of eye patients seen in the last 6 months
23. Tally of the different eye 
diseases diagnoses and 
Diagnosis 
(write)/ 
Number Treatment given 
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treatments in the last 6 
months 
24. Tally of eye patients referred in the last 6 months (if 
available) 
25. Where do you normally refer eye patients? 
Knowledge-information to be obtained from the person who usually sees eye patients or the in charge
26. What is your training in 
eye care? 
0=None, 1=partial (as part of my course), 2= 
Certificate in eye care, 3=Diploma in eye care, 
4=Specialist 
27. How much in percentage 
time of your training was 
spent on eye care? 
28. List about five common eye diseases that you know? 
29. Here is a picture of an eye condition (with and without 
staining). What clinical signs can you see? 
0=Not mentioned, 1=Mentioned 
Conjunctival 
Hyperaemia 
Epithelial breach 
Corneal opacity 
Hypopyon 
Corneal FB 
30. What is the most likely diagnosis? (write ) 
31. Assuming you had all the resources available to you, what would be your first 
line treatment? 
32. Which eye drops would you avoid? 
33. Have you seen such a case before? (0=No, 1=Yes) 
34. If yes, how did you manage it? 
35. What do you think are the risk factors to this condition? 
36. What do you think are the complications of this condition? 
B. Training School data collection tool 
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This tool will be used for collecting information from the training school on eye health training 
provided to the health workers. It has four parts; general information, knowledge content, skills 
content and competencies. 
General information 
1. Name of the Training school 
2. Study Number 
3. Location (district) 
4. Geo location of Training School 
5. What is the highest Level of 
Training school 
1=Certificate nursing school, 2=diploma 
nursing school, 3=clinical officer school 
6. Number of Trained students 
per year 
7. Duration of training 
Training School Capacity 
8. What is the training level of the 
principal 
1=certificate, 2=diploma, 3=degree, 
4=masters, 5=PhD 
9. Do you have eye health within 
your curriculum? 
1=Yes, 0=No 
10. What is the training level of the 
eye health tutor? 
1=certificate, 2=diploma, 3=degree, 
4=masters, 5=PhD 
11. What is the eye health training 
level of the eye health tutor? 
1=None (did eye health as part of their 
medical training), 2=Certificate in eye 
health, 3=Diploma in eye health, 
4=Masters in Eye health 
12. How much training in months 
do the trainees spend on eye 
health? 
13. Which are some of the topics 
covered under eye health 
training? 
Are covered, 1=yes, 0=No 
Anatomy of the eye 
Blinding diseases 
Eye Infections 
Microbial keratitis 
Examination of the eye 
Ocular Pharmacology 
14. What is specifically taught 
under microbial keratitis? 
(write) 
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Skills and competencies 
15. Do the trainees spend part of their training in hospital 
1=Yes, 0=No 
16. How much time of their training do the trainees spend time in hospital?
(Write in months) 
17. During the hospital rotations, do the trainees spend part of their time 
particularly in an eye ward/clinic/hospital?,(1=Yes, 0=No) 
18. How much time in months do the trainees spend in an eye 
ward/clinic/hospital? 
19. Do the trainees get hands on training while in an eye 
ward/clinic/hospital? (1=Yes, 0=No) 
20. While the trainees are in 
an eye 
ward/clinic/hospital, who 
supervises them? 
1=Ophthalmic Assistant, 2=Ophthalmic 
Nurse, 3=Ophthalmic clinical officer, 
4=Ophthalmologist 5=other (specify) 
21. Which skills do the 
trainees learn while in an 
eye ward/clinic/hospital?
skill 1=yes, 0=No 
Taking ocular history 
Assessing visual acuity 
Eye Examination using a torch 
Application of eye drops 
Staining the cornea with fluorescein 
Eye examination using magnifying loupes 
Removal of a corneal foreign body 
Diagnosing a corneal ulcer 
Eye examination using a direct 
ophthalmoscope 
Other, write 
C. Ophthalmic Assistants data collection tool
This tool will be used for collecting information from the OAs on knowledge, capacity, and practise 
in management of microbial keratitis. It has four parts; general information, knowledge on MK, 
capacity of the health centre and information on treatment practise for MK. 
General information 
1. Study Number 
2. Name of OA 
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3. Sex 1=male, 2=female 
4. Age in years 
5. Marital status 1=single, 2=married, 3=divorced, 
4=widow/widowed 
6. Does your spouse stay with you? 0= if N/A, 1=No, 2=Yes 
7. How long ago (in years) was your training?
8. Have you undertaken more training since 
your OA course? 
0=No, 1=Yes 
9. What is your highest level of Training 1=certificate, 2=diploma, 3=degree, 
4=masters 
10. Are you still in clinical practise for eye 
care? 
0=No, 1=Yes 
11. If No, which area of practise are you now? 0=N/A (still in eye care), 1=Another 
area of medicine (write), 2=Area 
outside medical practise (write) 
Why did you decide to change to another area of practise? 
12. What is the Level of the HC where you 
work? 
1=Clinic, 2=HCII, 3=HCIII, 4=HCIV, 
5=District Hospital 
13. Geo location of HC (write) 
14. How would you describe the road access 
to your HC? 
1=Not all weather, 2=all weather 
15. What is your population coverage 
16. Is there a latrine? 0 = No, 1 = Yes 
17. Is there a water source at the HC? 0 = No, 1 = Yes 
18. What type of water source is available at 
the HC? 
0= none, 1=Well, 2, 3 = Piped, 4= Roof 
collected tank, 5=Borehole, 
6=protected spring 
19. How far is the nearest water source 0= water at HC, distance in KM 
20. Main type of electricity supply? 0 = None, 1 = solar, 2=Hydro, 
4=Generator 
21. Is there mobile phone network? 0 = No 
1 = Yes 
22. What is the distance in KM of the next 
referral centre 
23. Geolocation of the next referral centre 
Capacity available 
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24. Which of the following eye equipment are 
currently available to you? 
Item Available 
0=No, 
1=Yes 
Condition 
0=N/A, 1=Not 
working, 
2=Working 
Direct Ophthalmoscope 
Magnifying loupes 
Torch 
Blue Light Torch 
Eye lid retractors 
Microscope 
Slit lamp 
25. Which of the following diagnostic 
consumables do you have available 
currently? 
Fluorescein 0=No, 
1=Yes 
Amethocaine eye drops 0=No, 
1=Yes 
Sterile gloves 0=No, 
1=Yes 
26. Which of the following treatment stocks do 
you have currently available to you? 
Tetracycline ointment 0=No, 
1=Yes 
Chloramphenicol 
ointment 
0=No, 
1=Yes 
Chloramphenicol eye 
drops 
0=No, 
1=Yes 
Gentamycin eye drops 0=No, 
1=Yes 
Gentamycin IV vails 0=No, 
1=Yes 
Ciprofloxacin eye drops 0=No, 
1=Yes 
Steroid eye drops 0=No, 
1=Yes 
Steroid/antibiotic eye 
drops 
0=No, 
1=Yes 
Iodine 0=No, 
1=Yes 
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Chlorohexidine 0=No, 
1=Yes 
Antifungal eye drops 
(write) 
Antifungal tablets (write)
Practise (Please refer to your log) 
27. What was the total number of eye patients you saw in the last 6 months 
28. What was the most common diagnosis? 
29. How many of those had MK? 
30. What was the most prescription given? 
31. How many eye patients did you refer in the last 6 months? 
32. What was the most commonly referred condition? 
33. Where do you normally refer eye patients? 
34. How do you usually manage MK in your setting? 
35. What do you think are the risk factors to this condition? 
36. What do you think are the complications of this condition? 
37. How do you think this condition can be prevented? 
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54. Treatment chronology: 
What was the order of your treatment after onset of symptoms? (Encourage the patient to carefully recollect the order of events in their treatment journey) 
Study 
numb
er 
Event 
numb
er 
Treat
ment 
Event 
Calen
dar 
date 
Where? Treatment received: 1=Traditional Eye Medicine, 2=Chloramphenicol, 3=Ciprofloxacin, 4=Tetracycline, 
5=Gentamycin,6=Iodine,7=antibiotic-steroid, 8=Acyclovir, 9=clotrimazole, 10=econazole, 11=Natamycin, 
12=referred, 13=other (specify), 99=Not able to ascertain 
DD/M
M/YY
YY 
1=Home remedy/traditional, 
2=clinic/pharmacy, 3=HC II, 
4=HCIII, 5=HC IV, 6=District 
hospital, 99=don’t know 
Treatment 1 Treatmen
t 2 
Treatmen
t 3 
Treatment 4 Approximate cost of care in 
UGX (write) 
Did you need 
an escort for 
this visit? 
0=No, 1=Yes consult
ation 
Medicin
e 
Direct 
cost 
1 
2 
3 
4 
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Bilateral Candida keratitis in an HIV patient with asymptomatic
genitourinary candidiasis in Uganda
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A B S T R A C T
A 35-year-old male presented with Candida keratitis in the left eye. He was HIV positive with a CD4 of 352 cells/
µL. The eye quickly deteriorated, despite intensive antifungal treatment and was eviscerated. Five months later,
he re-presented with Candida keratitis in his right eye. A focal source of Candida infection was suspected and a
urine culture identiﬁed Candida spp, despite being asymptomatic for genitourinary candidiasis. He was subse-
quently treated with good outcome (max. 75 words)
1. Introduction
Microbial keratitis (MK) is caused by a range of pathogens, in-
cluding bacteria, viruses, protozoa and fungi. It is characterized by
pain, conjunctival hyperemia and corneal ulceration with stromal in-
ﬂammatory cell inﬁltrate. MK frequently leads to sight-loss from dense
corneal scarring or even loss of the eye when severe.
In tropical regions approximately half of MK is attributable to fungal
pathogens [1,2]. Filamentous organisms predominate, with Fusarium
spp. and Aspergillus spp. accounting for the large majority [3]. Yeast
infections, mostly caused by Candida spp are less frequent. In contrast,
in temperate regions yeast often predominate, although some recent
reports suggest an increasing proportion of ﬁlamentous infections [4].
Reported risk factors for fungal keratitis include trauma, ocular surface
disease, contact lens use, prior surgery, traditional eye medicine (TEM),
steroid use and immunosuppression [4–6].
Candida keratitis is particularly associated with chronic ocular
surface disease and has been reported following various corneal pro-
cedures [4,7,8]. Although the source of the Candida is usually exo-
genous, it may sometimes have an endogenous source such as from the
oral and genitourinary surfaces or a disseminated systemic infection in
severely immunocompromised individuals [9,10]. Genitourinary Can-
dida infection is relatively common in Africa; it can be either sympto-
matic or asymptomatic [11]. It is reported to contribute 30–50% of all
cases treated with genitourinary infection [11–14]. However, it has not
been previously reported to be associated with keratitis.
Here we report a case of a 35-year-old man with sequential bilateral
Candida keratitis with a concomitant asymptomatic genitourinary
Candida infection. This provides important lessons on investigation,
treatment and preventative care in similar cases.
2. Case
2.1. First eye presentation
A 35-year-old male Ugandan presented to Mbarara University
Referral Hospital Eye Centre (MURHEC) in June 2017 with a 10-day
history of a painful, red left eye. There was no history of trauma,
contact lens or TEM use. He was not aware of his HIV status at the time
of presentation, but thought that he was HIV negative. He described a
somewhat similar eye problem in his teenage years, which followed
trauma, was treated and had healed. He had experienced no further
ocular problems until this new presentation.
On this admission (day0),the left visual acuity was hand movements
only, with no improvement on pinhole. There was a dense white
paraxial supratemporal corneal inﬁltrate (2.0 mm×1.5mm), an
overlying epithelial defect (2.0 mm×1.5mm), 80% corneal thinning
and a 3.5 mm hypopyon (Fig. 1a). Additionally, the left cornea had an
old inferior vascularized scar (7 mm×6mm). The right eye had an
unaided visual acuity of 6/5 and normal ocular examination.
Corneal scrapings were collected for microscopy (Gram stain,
Potassium Hydroxide [KOH] stain, Calcoﬂuor White [CFW] stain,
Lactophenol Cotton Blue stain[LPCB]) and culture (Blood Agar [BA],
Chocolate Agar [CA], Potato Dextrose Agar [PDA] and Brain Heart
Infusion [BHI]). Initial CFW slide revealed fungal elements. The Gram,
KOH and LPCB tests were negative. However, Candida spp. grew on BA,
https://doi.org/10.1016/j.mmcr.2018.07.007
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PDA, CA and BHI subculture within 48 h.
The patient was started on hourly Natamycin 5% eyedrops (Zonat
Sunways India) as well as Oﬂoxacin 0.3% eyedrops (Biomedica
Remedies-India) 4 times/day and Atropine eyedrops. By day3, the eye
had rapidly deteriorated (Fig. 1b) and hourly Chlorohexidine 0.2%
eyedrops (locally formulated) was added to his treatment. By day7 the
cornea had thinned further and was threatening to perforate (Fig. 1c).
Corneal tissue for transplantation is currently unavailable in Uganda.
On day8, a conjunctival ﬂap procedure was performed (Fig. 1d), in
conjunction with a subconjunctival injection of Fluconazole 2%
(0.5 ml). On day21, he returned with a total corneal and conjunctival
ﬂap melt (Fig. 1e). At this stage further active treatment was considered
futile and a decision was taken with the patient to perform an evis-
ceration. Subsequently, a prosthetic shell was ﬁtted.
It is our routine practice to oﬀer HIV counselling and testing to all
people presenting with MK. This individual accepted the oﬀer and was
found to be HIV positive. He was referred to HIV services and started
anti-retroviral therapy. His CD4 count was 352 cells/µL around the time
treatment was initiated.
2.2. Second eye presentation
Five months later, he returned to MURHEC with a 4 day history of a
painful right eye. Again, there was no history of trauma, contact lens or
TEM use. On this day0 for the righteye presentation, visual acuity in the
right eye was 6/12. Slit lamp examination showed a supra-temporal
dense corneal inﬁltrate (3.1 mm×2.8mm), Fig. 2a. Corneal scrape
samples were collected and sent for microbiological investigations, as
outlined above. Gram stain showed pseudo-hyphae. CFW and KOH
reported fungal hyphae and all culture plates (BHI subculture, BA, CA,
PDA) grew Candida spp. The same ﬁrst line protocol as previous (Na-
tamycin, Oﬂoxacin and Atropine) was started. At this point, we were
concerned that he might have a source of Candida elsewhere, that had
led to the sequential corneal infections. He reported no systemic
symptoms; speciﬁcally he did not have dysuria. As part of the assess-
ment a urine sample was cultured, which also grew Candida spp.
By day3 we noted a moderate deterioration (Fig. 2b). Therefore, we
added hourly Amphotericin B 0.15% eyedrops (locally formulated with
a hyper methylcellolose base) and oral ﬂuconazole 200mg twice a day
to his treatment. By day21, the ocular pain had greatly reduced and the
inﬁltrate had transitioned into a scar extending to the visual axis
(7 mm×4mm). He developed a small para-central perforation. This
self-sealed with iris plugging; the anterior chamber was deep and Sie-
del's test was negative (Fig. 2c). By 3 months (day90) the scar size had
reduced slightly (6 mm×3.2mm), and his right visual acuity was 6/
24.
Fig. 1. (a–e) showing appearance of the left eye from presentation (day0) to day21, in June 2017.
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3. Discussion
Although Candida keratitis has generally been found to be more
common in temperate climates, it has been reported, albeit less fre-
quently, in tropical regions [1,2,15]. This patient presented us a unique
opportunity to reﬂect on the presentation of Candida keratitis in HIV
infected patients and identify key considerations to ensure a good
outcome.
Firstly, the patient had undiagnosed HIV infection with a relatively
low CD4 count which could have predisposed him to the initial infec-
tion. We routinely provide HIV counselling and testing to MK patients
as part of our hospital protocol, based on previous studies in the region
that noted a high proportion of MK patients with HIV [16,17]. This is
consistent with our experience in Uganda, where we ﬁnd in ongoing
case-control work HIV is more frequent in people with MK (un-
published data).
Secondly, we did not initially suspect a systemic source of the
Candida infection. The patient was asymptomatic for this.
Endophthalmitis resulting from Candida septicemia is well character-
ized [10,18,19]. Blood culture for Candida septicemia was not per-
formed in our patient because he was afebrile, he did not have oral
thrush and otherwise clinically well. Patients with Candida septicemia
are usually very sick at presentation; they require hospitalization, with
a majority requiring intensive care treatment [18]. Our patient was
found to have asymptomatic genitourinary candidiasis on urine culture.
Therefore, we think that the most likely explanation for the acquisition
of his sequential case bilateral Candida keratitis was due to poor hy-
giene.
Thirdly, our patient rapidly deteriorated on the ﬁrst presentation
resulting loss of the eye, despite intensive treatment with two anti-
fungal agents. Candida keratitis rapidly causes corneal perforations,
corneal scars, endophthalmitis and loss of vision in many cases [20].
However, experience of managing his ﬁrst infection helped us to ag-
gressively manage his remaining eye when it became infected. Prompt
microbiological conﬁrmation of the Candida helped to initiate a dual
drug combination of hourly Natamycin 5% eyedrops and Amphotericin
B 0.15% eyedrops. We were able to save the eye and preserve useful
vision. Molecular strain typing which would be required to validate if
there was any similarity among the isolates, was not available.
This case graphically illustrates the increased risk to fungal keratitis
experienced by HIV positive individuals. It highlights the need in
unusual bilateral cases for careful assessment for a potential source
elsewhere in the body. It is a reminder of the high ocular morbidity
associated with these types of infections and the particular treatment
challenges they present
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